
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="ABCBAA3892650C533DAA380033F505A4.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="biomedicines">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8868626/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Biomedicines">
<meta name="citation_title" content="What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes">
<meta name="citation_author" content="Andrea Palicelli">
<meta name="citation_author_institution" content="Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)">
<meta name="citation_author" content="Stefania Croci">
<meta name="citation_author_institution" content="Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Stefania.Croci@ausl.re.it (S.C.); Martina.Bonacini@ausl.re.it (M.B.)">
<meta name="citation_author" content="Alessandra Bisagni">
<meta name="citation_author_institution" content="Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)">
<meta name="citation_author" content="Eleonora Zanetti">
<meta name="citation_author_institution" content="Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)">
<meta name="citation_author" content="Dario De Biase">
<meta name="citation_author_institution" content="Department of Pharmacy and Biotechnology (FABIT), University of Bologna, 40126 Bologna, Italy; dario.debiase@unibo.it">
<meta name="citation_author" content="Beatrice Melli">
<meta name="citation_author_institution" content="Fertility Center, Department of Obstetrics and Gynecology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Beatrice.Melli@ausl.re.it">
<meta name="citation_author_institution" content="Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy">
<meta name="citation_author" content="Francesca Sanguedolce">
<meta name="citation_author_institution" content="Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy; francesca.sanguedolce@unifg.it">
<meta name="citation_author" content="Moira Ragazzi">
<meta name="citation_author_institution" content="Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)">
<meta name="citation_author" content="Magda Zanelli">
<meta name="citation_author_institution" content="Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)">
<meta name="citation_author" content="Alcides Chaux">
<meta name="citation_author_institution" content="Department of Scientific Research, School of Postgraduate Studies, Norte University, Asuncion 1614, Paraguay; alcideschaux@uninorte.edu.py">
<meta name="citation_author" content="Sofia Cañete-Portillo">
<meta name="citation_author_institution" content="Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; scaneteportillo@uabmc.edu">
<meta name="citation_author" content="Maria Paola Bonasoni">
<meta name="citation_author_institution" content="Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)">
<meta name="citation_author" content="Stefano Ascani">
<meta name="citation_author_institution" content="Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy; s.ascani@aospterni.it">
<meta name="citation_author_institution" content="Haematopathology Unit, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06129 Perugia, Italy">
<meta name="citation_author" content="Antonio De Leo">
<meta name="citation_author_institution" content="Molecular Diagnostic Unit, Azienda USL Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy; antonio.deleo@unibo.it">
<meta name="citation_author" content="Guido Giordano">
<meta name="citation_author_institution" content="Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy; guido.giordano@unifg.it (G.G.); matteo.landriscina@unifg.it (M.L.)">
<meta name="citation_author" content="Matteo Landriscina">
<meta name="citation_author_institution" content="Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy; guido.giordano@unifg.it (G.G.); matteo.landriscina@unifg.it (M.L.)">
<meta name="citation_author" content="Giuseppe Carrieri">
<meta name="citation_author_institution" content="Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy; giuseppe.carrieri@unifg.it (G.C.); luigi.cormio@unifg.it (L.C.)">
<meta name="citation_author" content="Luigi Cormio">
<meta name="citation_author_institution" content="Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy; giuseppe.carrieri@unifg.it (G.C.); luigi.cormio@unifg.it (L.C.)">
<meta name="citation_author" content="Jatin Gandhi">
<meta name="citation_author_institution" content="Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA; jgandhi@uw.edu">
<meta name="citation_author" content="Davide Nicoli">
<meta name="citation_author_institution" content="Molecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Davide.Nicoli@ausl.re.it (D.N.); enrico.farnetti@ausl.re.it (E.F.)">
<meta name="citation_author" content="Enrico Farnetti">
<meta name="citation_author_institution" content="Molecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Davide.Nicoli@ausl.re.it (D.N.); enrico.farnetti@ausl.re.it (E.F.)">
<meta name="citation_author" content="Simonetta Piana">
<meta name="citation_author_institution" content="Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)">
<meta name="citation_author" content="Alessandro Tafuni">
<meta name="citation_author_institution" content="Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)">
<meta name="citation_author_institution" content="Pathology Unit, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy">
<meta name="citation_author" content="Martina Bonacini">
<meta name="citation_author_institution" content="Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Stefania.Croci@ausl.re.it (S.C.); Martina.Bonacini@ausl.re.it (M.B.)">
<meta name="citation_publication_date" content="2022 Jan 22">
<meta name="citation_volume" content="10">
<meta name="citation_issue" content="2">
<meta name="citation_firstpage" content="236">
<meta name="citation_doi" content="10.3390/biomedicines10020236">
<meta name="citation_pmid" content="35203446">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8868626/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8868626/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8868626/pdf/biomedicines-10-00236.pdf">
<meta name="description" content="Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency (MSI-H/dMMR). BRCA1/2 loss-of-function is linked to hereditary PCs ...">
<meta name="og:title" content="What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency (MSI-H/dMMR). BRCA1/2 loss-of-function is linked to hereditary PCs ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8868626/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="8868626">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3390/biomedicines10020236"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/biomedicines-10-00236.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8868626%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/8868626/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/8868626/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8868626/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-biomedicines.png" alt="Biomedicines logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Biomedicines" title="Link to Biomedicines" shape="default" href="http://www.mdpi.com/journal/biomedicines" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Biomedicines</button></div>. 2022 Jan 22;10(2):236. doi: <a href="https://doi.org/10.3390/biomedicines10020236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3390/biomedicines10020236</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Biomedicines%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Biomedicines%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biomedicines%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Biomedicines%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, <em>BRCA</em>, <em>PTEN</em>, and Other Genes</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Palicelli%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Andrea Palicelli</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Andrea Palicelli</span></h3>
<div class="p">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Palicelli%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Andrea Palicelli</span></a>
</div>
</div>
<sup>1,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Croci%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Stefania Croci</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Stefania Croci</span></h3>
<div class="p">
<sup>2</sup>Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Stefania.Croci@ausl.re.it (S.C.); Martina.Bonacini@ausl.re.it (M.B.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Croci%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Stefania Croci</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bisagni%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Alessandra Bisagni</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Alessandra Bisagni</span></h3>
<div class="p">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bisagni%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessandra Bisagni</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zanetti%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Eleonora Zanetti</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Eleonora Zanetti</span></h3>
<div class="p">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zanetti%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Eleonora Zanetti</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Biase%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Dario De Biase</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Dario De Biase</span></h3>
<div class="p">
<sup>3</sup>Department of Pharmacy and Biotechnology (FABIT), University of Bologna, 40126 Bologna, Italy; dario.debiase@unibo.it</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Biase%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dario De Biase</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Melli%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Beatrice Melli</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Beatrice Melli</span></h3>
<div class="p">
<sup>4</sup>Fertility Center, Department of Obstetrics and Gynecology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Beatrice.Melli@ausl.re.it</div>
<div class="p">
<sup>5</sup>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Melli%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Beatrice Melli</span></a>
</div>
</div>
<sup>4,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sanguedolce%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Francesca Sanguedolce</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Francesca Sanguedolce</span></h3>
<div class="p">
<sup>6</sup>Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy; francesca.sanguedolce@unifg.it</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sanguedolce%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francesca Sanguedolce</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ragazzi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Moira Ragazzi</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Moira Ragazzi</span></h3>
<div class="p">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ragazzi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Moira Ragazzi</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zanelli%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Magda Zanelli</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Magda Zanelli</span></h3>
<div class="p">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zanelli%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Magda Zanelli</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chaux%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Alcides Chaux</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Alcides Chaux</span></h3>
<div class="p">
<sup>7</sup>Department of Scientific Research, School of Postgraduate Studies, Norte University, Asuncion 1614, Paraguay; alcideschaux@uninorte.edu.py</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chaux%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alcides Chaux</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ca%C3%B1ete-Portillo%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Sofia Cañete-Portillo</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Sofia Cañete-Portillo</span></h3>
<div class="p">
<sup>8</sup>Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; scaneteportillo@uabmc.edu</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ca%C3%B1ete-Portillo%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sofia Cañete-Portillo</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bonasoni%20MP%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Maria Paola Bonasoni</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Maria Paola Bonasoni</span></h3>
<div class="p">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bonasoni%20MP%22%5BAuthor%5D" class="usa-link"><span class="name western">Maria Paola Bonasoni</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ascani%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Stefano Ascani</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Stefano Ascani</span></h3>
<div class="p">
<sup>9</sup>Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy; s.ascani@aospterni.it</div>
<div class="p">
<sup>10</sup>Haematopathology Unit, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06129 Perugia, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ascani%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Stefano Ascani</span></a>
</div>
</div>
<sup>9,</sup><sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Leo%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Antonio De Leo</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Antonio De Leo</span></h3>
<div class="p">
<sup>11</sup>Molecular Diagnostic Unit, Azienda USL Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy; antonio.deleo@unibo.it</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22De%20Leo%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Antonio De Leo</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Giordano%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Guido Giordano</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Guido Giordano</span></h3>
<div class="p">
<sup>12</sup>Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy; guido.giordano@unifg.it (G.G.); matteo.landriscina@unifg.it (M.L.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Giordano%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Guido Giordano</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Landriscina%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Matteo Landriscina</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Matteo Landriscina</span></h3>
<div class="p">
<sup>12</sup>Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy; guido.giordano@unifg.it (G.G.); matteo.landriscina@unifg.it (M.L.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Landriscina%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Matteo Landriscina</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Carrieri%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Giuseppe Carrieri</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Giuseppe Carrieri</span></h3>
<div class="p">
<sup>13</sup>Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy; giuseppe.carrieri@unifg.it (G.C.); luigi.cormio@unifg.it (L.C.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Carrieri%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giuseppe Carrieri</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cormio%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Luigi Cormio</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Luigi Cormio</span></h3>
<div class="p">
<sup>13</sup>Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy; giuseppe.carrieri@unifg.it (G.C.); luigi.cormio@unifg.it (L.C.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cormio%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Luigi Cormio</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gandhi%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Jatin Gandhi</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Jatin Gandhi</span></h3>
<div class="p">
<sup>14</sup>Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA; jgandhi@uw.edu</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gandhi%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jatin Gandhi</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nicoli%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Davide Nicoli</span></a><div hidden="hidden" id="id20">
<h3><span class="name western">Davide Nicoli</span></h3>
<div class="p">
<sup>15</sup>Molecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Davide.Nicoli@ausl.re.it (D.N.); enrico.farnetti@ausl.re.it (E.F.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nicoli%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Davide Nicoli</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Farnetti%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Enrico Farnetti</span></a><div hidden="hidden" id="id21">
<h3><span class="name western">Enrico Farnetti</span></h3>
<div class="p">
<sup>15</sup>Molecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Davide.Nicoli@ausl.re.it (D.N.); enrico.farnetti@ausl.re.it (E.F.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Farnetti%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Enrico Farnetti</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Piana%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Simonetta Piana</span></a><div hidden="hidden" id="id22">
<h3><span class="name western">Simonetta Piana</span></h3>
<div class="p">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Piana%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Simonetta Piana</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tafuni%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Alessandro Tafuni</span></a><div hidden="hidden" id="id23">
<h3><span class="name western">Alessandro Tafuni</span></h3>
<div class="p">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div class="p">
<sup>16</sup>Pathology Unit, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tafuni%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessandro Tafuni</span></a>
</div>
</div>
<sup>1,</sup><sup>16</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bonacini%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id24"><span class="name western">Martina Bonacini</span></a><div hidden="hidden" id="id24">
<h3><span class="name western">Martina Bonacini</span></h3>
<div class="p">
<sup>2</sup>Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Stefania.Croci@ausl.re.it (S.C.); Martina.Bonacini@ausl.re.it (M.B.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bonacini%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Martina Bonacini</span></a>
</div>
</div>
<sup>2</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-biomedicines-10-00236">
<sup>1</sup>Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Alessandra.Bisagni@ausl.re.it (A.B.); Eleonora.Zanetti@ausl.re.it (E.Z.); Moira.Ragazzi@ausl.re.it (M.R.); Magda.Zanelli@ausl.re.it (M.Z.); mariapaola.bonasoni@ausl.re.it (M.P.B.); simonetta.piana@ausl.re.it (S.P.); alessandro.tafuni@unipr.it (A.T.)</div>
<div id="af2-biomedicines-10-00236">
<sup>2</sup>Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Stefania.Croci@ausl.re.it (S.C.); Martina.Bonacini@ausl.re.it (M.B.)</div>
<div id="af3-biomedicines-10-00236">
<sup>3</sup>Department of Pharmacy and Biotechnology (FABIT), University of Bologna, 40126 Bologna, Italy; dario.debiase@unibo.it</div>
<div id="af4-biomedicines-10-00236">
<sup>4</sup>Fertility Center, Department of Obstetrics and Gynecology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Beatrice.Melli@ausl.re.it</div>
<div id="af5-biomedicines-10-00236">
<sup>5</sup>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy</div>
<div id="af6-biomedicines-10-00236">
<sup>6</sup>Pathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy; francesca.sanguedolce@unifg.it</div>
<div id="af7-biomedicines-10-00236">
<sup>7</sup>Department of Scientific Research, School of Postgraduate Studies, Norte University, Asuncion 1614, Paraguay; alcideschaux@uninorte.edu.py</div>
<div id="af8-biomedicines-10-00236">
<sup>8</sup>Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; scaneteportillo@uabmc.edu</div>
<div id="af9-biomedicines-10-00236">
<sup>9</sup>Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy; s.ascani@aospterni.it</div>
<div id="af10-biomedicines-10-00236">
<sup>10</sup>Haematopathology Unit, CREO, Azienda Ospedaliera di Perugia, University of Perugia, 06129 Perugia, Italy</div>
<div id="af11-biomedicines-10-00236">
<sup>11</sup>Molecular Diagnostic Unit, Azienda USL Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy; antonio.deleo@unibo.it</div>
<div id="af12-biomedicines-10-00236">
<sup>12</sup>Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy; guido.giordano@unifg.it (G.G.); matteo.landriscina@unifg.it (M.L.)</div>
<div id="af13-biomedicines-10-00236">
<sup>13</sup>Department of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy; giuseppe.carrieri@unifg.it (G.C.); luigi.cormio@unifg.it (L.C.)</div>
<div id="af14-biomedicines-10-00236">
<sup>14</sup>Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA; jgandhi@uw.edu</div>
<div id="af15-biomedicines-10-00236">
<sup>15</sup>Molecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy; Davide.Nicoli@ausl.re.it (D.N.); enrico.farnetti@ausl.re.it (E.F.)</div>
<div id="af16-biomedicines-10-00236">
<sup>16</sup>Pathology Unit, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy</div>
<div class="author-notes p"><div class="fn" id="c1-biomedicines-10-00236">
<sup>*</sup><p class="display-inline">Correspondence: <span>Andrea.Palicelli@ausl.re.it</span>; Tel.: +39-052-229-6864; Fax: +39-052-229-6945</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2022 Jan 5; Accepted 2022 Jan 21; Collection date 2022 Feb.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2022 by the authors.</div>
<p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC8868626  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35203446/" class="usa-link">35203446</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency (MSI-H/dMMR). <em>BRCA1/2</em> loss-of-function is linked to hereditary PCs and homologous recombination DNA-repair system deficiency: poly-ADP-ribose-polymerase inhibitors can be administered to <em>BRCA</em>-mutated PC patients. Recently, docetaxel-refractory metastatic castration-resistant PC patients with <em>BRCA1/2</em> or <em>ATM</em> somatic mutations had higher response rates to pembrolizumab. <em>PTEN</em> regulates cell cycle/proliferation/apoptosis through pathways including the AKT/mTOR, which upregulates PD-L1 expression in PC. Our systematic literature review (PRISMA guidelines) investigated the potential correlations between PD-L1 and MMR/MSI/<em>BRCA/PTEN</em> statuses in PC, discussing few other relevant genes. Excluding selection biases, 74/677 (11%) PCs showed dMMR/MSI; 8/67 (12%) of dMMR/MSI cases were PD-L1+. dMMR-PCs included ductal (3%) and acinar (14%) PCs (all cases tested for MSI were acinar-PCs). In total, 15/39 (39%) PCs harbored <em>BRCA1/2</em> aberrations: limited data are available for PD-L1 expression in these patients. 13/137 (10%) PTEN- PCs were PD-L1+; 10/29 (35%) PD-L1+ PCs showed PTEN negativity. <em>SPOP</em> mutations may increase PD-L1 levels, while the potential correlation between PD-L1 and ERG expression in PC should be clarified. Further research should verify how the efficacy of PD-1 inhibitors in metastatic castration-resistant PCs is related to dMMR/MSI, DNA-damage repair genes defects, or PD-L1 expression.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> PD-L1, prostate, cancer, <em>BRCA</em>, mismatch repair, microsatellite instability, <em>PTEN</em>, genes, immunotherapy</p></section></section><section id="sec1-biomedicines-10-00236"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Novel prognostic markers are urgently required to develop patient-tailored targeted-therapies in various tumors, including prostatic cancer (PC) [<a href="#B1-biomedicines-10-00236" class="usa-link" aria-describedby="B1-biomedicines-10-00236">1</a>,<a href="#B2-biomedicines-10-00236" class="usa-link" aria-describedby="B2-biomedicines-10-00236">2</a>,<a href="#B3-biomedicines-10-00236" class="usa-link" aria-describedby="B3-biomedicines-10-00236">3</a>,<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B5-biomedicines-10-00236" class="usa-link" aria-describedby="B5-biomedicines-10-00236">5</a>,<a href="#B6-biomedicines-10-00236" class="usa-link" aria-describedby="B6-biomedicines-10-00236">6</a>,<a href="#B7-biomedicines-10-00236" class="usa-link" aria-describedby="B7-biomedicines-10-00236">7</a>]. In particular, increasing attention has been paid to immunohistochemical biomarkers such as Programmed death-1 (PD-1) and its ligand PD-L1, evaluating their ability to predict the response to immunotherapy drugs. PD-1 and PD-L1 are type-I transmembrane glycoproteins encoded by the <em>PDCD1</em> gene (located on chromosome 2) and <em>CD274</em> gene (located on chromosome 9), respectively: they are present on the surface of various immune cells, and PD-L1 may be expressed by tumor cells (including PC cells) [<a href="#B2-biomedicines-10-00236" class="usa-link" aria-describedby="B2-biomedicines-10-00236">2</a>,<a href="#B3-biomedicines-10-00236" class="usa-link" aria-describedby="B3-biomedicines-10-00236">3</a>,<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B14-biomedicines-10-00236" class="usa-link" aria-describedby="B14-biomedicines-10-00236">14</a>,<a href="#B15-biomedicines-10-00236" class="usa-link" aria-describedby="B15-biomedicines-10-00236">15</a>,<a href="#B16-biomedicines-10-00236" class="usa-link" aria-describedby="B16-biomedicines-10-00236">16</a>,<a href="#B17-biomedicines-10-00236" class="usa-link" aria-describedby="B17-biomedicines-10-00236">17</a>,<a href="#B18-biomedicines-10-00236" class="usa-link" aria-describedby="B18-biomedicines-10-00236">18</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B20-biomedicines-10-00236" class="usa-link" aria-describedby="B20-biomedicines-10-00236">20</a>,<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>,<a href="#B22-biomedicines-10-00236" class="usa-link" aria-describedby="B22-biomedicines-10-00236">22</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B24-biomedicines-10-00236" class="usa-link" aria-describedby="B24-biomedicines-10-00236">24</a>,<a href="#B25-biomedicines-10-00236" class="usa-link" aria-describedby="B25-biomedicines-10-00236">25</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B27-biomedicines-10-00236" class="usa-link" aria-describedby="B27-biomedicines-10-00236">27</a>,<a href="#B28-biomedicines-10-00236" class="usa-link" aria-describedby="B28-biomedicines-10-00236">28</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B31-biomedicines-10-00236" class="usa-link" aria-describedby="B31-biomedicines-10-00236">31</a>,<a href="#B32-biomedicines-10-00236" class="usa-link" aria-describedby="B32-biomedicines-10-00236">32</a>,<a href="#B33-biomedicines-10-00236" class="usa-link" aria-describedby="B33-biomedicines-10-00236">33</a>,<a href="#B34-biomedicines-10-00236" class="usa-link" aria-describedby="B34-biomedicines-10-00236">34</a>,<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>,<a href="#B36-biomedicines-10-00236" class="usa-link" aria-describedby="B36-biomedicines-10-00236">36</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B39-biomedicines-10-00236" class="usa-link" aria-describedby="B39-biomedicines-10-00236">39</a>,<a href="#B40-biomedicines-10-00236" class="usa-link" aria-describedby="B40-biomedicines-10-00236">40</a>,<a href="#B41-biomedicines-10-00236" class="usa-link" aria-describedby="B41-biomedicines-10-00236">41</a>,<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B44-biomedicines-10-00236" class="usa-link" aria-describedby="B44-biomedicines-10-00236">44</a>,<a href="#B45-biomedicines-10-00236" class="usa-link" aria-describedby="B45-biomedicines-10-00236">45</a>,<a href="#B46-biomedicines-10-00236" class="usa-link" aria-describedby="B46-biomedicines-10-00236">46</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B49-biomedicines-10-00236" class="usa-link" aria-describedby="B49-biomedicines-10-00236">49</a>,<a href="#B50-biomedicines-10-00236" class="usa-link" aria-describedby="B50-biomedicines-10-00236">50</a>,<a href="#B51-biomedicines-10-00236" class="usa-link" aria-describedby="B51-biomedicines-10-00236">51</a>,<a href="#B52-biomedicines-10-00236" class="usa-link" aria-describedby="B52-biomedicines-10-00236">52</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B54-biomedicines-10-00236" class="usa-link" aria-describedby="B54-biomedicines-10-00236">54</a>,<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B57-biomedicines-10-00236" class="usa-link" aria-describedby="B57-biomedicines-10-00236">57</a>,<a href="#B58-biomedicines-10-00236" class="usa-link" aria-describedby="B58-biomedicines-10-00236">58</a>,<a href="#B59-biomedicines-10-00236" class="usa-link" aria-describedby="B59-biomedicines-10-00236">59</a>,<a href="#B60-biomedicines-10-00236" class="usa-link" aria-describedby="B60-biomedicines-10-00236">60</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B62-biomedicines-10-00236" class="usa-link" aria-describedby="B62-biomedicines-10-00236">62</a>,<a href="#B63-biomedicines-10-00236" class="usa-link" aria-describedby="B63-biomedicines-10-00236">63</a>,<a href="#B64-biomedicines-10-00236" class="usa-link" aria-describedby="B64-biomedicines-10-00236">64</a>,<a href="#B65-biomedicines-10-00236" class="usa-link" aria-describedby="B65-biomedicines-10-00236">65</a>,<a href="#B66-biomedicines-10-00236" class="usa-link" aria-describedby="B66-biomedicines-10-00236">66</a>,<a href="#B67-biomedicines-10-00236" class="usa-link" aria-describedby="B67-biomedicines-10-00236">67</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B69-biomedicines-10-00236" class="usa-link" aria-describedby="B69-biomedicines-10-00236">69</a>,<a href="#B70-biomedicines-10-00236" class="usa-link" aria-describedby="B70-biomedicines-10-00236">70</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B72-biomedicines-10-00236" class="usa-link" aria-describedby="B72-biomedicines-10-00236">72</a>,<a href="#B73-biomedicines-10-00236" class="usa-link" aria-describedby="B73-biomedicines-10-00236">73</a>,<a href="#B74-biomedicines-10-00236" class="usa-link" aria-describedby="B74-biomedicines-10-00236">74</a>,<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>,<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B78-biomedicines-10-00236" class="usa-link" aria-describedby="B78-biomedicines-10-00236">78</a>,<a href="#B79-biomedicines-10-00236" class="usa-link" aria-describedby="B79-biomedicines-10-00236">79</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B81-biomedicines-10-00236" class="usa-link" aria-describedby="B81-biomedicines-10-00236">81</a>,<a href="#B82-biomedicines-10-00236" class="usa-link" aria-describedby="B82-biomedicines-10-00236">82</a>,<a href="#B83-biomedicines-10-00236" class="usa-link" aria-describedby="B83-biomedicines-10-00236">83</a>,<a href="#B84-biomedicines-10-00236" class="usa-link" aria-describedby="B84-biomedicines-10-00236">84</a>,<a href="#B85-biomedicines-10-00236" class="usa-link" aria-describedby="B85-biomedicines-10-00236">85</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B87-biomedicines-10-00236" class="usa-link" aria-describedby="B87-biomedicines-10-00236">87</a>,<a href="#B88-biomedicines-10-00236" class="usa-link" aria-describedby="B88-biomedicines-10-00236">88</a>,<a href="#B89-biomedicines-10-00236" class="usa-link" aria-describedby="B89-biomedicines-10-00236">89</a>,<a href="#B90-biomedicines-10-00236" class="usa-link" aria-describedby="B90-biomedicines-10-00236">90</a>,<a href="#B91-biomedicines-10-00236" class="usa-link" aria-describedby="B91-biomedicines-10-00236">91</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>,<a href="#B94-biomedicines-10-00236" class="usa-link" aria-describedby="B94-biomedicines-10-00236">94</a>,<a href="#B95-biomedicines-10-00236" class="usa-link" aria-describedby="B95-biomedicines-10-00236">95</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>,<a href="#B97-biomedicines-10-00236" class="usa-link" aria-describedby="B97-biomedicines-10-00236">97</a>,<a href="#B98-biomedicines-10-00236" class="usa-link" aria-describedby="B98-biomedicines-10-00236">98</a>,<a href="#B99-biomedicines-10-00236" class="usa-link" aria-describedby="B99-biomedicines-10-00236">99</a>,<a href="#B100-biomedicines-10-00236" class="usa-link" aria-describedby="B100-biomedicines-10-00236">100</a>,<a href="#B101-biomedicines-10-00236" class="usa-link" aria-describedby="B101-biomedicines-10-00236">101</a>,<a href="#B102-biomedicines-10-00236" class="usa-link" aria-describedby="B102-biomedicines-10-00236">102</a>,<a href="#B103-biomedicines-10-00236" class="usa-link" aria-describedby="B103-biomedicines-10-00236">103</a>,<a href="#B104-biomedicines-10-00236" class="usa-link" aria-describedby="B104-biomedicines-10-00236">104</a>,<a href="#B105-biomedicines-10-00236" class="usa-link" aria-describedby="B105-biomedicines-10-00236">105</a>,<a href="#B106-biomedicines-10-00236" class="usa-link" aria-describedby="B106-biomedicines-10-00236">106</a>,<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B108-biomedicines-10-00236" class="usa-link" aria-describedby="B108-biomedicines-10-00236">108</a>,<a href="#B109-biomedicines-10-00236" class="usa-link" aria-describedby="B109-biomedicines-10-00236">109</a>,<a href="#B110-biomedicines-10-00236" class="usa-link" aria-describedby="B110-biomedicines-10-00236">110</a>,<a href="#B111-biomedicines-10-00236" class="usa-link" aria-describedby="B111-biomedicines-10-00236">111</a>,<a href="#B112-biomedicines-10-00236" class="usa-link" aria-describedby="B112-biomedicines-10-00236">112</a>,<a href="#B113-biomedicines-10-00236" class="usa-link" aria-describedby="B113-biomedicines-10-00236">113</a>,<a href="#B114-biomedicines-10-00236" class="usa-link" aria-describedby="B114-biomedicines-10-00236">114</a>,<a href="#B115-biomedicines-10-00236" class="usa-link" aria-describedby="B115-biomedicines-10-00236">115</a>,<a href="#B116-biomedicines-10-00236" class="usa-link" aria-describedby="B116-biomedicines-10-00236">116</a>,<a href="#B117-biomedicines-10-00236" class="usa-link" aria-describedby="B117-biomedicines-10-00236">117</a>,<a href="#B118-biomedicines-10-00236" class="usa-link" aria-describedby="B118-biomedicines-10-00236">118</a>,<a href="#B119-biomedicines-10-00236" class="usa-link" aria-describedby="B119-biomedicines-10-00236">119</a>,<a href="#B120-biomedicines-10-00236" class="usa-link" aria-describedby="B120-biomedicines-10-00236">120</a>,<a href="#B121-biomedicines-10-00236" class="usa-link" aria-describedby="B121-biomedicines-10-00236">121</a>,<a href="#B122-biomedicines-10-00236" class="usa-link" aria-describedby="B122-biomedicines-10-00236">122</a>,<a href="#B123-biomedicines-10-00236" class="usa-link" aria-describedby="B123-biomedicines-10-00236">123</a>,<a href="#B124-biomedicines-10-00236" class="usa-link" aria-describedby="B124-biomedicines-10-00236">124</a>,<a href="#B125-biomedicines-10-00236" class="usa-link" aria-describedby="B125-biomedicines-10-00236">125</a>,<a href="#B126-biomedicines-10-00236" class="usa-link" aria-describedby="B126-biomedicines-10-00236">126</a>,<a href="#B127-biomedicines-10-00236" class="usa-link" aria-describedby="B127-biomedicines-10-00236">127</a>,<a href="#B128-biomedicines-10-00236" class="usa-link" aria-describedby="B128-biomedicines-10-00236">128</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>,<a href="#B130-biomedicines-10-00236" class="usa-link" aria-describedby="B130-biomedicines-10-00236">130</a>,<a href="#B131-biomedicines-10-00236" class="usa-link" aria-describedby="B131-biomedicines-10-00236">131</a>,<a href="#B132-biomedicines-10-00236" class="usa-link" aria-describedby="B132-biomedicines-10-00236">132</a>,<a href="#B133-biomedicines-10-00236" class="usa-link" aria-describedby="B133-biomedicines-10-00236">133</a>,<a href="#B134-biomedicines-10-00236" class="usa-link" aria-describedby="B134-biomedicines-10-00236">134</a>,<a href="#B135-biomedicines-10-00236" class="usa-link" aria-describedby="B135-biomedicines-10-00236">135</a>,<a href="#B136-biomedicines-10-00236" class="usa-link" aria-describedby="B136-biomedicines-10-00236">136</a>,<a href="#B137-biomedicines-10-00236" class="usa-link" aria-describedby="B137-biomedicines-10-00236">137</a>,<a href="#B138-biomedicines-10-00236" class="usa-link" aria-describedby="B138-biomedicines-10-00236">138</a>,<a href="#B139-biomedicines-10-00236" class="usa-link" aria-describedby="B139-biomedicines-10-00236">139</a>,<a href="#B140-biomedicines-10-00236" class="usa-link" aria-describedby="B140-biomedicines-10-00236">140</a>,<a href="#B141-biomedicines-10-00236" class="usa-link" aria-describedby="B141-biomedicines-10-00236">141</a>,<a href="#B142-biomedicines-10-00236" class="usa-link" aria-describedby="B142-biomedicines-10-00236">142</a>,<a href="#B143-biomedicines-10-00236" class="usa-link" aria-describedby="B143-biomedicines-10-00236">143</a>,<a href="#B144-biomedicines-10-00236" class="usa-link" aria-describedby="B144-biomedicines-10-00236">144</a>,<a href="#B145-biomedicines-10-00236" class="usa-link" aria-describedby="B145-biomedicines-10-00236">145</a>,<a href="#B146-biomedicines-10-00236" class="usa-link" aria-describedby="B146-biomedicines-10-00236">146</a>,<a href="#B147-biomedicines-10-00236" class="usa-link" aria-describedby="B147-biomedicines-10-00236">147</a>,<a href="#B148-biomedicines-10-00236" class="usa-link" aria-describedby="B148-biomedicines-10-00236">148</a>,<a href="#B149-biomedicines-10-00236" class="usa-link" aria-describedby="B149-biomedicines-10-00236">149</a>,<a href="#B150-biomedicines-10-00236" class="usa-link" aria-describedby="B150-biomedicines-10-00236">150</a>,<a href="#B151-biomedicines-10-00236" class="usa-link" aria-describedby="B151-biomedicines-10-00236">151</a>,<a href="#B152-biomedicines-10-00236" class="usa-link" aria-describedby="B152-biomedicines-10-00236">152</a>,<a href="#B153-biomedicines-10-00236" class="usa-link" aria-describedby="B153-biomedicines-10-00236">153</a>,<a href="#B154-biomedicines-10-00236" class="usa-link" aria-describedby="B154-biomedicines-10-00236">154</a>,<a href="#B155-biomedicines-10-00236" class="usa-link" aria-describedby="B155-biomedicines-10-00236">155</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>,<a href="#B157-biomedicines-10-00236" class="usa-link" aria-describedby="B157-biomedicines-10-00236">157</a>]. PD-L1 expression on tumor cells is influenced by the tumor microenvironment, including the cytokines secreted by activated T cells and other immune cells (adaptive immune resistance) [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B6-biomedicines-10-00236" class="usa-link" aria-describedby="B6-biomedicines-10-00236">6</a>,<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B15-biomedicines-10-00236" class="usa-link" aria-describedby="B15-biomedicines-10-00236">15</a>,<a href="#B33-biomedicines-10-00236" class="usa-link" aria-describedby="B33-biomedicines-10-00236">33</a>,<a href="#B36-biomedicines-10-00236" class="usa-link" aria-describedby="B36-biomedicines-10-00236">36</a>,<a href="#B70-biomedicines-10-00236" class="usa-link" aria-describedby="B70-biomedicines-10-00236">70</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>,<a href="#B100-biomedicines-10-00236" class="usa-link" aria-describedby="B100-biomedicines-10-00236">100</a>,<a href="#B101-biomedicines-10-00236" class="usa-link" aria-describedby="B101-biomedicines-10-00236">101</a>,<a href="#B108-biomedicines-10-00236" class="usa-link" aria-describedby="B108-biomedicines-10-00236">108</a>,<a href="#B130-biomedicines-10-00236" class="usa-link" aria-describedby="B130-biomedicines-10-00236">130</a>]. However, PD-L1 constitutive expression could also be induced by genetic alterations (such as PTEN loss) or activation of signaling pathways (intrinsic immune resistance); epigenetic regulators may also interfere with PD-L1 expression [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B6-biomedicines-10-00236" class="usa-link" aria-describedby="B6-biomedicines-10-00236">6</a>,<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B24-biomedicines-10-00236" class="usa-link" aria-describedby="B24-biomedicines-10-00236">24</a>,<a href="#B58-biomedicines-10-00236" class="usa-link" aria-describedby="B58-biomedicines-10-00236">58</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B125-biomedicines-10-00236" class="usa-link" aria-describedby="B125-biomedicines-10-00236">125</a>,<a href="#B126-biomedicines-10-00236" class="usa-link" aria-describedby="B126-biomedicines-10-00236">126</a>]. Limited data are available for PC [<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B14-biomedicines-10-00236" class="usa-link" aria-describedby="B14-biomedicines-10-00236">14</a>,<a href="#B15-biomedicines-10-00236" class="usa-link" aria-describedby="B15-biomedicines-10-00236">15</a>,<a href="#B16-biomedicines-10-00236" class="usa-link" aria-describedby="B16-biomedicines-10-00236">16</a>,<a href="#B17-biomedicines-10-00236" class="usa-link" aria-describedby="B17-biomedicines-10-00236">17</a>,<a href="#B18-biomedicines-10-00236" class="usa-link" aria-describedby="B18-biomedicines-10-00236">18</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B20-biomedicines-10-00236" class="usa-link" aria-describedby="B20-biomedicines-10-00236">20</a>,<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>,<a href="#B22-biomedicines-10-00236" class="usa-link" aria-describedby="B22-biomedicines-10-00236">22</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B24-biomedicines-10-00236" class="usa-link" aria-describedby="B24-biomedicines-10-00236">24</a>,<a href="#B25-biomedicines-10-00236" class="usa-link" aria-describedby="B25-biomedicines-10-00236">25</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B27-biomedicines-10-00236" class="usa-link" aria-describedby="B27-biomedicines-10-00236">27</a>,<a href="#B28-biomedicines-10-00236" class="usa-link" aria-describedby="B28-biomedicines-10-00236">28</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B31-biomedicines-10-00236" class="usa-link" aria-describedby="B31-biomedicines-10-00236">31</a>,<a href="#B32-biomedicines-10-00236" class="usa-link" aria-describedby="B32-biomedicines-10-00236">32</a>,<a href="#B33-biomedicines-10-00236" class="usa-link" aria-describedby="B33-biomedicines-10-00236">33</a>,<a href="#B34-biomedicines-10-00236" class="usa-link" aria-describedby="B34-biomedicines-10-00236">34</a>,<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>,<a href="#B36-biomedicines-10-00236" class="usa-link" aria-describedby="B36-biomedicines-10-00236">36</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B39-biomedicines-10-00236" class="usa-link" aria-describedby="B39-biomedicines-10-00236">39</a>,<a href="#B40-biomedicines-10-00236" class="usa-link" aria-describedby="B40-biomedicines-10-00236">40</a>,<a href="#B41-biomedicines-10-00236" class="usa-link" aria-describedby="B41-biomedicines-10-00236">41</a>,<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B44-biomedicines-10-00236" class="usa-link" aria-describedby="B44-biomedicines-10-00236">44</a>,<a href="#B45-biomedicines-10-00236" class="usa-link" aria-describedby="B45-biomedicines-10-00236">45</a>,<a href="#B46-biomedicines-10-00236" class="usa-link" aria-describedby="B46-biomedicines-10-00236">46</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B49-biomedicines-10-00236" class="usa-link" aria-describedby="B49-biomedicines-10-00236">49</a>,<a href="#B50-biomedicines-10-00236" class="usa-link" aria-describedby="B50-biomedicines-10-00236">50</a>,<a href="#B51-biomedicines-10-00236" class="usa-link" aria-describedby="B51-biomedicines-10-00236">51</a>,<a href="#B52-biomedicines-10-00236" class="usa-link" aria-describedby="B52-biomedicines-10-00236">52</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B54-biomedicines-10-00236" class="usa-link" aria-describedby="B54-biomedicines-10-00236">54</a>,<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B57-biomedicines-10-00236" class="usa-link" aria-describedby="B57-biomedicines-10-00236">57</a>,<a href="#B58-biomedicines-10-00236" class="usa-link" aria-describedby="B58-biomedicines-10-00236">58</a>,<a href="#B59-biomedicines-10-00236" class="usa-link" aria-describedby="B59-biomedicines-10-00236">59</a>,<a href="#B60-biomedicines-10-00236" class="usa-link" aria-describedby="B60-biomedicines-10-00236">60</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B62-biomedicines-10-00236" class="usa-link" aria-describedby="B62-biomedicines-10-00236">62</a>,<a href="#B63-biomedicines-10-00236" class="usa-link" aria-describedby="B63-biomedicines-10-00236">63</a>,<a href="#B64-biomedicines-10-00236" class="usa-link" aria-describedby="B64-biomedicines-10-00236">64</a>,<a href="#B65-biomedicines-10-00236" class="usa-link" aria-describedby="B65-biomedicines-10-00236">65</a>,<a href="#B66-biomedicines-10-00236" class="usa-link" aria-describedby="B66-biomedicines-10-00236">66</a>,<a href="#B67-biomedicines-10-00236" class="usa-link" aria-describedby="B67-biomedicines-10-00236">67</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B69-biomedicines-10-00236" class="usa-link" aria-describedby="B69-biomedicines-10-00236">69</a>,<a href="#B70-biomedicines-10-00236" class="usa-link" aria-describedby="B70-biomedicines-10-00236">70</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B72-biomedicines-10-00236" class="usa-link" aria-describedby="B72-biomedicines-10-00236">72</a>,<a href="#B73-biomedicines-10-00236" class="usa-link" aria-describedby="B73-biomedicines-10-00236">73</a>,<a href="#B74-biomedicines-10-00236" class="usa-link" aria-describedby="B74-biomedicines-10-00236">74</a>,<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>,<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B78-biomedicines-10-00236" class="usa-link" aria-describedby="B78-biomedicines-10-00236">78</a>,<a href="#B79-biomedicines-10-00236" class="usa-link" aria-describedby="B79-biomedicines-10-00236">79</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B81-biomedicines-10-00236" class="usa-link" aria-describedby="B81-biomedicines-10-00236">81</a>,<a href="#B82-biomedicines-10-00236" class="usa-link" aria-describedby="B82-biomedicines-10-00236">82</a>,<a href="#B83-biomedicines-10-00236" class="usa-link" aria-describedby="B83-biomedicines-10-00236">83</a>,<a href="#B84-biomedicines-10-00236" class="usa-link" aria-describedby="B84-biomedicines-10-00236">84</a>,<a href="#B85-biomedicines-10-00236" class="usa-link" aria-describedby="B85-biomedicines-10-00236">85</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B87-biomedicines-10-00236" class="usa-link" aria-describedby="B87-biomedicines-10-00236">87</a>,<a href="#B88-biomedicines-10-00236" class="usa-link" aria-describedby="B88-biomedicines-10-00236">88</a>,<a href="#B89-biomedicines-10-00236" class="usa-link" aria-describedby="B89-biomedicines-10-00236">89</a>,<a href="#B90-biomedicines-10-00236" class="usa-link" aria-describedby="B90-biomedicines-10-00236">90</a>,<a href="#B91-biomedicines-10-00236" class="usa-link" aria-describedby="B91-biomedicines-10-00236">91</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>,<a href="#B94-biomedicines-10-00236" class="usa-link" aria-describedby="B94-biomedicines-10-00236">94</a>,<a href="#B95-biomedicines-10-00236" class="usa-link" aria-describedby="B95-biomedicines-10-00236">95</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>,<a href="#B97-biomedicines-10-00236" class="usa-link" aria-describedby="B97-biomedicines-10-00236">97</a>,<a href="#B98-biomedicines-10-00236" class="usa-link" aria-describedby="B98-biomedicines-10-00236">98</a>,<a href="#B99-biomedicines-10-00236" class="usa-link" aria-describedby="B99-biomedicines-10-00236">99</a>,<a href="#B100-biomedicines-10-00236" class="usa-link" aria-describedby="B100-biomedicines-10-00236">100</a>,<a href="#B101-biomedicines-10-00236" class="usa-link" aria-describedby="B101-biomedicines-10-00236">101</a>,<a href="#B102-biomedicines-10-00236" class="usa-link" aria-describedby="B102-biomedicines-10-00236">102</a>,<a href="#B103-biomedicines-10-00236" class="usa-link" aria-describedby="B103-biomedicines-10-00236">103</a>,<a href="#B104-biomedicines-10-00236" class="usa-link" aria-describedby="B104-biomedicines-10-00236">104</a>,<a href="#B105-biomedicines-10-00236" class="usa-link" aria-describedby="B105-biomedicines-10-00236">105</a>,<a href="#B106-biomedicines-10-00236" class="usa-link" aria-describedby="B106-biomedicines-10-00236">106</a>,<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B108-biomedicines-10-00236" class="usa-link" aria-describedby="B108-biomedicines-10-00236">108</a>,<a href="#B109-biomedicines-10-00236" class="usa-link" aria-describedby="B109-biomedicines-10-00236">109</a>,<a href="#B110-biomedicines-10-00236" class="usa-link" aria-describedby="B110-biomedicines-10-00236">110</a>,<a href="#B111-biomedicines-10-00236" class="usa-link" aria-describedby="B111-biomedicines-10-00236">111</a>,<a href="#B112-biomedicines-10-00236" class="usa-link" aria-describedby="B112-biomedicines-10-00236">112</a>,<a href="#B113-biomedicines-10-00236" class="usa-link" aria-describedby="B113-biomedicines-10-00236">113</a>,<a href="#B114-biomedicines-10-00236" class="usa-link" aria-describedby="B114-biomedicines-10-00236">114</a>,<a href="#B115-biomedicines-10-00236" class="usa-link" aria-describedby="B115-biomedicines-10-00236">115</a>,<a href="#B116-biomedicines-10-00236" class="usa-link" aria-describedby="B116-biomedicines-10-00236">116</a>,<a href="#B117-biomedicines-10-00236" class="usa-link" aria-describedby="B117-biomedicines-10-00236">117</a>,<a href="#B118-biomedicines-10-00236" class="usa-link" aria-describedby="B118-biomedicines-10-00236">118</a>,<a href="#B119-biomedicines-10-00236" class="usa-link" aria-describedby="B119-biomedicines-10-00236">119</a>,<a href="#B120-biomedicines-10-00236" class="usa-link" aria-describedby="B120-biomedicines-10-00236">120</a>,<a href="#B121-biomedicines-10-00236" class="usa-link" aria-describedby="B121-biomedicines-10-00236">121</a>,<a href="#B122-biomedicines-10-00236" class="usa-link" aria-describedby="B122-biomedicines-10-00236">122</a>,<a href="#B123-biomedicines-10-00236" class="usa-link" aria-describedby="B123-biomedicines-10-00236">123</a>,<a href="#B124-biomedicines-10-00236" class="usa-link" aria-describedby="B124-biomedicines-10-00236">124</a>,<a href="#B125-biomedicines-10-00236" class="usa-link" aria-describedby="B125-biomedicines-10-00236">125</a>,<a href="#B126-biomedicines-10-00236" class="usa-link" aria-describedby="B126-biomedicines-10-00236">126</a>,<a href="#B127-biomedicines-10-00236" class="usa-link" aria-describedby="B127-biomedicines-10-00236">127</a>,<a href="#B128-biomedicines-10-00236" class="usa-link" aria-describedby="B128-biomedicines-10-00236">128</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>,<a href="#B130-biomedicines-10-00236" class="usa-link" aria-describedby="B130-biomedicines-10-00236">130</a>,<a href="#B131-biomedicines-10-00236" class="usa-link" aria-describedby="B131-biomedicines-10-00236">131</a>,<a href="#B132-biomedicines-10-00236" class="usa-link" aria-describedby="B132-biomedicines-10-00236">132</a>,<a href="#B133-biomedicines-10-00236" class="usa-link" aria-describedby="B133-biomedicines-10-00236">133</a>,<a href="#B134-biomedicines-10-00236" class="usa-link" aria-describedby="B134-biomedicines-10-00236">134</a>,<a href="#B135-biomedicines-10-00236" class="usa-link" aria-describedby="B135-biomedicines-10-00236">135</a>,<a href="#B136-biomedicines-10-00236" class="usa-link" aria-describedby="B136-biomedicines-10-00236">136</a>,<a href="#B137-biomedicines-10-00236" class="usa-link" aria-describedby="B137-biomedicines-10-00236">137</a>,<a href="#B138-biomedicines-10-00236" class="usa-link" aria-describedby="B138-biomedicines-10-00236">138</a>,<a href="#B139-biomedicines-10-00236" class="usa-link" aria-describedby="B139-biomedicines-10-00236">139</a>,<a href="#B140-biomedicines-10-00236" class="usa-link" aria-describedby="B140-biomedicines-10-00236">140</a>,<a href="#B141-biomedicines-10-00236" class="usa-link" aria-describedby="B141-biomedicines-10-00236">141</a>,<a href="#B142-biomedicines-10-00236" class="usa-link" aria-describedby="B142-biomedicines-10-00236">142</a>,<a href="#B143-biomedicines-10-00236" class="usa-link" aria-describedby="B143-biomedicines-10-00236">143</a>,<a href="#B144-biomedicines-10-00236" class="usa-link" aria-describedby="B144-biomedicines-10-00236">144</a>,<a href="#B145-biomedicines-10-00236" class="usa-link" aria-describedby="B145-biomedicines-10-00236">145</a>,<a href="#B146-biomedicines-10-00236" class="usa-link" aria-describedby="B146-biomedicines-10-00236">146</a>,<a href="#B147-biomedicines-10-00236" class="usa-link" aria-describedby="B147-biomedicines-10-00236">147</a>,<a href="#B148-biomedicines-10-00236" class="usa-link" aria-describedby="B148-biomedicines-10-00236">148</a>,<a href="#B149-biomedicines-10-00236" class="usa-link" aria-describedby="B149-biomedicines-10-00236">149</a>,<a href="#B150-biomedicines-10-00236" class="usa-link" aria-describedby="B150-biomedicines-10-00236">150</a>,<a href="#B151-biomedicines-10-00236" class="usa-link" aria-describedby="B151-biomedicines-10-00236">151</a>,<a href="#B152-biomedicines-10-00236" class="usa-link" aria-describedby="B152-biomedicines-10-00236">152</a>,<a href="#B153-biomedicines-10-00236" class="usa-link" aria-describedby="B153-biomedicines-10-00236">153</a>,<a href="#B154-biomedicines-10-00236" class="usa-link" aria-describedby="B154-biomedicines-10-00236">154</a>,<a href="#B155-biomedicines-10-00236" class="usa-link" aria-describedby="B155-biomedicines-10-00236">155</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>,<a href="#B157-biomedicines-10-00236" class="usa-link" aria-describedby="B157-biomedicines-10-00236">157</a>].</p>
<p>The PD-1/PD-L1 pathway leads to the inactivation of PD-1 expressing cells, in particular CD8+ cytotoxic T cells, favoring tumor immune escape but also representing a target for immunotherapy drugs [<a href="#B2-biomedicines-10-00236" class="usa-link" aria-describedby="B2-biomedicines-10-00236">2</a>,<a href="#B3-biomedicines-10-00236" class="usa-link" aria-describedby="B3-biomedicines-10-00236">3</a>,<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B14-biomedicines-10-00236" class="usa-link" aria-describedby="B14-biomedicines-10-00236">14</a>,<a href="#B15-biomedicines-10-00236" class="usa-link" aria-describedby="B15-biomedicines-10-00236">15</a>,<a href="#B16-biomedicines-10-00236" class="usa-link" aria-describedby="B16-biomedicines-10-00236">16</a>,<a href="#B17-biomedicines-10-00236" class="usa-link" aria-describedby="B17-biomedicines-10-00236">17</a>,<a href="#B18-biomedicines-10-00236" class="usa-link" aria-describedby="B18-biomedicines-10-00236">18</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B20-biomedicines-10-00236" class="usa-link" aria-describedby="B20-biomedicines-10-00236">20</a>,<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>,<a href="#B22-biomedicines-10-00236" class="usa-link" aria-describedby="B22-biomedicines-10-00236">22</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B24-biomedicines-10-00236" class="usa-link" aria-describedby="B24-biomedicines-10-00236">24</a>,<a href="#B25-biomedicines-10-00236" class="usa-link" aria-describedby="B25-biomedicines-10-00236">25</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B27-biomedicines-10-00236" class="usa-link" aria-describedby="B27-biomedicines-10-00236">27</a>,<a href="#B28-biomedicines-10-00236" class="usa-link" aria-describedby="B28-biomedicines-10-00236">28</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B31-biomedicines-10-00236" class="usa-link" aria-describedby="B31-biomedicines-10-00236">31</a>,<a href="#B32-biomedicines-10-00236" class="usa-link" aria-describedby="B32-biomedicines-10-00236">32</a>,<a href="#B33-biomedicines-10-00236" class="usa-link" aria-describedby="B33-biomedicines-10-00236">33</a>,<a href="#B34-biomedicines-10-00236" class="usa-link" aria-describedby="B34-biomedicines-10-00236">34</a>,<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>,<a href="#B36-biomedicines-10-00236" class="usa-link" aria-describedby="B36-biomedicines-10-00236">36</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B39-biomedicines-10-00236" class="usa-link" aria-describedby="B39-biomedicines-10-00236">39</a>,<a href="#B40-biomedicines-10-00236" class="usa-link" aria-describedby="B40-biomedicines-10-00236">40</a>,<a href="#B41-biomedicines-10-00236" class="usa-link" aria-describedby="B41-biomedicines-10-00236">41</a>,<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B44-biomedicines-10-00236" class="usa-link" aria-describedby="B44-biomedicines-10-00236">44</a>,<a href="#B45-biomedicines-10-00236" class="usa-link" aria-describedby="B45-biomedicines-10-00236">45</a>,<a href="#B46-biomedicines-10-00236" class="usa-link" aria-describedby="B46-biomedicines-10-00236">46</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B49-biomedicines-10-00236" class="usa-link" aria-describedby="B49-biomedicines-10-00236">49</a>,<a href="#B50-biomedicines-10-00236" class="usa-link" aria-describedby="B50-biomedicines-10-00236">50</a>,<a href="#B51-biomedicines-10-00236" class="usa-link" aria-describedby="B51-biomedicines-10-00236">51</a>,<a href="#B52-biomedicines-10-00236" class="usa-link" aria-describedby="B52-biomedicines-10-00236">52</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B54-biomedicines-10-00236" class="usa-link" aria-describedby="B54-biomedicines-10-00236">54</a>,<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B57-biomedicines-10-00236" class="usa-link" aria-describedby="B57-biomedicines-10-00236">57</a>,<a href="#B58-biomedicines-10-00236" class="usa-link" aria-describedby="B58-biomedicines-10-00236">58</a>,<a href="#B59-biomedicines-10-00236" class="usa-link" aria-describedby="B59-biomedicines-10-00236">59</a>,<a href="#B60-biomedicines-10-00236" class="usa-link" aria-describedby="B60-biomedicines-10-00236">60</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B62-biomedicines-10-00236" class="usa-link" aria-describedby="B62-biomedicines-10-00236">62</a>,<a href="#B63-biomedicines-10-00236" class="usa-link" aria-describedby="B63-biomedicines-10-00236">63</a>,<a href="#B64-biomedicines-10-00236" class="usa-link" aria-describedby="B64-biomedicines-10-00236">64</a>,<a href="#B65-biomedicines-10-00236" class="usa-link" aria-describedby="B65-biomedicines-10-00236">65</a>,<a href="#B66-biomedicines-10-00236" class="usa-link" aria-describedby="B66-biomedicines-10-00236">66</a>,<a href="#B67-biomedicines-10-00236" class="usa-link" aria-describedby="B67-biomedicines-10-00236">67</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B69-biomedicines-10-00236" class="usa-link" aria-describedby="B69-biomedicines-10-00236">69</a>,<a href="#B70-biomedicines-10-00236" class="usa-link" aria-describedby="B70-biomedicines-10-00236">70</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B72-biomedicines-10-00236" class="usa-link" aria-describedby="B72-biomedicines-10-00236">72</a>,<a href="#B73-biomedicines-10-00236" class="usa-link" aria-describedby="B73-biomedicines-10-00236">73</a>,<a href="#B74-biomedicines-10-00236" class="usa-link" aria-describedby="B74-biomedicines-10-00236">74</a>,<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>,<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B78-biomedicines-10-00236" class="usa-link" aria-describedby="B78-biomedicines-10-00236">78</a>,<a href="#B79-biomedicines-10-00236" class="usa-link" aria-describedby="B79-biomedicines-10-00236">79</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B81-biomedicines-10-00236" class="usa-link" aria-describedby="B81-biomedicines-10-00236">81</a>,<a href="#B82-biomedicines-10-00236" class="usa-link" aria-describedby="B82-biomedicines-10-00236">82</a>,<a href="#B83-biomedicines-10-00236" class="usa-link" aria-describedby="B83-biomedicines-10-00236">83</a>,<a href="#B84-biomedicines-10-00236" class="usa-link" aria-describedby="B84-biomedicines-10-00236">84</a>,<a href="#B85-biomedicines-10-00236" class="usa-link" aria-describedby="B85-biomedicines-10-00236">85</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B87-biomedicines-10-00236" class="usa-link" aria-describedby="B87-biomedicines-10-00236">87</a>,<a href="#B88-biomedicines-10-00236" class="usa-link" aria-describedby="B88-biomedicines-10-00236">88</a>,<a href="#B89-biomedicines-10-00236" class="usa-link" aria-describedby="B89-biomedicines-10-00236">89</a>,<a href="#B90-biomedicines-10-00236" class="usa-link" aria-describedby="B90-biomedicines-10-00236">90</a>,<a href="#B91-biomedicines-10-00236" class="usa-link" aria-describedby="B91-biomedicines-10-00236">91</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>,<a href="#B94-biomedicines-10-00236" class="usa-link" aria-describedby="B94-biomedicines-10-00236">94</a>,<a href="#B95-biomedicines-10-00236" class="usa-link" aria-describedby="B95-biomedicines-10-00236">95</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>,<a href="#B97-biomedicines-10-00236" class="usa-link" aria-describedby="B97-biomedicines-10-00236">97</a>,<a href="#B98-biomedicines-10-00236" class="usa-link" aria-describedby="B98-biomedicines-10-00236">98</a>,<a href="#B99-biomedicines-10-00236" class="usa-link" aria-describedby="B99-biomedicines-10-00236">99</a>,<a href="#B100-biomedicines-10-00236" class="usa-link" aria-describedby="B100-biomedicines-10-00236">100</a>,<a href="#B101-biomedicines-10-00236" class="usa-link" aria-describedby="B101-biomedicines-10-00236">101</a>,<a href="#B102-biomedicines-10-00236" class="usa-link" aria-describedby="B102-biomedicines-10-00236">102</a>,<a href="#B103-biomedicines-10-00236" class="usa-link" aria-describedby="B103-biomedicines-10-00236">103</a>,<a href="#B104-biomedicines-10-00236" class="usa-link" aria-describedby="B104-biomedicines-10-00236">104</a>,<a href="#B105-biomedicines-10-00236" class="usa-link" aria-describedby="B105-biomedicines-10-00236">105</a>,<a href="#B106-biomedicines-10-00236" class="usa-link" aria-describedby="B106-biomedicines-10-00236">106</a>,<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B108-biomedicines-10-00236" class="usa-link" aria-describedby="B108-biomedicines-10-00236">108</a>,<a href="#B109-biomedicines-10-00236" class="usa-link" aria-describedby="B109-biomedicines-10-00236">109</a>,<a href="#B110-biomedicines-10-00236" class="usa-link" aria-describedby="B110-biomedicines-10-00236">110</a>,<a href="#B111-biomedicines-10-00236" class="usa-link" aria-describedby="B111-biomedicines-10-00236">111</a>,<a href="#B112-biomedicines-10-00236" class="usa-link" aria-describedby="B112-biomedicines-10-00236">112</a>,<a href="#B113-biomedicines-10-00236" class="usa-link" aria-describedby="B113-biomedicines-10-00236">113</a>,<a href="#B114-biomedicines-10-00236" class="usa-link" aria-describedby="B114-biomedicines-10-00236">114</a>,<a href="#B115-biomedicines-10-00236" class="usa-link" aria-describedby="B115-biomedicines-10-00236">115</a>,<a href="#B116-biomedicines-10-00236" class="usa-link" aria-describedby="B116-biomedicines-10-00236">116</a>,<a href="#B117-biomedicines-10-00236" class="usa-link" aria-describedby="B117-biomedicines-10-00236">117</a>,<a href="#B118-biomedicines-10-00236" class="usa-link" aria-describedby="B118-biomedicines-10-00236">118</a>,<a href="#B119-biomedicines-10-00236" class="usa-link" aria-describedby="B119-biomedicines-10-00236">119</a>,<a href="#B120-biomedicines-10-00236" class="usa-link" aria-describedby="B120-biomedicines-10-00236">120</a>,<a href="#B121-biomedicines-10-00236" class="usa-link" aria-describedby="B121-biomedicines-10-00236">121</a>,<a href="#B122-biomedicines-10-00236" class="usa-link" aria-describedby="B122-biomedicines-10-00236">122</a>,<a href="#B123-biomedicines-10-00236" class="usa-link" aria-describedby="B123-biomedicines-10-00236">123</a>,<a href="#B124-biomedicines-10-00236" class="usa-link" aria-describedby="B124-biomedicines-10-00236">124</a>,<a href="#B125-biomedicines-10-00236" class="usa-link" aria-describedby="B125-biomedicines-10-00236">125</a>,<a href="#B126-biomedicines-10-00236" class="usa-link" aria-describedby="B126-biomedicines-10-00236">126</a>,<a href="#B127-biomedicines-10-00236" class="usa-link" aria-describedby="B127-biomedicines-10-00236">127</a>,<a href="#B128-biomedicines-10-00236" class="usa-link" aria-describedby="B128-biomedicines-10-00236">128</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>,<a href="#B130-biomedicines-10-00236" class="usa-link" aria-describedby="B130-biomedicines-10-00236">130</a>,<a href="#B131-biomedicines-10-00236" class="usa-link" aria-describedby="B131-biomedicines-10-00236">131</a>,<a href="#B132-biomedicines-10-00236" class="usa-link" aria-describedby="B132-biomedicines-10-00236">132</a>,<a href="#B133-biomedicines-10-00236" class="usa-link" aria-describedby="B133-biomedicines-10-00236">133</a>,<a href="#B134-biomedicines-10-00236" class="usa-link" aria-describedby="B134-biomedicines-10-00236">134</a>,<a href="#B135-biomedicines-10-00236" class="usa-link" aria-describedby="B135-biomedicines-10-00236">135</a>,<a href="#B136-biomedicines-10-00236" class="usa-link" aria-describedby="B136-biomedicines-10-00236">136</a>,<a href="#B137-biomedicines-10-00236" class="usa-link" aria-describedby="B137-biomedicines-10-00236">137</a>,<a href="#B138-biomedicines-10-00236" class="usa-link" aria-describedby="B138-biomedicines-10-00236">138</a>,<a href="#B139-biomedicines-10-00236" class="usa-link" aria-describedby="B139-biomedicines-10-00236">139</a>,<a href="#B140-biomedicines-10-00236" class="usa-link" aria-describedby="B140-biomedicines-10-00236">140</a>,<a href="#B141-biomedicines-10-00236" class="usa-link" aria-describedby="B141-biomedicines-10-00236">141</a>,<a href="#B142-biomedicines-10-00236" class="usa-link" aria-describedby="B142-biomedicines-10-00236">142</a>,<a href="#B143-biomedicines-10-00236" class="usa-link" aria-describedby="B143-biomedicines-10-00236">143</a>,<a href="#B144-biomedicines-10-00236" class="usa-link" aria-describedby="B144-biomedicines-10-00236">144</a>,<a href="#B145-biomedicines-10-00236" class="usa-link" aria-describedby="B145-biomedicines-10-00236">145</a>,<a href="#B146-biomedicines-10-00236" class="usa-link" aria-describedby="B146-biomedicines-10-00236">146</a>,<a href="#B147-biomedicines-10-00236" class="usa-link" aria-describedby="B147-biomedicines-10-00236">147</a>,<a href="#B148-biomedicines-10-00236" class="usa-link" aria-describedby="B148-biomedicines-10-00236">148</a>,<a href="#B149-biomedicines-10-00236" class="usa-link" aria-describedby="B149-biomedicines-10-00236">149</a>,<a href="#B150-biomedicines-10-00236" class="usa-link" aria-describedby="B150-biomedicines-10-00236">150</a>,<a href="#B151-biomedicines-10-00236" class="usa-link" aria-describedby="B151-biomedicines-10-00236">151</a>,<a href="#B152-biomedicines-10-00236" class="usa-link" aria-describedby="B152-biomedicines-10-00236">152</a>,<a href="#B153-biomedicines-10-00236" class="usa-link" aria-describedby="B153-biomedicines-10-00236">153</a>,<a href="#B154-biomedicines-10-00236" class="usa-link" aria-describedby="B154-biomedicines-10-00236">154</a>,<a href="#B155-biomedicines-10-00236" class="usa-link" aria-describedby="B155-biomedicines-10-00236">155</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>,<a href="#B157-biomedicines-10-00236" class="usa-link" aria-describedby="B157-biomedicines-10-00236">157</a>]. Despite some limitations of this approach, PD-L1 immunohistochemical expression is frequently tested in various tumor types to select patients for immunotherapy administration [<a href="#B158-biomedicines-10-00236" class="usa-link" aria-describedby="B158-biomedicines-10-00236">158</a>,<a href="#B159-biomedicines-10-00236" class="usa-link" aria-describedby="B159-biomedicines-10-00236">159</a>,<a href="#B160-biomedicines-10-00236" class="usa-link" aria-describedby="B160-biomedicines-10-00236">160</a>,<a href="#B161-biomedicines-10-00236" class="usa-link" aria-describedby="B161-biomedicines-10-00236">161</a>,<a href="#B162-biomedicines-10-00236" class="usa-link" aria-describedby="B162-biomedicines-10-00236">162</a>]. </p>
<p>Pembrolizumab (anti-PD-1) is a highly selective IgG4-kappa humanized monoclonal antibody and immune checkpoint inhibitor; it binds with high affinity to the cell surface receptor PD-1 (expressed by T cells), blocking the inhibitory pathway, triggering a physiological shift to immune reactivity, and enhancing the antitumor immune response [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B34-biomedicines-10-00236" class="usa-link" aria-describedby="B34-biomedicines-10-00236">34</a>,<a href="#B64-biomedicines-10-00236" class="usa-link" aria-describedby="B64-biomedicines-10-00236">64</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>]. Recent evidence revealed good therapeutic activity of this drug in monotherapy, and the 2021 United States National Comprehensive Cancer Network (NCCN) guidelines have allowed pembrolizumab (as a second-line therapy or beyond) for selected patients with metastatic castration-resistant PCs (mCRPCs) showing high microsatellite instability/mismatch repair system protein deficiency (MSI-H/dMMR) or tumor mutation burden (TMB) &gt;10 mutations/Mb [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. In particular, the MSI/MMR status testing is recommended in mCRPC patients, and it may be considered in men with regional or castration-naïve metastatic PC [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. For these reasons, in current practice, the International Society of Urologic Pathology recommends, if clinically indicated, MMR assessment via immunohistochemical analysis of MSH2, MSH6, MLH1, and PMS2 protein expression, with or without MSI testing, sequencing of MMR genes, and/or TMB estimate [<a href="#B6-biomedicines-10-00236" class="usa-link" aria-describedby="B6-biomedicines-10-00236">6</a>]. However, the dMMR/H-MSI status, as well as PD-L1 expression, may not necessarily correlate to the response to targeted immunotherapy, and combined analysis of MMR/MSI and PD-L1 status in PC patients was rarely performed [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>]. </p>
<p>TMB is a phenotypic hallmark of MSI-H/dMMR tumors [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. Various genetic mutations, chromosomal aberrations, and molecular changes have been found in the genome of PC; however, most of them are still under investigation [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>]. Germline mutations in MMR genes are drivers for the Lynch syndrome, which is an autosomal dominant genetic disorder causing multiple cancers (including PC) in affected patients [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. In addition, the Breast Cancer 1-2 (<em>BRCA1/2</em>) genes are main regulators of a cellular DNA damage repair system (homologous recombination repair, HRR); the failure of HRR is due to combined germline and somatic mutations of <em>BRCA1/2</em> and/or other genes, favoring the activation of alternative and less effective DNA repair pathways (such as base/nucleotide excision repair or mismatch repair system) [<a href="#B7-biomedicines-10-00236" class="usa-link" aria-describedby="B7-biomedicines-10-00236">7</a>,<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B163-biomedicines-10-00236" class="usa-link" aria-describedby="B163-biomedicines-10-00236">163</a>,<a href="#B164-biomedicines-10-00236" class="usa-link" aria-describedby="B164-biomedicines-10-00236">164</a>]. Indeed, <em>BRCA1/2</em> mutations are responsible for a group of hereditary PCs; specific drugs (poly-ADP ribose polymerase inhibitors, PARPi) can be administered to <em>BRCA</em>-mutated PC patients, according to the NCCN guidelines [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>]. HRR gene testing is recommended for metastatic PC patients and considered for PC with spread to regional lymph nodes [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. To improve the survival of mCRPC patients, treatment combinations (such as immunotherapy and PARPi) have been increasingly tested; however, few studies simultaneously tested PARPi and drugs affecting the PD-1/PD-L1 pathway; combined analysis of the <em>BRCA</em> and PD-L1 status was rarely conducted in PC patients [<a href="#B7-biomedicines-10-00236" class="usa-link" aria-describedby="B7-biomedicines-10-00236">7</a>,<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>].</p>
<p>We have performed a systematic literature review of the studies combining the analysis of PD-L1 expression with the investigation of the MSI/MMR, <em>PTEN</em>, and/or <em>BRCA</em> status in PC, trying to delineate the potential links between these markers in PC patients. The retrieved data concerning other main genes involved in PC genesis and progression are also discussed.</p></section><section id="sec2-biomedicines-10-00236"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<p>Our systematic literature review was conducted according to the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guidelines (<a href="http://www.prisma-statement.org/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.prisma-statement.org/</a>, accessed on 8 May 2021) (<a href="#biomedicines-10-00236-f001" class="usa-link">Figure 1</a>). </p>
<figure class="fig xbox font-sm" id="biomedicines-10-00236-f001"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8868626_biomedicines-10-00236-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce75/8868626/81d4b8790d5a/biomedicines-10-00236-g001.jpg" loading="lazy" height="806" width="796" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/biomedicines-10-00236-f001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>PRISMA flowchart of the systematic literature review.</p></figcaption></figure><p>We summarized the literature data concerning the role of PD-L1 in PC, describing the clinic–pathologic features of the published cases, and answering the following “Population, Intervention, Comparison, Outcomes” (PICO) questions:</p>
<ul class="list" style="list-style-type:disc">
<li><p>Population: patients, tumor cell lines, and mouse models included in studies concerning the role of PD-L1 in PC.</p></li>
<li><p>Intervention: any treatment type.</p></li>
<li><p>Comparison: no expected comparisons.</p></li>
<li><p>Outcomes: patient’s status at last follow-up (no evidence of disease, alive with disease, dead of disease), response to therapy, overall survival (OS), progression-free survival (PFS), biochemical recurrence-free survival, metastasis-free survival (MFS), cancer-specific survival (CSS), disease-free survival, clinical failure-free survival.</p></li>
<li><p>Our retrospective observational study satisfied the following:</p></li>
<li><p>Eligibility/inclusion criteria: experimental studies (tumor cell lines, mouse models) or clinic–pathologic studies on human patients (case reports/series) concerning the role PD-L1 in PC.</p></li>
<li><p>Exclusion criteria: non-prostatic tumors; non-carcinomatous histotypes; studies not examining PD-L1; uncertain diagnosis; review articles without new cases. No further exclusion criteria (including language or publication date) were applied.</p></li>
</ul>
<p>We searched for (PD-L1 AND (prostate OR prostatic) AND (adenocarcinoma OR adenocarcinomas OR cancer)) in Web of Science (Topic/Title; 399 results; <a href="https://login.webofknowledge.com" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://login.webofknowledge.com</a>, accessed on 8 May 2021), Pubmed (all fields; 263 results; <a href="https://pubmed.ncbi.nlm.nih.gov" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov</a>, accessed on 8 May 2021), and Scopus (Title/Abstract/Keywords; 385 results; <a href="https://www.scopus.com/home.uri" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.scopus.com/home.uri</a>, accessed on 8 May 2021) databases. No limitations or additional filters were set. The bibliographic research ended on 8 May 2021. After duplicates exclusion, two independent reviewers screened the titles and abstracts of the 560 resulting records in order to verify the eligibility, inclusion, and exclusion criteria. The selected articles were obtained in full-text format: two other co-authors verified the relevance of the studies and searched for further pertinent references. Finally, two authors checked the extracted information. Globally, 155 full texts were considered for eligibility and, after reading them, seven articles were excluded as they were unfit according to the inclusion/exclusion criteria or because they presented scant or aggregated data; 148 articles were finally included [<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B14-biomedicines-10-00236" class="usa-link" aria-describedby="B14-biomedicines-10-00236">14</a>,<a href="#B15-biomedicines-10-00236" class="usa-link" aria-describedby="B15-biomedicines-10-00236">15</a>,<a href="#B16-biomedicines-10-00236" class="usa-link" aria-describedby="B16-biomedicines-10-00236">16</a>,<a href="#B17-biomedicines-10-00236" class="usa-link" aria-describedby="B17-biomedicines-10-00236">17</a>,<a href="#B18-biomedicines-10-00236" class="usa-link" aria-describedby="B18-biomedicines-10-00236">18</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B20-biomedicines-10-00236" class="usa-link" aria-describedby="B20-biomedicines-10-00236">20</a>,<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>,<a href="#B22-biomedicines-10-00236" class="usa-link" aria-describedby="B22-biomedicines-10-00236">22</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B24-biomedicines-10-00236" class="usa-link" aria-describedby="B24-biomedicines-10-00236">24</a>,<a href="#B25-biomedicines-10-00236" class="usa-link" aria-describedby="B25-biomedicines-10-00236">25</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B27-biomedicines-10-00236" class="usa-link" aria-describedby="B27-biomedicines-10-00236">27</a>,<a href="#B28-biomedicines-10-00236" class="usa-link" aria-describedby="B28-biomedicines-10-00236">28</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B31-biomedicines-10-00236" class="usa-link" aria-describedby="B31-biomedicines-10-00236">31</a>,<a href="#B32-biomedicines-10-00236" class="usa-link" aria-describedby="B32-biomedicines-10-00236">32</a>,<a href="#B33-biomedicines-10-00236" class="usa-link" aria-describedby="B33-biomedicines-10-00236">33</a>,<a href="#B34-biomedicines-10-00236" class="usa-link" aria-describedby="B34-biomedicines-10-00236">34</a>,<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>,<a href="#B36-biomedicines-10-00236" class="usa-link" aria-describedby="B36-biomedicines-10-00236">36</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B39-biomedicines-10-00236" class="usa-link" aria-describedby="B39-biomedicines-10-00236">39</a>,<a href="#B40-biomedicines-10-00236" class="usa-link" aria-describedby="B40-biomedicines-10-00236">40</a>,<a href="#B41-biomedicines-10-00236" class="usa-link" aria-describedby="B41-biomedicines-10-00236">41</a>,<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B44-biomedicines-10-00236" class="usa-link" aria-describedby="B44-biomedicines-10-00236">44</a>,<a href="#B45-biomedicines-10-00236" class="usa-link" aria-describedby="B45-biomedicines-10-00236">45</a>,<a href="#B46-biomedicines-10-00236" class="usa-link" aria-describedby="B46-biomedicines-10-00236">46</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B49-biomedicines-10-00236" class="usa-link" aria-describedby="B49-biomedicines-10-00236">49</a>,<a href="#B50-biomedicines-10-00236" class="usa-link" aria-describedby="B50-biomedicines-10-00236">50</a>,<a href="#B51-biomedicines-10-00236" class="usa-link" aria-describedby="B51-biomedicines-10-00236">51</a>,<a href="#B52-biomedicines-10-00236" class="usa-link" aria-describedby="B52-biomedicines-10-00236">52</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B54-biomedicines-10-00236" class="usa-link" aria-describedby="B54-biomedicines-10-00236">54</a>,<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B57-biomedicines-10-00236" class="usa-link" aria-describedby="B57-biomedicines-10-00236">57</a>,<a href="#B58-biomedicines-10-00236" class="usa-link" aria-describedby="B58-biomedicines-10-00236">58</a>,<a href="#B59-biomedicines-10-00236" class="usa-link" aria-describedby="B59-biomedicines-10-00236">59</a>,<a href="#B60-biomedicines-10-00236" class="usa-link" aria-describedby="B60-biomedicines-10-00236">60</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B62-biomedicines-10-00236" class="usa-link" aria-describedby="B62-biomedicines-10-00236">62</a>,<a href="#B63-biomedicines-10-00236" class="usa-link" aria-describedby="B63-biomedicines-10-00236">63</a>,<a href="#B64-biomedicines-10-00236" class="usa-link" aria-describedby="B64-biomedicines-10-00236">64</a>,<a href="#B65-biomedicines-10-00236" class="usa-link" aria-describedby="B65-biomedicines-10-00236">65</a>,<a href="#B66-biomedicines-10-00236" class="usa-link" aria-describedby="B66-biomedicines-10-00236">66</a>,<a href="#B67-biomedicines-10-00236" class="usa-link" aria-describedby="B67-biomedicines-10-00236">67</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B69-biomedicines-10-00236" class="usa-link" aria-describedby="B69-biomedicines-10-00236">69</a>,<a href="#B70-biomedicines-10-00236" class="usa-link" aria-describedby="B70-biomedicines-10-00236">70</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B72-biomedicines-10-00236" class="usa-link" aria-describedby="B72-biomedicines-10-00236">72</a>,<a href="#B73-biomedicines-10-00236" class="usa-link" aria-describedby="B73-biomedicines-10-00236">73</a>,<a href="#B74-biomedicines-10-00236" class="usa-link" aria-describedby="B74-biomedicines-10-00236">74</a>,<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>,<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B78-biomedicines-10-00236" class="usa-link" aria-describedby="B78-biomedicines-10-00236">78</a>,<a href="#B79-biomedicines-10-00236" class="usa-link" aria-describedby="B79-biomedicines-10-00236">79</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B81-biomedicines-10-00236" class="usa-link" aria-describedby="B81-biomedicines-10-00236">81</a>,<a href="#B82-biomedicines-10-00236" class="usa-link" aria-describedby="B82-biomedicines-10-00236">82</a>,<a href="#B83-biomedicines-10-00236" class="usa-link" aria-describedby="B83-biomedicines-10-00236">83</a>,<a href="#B84-biomedicines-10-00236" class="usa-link" aria-describedby="B84-biomedicines-10-00236">84</a>,<a href="#B85-biomedicines-10-00236" class="usa-link" aria-describedby="B85-biomedicines-10-00236">85</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B87-biomedicines-10-00236" class="usa-link" aria-describedby="B87-biomedicines-10-00236">87</a>,<a href="#B88-biomedicines-10-00236" class="usa-link" aria-describedby="B88-biomedicines-10-00236">88</a>,<a href="#B89-biomedicines-10-00236" class="usa-link" aria-describedby="B89-biomedicines-10-00236">89</a>,<a href="#B90-biomedicines-10-00236" class="usa-link" aria-describedby="B90-biomedicines-10-00236">90</a>,<a href="#B91-biomedicines-10-00236" class="usa-link" aria-describedby="B91-biomedicines-10-00236">91</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>,<a href="#B94-biomedicines-10-00236" class="usa-link" aria-describedby="B94-biomedicines-10-00236">94</a>,<a href="#B95-biomedicines-10-00236" class="usa-link" aria-describedby="B95-biomedicines-10-00236">95</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>,<a href="#B97-biomedicines-10-00236" class="usa-link" aria-describedby="B97-biomedicines-10-00236">97</a>,<a href="#B98-biomedicines-10-00236" class="usa-link" aria-describedby="B98-biomedicines-10-00236">98</a>,<a href="#B99-biomedicines-10-00236" class="usa-link" aria-describedby="B99-biomedicines-10-00236">99</a>,<a href="#B100-biomedicines-10-00236" class="usa-link" aria-describedby="B100-biomedicines-10-00236">100</a>,<a href="#B101-biomedicines-10-00236" class="usa-link" aria-describedby="B101-biomedicines-10-00236">101</a>,<a href="#B102-biomedicines-10-00236" class="usa-link" aria-describedby="B102-biomedicines-10-00236">102</a>,<a href="#B103-biomedicines-10-00236" class="usa-link" aria-describedby="B103-biomedicines-10-00236">103</a>,<a href="#B104-biomedicines-10-00236" class="usa-link" aria-describedby="B104-biomedicines-10-00236">104</a>,<a href="#B105-biomedicines-10-00236" class="usa-link" aria-describedby="B105-biomedicines-10-00236">105</a>,<a href="#B106-biomedicines-10-00236" class="usa-link" aria-describedby="B106-biomedicines-10-00236">106</a>,<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B108-biomedicines-10-00236" class="usa-link" aria-describedby="B108-biomedicines-10-00236">108</a>,<a href="#B109-biomedicines-10-00236" class="usa-link" aria-describedby="B109-biomedicines-10-00236">109</a>,<a href="#B110-biomedicines-10-00236" class="usa-link" aria-describedby="B110-biomedicines-10-00236">110</a>,<a href="#B111-biomedicines-10-00236" class="usa-link" aria-describedby="B111-biomedicines-10-00236">111</a>,<a href="#B112-biomedicines-10-00236" class="usa-link" aria-describedby="B112-biomedicines-10-00236">112</a>,<a href="#B113-biomedicines-10-00236" class="usa-link" aria-describedby="B113-biomedicines-10-00236">113</a>,<a href="#B114-biomedicines-10-00236" class="usa-link" aria-describedby="B114-biomedicines-10-00236">114</a>,<a href="#B115-biomedicines-10-00236" class="usa-link" aria-describedby="B115-biomedicines-10-00236">115</a>,<a href="#B116-biomedicines-10-00236" class="usa-link" aria-describedby="B116-biomedicines-10-00236">116</a>,<a href="#B117-biomedicines-10-00236" class="usa-link" aria-describedby="B117-biomedicines-10-00236">117</a>,<a href="#B118-biomedicines-10-00236" class="usa-link" aria-describedby="B118-biomedicines-10-00236">118</a>,<a href="#B119-biomedicines-10-00236" class="usa-link" aria-describedby="B119-biomedicines-10-00236">119</a>,<a href="#B120-biomedicines-10-00236" class="usa-link" aria-describedby="B120-biomedicines-10-00236">120</a>,<a href="#B121-biomedicines-10-00236" class="usa-link" aria-describedby="B121-biomedicines-10-00236">121</a>,<a href="#B122-biomedicines-10-00236" class="usa-link" aria-describedby="B122-biomedicines-10-00236">122</a>,<a href="#B123-biomedicines-10-00236" class="usa-link" aria-describedby="B123-biomedicines-10-00236">123</a>,<a href="#B124-biomedicines-10-00236" class="usa-link" aria-describedby="B124-biomedicines-10-00236">124</a>,<a href="#B125-biomedicines-10-00236" class="usa-link" aria-describedby="B125-biomedicines-10-00236">125</a>,<a href="#B126-biomedicines-10-00236" class="usa-link" aria-describedby="B126-biomedicines-10-00236">126</a>,<a href="#B127-biomedicines-10-00236" class="usa-link" aria-describedby="B127-biomedicines-10-00236">127</a>,<a href="#B128-biomedicines-10-00236" class="usa-link" aria-describedby="B128-biomedicines-10-00236">128</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>,<a href="#B130-biomedicines-10-00236" class="usa-link" aria-describedby="B130-biomedicines-10-00236">130</a>,<a href="#B131-biomedicines-10-00236" class="usa-link" aria-describedby="B131-biomedicines-10-00236">131</a>,<a href="#B132-biomedicines-10-00236" class="usa-link" aria-describedby="B132-biomedicines-10-00236">132</a>,<a href="#B133-biomedicines-10-00236" class="usa-link" aria-describedby="B133-biomedicines-10-00236">133</a>,<a href="#B134-biomedicines-10-00236" class="usa-link" aria-describedby="B134-biomedicines-10-00236">134</a>,<a href="#B135-biomedicines-10-00236" class="usa-link" aria-describedby="B135-biomedicines-10-00236">135</a>,<a href="#B136-biomedicines-10-00236" class="usa-link" aria-describedby="B136-biomedicines-10-00236">136</a>,<a href="#B137-biomedicines-10-00236" class="usa-link" aria-describedby="B137-biomedicines-10-00236">137</a>,<a href="#B138-biomedicines-10-00236" class="usa-link" aria-describedby="B138-biomedicines-10-00236">138</a>,<a href="#B139-biomedicines-10-00236" class="usa-link" aria-describedby="B139-biomedicines-10-00236">139</a>,<a href="#B140-biomedicines-10-00236" class="usa-link" aria-describedby="B140-biomedicines-10-00236">140</a>,<a href="#B141-biomedicines-10-00236" class="usa-link" aria-describedby="B141-biomedicines-10-00236">141</a>,<a href="#B142-biomedicines-10-00236" class="usa-link" aria-describedby="B142-biomedicines-10-00236">142</a>,<a href="#B143-biomedicines-10-00236" class="usa-link" aria-describedby="B143-biomedicines-10-00236">143</a>,<a href="#B144-biomedicines-10-00236" class="usa-link" aria-describedby="B144-biomedicines-10-00236">144</a>,<a href="#B145-biomedicines-10-00236" class="usa-link" aria-describedby="B145-biomedicines-10-00236">145</a>,<a href="#B146-biomedicines-10-00236" class="usa-link" aria-describedby="B146-biomedicines-10-00236">146</a>,<a href="#B147-biomedicines-10-00236" class="usa-link" aria-describedby="B147-biomedicines-10-00236">147</a>,<a href="#B148-biomedicines-10-00236" class="usa-link" aria-describedby="B148-biomedicines-10-00236">148</a>,<a href="#B149-biomedicines-10-00236" class="usa-link" aria-describedby="B149-biomedicines-10-00236">149</a>,<a href="#B150-biomedicines-10-00236" class="usa-link" aria-describedby="B150-biomedicines-10-00236">150</a>,<a href="#B151-biomedicines-10-00236" class="usa-link" aria-describedby="B151-biomedicines-10-00236">151</a>,<a href="#B152-biomedicines-10-00236" class="usa-link" aria-describedby="B152-biomedicines-10-00236">152</a>,<a href="#B153-biomedicines-10-00236" class="usa-link" aria-describedby="B153-biomedicines-10-00236">153</a>,<a href="#B154-biomedicines-10-00236" class="usa-link" aria-describedby="B154-biomedicines-10-00236">154</a>,<a href="#B155-biomedicines-10-00236" class="usa-link" aria-describedby="B155-biomedicines-10-00236">155</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>,<a href="#B157-biomedicines-10-00236" class="usa-link" aria-describedby="B157-biomedicines-10-00236">157</a>]. </p>
<p>Data collection was study-related (authors and year of study publication) and case-related (tumor stage at presentation, Grade Group, type of specimen, treatment, test methods, results of PD-L1 expression, follow-up and outcomes, experiment type).</p>
<p>The collected data were described as continuous variables (summarized by ranges, mean, and/or median values) or categorical variables (analyzed by frequencies and percentages).</p>
<p>As there was a lot of information to discuss, we have divided the presentation of our data into different articles, focusing on different sub-topics. Here, we analyze the studies of PC patients simultaneously evaluating PD-L1 expression and at least one of the following: status of mismatch repair system/microsatellite instability, <em>BRCA</em>, or <em>PTEN</em> genes. The potential correlations between PD-L1 expression and some of the other main genes involved in PC genesis and progression are also briefly discussed.</p></section><section id="sec3-biomedicines-10-00236"><h2 class="pmc_sec_title">3. Results</h2>
<section id="sec3dot1-biomedicines-10-00236"><h3 class="pmc_sec_title">3.1. Microsatellite Instability/Mismatch Repair System Deficiency and PD-L1 Expression in PC Patients</h3>
<p><a href="#biomedicines-10-00236-t001" class="usa-link">Table 1</a> reports the results of the studies on human PC patients, investigating both PD-L1 expression and the MMR/MSI status; <a href="#app1-biomedicines-10-00236" class="usa-link">supplementary data</a> are reported in <a href="#app1-biomedicines-10-00236" class="usa-link">Table S1</a>.</p>
<section class="tw xbox font-sm" id="biomedicines-10-00236-t001"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>PD-L1 expression and microsatellite instability/mismatch repair system protein status in patients with prostatic carcinoma.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PD-L1 IHC Positivity Rate (#)</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage and Treatment</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinic–Molecular Correlations</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">206/206 (100%) </td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEM + ENZ vs. PEM to mCRPC (T2-3 M0-1; no PT)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">206/206 (100%) MSI-H (all PD-L1+ and MSI-H as to the inclusion criteria).</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/33 (0%) (#) </td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atz to mCRPC (22 with ≥3 PT lines; 32 prior ENZ; 13 prior sipuleucel-T)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/16 (12.5%) MSI (1 MSH2 loss, 1 MSH2/MSH6 deletion). It was unclear if another MSI-H case showed MSH6 mutations.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156/258 (60%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEM to metastatic or locally confined CRPCs</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/6 (0%) responders (5/6, 83%: PD-L1+) with MSI; 1 long responder (&gt;2 years) with dMMR (IHC) below the cut-off for MSI-H (NGS).</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/28 (0%) (#)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ENZ + PEM to CRPC <br>(pT1c-3 N0-1 M1)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSI: 1/3 (33%) responders vs. 0/13 (0%) non-responders.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29/220 (13%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Short-term ADT (DEG) + PEM + WPC to hormone-sensitive PCs (pT2-3ab)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/220 (0.9%) MLH1- (all with loss of other MMRs); 6/220 (2.7%) MSH2- (all MSH6-); 37/220 (16.8%) MSH6-; 27/220 (12.3%) PMS2-. ML: ≥1 (50/220, 22.7%), ≥2 (15/220, 6.8%), ≥3 (5/220, 2.3%), 4 (2/220, 0.9%). ≥2 ML correlated to higher rate of PD-L1+ PC cells (17.2% vs. 5.2%, <em>p</em> = 0.033) (@). No association of MSI with age, family PC history, GS, stage, recurrence, or PD-L1+ PC cells. Significantly elevated preoperative PSA in dMMR men (not for ≥2 ML). Higher BCR risk for ≥1 ML and PD-L1+ TICs (<em>p</em> = 0.045). </td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20/91 (22%) a;<br>1/27 (4%) d/m</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 HR; 41 MPC</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/118 (3%) cases (2 MPC, 1 HR, 1 ductal PC) were dMMR (3 MSH2-/MSH6-, 1 PMS2-): only 1/4 (25%) cases was PD-L1+. </td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/42 (5%) a<br>1/34 (3%) d (#)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/73 (5%) dMMR PCs (3/40, 8% acinar: 3 MSH6-/PD-L1-; 1/33, 3% ductal: 1 MSH2-/MSH6-/PD-L1- but PD-L1+ immune cells) (<em>p</em> = 0.62). Two ductal PCs were indeterminate for MSH6 or MSH2/MSH6.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/34 (3%) d <br>1/30 (3%) a</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/28 ductal N+ <br>(unknown therapy)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/34 (3%) ductal PCs was MLH1-/PMS2-, while 0/30 (0%) acinar PCs showed dMMR.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/19 (5%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">androgen therapy (10 CSPC, 9 CRPC; N1 or M1)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/17 (6%) tested cases showed MSI (<em>MSH2</em> copy number loss) (PD-L1+ by IHC: weak, 5% cells; low rank for PD-L1: 26).</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/51 (18%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">variable stage; adjuvant RT (some cases)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/124 (8.1%) dMMR/MSI mCRPCs. Shorter median OS for dMMR/MSI (uni/multivariate analysis; 3.8 vs. 7.0 years; aHR 4.09; 95% CI, 1.52–10.94; <em>p</em> = 0.005) (no differences for GS, PSA, age, and stage). dMMR primary PCs strongly associate with developing CRPC. 5/85 (6%) matched HN and CRPC samples had dMMR primary PCs: 4/5 (80%) mCRPC biopsies were dMMR. Higher likelihood of PD-L1 positivity in dMMR mCRPC (5/10, 50% vs. 4/41, 9.8%) (MELRM, OR 14; 95% CI, 2–84; <em>p</em> = 0.005). dMMR/MSI mCRPCs have higher D-TIL levels. Germline (<em>n</em> = 1) or non-synonymous somatic (<em>n</em> = 6) mutations and biallelic events (<em>n</em> = 7) in MMR genes (total <em>n</em> = 14) had higher dMMR-associated DNA mutational signature activity and mRNA expression signatures. Higher MSI-NGS scores correlated to dMMR mutational signatures. PCs with dMMR mutational signatures overexpressed immune transcripts (CD200R1, BTLA, PD-L1, PD-L2, ADORA2A, PIK3CG, and TIGIT). 5/10 (50%) dMMR mCRPCs were PD-L1+, as 4/41 (9.8%) pMMR.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39/508 (8%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ADT in 57 mCRPC <br>(pT2-4 N0-1)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 primary PD-L1+ PCs were MSI.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/5 (40%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dur + Ola to mCRPC <br>(prior ENZ −/+ ABT)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/14 (7%) <em>PMS2</em> frameshift indel in a <em>BRCA2</em> mutated patient (intact second allele; no hypermutation phenotype). </td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/177 (12%):<br>18/130 (14%) (HN); 3/44 (7%) (AAPL)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pT2/3b Nx/0/1 <br>(44 AAPL; 130 HN)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/21 (5%) PD-L1+ PCs was MSH2-/MSH6- (GS 9, 5 + 4, pT3bN1, no prior neoadjuvant treatment; “interface pattern” of PD-L1+, TILs).</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/biomedicines-10-00236-t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn2"><p>a: acinar; AAPL: neoadjuvant abiraterone acetate + prednisone and leuprolide; ABT: abiraterone; ADT: androgen deprivation therapy; aHR: adjusted hazard ratio; Atz: atezolizumab; BCR: biochemical recurrence; CI: confidence interval; CRPC: castration-resistant prostate cancer; CSPC: castration-sensitive prostate cancer; d: ductal; DEG: degarelix; dMMR: deficient MMR; D-TILs: density of tumor-infiltrating lymphocytes; Dur: durvalumab; ENZ: enzalutamide; GS: Gleason score; HN: hormone-naïve; HR: high-risk prostate cancer; IHC: immunohistochemistry; m: mixed acinar/ductal; MELRM: mixed-effects logistic regression model; ML: MMR loss; MMR: mismatch repair system proteins; mCRPC: metastatic castration-resistant prostate cancer; MPC: metastatic prostatic cancer; MSI: microsatellite instability; MSI-H: high MSI; NGS: next-generation sequencing; NR: not reported; Ola: olaparib; OR: odds ratio; OS: overall survival; PC: prostate cancer; PEM: pembrolizumab; pMMR: proficient MMR; PT: prior therapy; Ref: reference number; RT: radiation therapy; TICs: tumor-infiltrating immune cells; TILs: tumor-infiltrating lymphocytes; WPC: whole-prostate cryoablation. Notes: (#): The PD-L1 positivity rate refers to positivity in tumor cells. Petrylak et al. [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>] found that 33/35 (94%) cases showed absent or &lt;5% positivity in immune cells. Graff et al. [<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>] reported that 3/28 (11%) cases resulted PD-L1+ in TILs. Lindh et al. [<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>] described 10/34 (29%) ductal (1–20% cells) and 6/42 (14%) acinar (1–30% cells) cases with PD-L1+ immune cells. (@): not valid for: ≥1 MMR loss and PD-L1+ PC cells (31.0% vs. 21.5%, <em>p</em> = 0.340); ≥1 MMR loss and PD-L1+ immune cells (18.2% vs. 23.5%, <em>p</em> = 0.653); ≥2 MMR loss and PD-L1+ immune cells (0% vs. 8%, <em>p</em> = 0.135).</p></div></div></section><p>Moreover, the PD-L1 status of the cases included in the following studies was unclear:</p>
<ul class="list" style="list-style-type:disc">
<li><p>In the series of Abida et al. [<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>], 47/1551 (3%) PCs were classified as hypermutated (TMB ≥10 mutations/Mb). 32/1033 (3.1%) cases were MSI-H or dMMR (age: 39–85 years, median 64.5 years; 30 acinar, 1 ductal, and 1 small cell carcinoma; Gleason score 6–10; stage, N1 or M1; 21 mCRPCs, 67.7%); 7/32 (21.9%) carried pathogenic or likely pathogenic germline mutations in MMR genes (5 <em>MSH2</em>, 1 <em>MSH6</em>, 1 <em>PMS2</em>). One additional patient harbored a usually pathogenic germline <em>MSH6</em> mutation without MSI or hypermutation, while 7/1033 (0.7%) men with deleterious MMR gene alterations (1 germline, 6 somatic) did not have MSI or hypermutation. 11/32 (34%) MSI-H/dMMR PC patients received an anti–PD-(L)1 drug for mCRPC (as monotherapy or plus other immunomodulatory agents); 6/11 (54.5%) cases resulted in a &gt;50% PSA decline, 4/8 (50%) evaluable cases achieved objective responses, 1 showed stable disease (6 months), and 3 progressed on radiographic exams.</p></li>
<li><p>A phase I clinical trial [<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>] tested PT-112 (pyrophosphate conjugate) (alone or combined with avelumab, a PD-L1 inhibitor) on CRPCs. PSA declined in 6/14 (43%) cases (3 cases: ≥50% decrease); the PFS of a microsatellite stable responder was 11.3 months.</p></li>
<li><p>McNeel et al. [<a href="#B65-biomedicines-10-00236" class="usa-link" aria-describedby="B65-biomedicines-10-00236">65</a>] found that 0/5 (0%) metastatic PC biopsies revealed a dMMR/MSI status; they were performed before vaccine treatment (alone or plus pembrolizumab).</p></li>
<li><p>A CRPC patient (pM1; Gleason score 10, 5 + 5) was variably treated (leuprolide, abiraterone, prednisone; carboplatin + docetaxel; carboplatin + cabazitaxel + radiotherapy) before the administration of pembrolizumab + radiotherapy; after two cycles of pembrolizumab, an exceptional response was obtained, and the tumor revealed MSI-H and multiple pathogenic mutations in <em>AR, ATM, BRCA1, BRCA2, CDK12, PTEN</em>, and <em>TP53</em> (mean allelic frequencies: 0.23–7.2%) [<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>].</p></li>
</ul>
<p>Globally, 280/883 (32%) PCs revealed MSI or loss of at least one MMR protein by immunohistochemistry (IHC) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>]. In particular, dMMR in ≥1 MMR protein was identified by IHC in 60/496 (12%) PCs [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>]: MSH6 was the most frequently lost (45/60, 75%), followed by PMS2 (29/60, 48%), MSH2 (11/60, 18%), and MLH1 (3/60, 5%). At least two MMR proteins were lost in 21/496 (4%) cases [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>] and ≥ 3 MMR proteins in 5/496 (1%) PCs [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>], while all the four proteins resulted negative in 2/496 (0.4%) cases [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>]. MSH6 IHC staining was indeterminate in two ductal PCs (MSH2 was also indeterminate in 1/2 cases) [<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>]. </p>
<p>MSI was found in 210/263 (80%) PCs [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>], including two cases with <em>MSH2</em> loss [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>] and one with <em>MSH2/MSH6</em> deletion [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>]. Four MSI cases revealed high TMB, while no further details were provided in the other cases [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>]. </p>
<p>It was usually unspecified how many dMMR/MSI PC patients harbored a Lynch syndrome. Some authors [<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>] found that germline mutations (<em>n</em> = 1), non-synonymous somatic mutations (<em>n</em> = 6), or biallelic events (<em>n</em> = 7) in MMR genes (total <em>n</em> = 14) had higher dMMR-associated DNA mutational signature activity and mRNA expression signatures. PCs with dMMR mutational signatures (<em>n</em> = 14) overexpressed a variety of immune transcripts, including CD200R1, BTLA, PD-L1, PD-L2, ADORA2A, PIK3CG, and TIGIT. </p>
<p>According to our review, 29% acinar PCs, 7% ductal PCs, and 46% neuroendocrine carcinomas/tumors were PD-L1+ by IHC [<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B14-biomedicines-10-00236" class="usa-link" aria-describedby="B14-biomedicines-10-00236">14</a>,<a href="#B15-biomedicines-10-00236" class="usa-link" aria-describedby="B15-biomedicines-10-00236">15</a>,<a href="#B16-biomedicines-10-00236" class="usa-link" aria-describedby="B16-biomedicines-10-00236">16</a>,<a href="#B17-biomedicines-10-00236" class="usa-link" aria-describedby="B17-biomedicines-10-00236">17</a>,<a href="#B18-biomedicines-10-00236" class="usa-link" aria-describedby="B18-biomedicines-10-00236">18</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B20-biomedicines-10-00236" class="usa-link" aria-describedby="B20-biomedicines-10-00236">20</a>,<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>,<a href="#B22-biomedicines-10-00236" class="usa-link" aria-describedby="B22-biomedicines-10-00236">22</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B24-biomedicines-10-00236" class="usa-link" aria-describedby="B24-biomedicines-10-00236">24</a>,<a href="#B25-biomedicines-10-00236" class="usa-link" aria-describedby="B25-biomedicines-10-00236">25</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B27-biomedicines-10-00236" class="usa-link" aria-describedby="B27-biomedicines-10-00236">27</a>,<a href="#B28-biomedicines-10-00236" class="usa-link" aria-describedby="B28-biomedicines-10-00236">28</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B31-biomedicines-10-00236" class="usa-link" aria-describedby="B31-biomedicines-10-00236">31</a>,<a href="#B32-biomedicines-10-00236" class="usa-link" aria-describedby="B32-biomedicines-10-00236">32</a>,<a href="#B33-biomedicines-10-00236" class="usa-link" aria-describedby="B33-biomedicines-10-00236">33</a>,<a href="#B34-biomedicines-10-00236" class="usa-link" aria-describedby="B34-biomedicines-10-00236">34</a>,<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>,<a href="#B36-biomedicines-10-00236" class="usa-link" aria-describedby="B36-biomedicines-10-00236">36</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B39-biomedicines-10-00236" class="usa-link" aria-describedby="B39-biomedicines-10-00236">39</a>,<a href="#B40-biomedicines-10-00236" class="usa-link" aria-describedby="B40-biomedicines-10-00236">40</a>,<a href="#B41-biomedicines-10-00236" class="usa-link" aria-describedby="B41-biomedicines-10-00236">41</a>,<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B44-biomedicines-10-00236" class="usa-link" aria-describedby="B44-biomedicines-10-00236">44</a>,<a href="#B45-biomedicines-10-00236" class="usa-link" aria-describedby="B45-biomedicines-10-00236">45</a>,<a href="#B46-biomedicines-10-00236" class="usa-link" aria-describedby="B46-biomedicines-10-00236">46</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B49-biomedicines-10-00236" class="usa-link" aria-describedby="B49-biomedicines-10-00236">49</a>,<a href="#B50-biomedicines-10-00236" class="usa-link" aria-describedby="B50-biomedicines-10-00236">50</a>,<a href="#B51-biomedicines-10-00236" class="usa-link" aria-describedby="B51-biomedicines-10-00236">51</a>,<a href="#B52-biomedicines-10-00236" class="usa-link" aria-describedby="B52-biomedicines-10-00236">52</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B54-biomedicines-10-00236" class="usa-link" aria-describedby="B54-biomedicines-10-00236">54</a>,<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B57-biomedicines-10-00236" class="usa-link" aria-describedby="B57-biomedicines-10-00236">57</a>,<a href="#B58-biomedicines-10-00236" class="usa-link" aria-describedby="B58-biomedicines-10-00236">58</a>,<a href="#B59-biomedicines-10-00236" class="usa-link" aria-describedby="B59-biomedicines-10-00236">59</a>,<a href="#B60-biomedicines-10-00236" class="usa-link" aria-describedby="B60-biomedicines-10-00236">60</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B62-biomedicines-10-00236" class="usa-link" aria-describedby="B62-biomedicines-10-00236">62</a>,<a href="#B63-biomedicines-10-00236" class="usa-link" aria-describedby="B63-biomedicines-10-00236">63</a>,<a href="#B64-biomedicines-10-00236" class="usa-link" aria-describedby="B64-biomedicines-10-00236">64</a>,<a href="#B65-biomedicines-10-00236" class="usa-link" aria-describedby="B65-biomedicines-10-00236">65</a>,<a href="#B66-biomedicines-10-00236" class="usa-link" aria-describedby="B66-biomedicines-10-00236">66</a>,<a href="#B67-biomedicines-10-00236" class="usa-link" aria-describedby="B67-biomedicines-10-00236">67</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B69-biomedicines-10-00236" class="usa-link" aria-describedby="B69-biomedicines-10-00236">69</a>,<a href="#B70-biomedicines-10-00236" class="usa-link" aria-describedby="B70-biomedicines-10-00236">70</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B72-biomedicines-10-00236" class="usa-link" aria-describedby="B72-biomedicines-10-00236">72</a>,<a href="#B73-biomedicines-10-00236" class="usa-link" aria-describedby="B73-biomedicines-10-00236">73</a>,<a href="#B74-biomedicines-10-00236" class="usa-link" aria-describedby="B74-biomedicines-10-00236">74</a>,<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>,<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B78-biomedicines-10-00236" class="usa-link" aria-describedby="B78-biomedicines-10-00236">78</a>,<a href="#B79-biomedicines-10-00236" class="usa-link" aria-describedby="B79-biomedicines-10-00236">79</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B81-biomedicines-10-00236" class="usa-link" aria-describedby="B81-biomedicines-10-00236">81</a>,<a href="#B82-biomedicines-10-00236" class="usa-link" aria-describedby="B82-biomedicines-10-00236">82</a>,<a href="#B83-biomedicines-10-00236" class="usa-link" aria-describedby="B83-biomedicines-10-00236">83</a>,<a href="#B84-biomedicines-10-00236" class="usa-link" aria-describedby="B84-biomedicines-10-00236">84</a>,<a href="#B85-biomedicines-10-00236" class="usa-link" aria-describedby="B85-biomedicines-10-00236">85</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B87-biomedicines-10-00236" class="usa-link" aria-describedby="B87-biomedicines-10-00236">87</a>,<a href="#B88-biomedicines-10-00236" class="usa-link" aria-describedby="B88-biomedicines-10-00236">88</a>,<a href="#B89-biomedicines-10-00236" class="usa-link" aria-describedby="B89-biomedicines-10-00236">89</a>,<a href="#B90-biomedicines-10-00236" class="usa-link" aria-describedby="B90-biomedicines-10-00236">90</a>,<a href="#B91-biomedicines-10-00236" class="usa-link" aria-describedby="B91-biomedicines-10-00236">91</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>,<a href="#B94-biomedicines-10-00236" class="usa-link" aria-describedby="B94-biomedicines-10-00236">94</a>,<a href="#B95-biomedicines-10-00236" class="usa-link" aria-describedby="B95-biomedicines-10-00236">95</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>,<a href="#B97-biomedicines-10-00236" class="usa-link" aria-describedby="B97-biomedicines-10-00236">97</a>,<a href="#B98-biomedicines-10-00236" class="usa-link" aria-describedby="B98-biomedicines-10-00236">98</a>,<a href="#B99-biomedicines-10-00236" class="usa-link" aria-describedby="B99-biomedicines-10-00236">99</a>,<a href="#B100-biomedicines-10-00236" class="usa-link" aria-describedby="B100-biomedicines-10-00236">100</a>,<a href="#B101-biomedicines-10-00236" class="usa-link" aria-describedby="B101-biomedicines-10-00236">101</a>,<a href="#B102-biomedicines-10-00236" class="usa-link" aria-describedby="B102-biomedicines-10-00236">102</a>,<a href="#B103-biomedicines-10-00236" class="usa-link" aria-describedby="B103-biomedicines-10-00236">103</a>,<a href="#B104-biomedicines-10-00236" class="usa-link" aria-describedby="B104-biomedicines-10-00236">104</a>,<a href="#B105-biomedicines-10-00236" class="usa-link" aria-describedby="B105-biomedicines-10-00236">105</a>,<a href="#B106-biomedicines-10-00236" class="usa-link" aria-describedby="B106-biomedicines-10-00236">106</a>,<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B108-biomedicines-10-00236" class="usa-link" aria-describedby="B108-biomedicines-10-00236">108</a>,<a href="#B109-biomedicines-10-00236" class="usa-link" aria-describedby="B109-biomedicines-10-00236">109</a>,<a href="#B110-biomedicines-10-00236" class="usa-link" aria-describedby="B110-biomedicines-10-00236">110</a>,<a href="#B111-biomedicines-10-00236" class="usa-link" aria-describedby="B111-biomedicines-10-00236">111</a>,<a href="#B112-biomedicines-10-00236" class="usa-link" aria-describedby="B112-biomedicines-10-00236">112</a>,<a href="#B113-biomedicines-10-00236" class="usa-link" aria-describedby="B113-biomedicines-10-00236">113</a>,<a href="#B114-biomedicines-10-00236" class="usa-link" aria-describedby="B114-biomedicines-10-00236">114</a>,<a href="#B115-biomedicines-10-00236" class="usa-link" aria-describedby="B115-biomedicines-10-00236">115</a>,<a href="#B116-biomedicines-10-00236" class="usa-link" aria-describedby="B116-biomedicines-10-00236">116</a>,<a href="#B117-biomedicines-10-00236" class="usa-link" aria-describedby="B117-biomedicines-10-00236">117</a>,<a href="#B118-biomedicines-10-00236" class="usa-link" aria-describedby="B118-biomedicines-10-00236">118</a>,<a href="#B119-biomedicines-10-00236" class="usa-link" aria-describedby="B119-biomedicines-10-00236">119</a>,<a href="#B120-biomedicines-10-00236" class="usa-link" aria-describedby="B120-biomedicines-10-00236">120</a>,<a href="#B121-biomedicines-10-00236" class="usa-link" aria-describedby="B121-biomedicines-10-00236">121</a>,<a href="#B122-biomedicines-10-00236" class="usa-link" aria-describedby="B122-biomedicines-10-00236">122</a>,<a href="#B123-biomedicines-10-00236" class="usa-link" aria-describedby="B123-biomedicines-10-00236">123</a>,<a href="#B124-biomedicines-10-00236" class="usa-link" aria-describedby="B124-biomedicines-10-00236">124</a>,<a href="#B125-biomedicines-10-00236" class="usa-link" aria-describedby="B125-biomedicines-10-00236">125</a>,<a href="#B126-biomedicines-10-00236" class="usa-link" aria-describedby="B126-biomedicines-10-00236">126</a>,<a href="#B127-biomedicines-10-00236" class="usa-link" aria-describedby="B127-biomedicines-10-00236">127</a>,<a href="#B128-biomedicines-10-00236" class="usa-link" aria-describedby="B128-biomedicines-10-00236">128</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>,<a href="#B130-biomedicines-10-00236" class="usa-link" aria-describedby="B130-biomedicines-10-00236">130</a>,<a href="#B131-biomedicines-10-00236" class="usa-link" aria-describedby="B131-biomedicines-10-00236">131</a>,<a href="#B132-biomedicines-10-00236" class="usa-link" aria-describedby="B132-biomedicines-10-00236">132</a>,<a href="#B133-biomedicines-10-00236" class="usa-link" aria-describedby="B133-biomedicines-10-00236">133</a>,<a href="#B134-biomedicines-10-00236" class="usa-link" aria-describedby="B134-biomedicines-10-00236">134</a>,<a href="#B135-biomedicines-10-00236" class="usa-link" aria-describedby="B135-biomedicines-10-00236">135</a>,<a href="#B136-biomedicines-10-00236" class="usa-link" aria-describedby="B136-biomedicines-10-00236">136</a>,<a href="#B137-biomedicines-10-00236" class="usa-link" aria-describedby="B137-biomedicines-10-00236">137</a>,<a href="#B138-biomedicines-10-00236" class="usa-link" aria-describedby="B138-biomedicines-10-00236">138</a>,<a href="#B139-biomedicines-10-00236" class="usa-link" aria-describedby="B139-biomedicines-10-00236">139</a>,<a href="#B140-biomedicines-10-00236" class="usa-link" aria-describedby="B140-biomedicines-10-00236">140</a>,<a href="#B141-biomedicines-10-00236" class="usa-link" aria-describedby="B141-biomedicines-10-00236">141</a>,<a href="#B142-biomedicines-10-00236" class="usa-link" aria-describedby="B142-biomedicines-10-00236">142</a>,<a href="#B143-biomedicines-10-00236" class="usa-link" aria-describedby="B143-biomedicines-10-00236">143</a>,<a href="#B144-biomedicines-10-00236" class="usa-link" aria-describedby="B144-biomedicines-10-00236">144</a>,<a href="#B145-biomedicines-10-00236" class="usa-link" aria-describedby="B145-biomedicines-10-00236">145</a>,<a href="#B146-biomedicines-10-00236" class="usa-link" aria-describedby="B146-biomedicines-10-00236">146</a>,<a href="#B147-biomedicines-10-00236" class="usa-link" aria-describedby="B147-biomedicines-10-00236">147</a>,<a href="#B148-biomedicines-10-00236" class="usa-link" aria-describedby="B148-biomedicines-10-00236">148</a>,<a href="#B149-biomedicines-10-00236" class="usa-link" aria-describedby="B149-biomedicines-10-00236">149</a>,<a href="#B150-biomedicines-10-00236" class="usa-link" aria-describedby="B150-biomedicines-10-00236">150</a>,<a href="#B151-biomedicines-10-00236" class="usa-link" aria-describedby="B151-biomedicines-10-00236">151</a>,<a href="#B152-biomedicines-10-00236" class="usa-link" aria-describedby="B152-biomedicines-10-00236">152</a>,<a href="#B153-biomedicines-10-00236" class="usa-link" aria-describedby="B153-biomedicines-10-00236">153</a>,<a href="#B154-biomedicines-10-00236" class="usa-link" aria-describedby="B154-biomedicines-10-00236">154</a>,<a href="#B155-biomedicines-10-00236" class="usa-link" aria-describedby="B155-biomedicines-10-00236">155</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>,<a href="#B157-biomedicines-10-00236" class="usa-link" aria-describedby="B157-biomedicines-10-00236">157</a>]. When data were analyzable, PD-L1 positivity was found in 214/273 (78%) MSI/dMMR cases [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>].</p>
<p>As to the data presentation, it was difficult to understand the frequency and significance of MMR deficiency in PD-L1+ and PD-L1- groups. Sharma et al. [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>] reported an association between the loss of ≥2 MMR proteins and higher PD-L1 expression rate in cancer cells (17.2% vs. 5.2%; <em>p</em> = 0.033; <em>n</em> = 127). Nava Rodrigues et al. [<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>] found a higher likelihood of PD-L1 positivity in MMR-deficient mCRPCs (5/10, 50%) compared to MMR-proficient cases (4/41, 9.8%) (<em>p</em> = 0.005); PD-L1 expression was associated with increased T-cells in mCRPCs (<em>p</em> = 0.007). Unfortunately, the study of Lin et al. [<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>] harbored a selection bias, as MSI-H and PD-L1 positivity in PC were inclusion criteria. Excluding this series (<em>n</em> = 206), only 74/677 (11%) PCs revealed MSI or loss of at least one MMR protein by IHC [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>] and the PD-L1 positivity rate in MSI/dMMR cases was reduced to 12% (8/67 PCs); in particular, only 4/57 (7%) PCs revealed MSI [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>] and just 1/35 (3%) MSI-PC was PD-L1+ [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>], while only 2/9 (22%) dMMR PCs were PD-L1+ [<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>]. </p>
<p>Subgrouping by histotypes, 57/402 (14%) acinar PCs and 3/94 (3%) ductal PCs were dMMR on IHC analysis (1 MSH2-/MSH6-; 1 MLH1-/PMS2-; 1 not otherwise specified) [<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>]. Moreover, MSH6 IHC staining was indeterminate in two ductal adenocarcinomas (MSH2 was also indeterminate in 1/2 cases) [<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>]. It was unclear if ductal PCs were both MMR-deficient and PD-L1+: 1/3 ductal PCs resulted PD-L1-, but the PD-L1 status of the other two cases was unspecified. All the cases tested for MSI seemed acinar PCs. Data of neuroendocrine carcinomas or carcinosarcomas were unavailable or unclear.</p>
<p>Somatic (or not specified as germline) aberrations in ≥1 DNA damage repair (DDR) genes were found in 3/5 (60%) MSI cases [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>] and in 8/23 (35%) microsatellite stable (MSS) PCs [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>] (<a href="#app1-biomedicines-10-00236" class="usa-link">Table S1</a>). These aberrations involved <em>BRCA2</em> (2 MSI cases, 3 MSS cases) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>], <em>BRCA1</em> (1 MSI) [<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>], <em>ATM</em> (1 MSI, 2 MSS) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>], <em>TP53</em> (2 MSI, 2 MSS) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>], <em>CDK12</em> (1 MSS) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>], <em>FANCA</em> (1 MSS) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>], <em>FANCD2</em> (1 MSS) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>], <em>MLH3</em> (1 MSS) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>], <em>NBN</em> (1 MSS) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>], <em>RAD54L</em> (1 MSS) [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>], and other genes. A MSI-PC showed <em>PTEN</em> mutation [<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>]. Some authors [<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>] found no association with the RNAseq rank of any tested genes, castration resistance vs. sensitivity status, or specimen type (primary vs. metastatic PC), nor between the DNA mutational profile, CD3/8 IHC status, RNA-seq CD8, PD-L1 IHC expression, or TMB and the expression profile of any genes (<em>n</em> = 17).</p>
<p>Few interesting results concerning the potential correlation of MMR/MSI with clinical outcome were reported in the studies resulting from our review. Some authors [<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>] found that dMMR was associated with decreased OS (<em>n</em> = 124; <em>p</em> = 0.005), while others (<em>n</em> = 220) [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>] described that cases with loss of ≥1 MMR protein and PD-L1 expression in tumor-infiltrating lymphocytes (TILs) had a significantly higher risk of biochemical recurrence (BCR) (<em>p</em> = 0.045). No convincing association was identified as regards Gleason score, stage, age, or other variables. The reported series were usually retrospective, sometimes harboring selection biases and/or testing a few samples. Moreover, limited clinic–pathologic information was available in some studies, while the PD-L1 and MMR/MSI statuses were variably analyzed (different assays or antibody clones; variable scoring systems), and their potential correlation was rarely or unclearly investigated. Finally, studies were typically monocentric: larger validation cohorts from multiple hospitals are required.</p>
<p>As regards the response to therapy, PD-1 inhibition may be active in mCRPCs (including those tumors lacking MSI, DNA-repair defects, or PD-L1 expression), while not all the d-MMR/MSI-H cases respond to immunotherapy [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>]. In the series of Abida et al. [<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>], 5/11 (45.5%) MSI-H/dMMR mCRPCs revealed durable clinical benefit upon continuous treatment, 5/11 (45.5%) cases had no benefit, while 1/11 (9.1%) PC revealed stable disease for 6 months; the PD-L1 status was unclear.</p>
<p>Graff et al. [<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>] found that only 1/5 (20%) responders to enzalutamide (ENZ) + pembrolizumab showed MSI, while 1/23 (4%) non-responders had a single MSI marker altered by polymerase chain reaction analysis (not deemed MSI-H by next-generation sequencing analysis, NGS), and 3/23 (13%) non-responders revealed heterozygous mutations in DDR pathways. As all the cases of Graff et al. were PD-L1-, there were no differences in PD-L1 expression (<em>n</em> = 10; <em>p</em> = 0.42) between responders and non-responders; molecular analysis found a higher number of neoepitopes among responders (679 vs. 405.5, <em>p</em> = 0.42) without differences in TMB [<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>]. </p>
<p>None of the six responders to pembrolizuab showed MSI in another series [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>]. Moreover, Petrylak et al. [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>] analyzed the MSI status of 14 CRPCs: 1 dMMR (MSH2-/MSH6-) CRPC responded to atezolizumab, while another MSI-H PC did not benefit from treatment. However, the PD-L1 status of these cases was unclear, despite all the tested tumors showing absent expression or &lt;5% positivity rate.</p>
<p>Lin et al. [<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>] recently reported a clinical trial including 206 men with previously untreated PD-L1+ (combined positive score, CPS ≥ 1) MSI-H-mCRPCs: pembrolizumab was administered alone (106/206, 51%; PA-group) or associated with ENZ (100/206, 49%; PE-group). In the first group, the PD-L1 CPS was 1–20 in 63%, 20–50 in 22%, and 50–100 in 15% of the cases, ranging from 1 to 20 in 64%, 20–50 in 22%, and 50–100 in 14% of PE-cases (<em>p</em> = 0.872). The median OS of PE-patients (vs. PA) was 28.6 vs. 21.3 months for CPS ≥ 50 (<em>p</em> = 0.001), 26.6 vs. 19.4 months for CPS ≥ 20 (<em>p</em> = 0.001) and 21.4 vs. 16.8 months for CPS ≥ 1 (<em>p</em> = 0.001): the benefit from PE therapy seemed more evident for higher PD-L1 expression in tumor cells. Regardless of the tumor mutation status, the addition of pembrolizumab to ENZ treatment was significantly associated with longer OS (median: 25.1 vs. 18.3 months; <em>p</em> = 0.001) and longer PFS (median: 6.1 vs. 4.9 months; <em>p</em> = 0.001) than pembrolizumab as monotherapy, despite the significantly major rate of adverse events (72% vs. 45%; <em>p</em> &lt; 0.001).</p></section><section id="sec3dot2-biomedicines-10-00236"><h3 class="pmc_sec_title">3.2. PD-L1 and BRCA1/2 Status in PC Patients</h3>
<p>Few studies analyzed PD-L1 expression and the status of <em>BRCA1/2</em> and other DDR genes in human PC patients (<a href="#biomedicines-10-00236-t002" class="usa-link">Table 2</a>); additional information are reported in <a href="#biomedicines-10-00236-t001" class="usa-link">Table 1</a> and <a href="#app1-biomedicines-10-00236" class="usa-link">Table S1</a>. </p>
<section class="tw xbox font-sm" id="biomedicines-10-00236-t002"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>PD-L1 expression and status of <em>BRCA1/2</em> and other DNA damage repair genes in patients with prostate cancer.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PD-L1+ IHC Rate</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<em>BRCA</em> and Other Relevant DDR Genes</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinic-Molecular Correlations</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/33 (0%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/16 (31%) <em>BRCA2</em> alterations</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/5 (40%) PCs with <em>BRCA2</em> aberrations showed PR to Atz (*).</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156/258 <br>(60%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) 19/153 (12%): <em>BRCA1/2</em> or <em>ATM</em> mut <br>(2) 10/153 (7%): other HHR genes mut (£) <br>(3) 124/153 (81%): no HHR genes mut</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) 2/19 (11%) ORR to PEM (§), 4/19 (22%) DCR; 2 (11%) PR, 2 (11%) SD, 1 (5%) non-CR/non-PD, 12 (63%) PD, 2 (11%) PSA response. <br>(2) 0% ORR/DCR, 2 (20%) SD, 5 (50%) PD, 1 (10%) PSA response. <br>(3) 4/124 (3%) ORR (RD: 1.9 - ≥ 16.6 mo), 22/124 (18%) DCR; 2 (2%) CR, 2 (2%) PR, 18 (15%) SD, 7 (6%) non-CR/non-PD, 80 (65%) PD, 4 (3%) PSA response. <br>4/6 (67%) responders (evaluable genomic data) with MSI showed somatic aberrations in ≥1 of 50 DDR genes (°)</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/28 <br>(0%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/16 (25%) DDR gene mut</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33%) ENZ+PEM responders with MSI, DDR genes mut, ≥1 heterozygous cancer-predisposing <em>ATM</em> variant. <br>0/13 non-responders with MSI ($): 3 with heterozygous mut in DDR pathways (2 cancer-associated).</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/19 <br>(5%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/17 <em>(29%) BRCA1/2</em> alterations: <em>BRCA1</em> (<em>n</em> = 1), <em>BRCA2</em> (<em>n</em> = 2), or <em>BRCA1/2</em> (<em>n</em> = 1) mut, or <em>BRCA2</em> copy loss (<em>n</em> = 1) (@)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No association with RNAseq rank of any gene, CRPC vs. CSPC status, or primary PC vs. metastases, nor between DNA mutational profile, CD3/8 IHC status, RNA-seq CD8, PD-L1 IHC status, or TMB and the expression profile of any genes. No difference in the DNA mutational profile (<em>p</em> &gt; 0.05) of CRPC vs. CSPC or primary vs. metastatic PC.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/5 <br>(40%)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">germline (three frameshift <em>BRCA2</em> indels + somatic del of the 2nd allele; one <em>NBN</em> mut) or somatic (two homozygous <em>BRCA2</em> mut) DDR genes alterations</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">These six patients were responders to durvalumab + olaparib.</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/biomedicines-10-00236-t002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn3"><p>(*): 3/14 (21%) PCs (baseline biopsy): <em>BRCA2</em> aberrations; 2 PR: (1) <em>MSH2/MHS6</em> del; high TMB (30 mut/Mb); <em>BRCA2</em> E49*, <em>TP53</em> Y236D, <em>AR</em> W742C mut; <em>MYC</em> amplification; <em>TMPRSS2-ERG</em> fusion; PD-L1- baseline biopsy, PD-L1+ post-treatment biopsy (≥5% immune cells, &lt;5% tumor cells); (2) low TMB, microsatellite-stable, <em>BRCA2/ATM</em> (?) mut (lymph node metastasis). (§): response duration: 4.4 vs. ≥21.8 mo (<em>ATM</em> vs. <em>BRCA2</em> mutations). (£): <em>BARD1</em>, <em>BRIP1</em>, <em>CDK12</em>, <em>CHEK1</em>, <em>CHEK2</em>, <em>FANCL</em>, <em>PALB2</em>, <em>PPP2R2A</em>, <em>RAD51C</em>, <em>RAD51B</em>, <em>RAD51D</em>, and <em>RAD54L</em> genes. (°): Four cases: (1) <em>ATM</em> splice site acceptor del, <em>BRCA2</em> A1162V sub, <em>CDK12</em> G1461Afs* del, <em>FANCA</em> sub, <em>FANCD2</em> R263H sub, <em>MLH3</em> T930Qfs*35 del, and <em>RAD54L</em> R511H sub; (2) <em>TP53</em> R273P sub; (3) <em>BRCA2</em> V1176Gfs*8 insertion; (4) <em>NBN</em> Q494P and <em>TP53</em> S241F sub. ($): a case with one marker of MSI (polymerase chain reaction, not high MSI). (@): details: (1) <em>BRCA1/2</em>, <em>PTEN, FBXW7</em>, <em>GATA3</em>, <em>SMO</em>, <em>TET2</em>, <em>TP53</em>, <em>TSC1</em> mut; <em>MSH2</em> copy number loss (cnl), PD-L1+; (2) cnl in <em>BRCA2</em>, <em>FBXW7</em>, <em>NF2</em>, <em>PIK3R1</em>, <em>RB1</em>, <em>SMAD4</em>, and <em>TET2</em> genes, <em>PTEN</em> mut; (3) <em>BRCA1</em> mut, <em>CCND1</em> copy number gain, <em>CDKN2A</em> cnl, <em>SMAD4</em> and <em>TP53</em> mut; (4) <em>BRCA2</em> and <em>KIT</em> mut, <em>TMPRSS2-ERG</em> fusion; (5) <em>BRCA2</em>, <em>APC</em>, <em>PIK3R1</em>, <em>RB1</em>, <em>TP53</em> mut. Atz: atezolizumab; CR: complete response; CRPC: castration-resistant prostate cancer; CSPC: castration-sensitive prostate cancer; del: deletion; DCR: disease control rate; DDR: DNA damage repair; ENZ: enzalutamide; HRR: homologous recombinant repair; IHC: immunohistochemistry; mo: months; MSI: microsatellite instability; mut: mutation; ORR: objective response rate (RECIST v1.1 criteria); PC: prostate cancer; PD: progression of disease; PEM: pembrolizumab; PR: partial response; RD: response duration; Ref.: Reference; SD: stable disease; sub: substitution; TMB: tumor mutation burden.</p></div></div></section><p>Combining the scant analyzable data, aberrations in <em>BRCA1/2</em> genes were found in 15/39 (39%) cases [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>], involving <em>BRCA1</em> (<em>n</em> = 1), <em>BRCA2</em> (<em>n</em> = 13), or both genes (<em>n</em> = 1). Moreover, 19/153 (12%) PCs of another series showed <em>BRCA1/2</em> or <em>ATM</em> mutations [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>]. Unfortunately, the relation of PD-L1 expression with the <em>BRCA</em> status was unclear for most of the cases; only 1/10 (10%) PCs with <em>BRCA</em> aberrations was clearly PD-L1+ [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>]. Some authors [<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>] found no association (<em>p</em> &gt; 0.05) between the DNA mutational profile, CD3/8 or PD-L1 IHC status, RNA-seq CD8, or TMB, and the expression profile of any analyzed genes, including <em>BRCA1/2</em>. The scant available information did not allow us to discuss the potential differences in PD-L1 expression between PCs with somatic vs. germline <em>BRCA</em> mutations.</p>
<p>PD-1 inhibition has activity in mCRPCs, including tumors without MSI, DDR defects, or PD-L1 expression [<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>]. The phase II KEYNOTE-199 study reported that pembrolizumab showed antitumor activity and disease control with acceptable safety in docetaxel-refractory mCRPCs, regardless of the PD-L1 status, in both RECIST-measurable and non-measurable cases: 19/153 (12%) PCs had aberrations in <em>BRCA1/2</em> or <em>ATM</em>, while 10/153 (7%) PCs revealed alterations in ≥1 of 12 other HRR genes. Patients with somatic mutations in <em>BRCA1/2</em> or <em>ATM</em> showed higher response rates compared to the HRR-aberrant or HRR-normal groups (11%, 0%, and 3%, respectively). Unfortunately, it was not completely clear if there was a correlation between the <em>BRCA</em> and the PD-L1 status [<a href="#B165-biomedicines-10-00236" class="usa-link" aria-describedby="B165-biomedicines-10-00236">165</a>]. In another series [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>], most of the CRPC patients with DDR genes alterations did not respond to atezolizumab (anti-PD-L1), and the DDR status was not a strong predictor of clinical benefit. Finally, some authors [<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>] included responders to durvalumab (anti-PD-L1) plus olaparib that harbored germline mutations in DDR genes, including <em>BRCA2</em> and <em>NBN</em>, but it was unclear if these cases were tested for PD-L1 by IHC.</p></section><section id="sec3dot3-biomedicines-10-00236"><h3 class="pmc_sec_title">3.3. PD-L1 and PTEN Status in PC Patients</h3>
<p>Very few studies performed a combined analysis of PD-L1 expression and <em>PTEN</em> status in human PC patients by using molecular or IHC assays (<a href="#biomedicines-10-00236-t003" class="usa-link">Table 3</a>) [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>]; additional information is reported in <a href="#biomedicines-10-00236-t001" class="usa-link">Table 1</a>, <a href="#biomedicines-10-00236-t002" class="usa-link">Table 2</a> and <a href="#app1-biomedicines-10-00236" class="usa-link">Table S1</a>.</p>
<section class="tw xbox font-sm" id="biomedicines-10-00236-t003"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>PD-L1 expression and <em>PTEN</em> status in patients with prostatic carcinoma.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PD-L1 IHC Positivity Rate</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/33 (0%)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/16 (6%) <em>PTEN</em> mutations</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20/91 (22%) a; 1/27 (4%) d/m</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No association between PD-L1 positivity (26% HR, 17% MPC, 4% ductal PCs) and PTEN or ERG status</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/19 (5%)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/17 (47%) <em>PTEN</em> mutations (<em>n</em> = 5, 29%) or CNL (<em>n</em> = 3, 18%) (*). No association with RNAseq rank of any gene, CRPC vs. CSPC status, primary PC vs. metastases, nor between DNA mutational profile, CD3/8 IHC status, RNA-seq CD8, PD-L1 IHC, or TMB and any gene expression profile.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/177 (12%): <br>18/130 (14%) (hormone-naïve);<br>3/44 (7%) (AAPL)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD-L1 expression is independent of PTEN status. PTEN IHC loss: <br>- 85/130 (65%) hormone-naïve PCs: 75/112 (67%) PD-L1-/PTEN-; 10/18 (56%) PD-L1+/PTEN-; 37/112 (33%) PD-L1-/PTEN<sup>normal</sup>; 8/18 (44%) PD-L1+/PTEN<sup>normal</sup> (<em>p</em> = 0.345).<br>- 22/44 (50%) neo-AAPL PCs and 20/44 (46%) matched untreated PC controls (<em>p</em> = 0.67).<br>In PCs with nodular pattern of PD-L1 positivity (<em>n</em> = 7), the PD-L1<sup>high</sup> and PD-L1<sup>low</sup> components showed concordant ERG status (°) but variable PTEN staining. </td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/129 (24%)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loss of PTEN protein expression (IHC, unclear score) in 47/88 (53%) PCs; only 3/47 (6%) PTEN- cases were PD-L1+. <em>CD274</em> gene amplification in 1/675 (0.1%) analyzed PCs (@).</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/20 (55%)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/20 (25%) PTEN loss (all PD-L1- PCs). No PD-L1+ PCs with PTEN loss (§).</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/biomedicines-10-00236-t003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn4"><p>a: acinar; AAPL: neoadjuvant abiraterone, prednisone and leuprolide; CNL: copy number loss; CRPC: castration-resistant prostate cancer; CSPC: castration-sensitive prostate cancer; d/m: ductal or mixed; IHC: immunohistochemistry; HR: high-risk prostate cancer; MPC: metastatic prostatic cancer; PC: prostate cancer; Ref.: reference; TMB: tumor mutation burden. Note: The clinic–pathologic features of a PC series [<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>] were not reported, while Martin et al. [<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>] tested a series of radical prostatectomies treated with leuprolide (<em>n</em> = 11). For additional molecular information (unrelated to the topic of our review), please read the original articles. (*): The three cases with <em>PTEN</em> CNL also showed: (1) CNL in <em>NF2</em>, <em>PIK3R1</em>, <em>RB1</em>, and <em>TET2</em>; <em>TMPRSS2-ERG</em> fusion; (2) CNL in <em>APC</em>, <em>PIK3R1</em>, <em>SMAD4</em>, and <em>TET2</em>; (3) <em>PTCH1</em> mutation; <em>TMPRSS2-ERG</em> fusion. The five cases with <em>PTEN</em> mutations also showed: (1) <em>BRCA1/2</em>, <em>FBXW7</em>, <em>GATA3</em>, <em>SMO</em>, <em>TET2</em>, <em>TP53</em>, and <em>TSC1</em> mutations; <em>MSH2</em> CNL; PD-L1 IHC positivity; (2) CNL in <em>FBXW7</em>, <em>BRCA2</em>, <em>NF2</em>, <em>PIK3R1</em>, <em>RB1</em>, <em>SMAD4</em>, and <em>TET2</em>; (3) CNL in <em>NF1</em> and <em>TSC1</em>; (4) CNL in <em>FBXW7</em> and <em>RB1</em>; <em>TMPRSS2-ERG</em> fusion; <em>TP53</em> mutation; (5) no other reported mutations. Gene alterations included (not being limited to): <em>AR</em> gene copy number gain (<em>n</em> = 1); <em>BRCA1</em> (<em>n</em> = 1), <em>BRCA2</em> (<em>n</em> = 2) or <em>BRCA1/2</em> (<em>n</em> = 1) mutation or <em>BRCA2</em> CNL (<em>n</em> = 1); <em>TMPRSS2-ERG</em> fusion (<em>n</em> = 7); <em>SPOP</em> mutation (<em>n</em> = 1); <em>TP53</em> mutation (<em>n</em> = 6); <em>RB</em> CNL (<em>n</em> = 3) or mutation (<em>n</em> = 1), <em>MSH2</em> loss (<em>n</em> = 1). (°): ERG+: 16/44 (36%) neo-AAPL PCs and 18/44 (41%) matched untreated PC controls (<em>p</em> = 0.5); 61/130 hormone-naïve PCs (five ERG+ PCs resulted PD-L1+, <em>p</em> = 0.08). The trend of PD-L1+ PCs toward a lower rate of ERG positivity and higher AR expression. The five PDL1+ PCs in ≥ 25% tumor cells were all ERG−. (@): hybrid capture-based comprehensive genomic profiling. (§): assays: IHC (clone D4.3 XP 9271) (negative for markedly decreased intensity or entirely negative staining across all tumor cells compared to the surrounding benign glands and/or stroma).</p></div></div></section><p>The assays and IHC scoring systems of PTEN and PD-L1 were variable and sometimes unclear. It was difficult to correlate the scant results in some cases; when data were analyzable, 179/326 (55%) PCs showed PTEN loss by IHC: 13/137 (10%) of PTEN- cases were PD-L1+, while 10/29 (35%) of PD-L1+ cases showed PTEN negativity [<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>]. In the series of Calagua et al. [<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>], the PD-L1<sup>high</sup> and PD-L1<sup>low</sup> components of the cases showing a nodular PD-L1 positivity pattern (<em>n</em> = 7; 39%) revealed a consistently concordant ERG status but a variable PTEN staining pattern. Conversely, Shaw et al. found no significant association between PD-L1+ tumors and ERG/PTEN status [<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>]. </p>
<p>Only two studies evaluated PD-L1 IHC expression and performed molecular analysis of the <em>PTEN</em> gene, finding <em>PTEN</em> mutations (4/33, 12%) or copy number losses (5/33, 15%) (total: 9/33, 27%) [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>]. The potential correlation between <em>PTEN</em> and PD-L1 status was usually unclear. Genomic analysis performed on a small series (<em>n</em> = 7) [<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>] reported no association (<em>p</em> &gt; 0.05) between <em>PTEN</em> loss/mutation status with RNA-seq ranks of any gene, castration-resistance/-sensitivity, or primary vs. metastatic status, as well as no correlation (<em>p</em> &gt; 0.05) of the DNA mutational profile, CD3/8 or PD-L1 IHC status, RNA-seq CD8, or TMB with the expression profile of any specific gene. </p>
<p>In a Phase I trial [<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>] testing PT-112 (plus or without Avelumab) on CRPCs, a case with <em>PIK3CB</em> mutation and <em>PTEN</em> loss showed a 4-month response (93% PSA decrease, 48% reduction in target lesions); the PD-L1 status was unclear. </p></section><section id="sec3dot4-biomedicines-10-00236"><h3 class="pmc_sec_title">3.4. PD-L1 and Other Genes Involved in PC Genesis and Progression</h3>
<p>The <em>TP53</em> gene encodes 12 isoforms through alternative promoters, translation start sites, and RNA splicing [<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>]. In a study [<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>], increased expression of the Δ133TP53β isoform defined high-risk PC patients, while PCs showing increased Δ40TP53 and TP53α mRNAs levels revealed good prognosis. High Δ133TP53β mRNA levels alone predicted poor outcome (accuracy: 88%), correlating to advanced stage, increased proliferative index, immune cell infiltrate (T cells, macrophages, immunosuppressive cells), PD-1 overexpression on T cells, and PD-L1 upregulation in PC cells and CD163+ CSF1R+ macrophages [<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>]. Indeed, this isoform increased the expression of PD-L1 mRNA levels—while its knockdown reduced them—and of genes involved in immune signaling and migration. IL-6 was directly regulated by Δ133p53; its transcription may be induced by hypoxia in <em>T53</em>-wild-type tumors [<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>]. In a large series analyzing The Cancer Genome Atlas (TCGA) database, the immune class subtype of PCs revealed higher <em>TP53</em> mutation frequency than the non-immune class sub-group (14% vs. 10%) (especially vs. the immune-suppressed PCs: 19%, <em>p</em> &lt; 0.001) [<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>]. <em>TP53</em> mutations were also found in 14 cases of our series [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>], but the PD-L1 status of these cases was unclear.</p>
<p>Shaw et al. found no significant association between PD-L1 positivity and ERG status [<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>]. Conversely, Calagua et al. [<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>] reported a concordant ERG status among the PD-L1<sup>high</sup> and PD-L1<sup>low</sup> expressor PCs showing a nodular pattern of PD-L1 IHC positivity. ERG positivity was found in 16/44 (36%) PCs treated with neoadjuvant abiraterone acetate (ABT) + prednisone and leuprolide, and in 18/44 (41%) matched untreated PC controls (<em>p</em> = 0.5). ERG expression was also reported in 61/130 (47%) hormone-naïve PCs: five ERG+ PCs resulted PD-L1+ (<em>p</em> = 0.08). PD-L1+ PCs revealed a trend toward a lower rate of ERG positivity and higher androgen receptor (AR) expression. All the five PCs showing PD-L1 positivity in ≥25% of the tumor cells were ERG− [<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>]. Some authors reported <em>TMPRSS2-ERG</em> fusions in 7/17 (41%) PCs (3/7, 43%, also harboring <em>PTEN</em> aberrations), as well as <em>SPOP</em> (<em>n</em> = 1), <em>TP53</em> (<em>n</em> = 6), or <em>RB</em> (<em>n</em> = 1) mutations, or <em>RB</em> copy number loss (<em>n</em> = 3) (<a href="#biomedicines-10-00236-t001" class="usa-link">Table 1</a>, <a href="#biomedicines-10-00236-t002" class="usa-link">Table 2</a> and <a href="#biomedicines-10-00236-t003" class="usa-link">Table 3</a>) [<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>]. However, it was not completely clear which cases resulted in PD-L1 positivity. A partial responder to atezolizumab harbored <em>TMPRSS2-ERG</em> fusion, <em>MSH2/MHS6</em> deletion, high TMB (30 mutations/Mb), as well as <em>BRCA2</em> E49*, <em>TP53</em> Y236D, <em>AR</em> W742C mutations, and <em>MYC</em> amplification; in this case, PD-L1 positivity was found in ≥5% immune cells and &lt;5% of tumor cells after treatment, while the previous baseline biopsy was negative [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>]. </p>
<p>In human tumors, mutations in the PD-L1 C-tail are mutually exclusive with those in the substrate-interacting N-terminal meprin and TRAF homology (MATH) domain of Speckle-type POZ protein (SPOP) [<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>]. SPOP promotes ubiquitin-mediated PD-L1 degradation; in a series (<em>n</em> = 97; 15 <em>SPOP<sup>mutant</sup></em> and 82 <em>SPOP<sup>wild-type</sup></em>), SPOP-deficient PCs correlated with increased PD-L1 expression and a decreased number of CD8+ TILs [<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>]. <em>SPOP<sup>mutant</sup></em> cases more frequently showed strong PD-L1 IHC positivity (80% vs. 10%), while 70% of <em>SPOP<sup>wild-type</sup> PCs</em> revealed weak/absent PD-L1 staining [<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>]. In a large series, the immune-suppressed PC group showed fewer <em>SPOP</em> mutations than the immune-activated and non-immune class (5.6%, 13.5%, and 13.2%, respectively, <em>p</em> &lt; 0.001) [<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>]. Other authors [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>] reported <em>SPOP</em> and <em>MYC</em> mutations in one and four cases, respectively: the PD-L1 status was unclear. Further studies are required. </p></section></section><section id="sec4-biomedicines-10-00236"><h2 class="pmc_sec_title">4. Discussion</h2>
<section id="sec4dot1-biomedicines-10-00236"><h3 class="pmc_sec_title">4.1. PD-L1 and dMMR/MSI</h3>
<p>The MMR system is a post-replicative, high-fidelity, single-strand repair mechanism, identifying and reversing the DNA base mismatches and insertion/deletion (indel) loops; MMR deficiency occurs through mutational or epigenetic events, resulting in MSI and hypermutator phenotypes associated with chemoresistance and immunotherapy sensitivity [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B166-biomedicines-10-00236" class="usa-link" aria-describedby="B166-biomedicines-10-00236">166</a>]. Hypermutation is correlated to the higher expression of tumor neoantigens, favoring immune recognition [<a href="#B167-biomedicines-10-00236" class="usa-link" aria-describedby="B167-biomedicines-10-00236">167</a>,<a href="#B168-biomedicines-10-00236" class="usa-link" aria-describedby="B168-biomedicines-10-00236">168</a>]. </p>
<p>According to the literature, about 1–12% of mCRPC are MSI-H/dMMR [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B39-biomedicines-10-00236" class="usa-link" aria-describedby="B39-biomedicines-10-00236">39</a>]. In our review, about 11% PCs globally revealed MSI or the IHC loss of at least one MMR protein [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>], while PD-L1 positivity was identified in about 12% of dMMR/MSI PCs [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>] after excluding a study with relevant selection bias [<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>]. Only 4/57 (7%) PCs clearly revealed MSI [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>], and just 1/35 (3%) MSI-PC was PD-L1+ [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>]. Subgrouping by histotype, 57/402 (14%) acinar PCs and 3/94 (3%) ductal PCs (high-grade PCs) of our review were dMMR, while all the cases tested for MSI apparently seemed acinar PCs [<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B14-biomedicines-10-00236" class="usa-link" aria-describedby="B14-biomedicines-10-00236">14</a>,<a href="#B15-biomedicines-10-00236" class="usa-link" aria-describedby="B15-biomedicines-10-00236">15</a>,<a href="#B16-biomedicines-10-00236" class="usa-link" aria-describedby="B16-biomedicines-10-00236">16</a>,<a href="#B17-biomedicines-10-00236" class="usa-link" aria-describedby="B17-biomedicines-10-00236">17</a>,<a href="#B18-biomedicines-10-00236" class="usa-link" aria-describedby="B18-biomedicines-10-00236">18</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B20-biomedicines-10-00236" class="usa-link" aria-describedby="B20-biomedicines-10-00236">20</a>,<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>,<a href="#B22-biomedicines-10-00236" class="usa-link" aria-describedby="B22-biomedicines-10-00236">22</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B24-biomedicines-10-00236" class="usa-link" aria-describedby="B24-biomedicines-10-00236">24</a>,<a href="#B25-biomedicines-10-00236" class="usa-link" aria-describedby="B25-biomedicines-10-00236">25</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B27-biomedicines-10-00236" class="usa-link" aria-describedby="B27-biomedicines-10-00236">27</a>,<a href="#B28-biomedicines-10-00236" class="usa-link" aria-describedby="B28-biomedicines-10-00236">28</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B31-biomedicines-10-00236" class="usa-link" aria-describedby="B31-biomedicines-10-00236">31</a>,<a href="#B32-biomedicines-10-00236" class="usa-link" aria-describedby="B32-biomedicines-10-00236">32</a>,<a href="#B33-biomedicines-10-00236" class="usa-link" aria-describedby="B33-biomedicines-10-00236">33</a>,<a href="#B34-biomedicines-10-00236" class="usa-link" aria-describedby="B34-biomedicines-10-00236">34</a>,<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>,<a href="#B36-biomedicines-10-00236" class="usa-link" aria-describedby="B36-biomedicines-10-00236">36</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B39-biomedicines-10-00236" class="usa-link" aria-describedby="B39-biomedicines-10-00236">39</a>,<a href="#B40-biomedicines-10-00236" class="usa-link" aria-describedby="B40-biomedicines-10-00236">40</a>,<a href="#B41-biomedicines-10-00236" class="usa-link" aria-describedby="B41-biomedicines-10-00236">41</a>,<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B44-biomedicines-10-00236" class="usa-link" aria-describedby="B44-biomedicines-10-00236">44</a>,<a href="#B45-biomedicines-10-00236" class="usa-link" aria-describedby="B45-biomedicines-10-00236">45</a>,<a href="#B46-biomedicines-10-00236" class="usa-link" aria-describedby="B46-biomedicines-10-00236">46</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B49-biomedicines-10-00236" class="usa-link" aria-describedby="B49-biomedicines-10-00236">49</a>,<a href="#B50-biomedicines-10-00236" class="usa-link" aria-describedby="B50-biomedicines-10-00236">50</a>,<a href="#B51-biomedicines-10-00236" class="usa-link" aria-describedby="B51-biomedicines-10-00236">51</a>,<a href="#B52-biomedicines-10-00236" class="usa-link" aria-describedby="B52-biomedicines-10-00236">52</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B54-biomedicines-10-00236" class="usa-link" aria-describedby="B54-biomedicines-10-00236">54</a>,<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B57-biomedicines-10-00236" class="usa-link" aria-describedby="B57-biomedicines-10-00236">57</a>,<a href="#B58-biomedicines-10-00236" class="usa-link" aria-describedby="B58-biomedicines-10-00236">58</a>,<a href="#B59-biomedicines-10-00236" class="usa-link" aria-describedby="B59-biomedicines-10-00236">59</a>,<a href="#B60-biomedicines-10-00236" class="usa-link" aria-describedby="B60-biomedicines-10-00236">60</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B62-biomedicines-10-00236" class="usa-link" aria-describedby="B62-biomedicines-10-00236">62</a>,<a href="#B63-biomedicines-10-00236" class="usa-link" aria-describedby="B63-biomedicines-10-00236">63</a>,<a href="#B64-biomedicines-10-00236" class="usa-link" aria-describedby="B64-biomedicines-10-00236">64</a>,<a href="#B65-biomedicines-10-00236" class="usa-link" aria-describedby="B65-biomedicines-10-00236">65</a>,<a href="#B66-biomedicines-10-00236" class="usa-link" aria-describedby="B66-biomedicines-10-00236">66</a>,<a href="#B67-biomedicines-10-00236" class="usa-link" aria-describedby="B67-biomedicines-10-00236">67</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B69-biomedicines-10-00236" class="usa-link" aria-describedby="B69-biomedicines-10-00236">69</a>,<a href="#B70-biomedicines-10-00236" class="usa-link" aria-describedby="B70-biomedicines-10-00236">70</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B72-biomedicines-10-00236" class="usa-link" aria-describedby="B72-biomedicines-10-00236">72</a>,<a href="#B73-biomedicines-10-00236" class="usa-link" aria-describedby="B73-biomedicines-10-00236">73</a>,<a href="#B74-biomedicines-10-00236" class="usa-link" aria-describedby="B74-biomedicines-10-00236">74</a>,<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>,<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B78-biomedicines-10-00236" class="usa-link" aria-describedby="B78-biomedicines-10-00236">78</a>,<a href="#B79-biomedicines-10-00236" class="usa-link" aria-describedby="B79-biomedicines-10-00236">79</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B81-biomedicines-10-00236" class="usa-link" aria-describedby="B81-biomedicines-10-00236">81</a>,<a href="#B82-biomedicines-10-00236" class="usa-link" aria-describedby="B82-biomedicines-10-00236">82</a>,<a href="#B83-biomedicines-10-00236" class="usa-link" aria-describedby="B83-biomedicines-10-00236">83</a>,<a href="#B84-biomedicines-10-00236" class="usa-link" aria-describedby="B84-biomedicines-10-00236">84</a>,<a href="#B85-biomedicines-10-00236" class="usa-link" aria-describedby="B85-biomedicines-10-00236">85</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B87-biomedicines-10-00236" class="usa-link" aria-describedby="B87-biomedicines-10-00236">87</a>,<a href="#B88-biomedicines-10-00236" class="usa-link" aria-describedby="B88-biomedicines-10-00236">88</a>,<a href="#B89-biomedicines-10-00236" class="usa-link" aria-describedby="B89-biomedicines-10-00236">89</a>,<a href="#B90-biomedicines-10-00236" class="usa-link" aria-describedby="B90-biomedicines-10-00236">90</a>,<a href="#B91-biomedicines-10-00236" class="usa-link" aria-describedby="B91-biomedicines-10-00236">91</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>,<a href="#B94-biomedicines-10-00236" class="usa-link" aria-describedby="B94-biomedicines-10-00236">94</a>,<a href="#B95-biomedicines-10-00236" class="usa-link" aria-describedby="B95-biomedicines-10-00236">95</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>,<a href="#B97-biomedicines-10-00236" class="usa-link" aria-describedby="B97-biomedicines-10-00236">97</a>,<a href="#B98-biomedicines-10-00236" class="usa-link" aria-describedby="B98-biomedicines-10-00236">98</a>,<a href="#B99-biomedicines-10-00236" class="usa-link" aria-describedby="B99-biomedicines-10-00236">99</a>,<a href="#B100-biomedicines-10-00236" class="usa-link" aria-describedby="B100-biomedicines-10-00236">100</a>,<a href="#B101-biomedicines-10-00236" class="usa-link" aria-describedby="B101-biomedicines-10-00236">101</a>,<a href="#B102-biomedicines-10-00236" class="usa-link" aria-describedby="B102-biomedicines-10-00236">102</a>,<a href="#B103-biomedicines-10-00236" class="usa-link" aria-describedby="B103-biomedicines-10-00236">103</a>,<a href="#B104-biomedicines-10-00236" class="usa-link" aria-describedby="B104-biomedicines-10-00236">104</a>,<a href="#B105-biomedicines-10-00236" class="usa-link" aria-describedby="B105-biomedicines-10-00236">105</a>,<a href="#B106-biomedicines-10-00236" class="usa-link" aria-describedby="B106-biomedicines-10-00236">106</a>,<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B108-biomedicines-10-00236" class="usa-link" aria-describedby="B108-biomedicines-10-00236">108</a>,<a href="#B109-biomedicines-10-00236" class="usa-link" aria-describedby="B109-biomedicines-10-00236">109</a>,<a href="#B110-biomedicines-10-00236" class="usa-link" aria-describedby="B110-biomedicines-10-00236">110</a>,<a href="#B111-biomedicines-10-00236" class="usa-link" aria-describedby="B111-biomedicines-10-00236">111</a>,<a href="#B112-biomedicines-10-00236" class="usa-link" aria-describedby="B112-biomedicines-10-00236">112</a>,<a href="#B113-biomedicines-10-00236" class="usa-link" aria-describedby="B113-biomedicines-10-00236">113</a>,<a href="#B114-biomedicines-10-00236" class="usa-link" aria-describedby="B114-biomedicines-10-00236">114</a>,<a href="#B115-biomedicines-10-00236" class="usa-link" aria-describedby="B115-biomedicines-10-00236">115</a>,<a href="#B116-biomedicines-10-00236" class="usa-link" aria-describedby="B116-biomedicines-10-00236">116</a>,<a href="#B117-biomedicines-10-00236" class="usa-link" aria-describedby="B117-biomedicines-10-00236">117</a>,<a href="#B118-biomedicines-10-00236" class="usa-link" aria-describedby="B118-biomedicines-10-00236">118</a>,<a href="#B119-biomedicines-10-00236" class="usa-link" aria-describedby="B119-biomedicines-10-00236">119</a>,<a href="#B120-biomedicines-10-00236" class="usa-link" aria-describedby="B120-biomedicines-10-00236">120</a>,<a href="#B121-biomedicines-10-00236" class="usa-link" aria-describedby="B121-biomedicines-10-00236">121</a>,<a href="#B122-biomedicines-10-00236" class="usa-link" aria-describedby="B122-biomedicines-10-00236">122</a>,<a href="#B123-biomedicines-10-00236" class="usa-link" aria-describedby="B123-biomedicines-10-00236">123</a>,<a href="#B124-biomedicines-10-00236" class="usa-link" aria-describedby="B124-biomedicines-10-00236">124</a>,<a href="#B125-biomedicines-10-00236" class="usa-link" aria-describedby="B125-biomedicines-10-00236">125</a>,<a href="#B126-biomedicines-10-00236" class="usa-link" aria-describedby="B126-biomedicines-10-00236">126</a>,<a href="#B127-biomedicines-10-00236" class="usa-link" aria-describedby="B127-biomedicines-10-00236">127</a>,<a href="#B128-biomedicines-10-00236" class="usa-link" aria-describedby="B128-biomedicines-10-00236">128</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>,<a href="#B130-biomedicines-10-00236" class="usa-link" aria-describedby="B130-biomedicines-10-00236">130</a>,<a href="#B131-biomedicines-10-00236" class="usa-link" aria-describedby="B131-biomedicines-10-00236">131</a>,<a href="#B132-biomedicines-10-00236" class="usa-link" aria-describedby="B132-biomedicines-10-00236">132</a>,<a href="#B133-biomedicines-10-00236" class="usa-link" aria-describedby="B133-biomedicines-10-00236">133</a>,<a href="#B134-biomedicines-10-00236" class="usa-link" aria-describedby="B134-biomedicines-10-00236">134</a>,<a href="#B135-biomedicines-10-00236" class="usa-link" aria-describedby="B135-biomedicines-10-00236">135</a>,<a href="#B136-biomedicines-10-00236" class="usa-link" aria-describedby="B136-biomedicines-10-00236">136</a>,<a href="#B137-biomedicines-10-00236" class="usa-link" aria-describedby="B137-biomedicines-10-00236">137</a>,<a href="#B138-biomedicines-10-00236" class="usa-link" aria-describedby="B138-biomedicines-10-00236">138</a>,<a href="#B139-biomedicines-10-00236" class="usa-link" aria-describedby="B139-biomedicines-10-00236">139</a>,<a href="#B140-biomedicines-10-00236" class="usa-link" aria-describedby="B140-biomedicines-10-00236">140</a>,<a href="#B141-biomedicines-10-00236" class="usa-link" aria-describedby="B141-biomedicines-10-00236">141</a>,<a href="#B142-biomedicines-10-00236" class="usa-link" aria-describedby="B142-biomedicines-10-00236">142</a>,<a href="#B143-biomedicines-10-00236" class="usa-link" aria-describedby="B143-biomedicines-10-00236">143</a>,<a href="#B144-biomedicines-10-00236" class="usa-link" aria-describedby="B144-biomedicines-10-00236">144</a>,<a href="#B145-biomedicines-10-00236" class="usa-link" aria-describedby="B145-biomedicines-10-00236">145</a>,<a href="#B146-biomedicines-10-00236" class="usa-link" aria-describedby="B146-biomedicines-10-00236">146</a>,<a href="#B147-biomedicines-10-00236" class="usa-link" aria-describedby="B147-biomedicines-10-00236">147</a>,<a href="#B148-biomedicines-10-00236" class="usa-link" aria-describedby="B148-biomedicines-10-00236">148</a>,<a href="#B149-biomedicines-10-00236" class="usa-link" aria-describedby="B149-biomedicines-10-00236">149</a>,<a href="#B150-biomedicines-10-00236" class="usa-link" aria-describedby="B150-biomedicines-10-00236">150</a>,<a href="#B151-biomedicines-10-00236" class="usa-link" aria-describedby="B151-biomedicines-10-00236">151</a>,<a href="#B152-biomedicines-10-00236" class="usa-link" aria-describedby="B152-biomedicines-10-00236">152</a>,<a href="#B153-biomedicines-10-00236" class="usa-link" aria-describedby="B153-biomedicines-10-00236">153</a>,<a href="#B154-biomedicines-10-00236" class="usa-link" aria-describedby="B154-biomedicines-10-00236">154</a>,<a href="#B155-biomedicines-10-00236" class="usa-link" aria-describedby="B155-biomedicines-10-00236">155</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>,<a href="#B157-biomedicines-10-00236" class="usa-link" aria-describedby="B157-biomedicines-10-00236">157</a>]. Data of other aggressive histotypes (such as neuroendocrine carcinomas or carcinosarcomas) were unavailable or unclear; further studies are required.</p>
<p>MMR deficiency could be associated with aggressive clinic–pathologic features in PC (high Gleason score, advanced stage, decreased OS); dMMR mutational signatures were sometimes associated with increased T cell-related and checkpoint-related transcripts (including PD-L1 and PD-L2) [<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B167-biomedicines-10-00236" class="usa-link" aria-describedby="B167-biomedicines-10-00236">167</a>,<a href="#B168-biomedicines-10-00236" class="usa-link" aria-describedby="B168-biomedicines-10-00236">168</a>]. In another series [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>], loss of ≥1 MMR protein and PD-L1 expression in TILs had a significantly higher BCR risk. </p>
<p>An association between MSI-H status and the efficacy of PD-L1/PD-1 inhibitors has been established in a range of solid tumors, including a relatively small number of PC cases; MMR deficiency was sometimes associated with favorable response to anti-PD-1 therapy or PD-L1 expression [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B167-biomedicines-10-00236" class="usa-link" aria-describedby="B167-biomedicines-10-00236">167</a>,<a href="#B168-biomedicines-10-00236" class="usa-link" aria-describedby="B168-biomedicines-10-00236">168</a>,<a href="#B169-biomedicines-10-00236" class="usa-link" aria-describedby="B169-biomedicines-10-00236">169</a>,<a href="#B170-biomedicines-10-00236" class="usa-link" aria-describedby="B170-biomedicines-10-00236">170</a>,<a href="#B171-biomedicines-10-00236" class="usa-link" aria-describedby="B171-biomedicines-10-00236">171</a>,<a href="#B172-biomedicines-10-00236" class="usa-link" aria-describedby="B172-biomedicines-10-00236">172</a>,<a href="#B173-biomedicines-10-00236" class="usa-link" aria-describedby="B173-biomedicines-10-00236">173</a>,<a href="#B174-biomedicines-10-00236" class="usa-link" aria-describedby="B174-biomedicines-10-00236">174</a>]. The 2021 NCCN guidelines have allowed immunotherapy in men with asymptomatic or minimally symptomatic mCRPCs; pembrolizumab can be administered as ≥2nd line systemic therapy to dMMR/MSI-H mCRPCs that have progressed through prior docetaxel and/or novel hormone therapy [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. Durable clinical benefit, sometimes with a 50% reduction in PSA levels, was occasionally reported in PC patients receiving checkpoint inhibitors as monotherapy or combination therapy, although with variable response rates: it was usually unclear if PD-L1 was tested in all these cases [<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B167-biomedicines-10-00236" class="usa-link" aria-describedby="B167-biomedicines-10-00236">167</a>,<a href="#B175-biomedicines-10-00236" class="usa-link" aria-describedby="B175-biomedicines-10-00236">175</a>]. However, the dMMR/H-MSI status does not necessarily correlate to the response to immunotherapy: emerging clinical data have reported that dMMR/MSI-H mCRPCs do not always respond, while responders are not necessarily dMMR/MSI-H (by IHC and/or polymerase chain reaction analysis) [<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>].</p>
<p>The NCCN guidelines recommend using a metastatic biopsy for histologic and molecular analysis of somatic tumor testing [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. Indeed, the MSI-H/dMMR phenotype may be acquired somatically during disease evolution; in a study, MSI may have been subclonal in earlier samples of two longitudinally profiled PCs, which is probably due to tumor heterogeneity (not favoring a truncal event) [<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>]. Unfortunately, the NCCN guidelines [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>] do not define how to evaluate the MSI-H/dMMR or the PD-L1 status: MSI-H or dMMR can be tested by using either DNA tests or IHC. The second approach is easy to use and cost-effective, but it may be insufficient to predict PC recurrence after radical prostatectomy [<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B168-biomedicines-10-00236" class="usa-link" aria-describedby="B168-biomedicines-10-00236">168</a>,<a href="#B169-biomedicines-10-00236" class="usa-link" aria-describedby="B169-biomedicines-10-00236">169</a>,<a href="#B170-biomedicines-10-00236" class="usa-link" aria-describedby="B170-biomedicines-10-00236">170</a>,<a href="#B171-biomedicines-10-00236" class="usa-link" aria-describedby="B171-biomedicines-10-00236">171</a>,<a href="#B172-biomedicines-10-00236" class="usa-link" aria-describedby="B172-biomedicines-10-00236">172</a>,<a href="#B173-biomedicines-10-00236" class="usa-link" aria-describedby="B173-biomedicines-10-00236">173</a>,<a href="#B174-biomedicines-10-00236" class="usa-link" aria-describedby="B174-biomedicines-10-00236">174</a>]. In case of molecular testing, validated NGS assays are preferred by the NCCN guidelines [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. NGS can assess for the MSI-H/dMMR status by interrogating microsatellite loci to identify MSI, finding mutations and copy number alterations in MMR-associated genes; it can also infer the TMB, which is a phenotypic hallmark of MSI-H/dMMR tumors [<a href="#B176-biomedicines-10-00236" class="usa-link" aria-describedby="B176-biomedicines-10-00236">176</a>,<a href="#B177-biomedicines-10-00236" class="usa-link" aria-describedby="B177-biomedicines-10-00236">177</a>]. In clinical practice, data on TMB and MMR genes mutational status could help in case of indeterminate MSI sensor scores or low-quality/purity tumor tissues [<a href="#B171-biomedicines-10-00236" class="usa-link" aria-describedby="B171-biomedicines-10-00236">171</a>,<a href="#B172-biomedicines-10-00236" class="usa-link" aria-describedby="B172-biomedicines-10-00236">172</a>]. </p>
<p>About 40–50% of PCs are hereditary, frequently showing earlier onset, familial clustering, and multifocality; mutations and polymorphisms of several tumor suppressor genes and proto-oncogenes play a key role in PC onset and progression [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B169-biomedicines-10-00236" class="usa-link" aria-describedby="B169-biomedicines-10-00236">169</a>]. The impairment of MMR genes has been linked not only to sporadic PC cases (usually harboring <em>MSH2</em> or <em>MSH6</em> gene defects), but also to some hereditary forms of PC [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B169-biomedicines-10-00236" class="usa-link" aria-describedby="B169-biomedicines-10-00236">169</a>,<a href="#B178-biomedicines-10-00236" class="usa-link" aria-describedby="B178-biomedicines-10-00236">178</a>,<a href="#B179-biomedicines-10-00236" class="usa-link" aria-describedby="B179-biomedicines-10-00236">179</a>]. Lynch syndrome is an autosomal-dominant genetic disorder driven by germline mutations in MMR genes (such as <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em>, and <em>PMS2</em>), harboring greater cancer risk (especially for colorectal adenocarcinoma, but also for PC) through MSI [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B169-biomedicines-10-00236" class="usa-link" aria-describedby="B169-biomedicines-10-00236">169</a>,<a href="#B178-biomedicines-10-00236" class="usa-link" aria-describedby="B178-biomedicines-10-00236">178</a>,<a href="#B179-biomedicines-10-00236" class="usa-link" aria-describedby="B179-biomedicines-10-00236">179</a>]. NGS may identify germline MMR mutations, and genetic counselling for Lynch syndrome is advised for MSI-H/dMMR patients by the NCCN guidelines [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. Unfortunately, the scant available information did not allow us to understand how many cases really harbored a Lynch syndrome and to discuss the potential differences in PD-L1 expression between somatic vs. germline MMR genes mutations.</p>
<p>NGS may also represent an efficient strategy to identify PC patients who may benefit from anti-PD-1/PD-L1 therapies, especially in cases with higher TMB (often associated with MMR genes alterations) [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>,<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B176-biomedicines-10-00236" class="usa-link" aria-describedby="B176-biomedicines-10-00236">176</a>]. In various neoplasms, higher TMB seems to predict favorable outcomes related to anti-PD-1/PD-L1 immunotherapy administration; indeed, the 2021 NCCN guidelines have also allowed pembrolizumab (as a second-line therapy or beyond) for mCRPCs, showing TMB &gt; 10 mutations/Mb [<a href="#B4-biomedicines-10-00236" class="usa-link" aria-describedby="B4-biomedicines-10-00236">4</a>]. In PC, the median PC TMB is 3.6–4 mutations/Mb, while only 2–7.7% of cases have &gt;20 mutations/Mb [<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B177-biomedicines-10-00236" class="usa-link" aria-describedby="B177-biomedicines-10-00236">177</a>,<a href="#B180-biomedicines-10-00236" class="usa-link" aria-describedby="B180-biomedicines-10-00236">180</a>]. CRPCs usually show low TMB with alterations in key regulatory pathways (such as <em>PI3K</em> and androgen pathways), while ≈50% of CRPCs carry gene fusions correlating with poor prognosis: fusion-positive PCs may still harbor many neoantigens from gene fusions, potentially serving as immunotherapy targets [<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B181-biomedicines-10-00236" class="usa-link" aria-describedby="B181-biomedicines-10-00236">181</a>,<a href="#B182-biomedicines-10-00236" class="usa-link" aria-describedby="B182-biomedicines-10-00236">182</a>]. In a PC series [<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>], high tumor fusion burden (TFB)—measuring the number of gene fusions in a tumor—inversely correlated with TMB and immune suppressive signatures; conversely, it was positively associated with immune infiltration, PD-L1 expression on immune cells, and immune signatures (representing activation of T cells and M1 macrophages, checkpoint inhibitors, IFN-γ-induced T-cell activity, T-effector activation, and class I antigen processing), cell cycle progression, AR signaling, and ERG/ETS transcriptional activity. Cases with <em>ERG</em> fusion had significantly higher overall fusion burden (<em>p</em> &lt; 0.0002) and higher <em>ERG</em> transcriptional activity (<em>p</em> &lt; 0.0001) [<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>]. On the other hand, Chen et al. reported that PD-L1, CD8A, or CYT expression was not associated with TMB and neoantigen number in PC [<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>].</p></section><section id="sec4dot2-biomedicines-10-00236"><h3 class="pmc_sec_title">4.2. PD-L1 and BRCA1/2</h3>
<p><em>BRCA1</em> regulates the cellular DNA damage response and repair, transcriptional regulation, and chromatin modeling, while <em>BRCA2</em> plays a role in the DDR processes [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B163-biomedicines-10-00236" class="usa-link" aria-describedby="B163-biomedicines-10-00236">163</a>]. In PC, <em>BRCA1</em> co-regulates the AR activity mediating tumor progression, while <em>BRCA2</em> limits the metastatic potential of PC by MMP9 downregulation and inhibition of the <em>PI3K/AKT</em> and <em>MAP/ERK</em> pathways (which also regulate PD-L1 expression) [<a href="#B163-biomedicines-10-00236" class="usa-link" aria-describedby="B163-biomedicines-10-00236">163</a>,<a href="#B164-biomedicines-10-00236" class="usa-link" aria-describedby="B164-biomedicines-10-00236">164</a>,<a href="#B183-biomedicines-10-00236" class="usa-link" aria-describedby="B183-biomedicines-10-00236">183</a>,<a href="#B184-biomedicines-10-00236" class="usa-link" aria-describedby="B184-biomedicines-10-00236">184</a>]. </p>
<p>Loss of <em>BRCA1</em> or <em>BRCA2</em> is linked to a deficiency in HRR of DNA double-strand breaks; the failure of the <em>BRCA</em>-mediated HRR mechanism is due to combined germline and somatic mutations, favoring the activation of alternative and less effective DNA repair pathways (such as base/nucleotide excision repair or mismatch repair system) (<a href="#biomedicines-10-00236-f002" class="usa-link">Figure 2</a>) [<a href="#B7-biomedicines-10-00236" class="usa-link" aria-describedby="B7-biomedicines-10-00236">7</a>,<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B163-biomedicines-10-00236" class="usa-link" aria-describedby="B163-biomedicines-10-00236">163</a>,<a href="#B164-biomedicines-10-00236" class="usa-link" aria-describedby="B164-biomedicines-10-00236">164</a>].</p>
<figure class="fig xbox font-sm" id="biomedicines-10-00236-f002"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8868626_biomedicines-10-00236-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce75/8868626/16608344f739/biomedicines-10-00236-g002.jpg" loading="lazy" height="451" width="728" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/biomedicines-10-00236-f002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Intracellular DNA damage repair pathways (BER: base excision repair; HRR: homologous recombination repair; MHC: major histocompatibility complex; MMR: mismatch repair system protein; PARP: poly-ADP-ribose polymerase; PARPi: PARP inhibitors; TCR: T-cell receptor).</p></figcaption></figure><p>Initial studies estimated a &lt;15% <em>BRCA1-2</em> mutation rate in PCs [<a href="#B169-biomedicines-10-00236" class="usa-link" aria-describedby="B169-biomedicines-10-00236">169</a>,<a href="#B185-biomedicines-10-00236" class="usa-link" aria-describedby="B185-biomedicines-10-00236">185</a>,<a href="#B186-biomedicines-10-00236" class="usa-link" aria-describedby="B186-biomedicines-10-00236">186</a>,<a href="#B187-biomedicines-10-00236" class="usa-link" aria-describedby="B187-biomedicines-10-00236">187</a>,<a href="#B188-biomedicines-10-00236" class="usa-link" aria-describedby="B188-biomedicines-10-00236">188</a>,<a href="#B189-biomedicines-10-00236" class="usa-link" aria-describedby="B189-biomedicines-10-00236">189</a>,<a href="#B190-biomedicines-10-00236" class="usa-link" aria-describedby="B190-biomedicines-10-00236">190</a>,<a href="#B191-biomedicines-10-00236" class="usa-link" aria-describedby="B191-biomedicines-10-00236">191</a>]. Some authors found that 1–2% of young-onset PC patients had a germline <em>BRCA2</em> mutation, conferring a five to seven-fold greater lifetime risk for developing PC (three to eight-fold greater risk for <em>BRCA1</em> mutations) [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B192-biomedicines-10-00236" class="usa-link" aria-describedby="B192-biomedicines-10-00236">192</a>]; other studies estimated a 20% lifetime risk for <em>BRCA2</em>-mutated patients (9.5% for <em>BRCA1</em>-mutated carriers) [<a href="#B169-biomedicines-10-00236" class="usa-link" aria-describedby="B169-biomedicines-10-00236">169</a>,<a href="#B186-biomedicines-10-00236" class="usa-link" aria-describedby="B186-biomedicines-10-00236">186</a>]. The TCGA (<em>n</em> = 333 PCs) identified several germline mutations of DDR genes, including <em>BRCA2</em> (13%), <em>ATM</em> (7.3%), <em>MSH2</em> (2%), and <em>BRCA1</em> (0.3%) [<a href="#B189-biomedicines-10-00236" class="usa-link" aria-describedby="B189-biomedicines-10-00236">189</a>]. More recently, other authors found higher <em>BRCA2</em> (24.3%) and <em>BRCA1</em> (6.4%) germline mutation rates (6.4%) [<a href="#B190-biomedicines-10-00236" class="usa-link" aria-describedby="B190-biomedicines-10-00236">190</a>]; mCRPCs may present up to 20–30% of DDR genes mutations [<a href="#B191-biomedicines-10-00236" class="usa-link" aria-describedby="B191-biomedicines-10-00236">191</a>].</p>
<p>Loss of function of <em>BRCA1/2</em>, <em>ATM</em> (a DNA-damage checkpoint indirectly activating HRR), and other HRR genes are associated with more aggressive PCs (higher Gleason score; lymph node involvement, and/or metastatic disease at presentation; worse CSS/MFS) [<a href="#B169-biomedicines-10-00236" class="usa-link" aria-describedby="B169-biomedicines-10-00236">169</a>,<a href="#B170-biomedicines-10-00236" class="usa-link" aria-describedby="B170-biomedicines-10-00236">170</a>]. In a study, the CSS of <em>BRCA</em>-mutated PC patients was 8.6 years compared to 15.7 years in non-carriers (MFS 77% vs. 93%) [<a href="#B187-biomedicines-10-00236" class="usa-link" aria-describedby="B187-biomedicines-10-00236">187</a>]. Compared to non-carriers, <em>BRCA2</em> mutation carriers showed a higher rate of &gt;50% PSA decline (Pomerantz et al.: 75% vs. 17%; Schmid et al.: 64% vs. 20–30%) and OS after platinum-based therapy (Pomerantz et al.: 18.9 vs. 9.5 months) [<a href="#B193-biomedicines-10-00236" class="usa-link" aria-describedby="B193-biomedicines-10-00236">193</a>,<a href="#B194-biomedicines-10-00236" class="usa-link" aria-describedby="B194-biomedicines-10-00236">194</a>].</p>
<p>Very few studies simultaneously analyzed PD-L1 expression and <em>BRCA</em> status [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>]. <em>BRCA1/2</em> genes aberrations were found in 15/39 (39%) PCs [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>], but the PD-L1 status was usually unclear, as only 1/10 (10%) PC with <em>BRCA</em> aberrations was clearly PD-L1+ [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>]. The scant available information did not allow the discussion of the potential differences in PD-L1 expression between somatic vs. germline <em>BRCA</em> mutations.</p>
<p><em>BRCA1/2</em> mutations also affect the response to treatment; metastatic PC patients with germline <em>BRCA2</em> mutations became resistant to the androgen deprivation therapy faster than non-carriers (13.2 vs. 28 months), showing a halved CSS [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B188-biomedicines-10-00236" class="usa-link" aria-describedby="B188-biomedicines-10-00236">188</a>]. Occasional studies investigated if the BRCA/DDR genes status may also affect the response to immunotherapy [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B170-biomedicines-10-00236" class="usa-link" aria-describedby="B170-biomedicines-10-00236">170</a>]. Petrylak et al. reported that most CRPC patients with DDR alterations did not respond to atezolizumab (anti-PD-L1): the DDR status was not a strong predictor of clinical benefit [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>]. However, in other studies, PD-1 inhibition revealed activity in mCRPCs, including tumors lacking MSI, DDR defects, or PD-L1 expression [<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>]. In the phase II KEYNOTE-199 study, pembrolizumab (anti-PD-1) showed antitumor activity and disease control with acceptable safety in docetaxel-refractory mCRPCs, regardless of PD-L1 status, in both RECIST-measurable and non-measurable cases; 19/153 (12%) tested PCs had <em>BRCA1/2</em> or <em>ATM</em> aberrations and higher responses rates, but it was unclear if there was a correlation between the <em>BRCA</em> and PD-L1 status [<a href="#B170-biomedicines-10-00236" class="usa-link" aria-describedby="B170-biomedicines-10-00236">170</a>]. Further studies are required.</p>
<p>PARPi are Food and Drug Administration (FDA)-approved drugs for <em>BRCA</em>-mutant ovarian and breast carcinomas [<a href="#B9-biomedicines-10-00236" class="usa-link" aria-describedby="B9-biomedicines-10-00236">9</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B195-biomedicines-10-00236" class="usa-link" aria-describedby="B195-biomedicines-10-00236">195</a>]. PARPi block the base excision DNA repair pathway (<a href="#biomedicines-10-00236-f002" class="usa-link">Figure 2</a>) while defects in <em>BRCA</em> simultaneously prevent HRR, leading to genomic instability and the accumulation of DNA damage; these effects can trigger cell cycle arrest and apoptosis [<a href="#B195-biomedicines-10-00236" class="usa-link" aria-describedby="B195-biomedicines-10-00236">195</a>]. Olaparib and rucaparib are PARPi approved for the treatment of mCRPCs with <em>BRCA</em> germline mutations, while new drugs are under investigation (niraparib and talazoparib) [<a href="#B191-biomedicines-10-00236" class="usa-link" aria-describedby="B191-biomedicines-10-00236">191</a>,<a href="#B196-biomedicines-10-00236" class="usa-link" aria-describedby="B196-biomedicines-10-00236">196</a>]. In a clinical study, compared to ABT alone, olaparib plus ABT improved the PFS (8.2 vs. 13.8 months) [<a href="#B197-biomedicines-10-00236" class="usa-link" aria-describedby="B197-biomedicines-10-00236">197</a>], which was probably regardless of the mutational status of HRR genes [<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>]. Rucaparib induced PSA and radiographic responses in 48% and 45%, respectively, in <em>BRCA2</em> mutation carriers (phase II trial) [<a href="#B196-biomedicines-10-00236" class="usa-link" aria-describedby="B196-biomedicines-10-00236">196</a>], while olaparib showed better PFS than AR signaling inhibitors (ARSi) in mCRPC patients with <em>BRCA1-2</em> germline mutations (7.4 vs. 3.55 months) (PROFOUND phase III trial) [<a href="#B191-biomedicines-10-00236" class="usa-link" aria-describedby="B191-biomedicines-10-00236">191</a>]. In mCRPCs having HRR genes alterations and progressing on ENZ or ABT, olaparib was associated with longer PFS and better response to therapy than ENZ/ABT alone, while niraparib revealed a higher objective response rate (ORR) (41% vs. 9%) and longer PFS (8.2 vs. 5.3 months) in mCRPC patients with DDR defects receiving ARSi and taxane-based chemotherapy [<a href="#B197-biomedicines-10-00236" class="usa-link" aria-describedby="B197-biomedicines-10-00236">197</a>,<a href="#B198-biomedicines-10-00236" class="usa-link" aria-describedby="B198-biomedicines-10-00236">198</a>,<a href="#B199-biomedicines-10-00236" class="usa-link" aria-describedby="B199-biomedicines-10-00236">199</a>]. The TALAPRO-1 phase II trial (<a href="https://clinicaltrials.gov/ct2/show/NCT03148795" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03148795</a>; <a href="https://clinicaltrials.gov" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov</a>, accessed on 26 December 2021) is evaluating talazoparib in mCRPC patients: initial data reported better ORR for <em>BRCA1-2</em> (43.9%) vs. <em>ATM</em> (11.8%) mutations carriers [<a href="#B191-biomedicines-10-00236" class="usa-link" aria-describedby="B191-biomedicines-10-00236">191</a>,<a href="#B200-biomedicines-10-00236" class="usa-link" aria-describedby="B200-biomedicines-10-00236">200</a>]. </p>
<p>Exceptionally, some authors performed a combined analysis of the effects of anti-PD-1/PD-L1 and PARPi in PC patients [<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>]. Durvalumab is a human anti-PD-L1 IgG1-K monoclonal antibody approved by the FDA for locally advanced or metastatic urothelial cancer and locally advanced, unresectable, stage 3 non-small cell lung cancer; Karzai et al. [<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>] found that olaparib (PARPi) plus durvalumab demonstrated activity in PC patients without biallelic inactivation of DDR pathways, reaching deep responses in mutated cases: this drug combination revealed acceptable toxicity and efficacy. It was unclear which cases were evaluated for PD-L1. Further studies are required.</p>
<p>Genotoxic stress and stalled DNA replication forks favor the expression of ligands for the NKG2D receptor of NK cells [<a href="#B195-biomedicines-10-00236" class="usa-link" aria-describedby="B195-biomedicines-10-00236">195</a>]; DDR inhibitors may also increase the NK killing activity [<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>]. In PC cell lines, olaparib significantly increased tumor cell sensitivity to NK-mediated killing and antibody-dependent cytotoxicity (ADCC), regardless of <em>BRCA</em> status, PD-L1, or epithelial growth factor receptor (EGFR) modulation [<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>]. PARPi activates the “stimulator of interferon genes” (STING) pathway in breast carcinoma, upregulating PD-L1; in <em>BRCA</em> wild-type PC cell lines, STING upregulation occurred after PARPi administration without increasing the PD-L1 expression [<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>]. Conversely, STING was not expressed in <em>BRCA</em> mutant 22RV1 DU145 PC cell lines, either before or after olaparib treatment; disparities may be due to differences in olaparib exposure [<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>]. </p>
<p>Olaparib may enhance the killing activity of endogenous or engineered high-affinity NK cells [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>]. ADCC is elicited by the interaction between CD16 (FcγRIII) on NK cells and the Fc portion of IgG1 antibodies of target cells; the NK-mediated immune surveillance and killing of non-self cells are induced by target cell surface death receptors, activating a caspase cascade and resulting in apoptosis [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>]. In PC cell lines, olaparib upregulated TRAIL-R2 (a death receptor targeted by the TRAIL ligand on NK cells), activating the caspase cascade [<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>]. The combined use of NK- and ADCC-mediating agents with PARPi in <em>BRCA</em> mutant and wild-type PC may improve treatment efficacy. A lack of PD-L1 upregulation suggests that ADCC-mediating antibodies not targeting PD-L1 (such as cetuximab) may also be exploited in combination with PARPi [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>].</p></section><section id="sec4dot3-biomedicines-10-00236"><h3 class="pmc_sec_title">4.3. PD-L1 and PTEN</h3>
<p>PD-L1 expression on tumor cells can be induced by cytokines secreted by activated T cells (favoring the adaptive immune resistance) or due to constitutive expression induced by genetic alterations (such as <em>EGFR/KRAS</em> mutations, <em>ALK</em> rearrangements, <em>PTEN</em> loss) or activation of signaling pathways (intrinsic immune resistance) [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>,<a href="#B200-biomedicines-10-00236" class="usa-link" aria-describedby="B200-biomedicines-10-00236">200</a>].</p>
<p><em>PTEN</em> is a tumor suppressor gene encoding the phosphatase and tensin homolog, a lipid and protein enzyme. It regulates cell cycle, proliferation, and apoptosis through different pathways, including the PI3K/AKT/mTOR (which upregulates PD-L1 in PC) [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>]. </p>
<p>PTEN loss and the associated <em>PI3K</em> gene activation correlated to PD-L1 expression in tumors such as glioblastoma [<a href="#B201-biomedicines-10-00236" class="usa-link" aria-describedby="B201-biomedicines-10-00236">201</a>,<a href="#B202-biomedicines-10-00236" class="usa-link" aria-describedby="B202-biomedicines-10-00236">202</a>,<a href="#B203-biomedicines-10-00236" class="usa-link" aria-describedby="B203-biomedicines-10-00236">203</a>]. <em>PTEN</em> activity may be also reduced in PC; its expression can lack in whole tumor or in some areas [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>]. <em>PTEN</em> loss is a relatively frequent, late event in mCRPCs, which is probably associated with worse prognosis [<a href="#B197-biomedicines-10-00236" class="usa-link" aria-describedby="B197-biomedicines-10-00236">197</a>,<a href="#B204-biomedicines-10-00236" class="usa-link" aria-describedby="B204-biomedicines-10-00236">204</a>,<a href="#B205-biomedicines-10-00236" class="usa-link" aria-describedby="B205-biomedicines-10-00236">205</a>]; however, it may indicate a sensitivity to Akt-inhibitors (such as ipatasertib) [<a href="#B200-biomedicines-10-00236" class="usa-link" aria-describedby="B200-biomedicines-10-00236">200</a>,<a href="#B206-biomedicines-10-00236" class="usa-link" aria-describedby="B206-biomedicines-10-00236">206</a>]. </p>
<p>According to our review, 179/326 (55%) PCs showed PTEN loss by IHC: 13/137 (10%) of PTEN- cases were PD-L1+, while 10/29 (35%) of PD-L1+ cases were PTEN- [<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>]. The few studies investigating PD-L1 and PTEN IHC expression did not find significant correlations [<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>]; however, various (sometimes unclear) assays and scoring systems of PTEN and PD-L1 were used, and few cases were tested. PTEN loss may increase the levels of several immunosuppressive cytokines, as well as the infiltration of granulocytic myeloid-derived suppressor cells, and the inhibition of T-cell–mediated tumor killing; it can also decrease the T-cell trafficking into the tumor microenvironment [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>]. </p>
<p><em>PTEN</em> expression can be altered by gene deletion (bi- or mono-allelic), DNA methylation, transcriptional repression, and translational disorder, possibly leading to distinctive signaling modulations [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>]. <em>PTEN</em> mutations (4/33, 12%) or copy number loss (5/33, 15%) were found in two molecular studies (total: 9/33, 27%) [<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>], but correlations between the PTEN and PD-L1 statuses were not reported in detail. </p>
<p>The PI3K/AKT/mTOR pathway contributes to regulate PD-L1 expression in PCs [<a href="#B8-biomedicines-10-00236" class="usa-link" aria-describedby="B8-biomedicines-10-00236">8</a>,<a href="#B11-biomedicines-10-00236" class="usa-link" aria-describedby="B11-biomedicines-10-00236">11</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>,<a href="#B13-biomedicines-10-00236" class="usa-link" aria-describedby="B13-biomedicines-10-00236">13</a>,<a href="#B14-biomedicines-10-00236" class="usa-link" aria-describedby="B14-biomedicines-10-00236">14</a>,<a href="#B15-biomedicines-10-00236" class="usa-link" aria-describedby="B15-biomedicines-10-00236">15</a>,<a href="#B16-biomedicines-10-00236" class="usa-link" aria-describedby="B16-biomedicines-10-00236">16</a>,<a href="#B17-biomedicines-10-00236" class="usa-link" aria-describedby="B17-biomedicines-10-00236">17</a>,<a href="#B18-biomedicines-10-00236" class="usa-link" aria-describedby="B18-biomedicines-10-00236">18</a>,<a href="#B19-biomedicines-10-00236" class="usa-link" aria-describedby="B19-biomedicines-10-00236">19</a>,<a href="#B20-biomedicines-10-00236" class="usa-link" aria-describedby="B20-biomedicines-10-00236">20</a>,<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>,<a href="#B22-biomedicines-10-00236" class="usa-link" aria-describedby="B22-biomedicines-10-00236">22</a>,<a href="#B23-biomedicines-10-00236" class="usa-link" aria-describedby="B23-biomedicines-10-00236">23</a>,<a href="#B24-biomedicines-10-00236" class="usa-link" aria-describedby="B24-biomedicines-10-00236">24</a>,<a href="#B25-biomedicines-10-00236" class="usa-link" aria-describedby="B25-biomedicines-10-00236">25</a>,<a href="#B26-biomedicines-10-00236" class="usa-link" aria-describedby="B26-biomedicines-10-00236">26</a>,<a href="#B27-biomedicines-10-00236" class="usa-link" aria-describedby="B27-biomedicines-10-00236">27</a>,<a href="#B28-biomedicines-10-00236" class="usa-link" aria-describedby="B28-biomedicines-10-00236">28</a>,<a href="#B29-biomedicines-10-00236" class="usa-link" aria-describedby="B29-biomedicines-10-00236">29</a>,<a href="#B30-biomedicines-10-00236" class="usa-link" aria-describedby="B30-biomedicines-10-00236">30</a>,<a href="#B31-biomedicines-10-00236" class="usa-link" aria-describedby="B31-biomedicines-10-00236">31</a>,<a href="#B32-biomedicines-10-00236" class="usa-link" aria-describedby="B32-biomedicines-10-00236">32</a>,<a href="#B33-biomedicines-10-00236" class="usa-link" aria-describedby="B33-biomedicines-10-00236">33</a>,<a href="#B34-biomedicines-10-00236" class="usa-link" aria-describedby="B34-biomedicines-10-00236">34</a>,<a href="#B35-biomedicines-10-00236" class="usa-link" aria-describedby="B35-biomedicines-10-00236">35</a>,<a href="#B36-biomedicines-10-00236" class="usa-link" aria-describedby="B36-biomedicines-10-00236">36</a>,<a href="#B37-biomedicines-10-00236" class="usa-link" aria-describedby="B37-biomedicines-10-00236">37</a>,<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B39-biomedicines-10-00236" class="usa-link" aria-describedby="B39-biomedicines-10-00236">39</a>,<a href="#B40-biomedicines-10-00236" class="usa-link" aria-describedby="B40-biomedicines-10-00236">40</a>,<a href="#B41-biomedicines-10-00236" class="usa-link" aria-describedby="B41-biomedicines-10-00236">41</a>,<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B43-biomedicines-10-00236" class="usa-link" aria-describedby="B43-biomedicines-10-00236">43</a>,<a href="#B44-biomedicines-10-00236" class="usa-link" aria-describedby="B44-biomedicines-10-00236">44</a>,<a href="#B45-biomedicines-10-00236" class="usa-link" aria-describedby="B45-biomedicines-10-00236">45</a>,<a href="#B46-biomedicines-10-00236" class="usa-link" aria-describedby="B46-biomedicines-10-00236">46</a>,<a href="#B47-biomedicines-10-00236" class="usa-link" aria-describedby="B47-biomedicines-10-00236">47</a>,<a href="#B48-biomedicines-10-00236" class="usa-link" aria-describedby="B48-biomedicines-10-00236">48</a>,<a href="#B49-biomedicines-10-00236" class="usa-link" aria-describedby="B49-biomedicines-10-00236">49</a>,<a href="#B50-biomedicines-10-00236" class="usa-link" aria-describedby="B50-biomedicines-10-00236">50</a>,<a href="#B51-biomedicines-10-00236" class="usa-link" aria-describedby="B51-biomedicines-10-00236">51</a>,<a href="#B52-biomedicines-10-00236" class="usa-link" aria-describedby="B52-biomedicines-10-00236">52</a>,<a href="#B53-biomedicines-10-00236" class="usa-link" aria-describedby="B53-biomedicines-10-00236">53</a>,<a href="#B54-biomedicines-10-00236" class="usa-link" aria-describedby="B54-biomedicines-10-00236">54</a>,<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>,<a href="#B56-biomedicines-10-00236" class="usa-link" aria-describedby="B56-biomedicines-10-00236">56</a>,<a href="#B57-biomedicines-10-00236" class="usa-link" aria-describedby="B57-biomedicines-10-00236">57</a>,<a href="#B58-biomedicines-10-00236" class="usa-link" aria-describedby="B58-biomedicines-10-00236">58</a>,<a href="#B59-biomedicines-10-00236" class="usa-link" aria-describedby="B59-biomedicines-10-00236">59</a>,<a href="#B60-biomedicines-10-00236" class="usa-link" aria-describedby="B60-biomedicines-10-00236">60</a>,<a href="#B61-biomedicines-10-00236" class="usa-link" aria-describedby="B61-biomedicines-10-00236">61</a>,<a href="#B62-biomedicines-10-00236" class="usa-link" aria-describedby="B62-biomedicines-10-00236">62</a>,<a href="#B63-biomedicines-10-00236" class="usa-link" aria-describedby="B63-biomedicines-10-00236">63</a>,<a href="#B64-biomedicines-10-00236" class="usa-link" aria-describedby="B64-biomedicines-10-00236">64</a>,<a href="#B65-biomedicines-10-00236" class="usa-link" aria-describedby="B65-biomedicines-10-00236">65</a>,<a href="#B66-biomedicines-10-00236" class="usa-link" aria-describedby="B66-biomedicines-10-00236">66</a>,<a href="#B67-biomedicines-10-00236" class="usa-link" aria-describedby="B67-biomedicines-10-00236">67</a>,<a href="#B68-biomedicines-10-00236" class="usa-link" aria-describedby="B68-biomedicines-10-00236">68</a>,<a href="#B69-biomedicines-10-00236" class="usa-link" aria-describedby="B69-biomedicines-10-00236">69</a>,<a href="#B70-biomedicines-10-00236" class="usa-link" aria-describedby="B70-biomedicines-10-00236">70</a>,<a href="#B71-biomedicines-10-00236" class="usa-link" aria-describedby="B71-biomedicines-10-00236">71</a>,<a href="#B72-biomedicines-10-00236" class="usa-link" aria-describedby="B72-biomedicines-10-00236">72</a>,<a href="#B73-biomedicines-10-00236" class="usa-link" aria-describedby="B73-biomedicines-10-00236">73</a>,<a href="#B74-biomedicines-10-00236" class="usa-link" aria-describedby="B74-biomedicines-10-00236">74</a>,<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>,<a href="#B76-biomedicines-10-00236" class="usa-link" aria-describedby="B76-biomedicines-10-00236">76</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B78-biomedicines-10-00236" class="usa-link" aria-describedby="B78-biomedicines-10-00236">78</a>,<a href="#B79-biomedicines-10-00236" class="usa-link" aria-describedby="B79-biomedicines-10-00236">79</a>,<a href="#B80-biomedicines-10-00236" class="usa-link" aria-describedby="B80-biomedicines-10-00236">80</a>,<a href="#B81-biomedicines-10-00236" class="usa-link" aria-describedby="B81-biomedicines-10-00236">81</a>,<a href="#B82-biomedicines-10-00236" class="usa-link" aria-describedby="B82-biomedicines-10-00236">82</a>,<a href="#B83-biomedicines-10-00236" class="usa-link" aria-describedby="B83-biomedicines-10-00236">83</a>,<a href="#B84-biomedicines-10-00236" class="usa-link" aria-describedby="B84-biomedicines-10-00236">84</a>,<a href="#B85-biomedicines-10-00236" class="usa-link" aria-describedby="B85-biomedicines-10-00236">85</a>,<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>,<a href="#B87-biomedicines-10-00236" class="usa-link" aria-describedby="B87-biomedicines-10-00236">87</a>,<a href="#B88-biomedicines-10-00236" class="usa-link" aria-describedby="B88-biomedicines-10-00236">88</a>,<a href="#B89-biomedicines-10-00236" class="usa-link" aria-describedby="B89-biomedicines-10-00236">89</a>,<a href="#B90-biomedicines-10-00236" class="usa-link" aria-describedby="B90-biomedicines-10-00236">90</a>,<a href="#B91-biomedicines-10-00236" class="usa-link" aria-describedby="B91-biomedicines-10-00236">91</a>,<a href="#B92-biomedicines-10-00236" class="usa-link" aria-describedby="B92-biomedicines-10-00236">92</a>,<a href="#B93-biomedicines-10-00236" class="usa-link" aria-describedby="B93-biomedicines-10-00236">93</a>,<a href="#B94-biomedicines-10-00236" class="usa-link" aria-describedby="B94-biomedicines-10-00236">94</a>,<a href="#B95-biomedicines-10-00236" class="usa-link" aria-describedby="B95-biomedicines-10-00236">95</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>,<a href="#B97-biomedicines-10-00236" class="usa-link" aria-describedby="B97-biomedicines-10-00236">97</a>,<a href="#B98-biomedicines-10-00236" class="usa-link" aria-describedby="B98-biomedicines-10-00236">98</a>,<a href="#B99-biomedicines-10-00236" class="usa-link" aria-describedby="B99-biomedicines-10-00236">99</a>,<a href="#B100-biomedicines-10-00236" class="usa-link" aria-describedby="B100-biomedicines-10-00236">100</a>,<a href="#B101-biomedicines-10-00236" class="usa-link" aria-describedby="B101-biomedicines-10-00236">101</a>,<a href="#B102-biomedicines-10-00236" class="usa-link" aria-describedby="B102-biomedicines-10-00236">102</a>,<a href="#B103-biomedicines-10-00236" class="usa-link" aria-describedby="B103-biomedicines-10-00236">103</a>,<a href="#B104-biomedicines-10-00236" class="usa-link" aria-describedby="B104-biomedicines-10-00236">104</a>,<a href="#B105-biomedicines-10-00236" class="usa-link" aria-describedby="B105-biomedicines-10-00236">105</a>,<a href="#B106-biomedicines-10-00236" class="usa-link" aria-describedby="B106-biomedicines-10-00236">106</a>,<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>,<a href="#B108-biomedicines-10-00236" class="usa-link" aria-describedby="B108-biomedicines-10-00236">108</a>,<a href="#B109-biomedicines-10-00236" class="usa-link" aria-describedby="B109-biomedicines-10-00236">109</a>,<a href="#B110-biomedicines-10-00236" class="usa-link" aria-describedby="B110-biomedicines-10-00236">110</a>,<a href="#B111-biomedicines-10-00236" class="usa-link" aria-describedby="B111-biomedicines-10-00236">111</a>,<a href="#B112-biomedicines-10-00236" class="usa-link" aria-describedby="B112-biomedicines-10-00236">112</a>,<a href="#B113-biomedicines-10-00236" class="usa-link" aria-describedby="B113-biomedicines-10-00236">113</a>,<a href="#B114-biomedicines-10-00236" class="usa-link" aria-describedby="B114-biomedicines-10-00236">114</a>,<a href="#B115-biomedicines-10-00236" class="usa-link" aria-describedby="B115-biomedicines-10-00236">115</a>,<a href="#B116-biomedicines-10-00236" class="usa-link" aria-describedby="B116-biomedicines-10-00236">116</a>,<a href="#B117-biomedicines-10-00236" class="usa-link" aria-describedby="B117-biomedicines-10-00236">117</a>,<a href="#B118-biomedicines-10-00236" class="usa-link" aria-describedby="B118-biomedicines-10-00236">118</a>,<a href="#B119-biomedicines-10-00236" class="usa-link" aria-describedby="B119-biomedicines-10-00236">119</a>,<a href="#B120-biomedicines-10-00236" class="usa-link" aria-describedby="B120-biomedicines-10-00236">120</a>,<a href="#B121-biomedicines-10-00236" class="usa-link" aria-describedby="B121-biomedicines-10-00236">121</a>,<a href="#B122-biomedicines-10-00236" class="usa-link" aria-describedby="B122-biomedicines-10-00236">122</a>,<a href="#B123-biomedicines-10-00236" class="usa-link" aria-describedby="B123-biomedicines-10-00236">123</a>,<a href="#B124-biomedicines-10-00236" class="usa-link" aria-describedby="B124-biomedicines-10-00236">124</a>,<a href="#B125-biomedicines-10-00236" class="usa-link" aria-describedby="B125-biomedicines-10-00236">125</a>,<a href="#B126-biomedicines-10-00236" class="usa-link" aria-describedby="B126-biomedicines-10-00236">126</a>,<a href="#B127-biomedicines-10-00236" class="usa-link" aria-describedby="B127-biomedicines-10-00236">127</a>,<a href="#B128-biomedicines-10-00236" class="usa-link" aria-describedby="B128-biomedicines-10-00236">128</a>,<a href="#B129-biomedicines-10-00236" class="usa-link" aria-describedby="B129-biomedicines-10-00236">129</a>,<a href="#B130-biomedicines-10-00236" class="usa-link" aria-describedby="B130-biomedicines-10-00236">130</a>,<a href="#B131-biomedicines-10-00236" class="usa-link" aria-describedby="B131-biomedicines-10-00236">131</a>,<a href="#B132-biomedicines-10-00236" class="usa-link" aria-describedby="B132-biomedicines-10-00236">132</a>,<a href="#B133-biomedicines-10-00236" class="usa-link" aria-describedby="B133-biomedicines-10-00236">133</a>,<a href="#B134-biomedicines-10-00236" class="usa-link" aria-describedby="B134-biomedicines-10-00236">134</a>,<a href="#B135-biomedicines-10-00236" class="usa-link" aria-describedby="B135-biomedicines-10-00236">135</a>,<a href="#B136-biomedicines-10-00236" class="usa-link" aria-describedby="B136-biomedicines-10-00236">136</a>,<a href="#B137-biomedicines-10-00236" class="usa-link" aria-describedby="B137-biomedicines-10-00236">137</a>,<a href="#B138-biomedicines-10-00236" class="usa-link" aria-describedby="B138-biomedicines-10-00236">138</a>,<a href="#B139-biomedicines-10-00236" class="usa-link" aria-describedby="B139-biomedicines-10-00236">139</a>,<a href="#B140-biomedicines-10-00236" class="usa-link" aria-describedby="B140-biomedicines-10-00236">140</a>,<a href="#B141-biomedicines-10-00236" class="usa-link" aria-describedby="B141-biomedicines-10-00236">141</a>,<a href="#B142-biomedicines-10-00236" class="usa-link" aria-describedby="B142-biomedicines-10-00236">142</a>,<a href="#B143-biomedicines-10-00236" class="usa-link" aria-describedby="B143-biomedicines-10-00236">143</a>,<a href="#B144-biomedicines-10-00236" class="usa-link" aria-describedby="B144-biomedicines-10-00236">144</a>,<a href="#B145-biomedicines-10-00236" class="usa-link" aria-describedby="B145-biomedicines-10-00236">145</a>,<a href="#B146-biomedicines-10-00236" class="usa-link" aria-describedby="B146-biomedicines-10-00236">146</a>,<a href="#B147-biomedicines-10-00236" class="usa-link" aria-describedby="B147-biomedicines-10-00236">147</a>,<a href="#B148-biomedicines-10-00236" class="usa-link" aria-describedby="B148-biomedicines-10-00236">148</a>,<a href="#B149-biomedicines-10-00236" class="usa-link" aria-describedby="B149-biomedicines-10-00236">149</a>,<a href="#B150-biomedicines-10-00236" class="usa-link" aria-describedby="B150-biomedicines-10-00236">150</a>,<a href="#B151-biomedicines-10-00236" class="usa-link" aria-describedby="B151-biomedicines-10-00236">151</a>,<a href="#B152-biomedicines-10-00236" class="usa-link" aria-describedby="B152-biomedicines-10-00236">152</a>,<a href="#B153-biomedicines-10-00236" class="usa-link" aria-describedby="B153-biomedicines-10-00236">153</a>,<a href="#B154-biomedicines-10-00236" class="usa-link" aria-describedby="B154-biomedicines-10-00236">154</a>,<a href="#B155-biomedicines-10-00236" class="usa-link" aria-describedby="B155-biomedicines-10-00236">155</a>,<a href="#B156-biomedicines-10-00236" class="usa-link" aria-describedby="B156-biomedicines-10-00236">156</a>,<a href="#B157-biomedicines-10-00236" class="usa-link" aria-describedby="B157-biomedicines-10-00236">157</a>]. Activating <em>PIK3CA</em> mutations increased PD-L1 expression in PC, while <em>RAS/MAPK</em> activating mutations may represent a “second hit” to the PTEN/PI3K/AKT pathway loss in mCRPCs [<a href="#B202-biomedicines-10-00236" class="usa-link" aria-describedby="B202-biomedicines-10-00236">202</a>,<a href="#B203-biomedicines-10-00236" class="usa-link" aria-describedby="B203-biomedicines-10-00236">203</a>]. To our review, <em>PTEN</em> upregulation with consequent inhibition of mTOR and PD-L1 expression has been documented in mice injected with PC cells treated with recombinant human chemerin (chemoattractant protein and <em>PTEN</em> activator) [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>]. The chemerin-induced AKT-mTOR and PD-L1 downregulation significantly reduced PC growth: <em>CMKLR1</em> knockdown abrogated this pathway. These data revealed a potential <em>CMKLR1/PTEN</em>/PD-L1 signaling cascade that may occur through the PI3K/AKT/mTOR pathway (as also suggested by experiments with targeted inhibitors) [<a href="#B105-biomedicines-10-00236" class="usa-link" aria-describedby="B105-biomedicines-10-00236">105</a>,<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>]. In a study [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>], the PC cells of a patient also expressed CMKLR1: as in PC cell lines, chemerin may act through CMKLR1 on tumor cells to modulate PTEN and PD-L1. The type of <em>PTEN</em> loss may dictate the relevance of chemerin modulation in humans [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>]. In PC cell lines with complete allelic <em>PTEN</em> loss, modulating tumor chemerin levels did not result in changes in PD-L1 expression by the tumor; however, chemerin may recruit immune effector cells into the tumor microenvironment, still having benefits in outcomes [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>]. Conversely, in PCs with intact (but decreased) <em>PTEN</em> expression, chemerin modulation may decrease PD-L1, suppressing tumor growth and improving responses to immunotherapy [<a href="#B107-biomedicines-10-00236" class="usa-link" aria-describedby="B107-biomedicines-10-00236">107</a>]. </p>
<p>Analyzing PCs of <em>PTEN</em>-null mice, some authors reported that IL-17rc wild-type mice showed higher levels of PD-1, PD-L1, and PD-L2, developing more invasive PCs than IL-17rc knockout mice [<a href="#B150-biomedicines-10-00236" class="usa-link" aria-describedby="B150-biomedicines-10-00236">150</a>,<a href="#B151-biomedicines-10-00236" class="usa-link" aria-describedby="B151-biomedicines-10-00236">151</a>,<a href="#B152-biomedicines-10-00236" class="usa-link" aria-describedby="B152-biomedicines-10-00236">152</a>]. Combined treatment with anti-PD-L1 antibody (clone D265A, mouse/IgG1 kappa) and AZD1480 (JAK1/2 inhibitor), followed by androgen deprivation therapy, improved the antitumor immune responses over monotherapy in <em>PTEN</em>-knockout mice, potentially decreasing the immunosuppressive effects of androgen withdrawal [<a href="#B142-biomedicines-10-00236" class="usa-link" aria-describedby="B142-biomedicines-10-00236">142</a>]. Shimizu et al. reported that <em>PTEN/P53-DKO</em> mice with advanced PCs tended to longer OS after treatment with anti-PD-L1 drugs [<a href="#B138-biomedicines-10-00236" class="usa-link" aria-describedby="B138-biomedicines-10-00236">138</a>].</p>
<p>Unfortunately, the relationship of the innate immune resistance (whereby PD-L1 is constitutively upregulated when <em>PTEN</em> is lost) has not been explored in depth in PC patients. In a few series, PD-L1 expression was independent from <em>PTEN</em> status [<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>,<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>,<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>] or <em>PI3K</em> pathway activation [<a href="#B96-biomedicines-10-00236" class="usa-link" aria-describedby="B96-biomedicines-10-00236">96</a>]. Further larger studies on human patients have to investigate the potential correlation between <em>PTEN</em> and PD-L1.</p></section><section id="sec4dot4-biomedicines-10-00236"><h3 class="pmc_sec_title">4.4. Comments on Some Other Genes Involved in PC Carcinogenesis and Progression</h3>
<p><em>TP53</em> is a tumor-suppressor gene encoding a nuclear transcription factor (p53). In case of DNA damages, p53 blocks cell cycle progression, regulating the G1/S and G2/M checkpoints [<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B207-biomedicines-10-00236" class="usa-link" aria-describedby="B207-biomedicines-10-00236">207</a>]. <em>TP53</em> gene mutations can adversely affect PC prognosis; they seem more common in advanced stage, metastatic, and/or androgen-independent PCs [<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>,<a href="#B207-biomedicines-10-00236" class="usa-link" aria-describedby="B207-biomedicines-10-00236">207</a>]. The <em>TP53</em> gene encodes 12 isoforms through alternative promoters, translation start sites, and RNA splicing. The Δ133p53 isoform has pro-tumorigenic functions, favoring cell cycle progression, anti-apoptotic activity, angiogenesis, migration, increased DNA repair and telomerase activity, and reduced chemosensitivity; it may also promote inflammation in cancer [<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>]. In a study [<a href="#B42-biomedicines-10-00236" class="usa-link" aria-describedby="B42-biomedicines-10-00236">42</a>], increased expression of the Δ133TP53β isoform seemed to define high-risk PC patients. Other authors [<a href="#B208-biomedicines-10-00236" class="usa-link" aria-describedby="B208-biomedicines-10-00236">208</a>] reported that only the number of active mast cells showed significant differences between low- and high-risk prognostic groups of <em>TP53</em>-mutated PCs [<a href="#B208-biomedicines-10-00236" class="usa-link" aria-describedby="B208-biomedicines-10-00236">208</a>]. </p>
<p>The tumor-suppressor <em>RB</em> gene encodes a nuclear transcription factor regulating the cell cycle at the G0/G1 phase, DNA damage response, checkpoint activation, and differentiation [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>]. At the end of the mitotic phase, the RB protein is dephosphorylated; in this active form, it interacts with E2F transcription factors and inhibits the G1/S phase transition [<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>]. Upon mitogen stimulation or in the late G1 phase, cyclin-dependent kinases (CDKs) phosphorylate and inhibit RB, resulting in E2F factors release from RB sequestration and allowing progression to the S phase [<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>]. RB may also have E2F-independent tumor-suppressor functions [<a href="#B209-biomedicines-10-00236" class="usa-link" aria-describedby="B209-biomedicines-10-00236">209</a>]. <em>RB</em> mutations allow cell cycle progression; it is controversial if the RB/p16 pathway loss is an early or late event in PC [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>]. Experimental studies suggested that <em>RB</em> deletion could be associated with PD-L1 overexpression in mCRPCs [<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>]. RB binds to the NFκB protein: in PC cell lines, CDK4/6-phosphorylated RB may promote cancer immunity through inhibition of NF-kB transcriptional activity and of PD-L1 expression [<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>]. CDK4/6-inhibitors, <em>RB</em> deletion, and irradiation can induce PD-L1 upregulation, thus causing immune evasion of PC cells [<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>]. A small bioactive RB-derived serine-249/threonine-252 phosphorylation-mimetic peptide decreased PD-L1 expression via NF-kB inhibition and by enhancing the anti-cancer efficacy of radiotherapy; it blocked the p65 binding to the cognate DNA sequence in the PD-L1 promoter [<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>]. Upon stimulation of proinflammatory cytokines, the MAP3K7–IKK signaling axis activates the transcription factor NF-kB, which regulates pro-survival genes and PD-L1 mRNA expression in various cancer types (including PC), probably favoring cancer immune escape [<a href="#B55-biomedicines-10-00236" class="usa-link" aria-describedby="B55-biomedicines-10-00236">55</a>].</p>
<p><em>c-MYC</em> regulates cell growth and proliferation, cycle progression, transcription, differentiation, and apoptosis. <em>c-MYC</em> amplification leads to high-grade, metastatic, and/or androgen-resistant PCs [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>]. However, <em>c-MYC</em> activation may also appear in early phases of PC [<a href="#B210-biomedicines-10-00236" class="usa-link" aria-describedby="B210-biomedicines-10-00236">210</a>]. In PC experimental studies, <em>c-MYC</em> expression and/or the combined deletion of <em>PTEN/SMAD4</em> or <em>PTEN/TP53</em> expanded immunosuppressive tumor-associated macrophages and myeloid-derived suppressor cells, promoting tumor immunotolerance and vascularization [<a href="#B132-biomedicines-10-00236" class="usa-link" aria-describedby="B132-biomedicines-10-00236">132</a>]. Moreover, <em>c-MYC</em> seems involved in PD-L1 regulation. The MYC inhibitor 361 (MYCi361) suppressed the tumor growth of MycCaP PC cell lines in mice, increased the tumor immune cell infiltration, upregulated PD-L1 on tumor cells, and sensitized cancer to anti-PD-1 immunotherapy [<a href="#B211-biomedicines-10-00236" class="usa-link" aria-describedby="B211-biomedicines-10-00236">211</a>]. In PC cell lines, the IFN-γ-induced PD-L1 mRNA and protein levels were significantly abrogated by knockdown of the histone methylation regulators WDR5 or MLL1 (not by <em>C-MYC</em> silencing); WDR5 seemed important for PD-L1 transcription, while OICR-9429 (antagonist of WDR5 interactions with MLL1, C-MYC, and other partners) blocked this process [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>]. OICR-9429 and WDR5 knockdown also significantly reduced c-Myc recruitment [<a href="#B10-biomedicines-10-00236" class="usa-link" aria-describedby="B10-biomedicines-10-00236">10</a>,<a href="#B12-biomedicines-10-00236" class="usa-link" aria-describedby="B12-biomedicines-10-00236">12</a>]. </p>
<p>The <em>ERG</em> gene encodes for a transcription factor of the ETS family; it is fused with the prostate-specific and androgen-responsive <em>TMPRSS2</em> (transmembrane protease, serine 2) gene in about 50% of PCs, resulting in ERG overexpression. Two other <em>ERG</em> gene fusions (<em>SLC45A3</em>:<em>ERG</em>, <em>NDRG1</em>:<em>ERG</em>) can increase ERG expression, despite them occuring in &lt;5% of PCs [<a href="#B166-biomedicines-10-00236" class="usa-link" aria-describedby="B166-biomedicines-10-00236">166</a>]. The <em>ETS-TMPRSS2</em> fusions are apparently mutually exclusive from certain genomic aberrations: <em>RAF-RAS-FGFR</em> gene fusions may occur only in ETS-negative tumors [<a href="#B166-biomedicines-10-00236" class="usa-link" aria-describedby="B166-biomedicines-10-00236">166</a>,<a href="#B212-biomedicines-10-00236" class="usa-link" aria-describedby="B212-biomedicines-10-00236">212</a>]. ERG overexpression is a driver event in the transition from prostatic intraepithelial neoplasia to carcinoma [<a href="#B212-biomedicines-10-00236" class="usa-link" aria-describedby="B212-biomedicines-10-00236">212</a>]. Moreover, the high expression of ERG seemed associated with PCs showing advanced stage, high Gleason score, metastatic behavior, and/or shorter survival [<a href="#B213-biomedicines-10-00236" class="usa-link" aria-describedby="B213-biomedicines-10-00236">213</a>]. Androgen-driven <em>ERG-TMPRSS2</em> gene fusions were associated with disease recurrence and tumor relapse [<a href="#B212-biomedicines-10-00236" class="usa-link" aria-describedby="B212-biomedicines-10-00236">212</a>,<a href="#B213-biomedicines-10-00236" class="usa-link" aria-describedby="B213-biomedicines-10-00236">213</a>]. Although <em>ERG</em> fusions/overexpression may have a diagnostic and predictive role for aggressiveness in PCs, few studies investigated their relationship with the PD-L1 status. Some authors found no significant association between PD-L1+ tumors and ERG status [<a href="#B38-biomedicines-10-00236" class="usa-link" aria-describedby="B38-biomedicines-10-00236">38</a>], while others reported a concordant ERG status with a nodular pattern of PD-L1 IHC positivity [<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>]. A trend of PD-L1+ PCs toward a lower rate of ERG positivity and higher AR expression was suggested [<a href="#B77-biomedicines-10-00236" class="usa-link" aria-describedby="B77-biomedicines-10-00236">77</a>]. Further data are required. The bromodomain and extraterminal (BET) family of proteins are transcriptional coactivators of cell cycle, apoptosis, migration, and invasion, frequently enhancing the expression/transcription of oncogenic drivers, such as <em>AR</em> and <em>ERG</em> in PC [<a href="#B213-biomedicines-10-00236" class="usa-link" aria-describedby="B213-biomedicines-10-00236">213</a>]. In PC cells lines, ERG negatively regulates miR-200c expression [<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>]. In a large series, miR-200a-c positively correlated to PD-L1 mRNA levels, being inversely associated with methylation of the PD-L1 promoter [<a href="#B86-biomedicines-10-00236" class="usa-link" aria-describedby="B86-biomedicines-10-00236">86</a>]. </p>
<p><em>SPOP</em> mutations occur in about 10–15% PCs, representing potential predictors of CRPC response to ABT [<a href="#B163-biomedicines-10-00236" class="usa-link" aria-describedby="B163-biomedicines-10-00236">163</a>]. These mutations are largely clustered within the MATH domain, which is responsible for substrate recognition and interaction, while the C-terminal BTB domain binds CUL3, forming the functional E3 ubiquitin ligase complex. <em>SPOP</em> mutations have a dominant-negative effect on substrate binding and degradation, being mutually exclusive with <em>ERG</em> gene fusions (the most frequent genetic alterations in PC); they increase the mRNA and protein levels of ERG and its downstream targets, promoting cellular migration and invasion [<a href="#B2-biomedicines-10-00236" class="usa-link" aria-describedby="B2-biomedicines-10-00236">2</a>]. Both the MATH and BTB domains are required for the SPOP-mediated BRD4 ubiquitination and degradation [<a href="#B2-biomedicines-10-00236" class="usa-link" aria-describedby="B2-biomedicines-10-00236">2</a>,<a href="#B214-biomedicines-10-00236" class="usa-link" aria-describedby="B214-biomedicines-10-00236">214</a>]. In PCs, <em>SPOP</em> mutations confer resistance to BET inhibitors through the stabilization of BRD4. Mutations at the E3 ligase (SPOP) or the substrate (BRD4) may inhibit the SPOP-mediated BRD4 destruction by disrupting the SPOP–BRD4 interaction, stabilizing BRD4, and leading to its cooperation with AR, ERG, and other oncogenic transcription factors [<a href="#B214-biomedicines-10-00236" class="usa-link" aria-describedby="B214-biomedicines-10-00236">214</a>]. Cyclin D-CDK4 kinase destabilizes PD-L1 via culliculin 3-SPOP to control tumor surveillance: proteasome or ubiquitin E3 ligase inhibitors incremented PD-L1 expression [<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>]. Cancer-derived <em>SPOP</em> mutants failed to promote PD-L1 degradation by poly-ubiquitination because of their deficiency in binding to PD-L1 [<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>]. In human tumors, <em>SPOP</em> mutations in the PD-L1 C-tail are mutually exclusive with those in the substrate-interacting MATH domain [<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>]. SPOP can promote ubiquitin-mediated PD-L1 degradation: <em>SPOP</em>-mutant PCs showed increased PD-L1 expression in a series [<a href="#B75-biomedicines-10-00236" class="usa-link" aria-describedby="B75-biomedicines-10-00236">75</a>]. Finally, the immune-suppressed PC group showed fewer <em>SPOP</em> mutations than the immune-activated and non-immune class in another study (5.6%, 13.5%, and 13.2%, respectively, <em>p</em> &lt; 0.001) [<a href="#B21-biomedicines-10-00236" class="usa-link" aria-describedby="B21-biomedicines-10-00236">21</a>]. </p>
<p>Systematic literature reviews and metanalyses (SLRs) conducted according to the PRISMA guidelines (including an evidence-based minimum set of items for reporting) (<a href="http://www.prisma-statement.org/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.prisma-statement.org/</a>, accessed on 8 May 2021) are increasingly important in health care, keeping medical doctors up to date, and also representing the background for developing clinical guidelines/trials, as well as the justification for financial supports of research projects. Usually conducted by multidisciplinary teams, SLRs performed according to these guidelines could be applicable in various topics/contexts, improving the research quality not only of pure meta-analyses but also of SLRs applied to case report/series [<a href="#B215-biomedicines-10-00236" class="usa-link" aria-describedby="B215-biomedicines-10-00236">215</a>,<a href="#B216-biomedicines-10-00236" class="usa-link" aria-describedby="B216-biomedicines-10-00236">216</a>,<a href="#B217-biomedicines-10-00236" class="usa-link" aria-describedby="B217-biomedicines-10-00236">217</a>,<a href="#B218-biomedicines-10-00236" class="usa-link" aria-describedby="B218-biomedicines-10-00236">218</a>,<a href="#B219-biomedicines-10-00236" class="usa-link" aria-describedby="B219-biomedicines-10-00236">219</a>,<a href="#B220-biomedicines-10-00236" class="usa-link" aria-describedby="B220-biomedicines-10-00236">220</a>,<a href="#B221-biomedicines-10-00236" class="usa-link" aria-describedby="B221-biomedicines-10-00236">221</a>,<a href="#B222-biomedicines-10-00236" class="usa-link" aria-describedby="B222-biomedicines-10-00236">222</a>,<a href="#B223-biomedicines-10-00236" class="usa-link" aria-describedby="B223-biomedicines-10-00236">223</a>,<a href="#B224-biomedicines-10-00236" class="usa-link" aria-describedby="B224-biomedicines-10-00236">224</a>,<a href="#B225-biomedicines-10-00236" class="usa-link" aria-describedby="B225-biomedicines-10-00236">225</a>,<a href="#B226-biomedicines-10-00236" class="usa-link" aria-describedby="B226-biomedicines-10-00236">226</a>,<a href="#B227-biomedicines-10-00236" class="usa-link" aria-describedby="B227-biomedicines-10-00236">227</a>,<a href="#B228-biomedicines-10-00236" class="usa-link" aria-describedby="B228-biomedicines-10-00236">228</a>,<a href="#B229-biomedicines-10-00236" class="usa-link" aria-describedby="B229-biomedicines-10-00236">229</a>,<a href="#B230-biomedicines-10-00236" class="usa-link" aria-describedby="B230-biomedicines-10-00236">230</a>,<a href="#B231-biomedicines-10-00236" class="usa-link" aria-describedby="B231-biomedicines-10-00236">231</a>,<a href="#B232-biomedicines-10-00236" class="usa-link" aria-describedby="B232-biomedicines-10-00236">232</a>,<a href="#B233-biomedicines-10-00236" class="usa-link" aria-describedby="B233-biomedicines-10-00236">233</a>,<a href="#B234-biomedicines-10-00236" class="usa-link" aria-describedby="B234-biomedicines-10-00236">234</a>,<a href="#B235-biomedicines-10-00236" class="usa-link" aria-describedby="B235-biomedicines-10-00236">235</a>,<a href="#B236-biomedicines-10-00236" class="usa-link" aria-describedby="B236-biomedicines-10-00236">236</a>,<a href="#B237-biomedicines-10-00236" class="usa-link" aria-describedby="B237-biomedicines-10-00236">237</a>,<a href="#B238-biomedicines-10-00236" class="usa-link" aria-describedby="B238-biomedicines-10-00236">238</a>,<a href="#B239-biomedicines-10-00236" class="usa-link" aria-describedby="B239-biomedicines-10-00236">239</a>,<a href="#B240-biomedicines-10-00236" class="usa-link" aria-describedby="B240-biomedicines-10-00236">240</a>,<a href="#B241-biomedicines-10-00236" class="usa-link" aria-describedby="B241-biomedicines-10-00236">241</a>,<a href="#B242-biomedicines-10-00236" class="usa-link" aria-describedby="B242-biomedicines-10-00236">242</a>,<a href="#B243-biomedicines-10-00236" class="usa-link" aria-describedby="B243-biomedicines-10-00236">243</a>,<a href="#B244-biomedicines-10-00236" class="usa-link" aria-describedby="B244-biomedicines-10-00236">244</a>,<a href="#B245-biomedicines-10-00236" class="usa-link" aria-describedby="B245-biomedicines-10-00236">245</a>,<a href="#B246-biomedicines-10-00236" class="usa-link" aria-describedby="B246-biomedicines-10-00236">246</a>,<a href="#B247-biomedicines-10-00236" class="usa-link" aria-describedby="B247-biomedicines-10-00236">247</a>,<a href="#B248-biomedicines-10-00236" class="usa-link" aria-describedby="B248-biomedicines-10-00236">248</a>,<a href="#B249-biomedicines-10-00236" class="usa-link" aria-describedby="B249-biomedicines-10-00236">249</a>,<a href="#B250-biomedicines-10-00236" class="usa-link" aria-describedby="B250-biomedicines-10-00236">250</a>,<a href="#B251-biomedicines-10-00236" class="usa-link" aria-describedby="B251-biomedicines-10-00236">251</a>,<a href="#B252-biomedicines-10-00236" class="usa-link" aria-describedby="B252-biomedicines-10-00236">252</a>,<a href="#B253-biomedicines-10-00236" class="usa-link" aria-describedby="B253-biomedicines-10-00236">253</a>,<a href="#B254-biomedicines-10-00236" class="usa-link" aria-describedby="B254-biomedicines-10-00236">254</a>,<a href="#B255-biomedicines-10-00236" class="usa-link" aria-describedby="B255-biomedicines-10-00236">255</a>,<a href="#B256-biomedicines-10-00236" class="usa-link" aria-describedby="B256-biomedicines-10-00236">256</a>,<a href="#B257-biomedicines-10-00236" class="usa-link" aria-describedby="B257-biomedicines-10-00236">257</a>,<a href="#B258-biomedicines-10-00236" class="usa-link" aria-describedby="B258-biomedicines-10-00236">258</a>,<a href="#B259-biomedicines-10-00236" class="usa-link" aria-describedby="B259-biomedicines-10-00236">259</a>]. To better present the data of our SLR, we have split the discussion of our results into different articles, highlighting relevant subtopics: PD-L1 IHC expression in PC with discussion of pre-analytical and interpretation variables; correlations of PD-L1 expression with clinic–pathological features in PC patients; PD-L1 intracellular signaling pathways in PC cells and regulation of the tumor microenvironment; pre-clinical models (cell lines, mouse models) and experimental treatments affecting PD-L1 expression in PC cells; genetic and epigenetic regulation of PD-L1; PD-L1 expression in liquid biopsies, etc. [<a href="#B260-biomedicines-10-00236" class="usa-link" aria-describedby="B260-biomedicines-10-00236">260</a>,<a href="#B261-biomedicines-10-00236" class="usa-link" aria-describedby="B261-biomedicines-10-00236">261</a>,<a href="#B262-biomedicines-10-00236" class="usa-link" aria-describedby="B262-biomedicines-10-00236">262</a>,<a href="#B263-biomedicines-10-00236" class="usa-link" aria-describedby="B263-biomedicines-10-00236">263</a>,<a href="#B264-biomedicines-10-00236" class="usa-link" aria-describedby="B264-biomedicines-10-00236">264</a>,<a href="#B265-biomedicines-10-00236" class="usa-link" aria-describedby="B265-biomedicines-10-00236">265</a>].</p></section></section><section id="sec5-biomedicines-10-00236"><h2 class="pmc_sec_title">5. Conclusions</h2>
<p>The NCCN guidelines allow pembrolizumab in selected MSI-H/dMMR mCRPC patients. Excluding cases with clear selection biases, we found 74/677 (11%) PCs with dMMR/MSI: 8/67 (12%) MSI/dMMR cases resulted in PD-L1 positivity. dMMR-PCs (tested by IHC) included ductal PCs (3%), and acinar PCs (14%), while all the cases tested for MSI by molecular analysis were acinar PCs. dMMR may be associated with worse clinical outcome, but further data are required, also as regards the differences in response to therapy. </p>
<p><em>PTEN</em> is a tumor-suppressor gene regulating cell cycle, proliferation, and apoptosis via different pathways including the <em>AKT/mTOR</em>, which upregulates PD-L1 expression in PC. In total, 13/137 (10%) PTEN- PCs were PD-L1+, while 10/29 (35%) PD-L1+ PCs were PTEN-. In PCs, <em>SPOP</em> mutations may increase PD-L1 expression, while the potential correlation of PD-L1 with PTEN/ERG IHC positivity should be further clarified.</p>
<p><em>BRCA1/2</em> loss of function is linked to hereditary PCs and HRR deficiency: PARPi can be administered to <em>BRCA</em>-mutated PC patients. In total, 15/39 (39%) PCs harbored <em>BRCA1/2</em> aberrations. In a recent trial, somatic mutations in <em>BRCA1/2</em> or <em>ATM</em> had higher responses rates after pembrolizumab in docetaxel-refractory mCRPCs. However, limited data are available for PD-L1 IHC expression in <em>BRCA1/2</em>-mutated PC patients; the relation of PD-L1 expression with the DDR genes status is still unclear. Further research has to verify how the efficacy of PD-1 inhibition in mCRPCs could be related to dMMR/MSI, DDR genes defects, or PD-L1 status. </p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>Andrea Palicelli thanks his family for their personal support.</p></section><section id="app1-biomedicines-10-00236" class="app"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<p>The following supporting information can be downloaded at: <a href="https://www.mdpi.com/article/10.3390/biomedicines10020236/s1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.mdpi.com/article/10.3390/biomedicines10020236/s1</a>, Table S1: Detailed results of the studies evaluating PD-L1 expression and microsatellite instability/mismatch repair system proteins status in patients with prostatic carcinoma.</p>
<section class="sm xbox font-sm" id="biomedicines-10-00236-s001"><div class="media p"><div class="caption">
<a href="/articles/instance/8868626/bin/biomedicines-10-00236-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (373.1KB, zip) </sup>
</div></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization, A.P., M.B., S.C. and M.Z.; methodology, A.P., M.B., S.C., M.R. and M.P.B.; validation, A.P., A.C. and S.C.-P.; formal analysis, A.P., D.D.B. and F.S.; investigation, A.P., S.C. and M.B.; resources, A.T., A.P., D.N. and E.F.; data curation, A.P. and S.A.; writing—original draft preparation, A.P., M.B., S.C., F.S. and M.Z.; writing—review and editing, A.P., M.B., S.C., D.D.B., A.B. and E.Z.; visualization, A.T., D.D.B. and B.M.; supervision, A.P., A.D.L. and M.L.; project administration, A.P., S.P., G.G., J.G., L.C. and G.C.; funding acquisition, A.P. and M.Z. All authors have read and agreed to the published version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This research received no external funding.</p></section><section id="notes3"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflict of interest.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1"><p><strong>Publisher’s Note:</strong> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1-biomedicines-10-00236">
<span class="label">1.</span><cite>Santandrea G., Piana S., Valli R., Zanelli M., Gasparini E., De Leo A., Mandato V.D., Palicelli A. Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. Diagnostics. 2021;11:199.  doi: 10.3390/diagnostics11020199.</cite> [<a href="https://doi.org/10.3390/diagnostics11020199" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7911119/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33572888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics&amp;title=Immunohistochemical%20Biomarkers%20as%20a%20Surrogate%20of%20Molecular%20Analysis%20in%20Ovarian%20Carcinomas:%20A%20Review%20of%20the%20Literature&amp;author=G.%20Santandrea&amp;author=S.%20Piana&amp;author=R.%20Valli&amp;author=M.%20Zanelli&amp;author=E.%20Gasparini&amp;volume=11&amp;publication_year=2021&amp;pages=199&amp;pmid=33572888&amp;doi=10.3390/diagnostics11020199&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2-biomedicines-10-00236">
<span class="label">2.</span><cite>Dai S., Jia R., Zhang X., Fang Q., Huang L. The PD-1/PD-Ls pathway and autoimmune diseases. Cell. Immunol. 2014;290:72–79. doi: 10.1016/j.cellimm.2014.05.006.</cite> [<a href="https://doi.org/10.1016/j.cellimm.2014.05.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24908630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell.%20Immunol.&amp;title=The%20PD-1/PD-Ls%20pathway%20and%20autoimmune%20diseases&amp;author=S.%20Dai&amp;author=R.%20Jia&amp;author=X.%20Zhang&amp;author=Q.%20Fang&amp;author=L.%20Huang&amp;volume=290&amp;publication_year=2014&amp;pages=72-79&amp;pmid=24908630&amp;doi=10.1016/j.cellimm.2014.05.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3-biomedicines-10-00236">
<span class="label">3.</span><cite>Patsoukis N., Wang Q., Strauss L., Boussiotis V.A. Revisiting the PD-1 pathway. Sci. Adv. 2020;6:eabd2712. doi: 10.1126/sciadv.abd2712.</cite> [<a href="https://doi.org/10.1126/sciadv.abd2712" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7500922/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32948597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci.%20Adv.&amp;title=Revisiting%20the%20PD-1%20pathway&amp;author=N.%20Patsoukis&amp;author=Q.%20Wang&amp;author=L.%20Strauss&amp;author=V.A.%20Boussiotis&amp;volume=6&amp;publication_year=2020&amp;pages=eabd2712&amp;pmid=32948597&amp;doi=10.1126/sciadv.abd2712&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4-biomedicines-10-00236">
<span class="label">4.</span><cite>National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2.2021. 17 February 2021.  [(accessed on 29 May 2021)].  Available online:  <a href="https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf</a>.</cite>
</li>
<li id="B5-biomedicines-10-00236">
<span class="label">5.</span><cite>Foda A.A., Palicelli A., Shebl A., Boldorini R., Elnaghi K., ElHawary A.K. Role of ERCC1 expression in colorectal adenoma-carcinoma sequence and relation to other mismatch repair proteins expression, clinicopathological features and prognosis in mucinous and non-mucinous colorectal carcinoma. Indian J. Pathol. Microbiol. 2019;62:405–412. doi: 10.4103/IJPM.IJPM_684_18.</cite> [<a href="https://doi.org/10.4103/IJPM.IJPM_684_18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31361228/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Indian%20J.%20Pathol.%20Microbiol.&amp;title=Role%20of%20ERCC1%20expression%20in%20colorectal%20adenoma-carcinoma%20sequence%20and%20relation%20to%20other%20mismatch%20repair%20proteins%20expression,%20clinicopathological%20features%20and%20prognosis%20in%20mucinous%20and%20non-mucinous%20colorectal%20carcinoma&amp;author=A.A.%20Foda&amp;author=A.%20Palicelli&amp;author=A.%20Shebl&amp;author=R.%20Boldorini&amp;author=K.%20Elnaghi&amp;volume=62&amp;publication_year=2019&amp;pages=405-412&amp;pmid=31361228&amp;doi=10.4103/IJPM.IJPM_684_18&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6-biomedicines-10-00236">
<span class="label">6.</span><cite>Lotan T.L., Tomlins S.A., Bismar T.A., Van der Kwast T.H., Grignon D., Egevad L., Kristiansen G., Pritchard C.C., Rubin M.A., Bubendorf L. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. Am. J. Surg. Pathol. 2020;44:e15–e29. doi: 10.1097/PAS.0000000000001450.</cite> [<a href="https://doi.org/10.1097/PAS.0000000000001450" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32044806/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Surg.%20Pathol.&amp;title=Report%20From%20the%20International%20Society%20of%20Urological%20Pathology%20(ISUP)%20Consultation%20Conference%20on%20Molecular%20Pathology%20of%20Urogenital%20Cancers.%20I.%20Molecular%20Biomarkers%20in%20Prostate%20Cancer&amp;author=T.L.%20Lotan&amp;author=S.A.%20Tomlins&amp;author=T.A.%20Bismar&amp;author=T.H.%20Van%20der%20Kwast&amp;author=D.%20Grignon&amp;volume=44&amp;publication_year=2020&amp;pages=e15-e29&amp;pmid=32044806&amp;doi=10.1097/PAS.0000000000001450&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7-biomedicines-10-00236">
<span class="label">7.</span><cite>Fay A.P., Antonarakis E.S. Blocking the PD-1/PD-L1 axis in advanced prostate cancer: Are we moving in the right direction? Ann. Transl. Med. 2019;7((Suppl. 1)):S7. doi: 10.21037/atm.2019.01.37.</cite> [<a href="https://doi.org/10.21037/atm.2019.01.37" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6462610/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31032288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Transl.%20Med.&amp;title=Blocking%20the%20PD-1/PD-L1%20axis%20in%20advanced%20prostate%20cancer:%20Are%20we%20moving%20in%20the%20right%20direction?&amp;author=A.P.%20Fay&amp;author=E.S.%20Antonarakis&amp;volume=7&amp;issue=(Suppl.%201)&amp;publication_year=2019&amp;pages=S7&amp;pmid=31032288&amp;doi=10.21037/atm.2019.01.37&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8-biomedicines-10-00236">
<span class="label">8.</span><cite>Antonarakis E.S., Isaacsson Velho P., Fu W., Wang H., Agarwal N., Sacristan Santos V., Maughan B.L., Pili R., Adra N., Sternberg C.N., et al.  CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis. Oncol. 2020;4:370–381. doi: 10.1200/PO.19.00399.</cite> [<a href="https://doi.org/10.1200/PO.19.00399" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7252221/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32462107/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Precis.%20Oncol.&amp;title=CDK12-Altered%20Prostate%20Cancer:%20Clinical%20Features%20and%20Therapeutic%20Outcomes%20to%20Standard%20Systemic%20Therapies,%20Poly%20(ADP-Ribose)%20Polymerase%20Inhibitors,%20and%20PD-1%20Inhibitors&amp;author=E.S.%20Antonarakis&amp;author=P.%20Isaacsson%20Velho&amp;author=W.%20Fu&amp;author=H.%20Wang&amp;author=N.%20Agarwal&amp;volume=4&amp;publication_year=2020&amp;pages=370-381&amp;pmid=32462107&amp;doi=10.1200/PO.19.00399&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9-biomedicines-10-00236">
<span class="label">9.</span><cite>Antonarakis E.S., Piulats J.M., Gross-Goupil M., Goh J., Ojamaa K., Hoimes C.J., Vaishampayan U., Berger R., Sezer A., Alanko T., et al.  Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J. Clin. Oncol. 2020;38:395–405. doi: 10.1200/JCO.19.01638.</cite> [<a href="https://doi.org/10.1200/JCO.19.01638" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7186583/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31774688/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Pembrolizumab%20for%20Treatment-Refractory%20Metastatic%20Castration-Resistant%20Prostate%20Cancer:%20Multicohort,%20Open-Label%20Phase%20II%20KEYNOTE-199%20Study&amp;author=E.S.%20Antonarakis&amp;author=J.M.%20Piulats&amp;author=M.%20Gross-Goupil&amp;author=J.%20Goh&amp;author=K.%20Ojamaa&amp;volume=38&amp;publication_year=2020&amp;pages=395-405&amp;pmid=31774688&amp;doi=10.1200/JCO.19.01638&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10-biomedicines-10-00236">
<span class="label">10.</span><cite>Gandhi J., Afridi A., Vatsia S., Joshi G., Joshi G., Kaplan S.A., Smith N.L., Khan S.A. The molecular biology of prostate cancer: Current understanding and clinical implications. Prostate Cancer Prostatic Dis. 2018;21:22–36. doi: 10.1038/s41391-017-0023-8.</cite> [<a href="https://doi.org/10.1038/s41391-017-0023-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29282359/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate%20Cancer%20Prostatic%20Dis.&amp;title=The%20molecular%20biology%20of%20prostate%20cancer:%20Current%20understanding%20and%20clinical%20implications&amp;author=J.%20Gandhi&amp;author=A.%20Afridi&amp;author=S.%20Vatsia&amp;author=G.%20Joshi&amp;author=G.%20Joshi&amp;volume=21&amp;publication_year=2018&amp;pages=22-36&amp;pmid=29282359&amp;doi=10.1038/s41391-017-0023-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11-biomedicines-10-00236">
<span class="label">11.</span><cite>Sharma P., Pachynski R.K., Narayan V., Fléchon A., Gravis G., Galsky M.D., Mahammedi H., Patnaik A., Subudhi S.K., Ciprotti M., et al.  Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020;38:489–499.e3. doi: 10.1016/j.ccell.2020.08.007.</cite> [<a href="https://doi.org/10.1016/j.ccell.2020.08.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32916128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Nivolumab%20Plus%20Ipilimumab%20for%20Metastatic%20Castration-Resistant%20Prostate%20Cancer:%20Preliminary%20Analysis%20of%20Patients%20in%20the%20CheckMate%20650%20Trial&amp;author=P.%20Sharma&amp;author=R.K.%20Pachynski&amp;author=V.%20Narayan&amp;author=A.%20Fl%C3%A9chon&amp;author=G.%20Gravis&amp;volume=38&amp;publication_year=2020&amp;pages=489-499.e3&amp;pmid=32916128&amp;doi=10.1016/j.ccell.2020.08.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12-biomedicines-10-00236">
<span class="label">12.</span><cite>Zhou Q., Chen X., He H., Peng S., Zhang Y., Zhang J., Cheng L., Liu S., Huang M., Xie R., et al.  WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer. Theranostics. 2021;11:4809–4824. doi: 10.7150/thno.55814.</cite> [<a href="https://doi.org/10.7150/thno.55814" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7978315/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33754029/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=WD%20repeat%20domain%205%20promotes%20chemoresistance%20and%20Programmed%20Death-Ligand%201%20expression%20in%20prostate%20cancer&amp;author=Q.%20Zhou&amp;author=X.%20Chen&amp;author=H.%20He&amp;author=S.%20Peng&amp;author=Y.%20Zhang&amp;volume=11&amp;publication_year=2021&amp;pages=4809-4824&amp;pmid=33754029&amp;doi=10.7150/thno.55814&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13-biomedicines-10-00236">
<span class="label">13.</span><cite>Vardaki I., Corn P., Gentile E., Song J.H., Madan N., Hoang A., Parikh N., Guerra L., Lee Y.C., Lin S.C., et al.  Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2021;27:3253–3264. doi: 10.1158/1078-0432.CCR-20-4790.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-4790" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8172463/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33753455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=Radium-223%20Treatment%20Increases%20Immune%20Checkpoint%20Expression%20in%20Extracellular%20Vesicles%20from%20the%20Metastatic%20Prostate%20Cancer%20Bone%20Microenvironment&amp;author=I.%20Vardaki&amp;author=P.%20Corn&amp;author=E.%20Gentile&amp;author=J.H.%20Song&amp;author=N.%20Madan&amp;volume=27&amp;publication_year=2021&amp;pages=3253-3264&amp;pmid=33753455&amp;doi=10.1158/1078-0432.CCR-20-4790&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14-biomedicines-10-00236">
<span class="label">14.</span><cite>Shim K.H., Kwon J.E., Park S.G., Choo S.H., Kim S.J., Kim S.I. Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy. Urol. Oncol. 2021;39:298.e13–298.e20. doi: 10.1016/j.urolonc.2021.01.032.</cite> [<a href="https://doi.org/10.1016/j.urolonc.2021.01.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33712343/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Urol.%20Oncol.&amp;title=Cell%20membrane%20and%20nuclear%20expression%20of%20programmed%20death%20ligand-1%20in%20prostate%20needle%20biopsy%20tissue%20in%20prostate%20cancer%20patients%20undergoing%20primary%20radiation%20therapy&amp;author=K.H.%20Shim&amp;author=J.E.%20Kwon&amp;author=S.G.%20Park&amp;author=S.H.%20Choo&amp;author=S.J.%20Kim&amp;volume=39&amp;publication_year=2021&amp;pages=298.e13-298.e20&amp;pmid=33712343&amp;doi=10.1016/j.urolonc.2021.01.032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15-biomedicines-10-00236">
<span class="label">15.</span><cite>Sun Y., Jing J., Xu H., Xu L., Hu H., Tang C., Liu S., Wei Q., Duan R., Guo J., et al.  N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. J. Immunother. Cancer. 2021;9:e002138. doi: 10.1136/jitc-2020-002138.</cite> [<a href="https://doi.org/10.1136/jitc-2020-002138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7949480/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33692219/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=N-cadherin%20inhibitor%20creates%20a%20microenvironment%20that%20protect%20TILs%20from%20immune%20checkpoints%20and%20Treg%20cells&amp;author=Y.%20Sun&amp;author=J.%20Jing&amp;author=H.%20Xu&amp;author=L.%20Xu&amp;author=H.%20Hu&amp;volume=9&amp;publication_year=2021&amp;pages=e002138&amp;pmid=33692219&amp;doi=10.1136/jitc-2020-002138&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16-biomedicines-10-00236">
<span class="label">16.</span><cite>Zavridou M., Strati A., Bournakis E., Smilkou S., Tserpeli V., Lianidou E. Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer. Cancers. 2021;13:780.  doi: 10.3390/cancers13040780.</cite> [<a href="https://doi.org/10.3390/cancers13040780" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7918693/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33668490/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Prognostic%20Significance%20of%20Gene%20Expression%20and%20DNA%20Methylation%20Markers%20in%20Circulating%20Tumor%20Cells%20and%20Paired%20Plasma%20Derived%20Exosomes%20in%20Metastatic%20Castration%20Resistant%20Prostate%20Cancer&amp;author=M.%20Zavridou&amp;author=A.%20Strati&amp;author=E.%20Bournakis&amp;author=S.%20Smilkou&amp;author=V.%20Tserpeli&amp;volume=13&amp;publication_year=2021&amp;pages=780&amp;pmid=33668490&amp;doi=10.3390/cancers13040780&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17-biomedicines-10-00236">
<span class="label">17.</span><cite>Brady L., Kriner M., Coleman I., Morrissey C., Roudier M., True L.D., Gulati R., Plymate S.R., Zhou Z., Birditt B., et al.  Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat. Commun. 2021;12:1426. doi: 10.1038/s41467-021-21615-4.</cite> [<a href="https://doi.org/10.1038/s41467-021-21615-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7930198/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33658518/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Inter-%20and%20intra-tumor%20heterogeneity%20of%20metastatic%20prostate%20cancer%20determined%20by%20digital%20spatial%20gene%20expression%20profiling&amp;author=L.%20Brady&amp;author=M.%20Kriner&amp;author=I.%20Coleman&amp;author=C.%20Morrissey&amp;author=M.%20Roudier&amp;volume=12&amp;publication_year=2021&amp;pages=1426&amp;pmid=33658518&amp;doi=10.1038/s41467-021-21615-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18-biomedicines-10-00236">
<span class="label">18.</span><cite>Zhang T., Agarwal A., Almquist R.G., Runyambo D., Park S., Bronson E., Boominathan R., Rao C., Anand M., Oyekunle T., et al.  Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomark. Res. 2021;9:14. doi: 10.1186/s40364-021-00267-y.</cite> [<a href="https://doi.org/10.1186/s40364-021-00267-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7890610/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33602330/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomark.%20Res.&amp;title=Expression%20of%20immune%20checkpoints%20on%20circulating%20tumor%20cells%20in%20men%20with%20metastatic%20prostate%20cancer&amp;author=T.%20Zhang&amp;author=A.%20Agarwal&amp;author=R.G.%20Almquist&amp;author=D.%20Runyambo&amp;author=S.%20Park&amp;volume=9&amp;publication_year=2021&amp;pages=14&amp;pmid=33602330&amp;doi=10.1186/s40364-021-00267-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19-biomedicines-10-00236">
<span class="label">19.</span><cite>Petrylak D.P., Loriot Y., Shaffer D.R., Braiteh F., Powderly J., Harshman L.C., Conkling P., Delord J.P., Gordon M., Kim J.W., et al.  Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2021;27:3360–3369. doi: 10.1158/1078-0432.CCR-20-1981.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-1981" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33568344/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=Safety%20and%20Clinical%20Activity%20of%20Atezolizumab%20in%20Patients%20with%20Metastatic%20Castration-Resistant%20Prostate%20Cancer:%20A%20Phase%20I%20Study&amp;author=D.P.%20Petrylak&amp;author=Y.%20Loriot&amp;author=D.R.%20Shaffer&amp;author=F.%20Braiteh&amp;author=J.%20Powderly&amp;volume=27&amp;publication_year=2021&amp;pages=3360-3369&amp;pmid=33568344&amp;doi=10.1158/1078-0432.CCR-20-1981&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B20-biomedicines-10-00236">
<span class="label">20.</span><cite>Imamura R., Kitagawa S., Kubo T., Irie A., Kariu T., Yoneda M., Kamba T., Imamura T. Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a. Prostate. 2021;81:147–156. doi: 10.1002/pros.24090.</cite> [<a href="https://doi.org/10.1002/pros.24090" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33368414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=Prostate%20cancer%20C5a%20receptor%20expression%20and%20augmentation%20of%20cancer%20cell%20proliferation,%20invasion,%20and%20PD-L1%20expression%20by%20C5a&amp;author=R.%20Imamura&amp;author=S.%20Kitagawa&amp;author=T.%20Kubo&amp;author=A.%20Irie&amp;author=T.%20Kariu&amp;volume=81&amp;publication_year=2021&amp;pages=147-156&amp;pmid=33368414&amp;doi=10.1002/pros.24090&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21-biomedicines-10-00236">
<span class="label">21.</span><cite>Meng J., Zhou Y., Lu X., Bian Z., Chen Y., Zhou J., Zhang L., Hao Z., Zhang M., Liang C. Immune response drives outcomes in prostate cancer: Implications for immunotherapy. Mol. Oncol. 2021;15:1358–1375. doi: 10.1002/1878-0261.12887.</cite> [<a href="https://doi.org/10.1002/1878-0261.12887" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8096785/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33338321/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Oncol.&amp;title=Immune%20response%20drives%20outcomes%20in%20prostate%20cancer:%20Implications%20for%20immunotherapy&amp;author=J.%20Meng&amp;author=Y.%20Zhou&amp;author=X.%20Lu&amp;author=Z.%20Bian&amp;author=Y.%20Chen&amp;volume=15&amp;publication_year=2021&amp;pages=1358-1375&amp;pmid=33338321&amp;doi=10.1002/1878-0261.12887&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22-biomedicines-10-00236">
<span class="label">22.</span><cite>Wong J.K., MacFarlane A., Devarajan K., Shulman R.M., Alpaugh R.K., Burbure N., Hallman M.A., Geynisman D.M., Horwitz E.M., Campbell K., et al.  Hypofractionated Short Course Radiation Treatment Results in Systemic Immune Activation and Upregulation of the PD-1/PD-L1 Exhaustion Axis: A Prospective Pilot Study in Early Stage Prostate Cancer Patients. Int. J. Radiat. Oncol. Biol. Phys. 2020;108:S120. doi: 10.1016/j.ijrobp.2020.07.837.</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2020.07.837" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.&amp;title=Hypofractionated%20Short%20Course%20Radiation%20Treatment%20Results%20in%20Systemic%20Immune%20Activation%20and%20Upregulation%20of%20the%20PD-1/PD-L1%20Exhaustion%20Axis:%20A%20Prospective%20Pilot%20Study%20in%20Early%20Stage%20Prostate%20Cancer%20Patients&amp;author=J.K.%20Wong&amp;author=A.%20MacFarlane&amp;author=K.%20Devarajan&amp;author=R.M.%20Shulman&amp;author=R.K.%20Alpaugh&amp;volume=108&amp;publication_year=2020&amp;pages=S120&amp;doi=10.1016/j.ijrobp.2020.07.837&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23-biomedicines-10-00236">
<span class="label">23.</span><cite>Graff J.N., Beer T.M., Alumkal J.J., Slottke R.E., Redmond W.L., Thomas G.V., Thompson R.F., Wood M.A., Koguchi Y., Chen Y., et al.  A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J. Immunother. Cancer. 2020;8:e000642. doi: 10.1136/jitc-2020-000642.</cite> [<a href="https://doi.org/10.1136/jitc-2020-000642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7333874/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32616555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=A%20phase%20II%20single-arm%20study%20of%20pembrolizumab%20with%20enzalutamide%20in%20men%20with%20metastatic%20castration-resistant%20prostate%20cancer%20progressing%20on%20enzalutamide%20alone&amp;author=J.N.%20Graff&amp;author=T.M.%20Beer&amp;author=J.J.%20Alumkal&amp;author=R.E.%20Slottke&amp;author=W.L.%20Redmond&amp;volume=8&amp;publication_year=2020&amp;pages=e000642&amp;pmid=32616555&amp;doi=10.1136/jitc-2020-000642&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24-biomedicines-10-00236">
<span class="label">24.</span><cite>Chen Q.H., Li B., Liu D.G., Zhang B., Yang X., Tu Y.L. LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. Cancer Cell Int. 2020;20:394. doi: 10.1186/s12935-020-01481-8.</cite> [<a href="https://doi.org/10.1186/s12935-020-01481-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7429893/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32821247/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell%20Int.&amp;title=LncRNA%20KCNQ1OT1%20sponges%20miR-15a%20to%20promote%20immune%20evasion%20and%20malignant%20progression%20of%20prostate%20cancer%20via%20up-regulating%20PD-L1&amp;author=Q.H.%20Chen&amp;author=B.%20Li&amp;author=D.G.%20Liu&amp;author=B.%20Zhang&amp;author=X.%20Yang&amp;volume=20&amp;publication_year=2020&amp;pages=394&amp;pmid=32821247&amp;doi=10.1186/s12935-020-01481-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25-biomedicines-10-00236">
<span class="label">25.</span><cite>Wang Q., Ye Y., Yu H., Lin S.H., Tu H., Liang D., Chang D.W., Huang M., Wu X. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study. Cancer Immunol. Immunother. CII. 2021;70:701–712. doi: 10.1007/s00262-020-02718-1.</cite> [<a href="https://doi.org/10.1007/s00262-020-02718-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7907032/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32909077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Immunol.%20Immunother.%20CII&amp;title=Immune%20checkpoint-related%20serum%20proteins%20and%20genetic%20variants%20predict%20outcomes%20of%20localized%20prostate%20cancer,%20a%20cohort%20study&amp;author=Q.%20Wang&amp;author=Y.%20Ye&amp;author=H.%20Yu&amp;author=S.H.%20Lin&amp;author=H.%20Tu&amp;volume=70&amp;publication_year=2021&amp;pages=701-712&amp;pmid=32909077&amp;doi=10.1007/s00262-020-02718-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B26-biomedicines-10-00236">
<span class="label">26.</span><cite>Han H.J., Li Y.R., Roach M., III, Aggarwal R. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Ther. Adv. Med. Oncol. 2020;12:1758835920936084. doi: 10.1177/1758835920936084.</cite> [<a href="https://doi.org/10.1177/1758835920936084" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7450451/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32922519/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ther.%20Adv.%20Med.%20Oncol.&amp;title=Dramatic%20response%20to%20combination%20pembrolizumab%20and%20radiation%20in%20metastatic%20castration%20resistant%20prostate%20cancer&amp;author=H.J.%20Han&amp;author=Y.R.%20Li&amp;author=M.%20Roach&amp;author=R.%20Aggarwal&amp;volume=12&amp;publication_year=2020&amp;pages=1758835920936084&amp;pmid=32922519&amp;doi=10.1177/1758835920936084&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B27-biomedicines-10-00236">
<span class="label">27.</span><cite>Vicier C., Ravi P., Kwak L., Werner L., Huang Y., Evan C., Loda M., Hamid A.A., Sweeney C.J. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate. 2021;81:50–57. doi: 10.1002/pros.24079.</cite> [<a href="https://doi.org/10.1002/pros.24079" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32986884/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=Association%20between%20CD8%20and%20PD-L1%20expression%20and%20outcomes%20after%20radical%20prostatectomy%20for%20localized%20prostate%20cancer&amp;author=C.%20Vicier&amp;author=P.%20Ravi&amp;author=L.%20Kwak&amp;author=L.%20Werner&amp;author=Y.%20Huang&amp;volume=81&amp;publication_year=2021&amp;pages=50-57&amp;pmid=32986884&amp;doi=10.1002/pros.24079&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B28-biomedicines-10-00236">
<span class="label">28.</span><cite>Ryan S.T., Zhang J., Burner D.N., Liss M., Pittman E., Muldong M., Shabaik A., Woo J., Basler N., Cunha J., et al.  Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. J. Transl. Med. 2020;18:214. doi: 10.1186/s12967-020-02370-4.</cite> [<a href="https://doi.org/10.1186/s12967-020-02370-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7257145/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32466781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Transl.%20Med.&amp;title=Neoadjuvant%20rituximab%20modulates%20the%20tumor%20immune%20environment%20in%20patients%20with%20high%20risk%20prostate%20cancer&amp;author=S.T.%20Ryan&amp;author=J.%20Zhang&amp;author=D.N.%20Burner&amp;author=M.%20Liss&amp;author=E.%20Pittman&amp;volume=18&amp;publication_year=2020&amp;pages=214&amp;pmid=32466781&amp;doi=10.1186/s12967-020-02370-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B29-biomedicines-10-00236">
<span class="label">29.</span><cite>Sharma M., Yang Z., Miyamoto H. Loss of DNA mismatch repair proteins in prostate cancer. Medicine. 2020;99:e20124. doi: 10.1097/MD.0000000000020124.</cite> [<a href="https://doi.org/10.1097/MD.0000000000020124" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7220555/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32384491/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine&amp;title=Loss%20of%20DNA%20mismatch%20repair%20proteins%20in%20prostate%20cancer&amp;author=M.%20Sharma&amp;author=Z.%20Yang&amp;author=H.%20Miyamoto&amp;volume=99&amp;publication_year=2020&amp;pages=e20124&amp;pmid=32384491&amp;doi=10.1097/MD.0000000000020124&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B30-biomedicines-10-00236">
<span class="label">30.</span><cite>Wagle M.C., Castillo J., Srinivasan S., Holcomb T., Yuen K.C., Kadel E.E., Mariathasan S., Halligan D.L., Carr A.R., Bylesjo M., et al.  Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. Cancer Immunol. Res. 2020;8:844–850. doi: 10.1158/2326-6066.CIR-19-0568.</cite> [<a href="https://doi.org/10.1158/2326-6066.CIR-19-0568" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32321776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Immunol.%20Res.&amp;title=Tumor%20Fusion%20Burden%20as%20a%20Hallmark%20of%20Immune%20Infiltration%20in%20Prostate%20Cancer&amp;author=M.C.%20Wagle&amp;author=J.%20Castillo&amp;author=S.%20Srinivasan&amp;author=T.%20Holcomb&amp;author=K.C.%20Yuen&amp;volume=8&amp;publication_year=2020&amp;pages=844-850&amp;pmid=32321776&amp;doi=10.1158/2326-6066.CIR-19-0568&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B31-biomedicines-10-00236">
<span class="label">31.</span><cite>Obradovic A.Z., Dallos M.C., Zahurak M.L., Partin A.W., Schaeffer E.M., Ross A.E., Allaf M.E., Nirschl T.R., Liu D., Chapman C.G., et al.  T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2020;26:3182–3192. doi: 10.1158/1078-0432.CCR-19-3372.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-3372" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7334055/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32173650/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=T-Cell%20Infiltration%20and%20Adaptive%20Treg%20Resistance%20in%20Response%20to%20Androgen%20Deprivation%20With%20or%20Without%20Vaccination%20in%20Localized%20Prostate%20Cancer&amp;author=A.Z.%20Obradovic&amp;author=M.C.%20Dallos&amp;author=M.L.%20Zahurak&amp;author=A.W.%20Partin&amp;author=E.M.%20Schaeffer&amp;volume=26&amp;publication_year=2020&amp;pages=3182-3192&amp;pmid=32173650&amp;doi=10.1158/1078-0432.CCR-19-3372&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B32-biomedicines-10-00236">
<span class="label">32.</span><cite>Goswami S., Walle T., Cornish A.E., Basu S., Anandhan S., Fernandez I., Vence L., Blando J., Zhao H., Yadav S.S., et al.  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat. Med. 2020;26:39–46. doi: 10.1038/s41591-019-0694-x.</cite> [<a href="https://doi.org/10.1038/s41591-019-0694-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7182038/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31873309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Med.&amp;title=Immune%20profiling%20of%20human%20tumors%20identifies%20CD73%20as%20a%20combinatorial%20target%20in%20glioblastoma&amp;author=S.%20Goswami&amp;author=T.%20Walle&amp;author=A.E.%20Cornish&amp;author=S.%20Basu&amp;author=S.%20Anandhan&amp;volume=26&amp;publication_year=2020&amp;pages=39-46&amp;pmid=31873309&amp;doi=10.1038/s41591-019-0694-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B33-biomedicines-10-00236">
<span class="label">33.</span><cite>Ihle C.L., Provera M.D., Straign D.M., Smith E.E., Edgerton S.M., Van Bokhoven A., Lucia M.S., Owens P. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. J. Immunother. Cancer. 2019;7:293. doi: 10.1186/s40425-019-0753-3.</cite> [<a href="https://doi.org/10.1186/s40425-019-0753-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6839115/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31703602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=Distinct%20tumor%20microenvironments%20of%20lytic%20and%20blastic%20bone%20metastases%20in%20prostate%20cancer%20patients&amp;author=C.L.%20Ihle&amp;author=M.D.%20Provera&amp;author=D.M.%20Straign&amp;author=E.E.%20Smith&amp;author=S.M.%20Edgerton&amp;volume=7&amp;publication_year=2019&amp;pages=293&amp;pmid=31703602&amp;doi=10.1186/s40425-019-0753-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B34-biomedicines-10-00236">
<span class="label">34.</span><cite>Ross A.E., Hurley P.J., Tran P.T., Rowe S.P., Benzon B., Neal T.O., Chapman C., Harb R., Milman Y., Trock B.J., et al.  A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:184–193. doi: 10.1038/s41391-019-0176-8.</cite> [<a href="https://doi.org/10.1038/s41391-019-0176-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7031012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31611635/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate%20Cancer%20Prostatic%20Dis.&amp;title=A%20pilot%20trial%20of%20pembrolizumab%20plus%20prostatic%20cryotherapy%20for%20men%20with%20newly%20diagnosed%20oligometastatic%20hormone-sensitive%20prostate%20cancer&amp;author=A.E.%20Ross&amp;author=P.J.%20Hurley&amp;author=P.T.%20Tran&amp;author=S.P.%20Rowe&amp;author=B.%20Benzon&amp;volume=23&amp;publication_year=2020&amp;pages=184-193&amp;pmid=31611635&amp;doi=10.1038/s41391-019-0176-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B35-biomedicines-10-00236">
<span class="label">35.</span><cite>Bryce A.H., Dronca R.S., Costello B.A., Infante J.R., Ames T.D., Jimeno J., Karp D.D. PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies. J. Clin. Oncol. 2020;38((Suppl. 6)):83. doi: 10.1200/JCO.2020.38.6_suppl.83.</cite> [<a href="https://doi.org/10.1200/JCO.2020.38.6_suppl.83" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=PT-112%20in%20advanced%20metastatic%20castrate-resistant%20prostate%20cancer%20(mCRPC),%20as%20monotherapy%20or%20in%20combination%20with%20PD-L1%20inhibitor%20avelumab:%20Findings%20from%20two%20phase%20I%20studies&amp;author=A.H.%20Bryce&amp;author=R.S.%20Dronca&amp;author=B.A.%20Costello&amp;author=J.R.%20Infante&amp;author=T.D.%20Ames&amp;volume=38&amp;issue=(Suppl.%206)&amp;publication_year=2020&amp;pages=83&amp;doi=10.1200/JCO.2020.38.6_suppl.83&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B36-biomedicines-10-00236">
<span class="label">36.</span><cite>Abdul Sater H., Marté J.L., Donahue R.N., Walter-Rodriguez B., Heery C.R., Steinberg S.M., Cordes L.M., Chun G., Karzai F., Bilusic M., et al.  Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. J. Immunother. Cancer. 2020;8:e000655. doi: 10.1136/jitc-2020-000655.</cite> [<a href="https://doi.org/10.1136/jitc-2020-000655" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7174144/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32269146/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=Neoadjuvant%20PROSTVAC%20prior%20to%20radical%20prostatectomy%20enhances%20T-cell%20infiltration%20into%20the%20tumor%20immune%20microenvironment%20in%20men%20with%20prostate%20cancer&amp;author=H.%20Abdul%20Sater&amp;author=J.L.%20Mart%C3%A9&amp;author=R.N.%20Donahue&amp;author=B.%20Walter-Rodriguez&amp;author=C.R.%20Heery&amp;volume=8&amp;publication_year=2020&amp;pages=e000655&amp;pmid=32269146&amp;doi=10.1136/jitc-2020-000655&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B37-biomedicines-10-00236">
<span class="label">37.</span><cite>Sharma M., Yang Z., Miyamoto H. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer. Medicine. 2019;98:e17257. doi: 10.1097/MD.0000000000017257.</cite> [<a href="https://doi.org/10.1097/MD.0000000000017257" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6756626/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31567999/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine&amp;title=Immunohistochemistry%20of%20immune%20checkpoint%20markers%20PD-1%20and%20PD-L1%20in%20prostate%20cancer&amp;author=M.%20Sharma&amp;author=Z.%20Yang&amp;author=H.%20Miyamoto&amp;volume=98&amp;publication_year=2019&amp;pages=e17257&amp;pmid=31567999&amp;doi=10.1097/MD.0000000000017257&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B38-biomedicines-10-00236">
<span class="label">38.</span><cite>Shaw K., Calagua C., Russo J., Einstein D., Balk S., Ye H. Tumor PD-L1 Expression is Detected in a Significant Subset of High-Risk Localized and Metastatic Prostate Cancer but is Rare in Ductal Subtype. Abstracts from USCAP 2019: Genitourinary Pathology (including renal tumors) (776–992) Mod. Pathol. 2019;32:143–144.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Mod.%20Pathol.&amp;title=Tumor%20PD-L1%20Expression%20is%20Detected%20in%20a%20Significant%20Subset%20of%20High-Risk%20Localized%20and%20Metastatic%20Prostate%20Cancer%20but%20is%20Rare%20in%20Ductal%20Subtype.%20Abstracts%20from%20USCAP%202019:%20Genitourinary%20Pathology%20(including%20renal%20tumors)%20(776%E2%80%93992)&amp;author=K.%20Shaw&amp;author=C.%20Calagua&amp;author=J.%20Russo&amp;author=D.%20Einstein&amp;author=S.%20Balk&amp;volume=32&amp;publication_year=2019&amp;pages=143-144&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B39-biomedicines-10-00236">
<span class="label">39.</span><cite>Matveev V.B., Kirichek A.A., Safronova V.M., Khafizov K.O., Filippova M.G., Lyubchenko L.N. Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer. Urologiia. 2019;4:51–57. doi: 10.18565/urology.2019.4.51-57.</cite> [<a href="https://doi.org/10.18565/urology.2019.4.51-57" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31535805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Urologiia&amp;title=Impact%20of%20PD-L1%20status%20on%20the%20long-term%20outcomes%20of%20radical%20treatment%20of%20patients%20with%20prostate%20cancer&amp;author=V.B.%20Matveev&amp;author=A.A.%20Kirichek&amp;author=V.M.%20Safronova&amp;author=K.O.%20Khafizov&amp;author=M.G.%20Filippova&amp;volume=4&amp;publication_year=2019&amp;pages=51-57&amp;pmid=31535805&amp;doi=10.18565/urology.2019.4.51-57&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B40-biomedicines-10-00236">
<span class="label">40.</span><cite>Matveev V., Kirichek A., Safronova V., Kokosadze N., Khalmurzaev O., Kamolov B., Liubchenko L. The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer. Cancer Urol. 2019;15:57–65. doi: 10.17650/1726-9776-2019-15-1-57-65.</cite> [<a href="https://doi.org/10.17650/1726-9776-2019-15-1-57-65" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Urol.&amp;title=The%20prognostic%20value%20of%20tumor%20PD-L1%20status%20in%20patients%20with%20metastatic%20prostate%20cancer&amp;author=V.%20Matveev&amp;author=A.%20Kirichek&amp;author=V.%20Safronova&amp;author=N.%20Kokosadze&amp;author=O.%20Khalmurzaev&amp;volume=15&amp;publication_year=2019&amp;pages=57-65&amp;doi=10.17650/1726-9776-2019-15-1-57-65&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B41-biomedicines-10-00236">
<span class="label">41.</span><cite>Iacovelli R., Ciccarese C., Brunelli M., Bogina G., Munari E., Bimbatti D., Mosillo C., Fantinel E., Bria E., Martignoni G., et al.  PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. J. Immunother. 2019;42:269–273. doi: 10.1097/CJI.0000000000000287.</cite> [<a href="https://doi.org/10.1097/CJI.0000000000000287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31261165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.&amp;title=PD-L1%20Expression%20in%20De%20Novo%20Metastatic%20Castration-sensitive%20Prostate%20Cancer&amp;author=R.%20Iacovelli&amp;author=C.%20Ciccarese&amp;author=M.%20Brunelli&amp;author=G.%20Bogina&amp;author=E.%20Munari&amp;volume=42&amp;publication_year=2019&amp;pages=269-273&amp;pmid=31261165&amp;doi=10.1097/CJI.0000000000000287&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B42-biomedicines-10-00236">
<span class="label">42.</span><cite>Kazantseva M., Mehta S., Eiholzer R.A., Gimenez G., Bowie S., Campbell H., Reily-Bell A.L., Roth I., Ray S., Drummond C.J., et al.  The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. Cell Death Dis. 2019;10:631. doi: 10.1038/s41419-019-1861-1.</cite> [<a href="https://doi.org/10.1038/s41419-019-1861-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6702175/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31431617/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Death%20Dis.&amp;title=The%20%CE%94133p53%CE%B2%20isoform%20promotes%20an%20immunosuppressive%20environment%20leading%20to%20aggressive%20prostate%20cancer&amp;author=M.%20Kazantseva&amp;author=S.%20Mehta&amp;author=R.A.%20Eiholzer&amp;author=G.%20Gimenez&amp;author=S.%20Bowie&amp;volume=10&amp;publication_year=2019&amp;pages=631&amp;pmid=31431617&amp;doi=10.1038/s41419-019-1861-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B43-biomedicines-10-00236">
<span class="label">43.</span><cite>Lindh C., Kis L., Delahunt B., Samaratunga H., Yaxley J., Wiklund N.P., Clements M., Egevad L. PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate. APMIS. 2019;127:554–560. doi: 10.1111/apm.12970.</cite> [<a href="https://doi.org/10.1111/apm.12970" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31127651/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=APMIS&amp;title=PD-L1%20expression%20and%20deficient%20mismatch%20repair%20in%20ductal%20adenocarcinoma%20of%20the%20prostate&amp;author=C.%20Lindh&amp;author=L.%20Kis&amp;author=B.%20Delahunt&amp;author=H.%20Samaratunga&amp;author=J.%20Yaxley&amp;volume=127&amp;publication_year=2019&amp;pages=554-560&amp;pmid=31127651&amp;doi=10.1111/apm.12970&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B44-biomedicines-10-00236">
<span class="label">44.</span><cite>Richardsen E., Andersen S., Al-Saad S., Rakaee M., Nordby Y., Pedersen M.I., Ness N., Ingebriktsen L.M., Fassina A., Taskén K.A., et al.  Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. Sci. Rep. 2019;9:10662. doi: 10.1038/s41598-019-47234-0.</cite> [<a href="https://doi.org/10.1038/s41598-019-47234-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6650397/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31337863/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci.%20Rep.&amp;title=Low%20Expression%20of%20miR-424-3p%20is%20Highly%20Correlated%20with%20Clinical%20Failure%20in%20Prostate%20Cancer&amp;author=E.%20Richardsen&amp;author=S.%20Andersen&amp;author=S.%20Al-Saad&amp;author=M.%20Rakaee&amp;author=Y.%20Nordby&amp;volume=9&amp;publication_year=2019&amp;pages=10662&amp;pmid=31337863&amp;doi=10.1038/s41598-019-47234-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B45-biomedicines-10-00236">
<span class="label">45.</span><cite>Xian P., Ge D., Wu V.J., Patel A., Tang W.W., Wu X., Zhang K., Li L., You Z. PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors. Am. J. Clin. Exp. Urol. 2019;7:159–169.</cite> [<a href="/articles/PMC6627547/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31317055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Clin.%20Exp.%20Urol.&amp;title=PD-L1%20instead%20of%20PD-1%20status%20is%20associated%20with%20the%20clinical%20features%20in%20human%20primary%20prostate%20tumors&amp;author=P.%20Xian&amp;author=D.%20Ge&amp;author=V.J.%20Wu&amp;author=A.%20Patel&amp;author=W.W.%20Tang&amp;volume=7&amp;publication_year=2019&amp;pages=159-169&amp;pmid=31317055&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B46-biomedicines-10-00236">
<span class="label">46.</span><cite>Li H., Wang Z., Zhang Y., Sun G., Ding B., Yan L., Liu H., Guan W., Hu Z., Wang S., et al.  The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy. J. Cancer. 2019;10:3102–3111. doi: 10.7150/jca.30384.</cite> [<a href="https://doi.org/10.7150/jca.30384" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6603373/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31289580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Cancer&amp;title=The%20Immune%20Checkpoint%20Regulator%20PDL1%20is%20an%20Independent%20Prognostic%20Biomarker%20for%20Biochemical%20Recurrence%20in%20Prostate%20Cancer%20Patients%20Following%20Adjuvant%20Hormonal%20Therapy&amp;author=H.%20Li&amp;author=Z.%20Wang&amp;author=Y.%20Zhang&amp;author=G.%20Sun&amp;author=B.%20Ding&amp;volume=10&amp;publication_year=2019&amp;pages=3102-3111&amp;pmid=31289580&amp;doi=10.7150/jca.30384&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B47-biomedicines-10-00236">
<span class="label">47.</span><cite>Pal S.K., Moreira D., Won H., White S.W., Duttagupta P., Lucia M., Jones J., Hsu J., Kortylewski M. Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy. Int. J. Mol. Sci. 2019;20:1831.  doi: 10.3390/ijms20081831.</cite> [<a href="https://doi.org/10.3390/ijms20081831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6515443/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31013891/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=Reduced%20T-cell%20Numbers%20and%20Elevated%20Levels%20of%20Immunomodulatory%20Cytokines%20in%20Metastatic%20Prostate%20Cancer%20Patients%20De%20Novo%20Resistant%20to%20Abiraterone%20and/or%20Enzalutamide%20Therapy&amp;author=S.K.%20Pal&amp;author=D.%20Moreira&amp;author=H.%20Won&amp;author=S.W.%20White&amp;author=P.%20Duttagupta&amp;volume=20&amp;publication_year=2019&amp;pages=1831&amp;pmid=31013891&amp;doi=10.3390/ijms20081831&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B48-biomedicines-10-00236">
<span class="label">48.</span><cite>Abida W., Cheng M.L., Armenia J., Middha S., Autio K.A., Vargas H.A., Rathkopf D., Morris M.J., Danila D.C., Slovin S.F., et al.  Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019;5:471–478. doi: 10.1001/jamaoncol.2018.5801.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2018.5801" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6459218/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30589920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&amp;title=Analysis%20of%20the%20Prevalence%20of%20Microsatellite%20Instability%20in%20Prostate%20Cancer%20and%20Response%20to%20Immune%20Checkpoint%20Blockade&amp;author=W.%20Abida&amp;author=M.L.%20Cheng&amp;author=J.%20Armenia&amp;author=S.%20Middha&amp;author=K.A.%20Autio&amp;volume=5&amp;publication_year=2019&amp;pages=471-478&amp;pmid=30589920&amp;doi=10.1001/jamaoncol.2018.5801&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B49-biomedicines-10-00236">
<span class="label">49.</span><cite>Zhao S.G., Lehrer J., Chang S.L., Das R., Erho N., Liu Y., Sjöström M., Den R.B., Freedland S.J., Klein E.A., et al.  The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J. Natl. Cancer Inst. 2019;111:301–310. doi: 10.1093/jnci/djy141.</cite> [<a href="https://doi.org/10.1093/jnci/djy141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30321406/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Natl.%20Cancer%20Inst.&amp;title=The%20Immune%20Landscape%20of%20Prostate%20Cancer%20and%20Nomination%20of%20PD-L2%20as%20a%20Potential%20Therapeutic%20Target&amp;author=S.G.%20Zhao&amp;author=J.%20Lehrer&amp;author=S.L.%20Chang&amp;author=R.%20Das&amp;author=N.%20Erho&amp;volume=111&amp;publication_year=2019&amp;pages=301-310&amp;pmid=30321406&amp;doi=10.1093/jnci/djy141&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B50-biomedicines-10-00236">
<span class="label">50.</span><cite>Scimeca M., Bonfiglio R., Urbano N., Cerroni C., Anemona L., Montanaro M., Fazi S., Schillaci O., Mauriello A., Bonanno E. Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition. Urol. Oncol. 2019;37:297.e19–297.e31. doi: 10.1016/j.urolonc.2019.02.013.</cite> [<a href="https://doi.org/10.1016/j.urolonc.2019.02.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30827759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Urol.%20Oncol.&amp;title=Programmed%20death%20ligand%201%20expression%20in%20prostate%20cancer%20cells%20is%20associated%20with%20deep%20changes%20of%20the%20tumor%20inflammatory%20infiltrate%20composition&amp;author=M.%20Scimeca&amp;author=R.%20Bonfiglio&amp;author=N.%20Urbano&amp;author=C.%20Cerroni&amp;author=L.%20Anemona&amp;volume=37&amp;publication_year=2019&amp;pages=297.e19-297.e31&amp;pmid=30827759&amp;doi=10.1016/j.urolonc.2019.02.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B51-biomedicines-10-00236">
<span class="label">51.</span><cite>Jung K.H., LoRusso P., Burris H., Gordon M., Bang Y.J., Hellmann M.D., Cervantes A., Ochoa de Olza M., Marabelle A., Hodi F.S., et al.  Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2019;25:3220–3228. doi: 10.1158/1078-0432.CCR-18-2740.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-2740" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7980952/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30770348/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=Phase%20I%20Study%20of%20the%20Indoleamine%202,3-Dioxygenase%201%20(IDO1)%20Inhibitor%20Navoximod%20(GDC-0919)%20Administered%20with%20PD-L1%20Inhibitor%20(Atezolizumab)%20in%20Advanced%20Solid%20Tumors&amp;author=K.H.%20Jung&amp;author=P.%20LoRusso&amp;author=H.%20Burris&amp;author=M.%20Gordon&amp;author=Y.J.%20Bang&amp;volume=25&amp;publication_year=2019&amp;pages=3220-3228&amp;pmid=30770348&amp;doi=10.1158/1078-0432.CCR-18-2740&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B52-biomedicines-10-00236">
<span class="label">52.</span><cite>Mo R.J., Han Z.D., Liang Y.K., Ye J.H., Wu S.L., Lin S.X., Zhang Y.Q., Song S.D., Jiang F.N., Zhong W.D., et al.  Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8(+) tumor-associated lymphocytes and poor prognosis in prostate cancer. Int. J. Cancer. 2019;144:3099–3110. doi: 10.1002/ijc.32061.</cite> [<a href="https://doi.org/10.1002/ijc.32061" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30537104/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Cancer&amp;title=Expression%20of%20PD-L1%20in%20tumor-associated%20nerves%20correlates%20with%20reduced%20CD8(+)%20tumor-associated%20lymphocytes%20and%20poor%20prognosis%20in%20prostate%20cancer&amp;author=R.J.%20Mo&amp;author=Z.D.%20Han&amp;author=Y.K.%20Liang&amp;author=J.H.%20Ye&amp;author=S.L.%20Wu&amp;volume=144&amp;publication_year=2019&amp;pages=3099-3110&amp;pmid=30537104&amp;doi=10.1002/ijc.32061&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B53-biomedicines-10-00236">
<span class="label">53.</span><cite>Papanicolau-Sengos A., Yang Y., Pabla S., Lenzo F.L., Kato S., Kurzrock R., DePietro P., Nesline M., Conroy J., Glenn S., et al.  Identification of targets for prostate cancer immunotherapy. Prostate. 2019;79:498–505. doi: 10.1002/pros.23756.</cite> [<a href="https://doi.org/10.1002/pros.23756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30614027/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=Identification%20of%20targets%20for%20prostate%20cancer%20immunotherapy&amp;author=A.%20Papanicolau-Sengos&amp;author=Y.%20Yang&amp;author=S.%20Pabla&amp;author=F.L.%20Lenzo&amp;author=S.%20Kato&amp;volume=79&amp;publication_year=2019&amp;pages=498-505&amp;pmid=30614027&amp;doi=10.1002/pros.23756&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B54-biomedicines-10-00236">
<span class="label">54.</span><cite>von Hardenberg J., Hartmann S., Nitschke K., Worst T.S., Ting S., Reis H., Nuhn P., Weis C.A., Erben P. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation. Clin. Genitourin. Cancer. 2019;17:145–153.e5. doi: 10.1016/j.clgc.2018.12.007.</cite> [<a href="https://doi.org/10.1016/j.clgc.2018.12.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30709785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Genitourin.%20Cancer&amp;title=Programmed%20Death%20Ligand%201%20(PD-L1)%20Status%20and%20Tumor-Infiltrating%20Lymphocytes%20in%20Hot%20Spots%20of%20Primary%20and%20Liver%20Metastases%20in%20Prostate%20Cancer%20With%20Neuroendocrine%20Differentiation&amp;author=J.%20von%20Hardenberg&amp;author=S.%20Hartmann&amp;author=K.%20Nitschke&amp;author=T.S.%20Worst&amp;author=S.%20Ting&amp;volume=17&amp;publication_year=2019&amp;pages=145-153.e5&amp;pmid=30709785&amp;doi=10.1016/j.clgc.2018.12.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B55-biomedicines-10-00236">
<span class="label">55.</span><cite>Jin X., Ding D., Yan Y., Li H., Wang B., Ma L., Ye Z., Ma T., Wu Q., Rodrigues D.N., et al.  Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Mol. Cell. 2019;73:22–35.e6. doi: 10.1016/j.molcel.2018.10.034.</cite> [<a href="https://doi.org/10.1016/j.molcel.2018.10.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8968458/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30527665/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cell&amp;title=Phosphorylated%20RB%20Promotes%20Cancer%20Immunity%20by%20Inhibiting%20NF-%CE%BAB%20Activation%20and%20PD-L1%20Expression&amp;author=X.%20Jin&amp;author=D.%20Ding&amp;author=Y.%20Yan&amp;author=H.%20Li&amp;author=B.%20Wang&amp;volume=73&amp;publication_year=2019&amp;pages=22-35.e6&amp;pmid=30527665&amp;doi=10.1016/j.molcel.2018.10.034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B56-biomedicines-10-00236">
<span class="label">56.</span><cite>Karzai F., VanderWeele D., Madan R.A., Owens H., Cordes L.M., Hankin A., Couvillon A., Nichols E., Bilusic M., Beshiri M.L., et al.  Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J. Immunother. Cancer. 2018;6:141. doi: 10.1186/s40425-018-0463-2.</cite> [<a href="https://doi.org/10.1186/s40425-018-0463-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6280368/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30514390/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=Activity%20of%20durvalumab%20plus%20olaparib%20in%20metastatic%20castration-resistant%20prostate%20cancer%20in%20men%20with%20and%20without%20DNA%20damage%20repair%20mutations&amp;author=F.%20Karzai&amp;author=D.%20VanderWeele&amp;author=R.A.%20Madan&amp;author=H.%20Owens&amp;author=L.M.%20Cordes&amp;volume=6&amp;publication_year=2018&amp;pages=141&amp;pmid=30514390&amp;doi=10.1186/s40425-018-0463-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B57-biomedicines-10-00236">
<span class="label">57.</span><cite>Richter I., Jirasek T., Havlickova I., Curcikova R., Samal V., Dvorak J., Bartos J. The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide. J. B.U.ON. Off. J. Balk. Union Oncol. 2018;23:1796–1802.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/30610805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20B.U.ON.%20Off.%20J.%20Balk.%20Union%20Oncol.&amp;title=The%20expression%20of%20PD-L1%20in%20patients%20with%20castrate%20prostate%20cancer%20treated%20with%20enzalutamide&amp;author=I.%20Richter&amp;author=T.%20Jirasek&amp;author=I.%20Havlickova&amp;author=R.%20Curcikova&amp;author=V.%20Samal&amp;volume=23&amp;publication_year=2018&amp;pages=1796-1802&amp;pmid=30610805&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B58-biomedicines-10-00236">
<span class="label">58.</span><cite>Xiong W., Deng H., Huang C., Zen C., Jian C., Ye K., Zhong Z., Zhao X., Zhu L. MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity. Biochim. Biophys. Acta. Mol. Basis Dis. 2019;1865:454–463. doi: 10.1016/j.bbadis.2018.10.027.</cite> [<a href="https://doi.org/10.1016/j.bbadis.2018.10.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30385408/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochim.%20Biophys.%20Acta.%20Mol.%20Basis%20Dis.&amp;title=MLL3%20enhances%20the%20transcription%20of%20PD-L1%20and%20regulates%20anti-tumor%20immunity&amp;author=W.%20Xiong&amp;author=H.%20Deng&amp;author=C.%20Huang&amp;author=C.%20Zen&amp;author=C.%20Jian&amp;volume=1865&amp;publication_year=2019&amp;pages=454-463&amp;pmid=30385408&amp;doi=10.1016/j.bbadis.2018.10.027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B59-biomedicines-10-00236">
<span class="label">59.</span><cite>Hahn E., Liu S.K., Vesprini D., Xu B., Downes M.R. Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: An exploratory analysis. J. Clin. Pathol. 2018;71:1023–1027. doi: 10.1136/jclinpath-2018-205404.</cite> [<a href="https://doi.org/10.1136/jclinpath-2018-205404" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30257853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Pathol.&amp;title=Immune%20infiltrates%20and%20PD-L1%20expression%20in%20treatment-na%C3%AFve%20acinar%20prostatic%20adenocarcinoma:%20An%20exploratory%20analysis&amp;author=E.%20Hahn&amp;author=S.K.%20Liu&amp;author=D.%20Vesprini&amp;author=B.%20Xu&amp;author=M.R.%20Downes&amp;volume=71&amp;publication_year=2018&amp;pages=1023-1027&amp;pmid=30257853&amp;doi=10.1136/jclinpath-2018-205404&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B60-biomedicines-10-00236">
<span class="label">60.</span><cite>Redman J.M., Steinberg S.M., Gulley J.L. Quick efficacy seeking trial (QuEST1): A novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. J. Immunother. Cancer. 2018;6:91. doi: 10.1186/s40425-018-0409-8.</cite> [<a href="https://doi.org/10.1186/s40425-018-0409-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6145343/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30227893/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=Quick%20efficacy%20seeking%20trial%20(QuEST1):%20A%20novel%20combination%20immunotherapy%20study%20designed%20for%20rapid%20clinical%20signal%20assessment%20metastatic%20castration-resistant%20prostate%20cancer&amp;author=J.M.%20Redman&amp;author=S.M.%20Steinberg&amp;author=J.L.%20Gulley&amp;volume=6&amp;publication_year=2018&amp;pages=91&amp;pmid=30227893&amp;doi=10.1186/s40425-018-0409-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B61-biomedicines-10-00236">
<span class="label">61.</span><cite>Nava Rodrigues D., Rescigno P., Liu D., Yuan W., Carreira S., Lambros M.B., Seed G., Mateo J., Riisnaes R., Mullane S., et al.  Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J. Clin. Investig. 2018;128:4441–4453. doi: 10.1172/JCI121924.</cite> [<a href="https://doi.org/10.1172/JCI121924" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6159966/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30179225/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Investig.&amp;title=Immunogenomic%20analyses%20associate%20immunological%20alterations%20with%20mismatch%20repair%20defects%20in%20prostate%20cancer&amp;author=D.%20Nava%20Rodrigues&amp;author=P.%20Rescigno&amp;author=D.%20Liu&amp;author=W.%20Yuan&amp;author=S.%20Carreira&amp;volume=128&amp;publication_year=2018&amp;pages=4441-4453&amp;pmid=30179225&amp;doi=10.1172/JCI121924&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B62-biomedicines-10-00236">
<span class="label">62.</span><cite>Salvi S., Casadio V., Martignano F., Gurioli G., Tumedei M.M., Calistri D., Gunelli R., Costantini M. Carcinosarcoma of the prostate: Case report with molecular and histological characterization. Int. J. Biol. Markers. 2018;33:540–544. doi: 10.1177/1724600818791463.</cite> [<a href="https://doi.org/10.1177/1724600818791463" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30101629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Biol.%20Markers&amp;title=Carcinosarcoma%20of%20the%20prostate:%20Case%20report%20with%20molecular%20and%20histological%20characterization&amp;author=S.%20Salvi&amp;author=V.%20Casadio&amp;author=F.%20Martignano&amp;author=G.%20Gurioli&amp;author=M.M.%20Tumedei&amp;volume=33&amp;publication_year=2018&amp;pages=540-544&amp;pmid=30101629&amp;doi=10.1177/1724600818791463&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B63-biomedicines-10-00236">
<span class="label">63.</span><cite>Wang C., Hahn E., Slodkowska E., Eskander A., Enepekides D., Higgins K., Vesprini D., Liu S.K., Downes M.R., Xu B. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. Hum. Pathol. 2018;82:131–139. doi: 10.1016/j.humpath.2018.07.024.</cite> [<a href="https://doi.org/10.1016/j.humpath.2018.07.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30075156/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum.%20Pathol.&amp;title=Reproducibility%20of%20PD-L1%20immunohistochemistry%20interpretation%20across%20various%20types%20of%20genitourinary%20and%20head/neck%20carcinomas,%20antibody%20clones,%20and%20tissue%20types&amp;author=C.%20Wang&amp;author=E.%20Hahn&amp;author=E.%20Slodkowska&amp;author=A.%20Eskander&amp;author=D.%20Enepekides&amp;volume=82&amp;publication_year=2018&amp;pages=131-139&amp;pmid=30075156&amp;doi=10.1016/j.humpath.2018.07.024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B64-biomedicines-10-00236">
<span class="label">64.</span><cite>Hansen A.R., Massard C., Ott P.A., Haas N.B., Lopez J.S., Ejadi S., Wallmark J.M., Keam B., Delord J.P., Aggarwal R., et al.  Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018;29:1807–1813. doi: 10.1093/annonc/mdy232.</cite> [<a href="https://doi.org/10.1093/annonc/mdy232" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29992241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.%20Off.%20J.%20Eur.%20Soc.%20Med.%20Oncol.&amp;title=Pembrolizumab%20for%20advanced%20prostate%20adenocarcinoma:%20Findings%20of%20the%20KEYNOTE-028%20study&amp;author=A.R.%20Hansen&amp;author=C.%20Massard&amp;author=P.A.%20Ott&amp;author=N.B.%20Haas&amp;author=J.S.%20Lopez&amp;volume=29&amp;publication_year=2018&amp;pages=1807-1813&amp;pmid=29992241&amp;doi=10.1093/annonc/mdy232&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B65-biomedicines-10-00236">
<span class="label">65.</span><cite>McNeel D.G., Eickhoff J.C., Wargowski E., Zahm C., Staab M.J., Straus J., Liu G. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2018;9:25586–25596. doi: 10.18632/oncotarget.25387.</cite> [<a href="https://doi.org/10.18632/oncotarget.25387" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5986652/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29876010/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Concurrent,%20but%20not%20sequential,%20PD-1%20blockade%20with%20a%20DNA%20vaccine%20elicits%20anti-tumor%20responses%20in%20patients%20with%20metastatic,%20castration-resistant%20prostate%20cancer&amp;author=D.G.%20McNeel&amp;author=J.C.%20Eickhoff&amp;author=E.%20Wargowski&amp;author=C.%20Zahm&amp;author=M.J.%20Staab&amp;volume=9&amp;publication_year=2018&amp;pages=25586-25596&amp;pmid=29876010&amp;doi=10.18632/oncotarget.25387&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B66-biomedicines-10-00236">
<span class="label">66.</span><cite>Ishiba T., Hoffmann A.C., Usher J., Elshimali Y., Sturdevant T., Dang M., Jaimes Y., Tyagi R., Gonzales R., Grino M., et al.  Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem. Biophys. Res. Commun. 2018;500:621–625. doi: 10.1016/j.bbrc.2018.04.120.</cite> [<a href="https://doi.org/10.1016/j.bbrc.2018.04.120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9165692/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29679564/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.%20Biophys.%20Res.%20Commun.&amp;title=Frequencies%20and%20expression%20levels%20of%20programmed%20death%20ligand%201%20(PD-L1)%20in%20circulating%20tumor%20RNA%20(ctRNA)%20in%20various%20cancer%20types&amp;author=T.%20Ishiba&amp;author=A.C.%20Hoffmann&amp;author=J.%20Usher&amp;author=Y.%20Elshimali&amp;author=T.%20Sturdevant&amp;volume=500&amp;publication_year=2018&amp;pages=621-625&amp;pmid=29679564&amp;doi=10.1016/j.bbrc.2018.04.120&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B67-biomedicines-10-00236">
<span class="label">67.</span><cite>Xu L.J., Ma Q., Zhu J., Li J., Xue B.X., Gao J., Sun C.Y., Zang Y.C., Zhou Y.B., Yang D.R., et al.  Combined inhibition of JAK1,2/Stat3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia. Mol. Med. Rep. 2018;17:8111–8120. doi: 10.3892/mmr.2018.8905.</cite> [<a href="https://doi.org/10.3892/mmr.2018.8905" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5983983/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29693186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Med.%20Rep.&amp;title=Combined%20inhibition%20of%20JAK1,2/Stat3-PD-L1%20signaling%20pathway%20suppresses%20the%20immune%20escape%20of%20castration-resistant%20prostate%20cancer%20to%20NK%20cells%20in%20hypoxia&amp;author=L.J.%20Xu&amp;author=Q.%20Ma&amp;author=J.%20Zhu&amp;author=J.%20Li&amp;author=B.X.%20Xue&amp;volume=17&amp;publication_year=2018&amp;pages=8111-8120&amp;pmid=29693186&amp;doi=10.3892/mmr.2018.8905&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B68-biomedicines-10-00236">
<span class="label">68.</span><cite>Haffner M.C., Guner G., Taheri D., Netto G.J., Palsgrove D.N., Zheng Q., Guedes L.B., Kim K., Tsai H., Esopi D.M., et al.  Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. Am. J. Pathol. 2018;188:1478–1485. doi: 10.1016/j.ajpath.2018.02.014.</cite> [<a href="https://doi.org/10.1016/j.ajpath.2018.02.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5971230/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29577933/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Pathol.&amp;title=Comprehensive%20Evaluation%20of%20Programmed%20Death-Ligand%201%20Expression%20in%20Primary%20and%20Metastatic%20Prostate%20Cancer&amp;author=M.C.%20Haffner&amp;author=G.%20Guner&amp;author=D.%20Taheri&amp;author=G.J.%20Netto&amp;author=D.N.%20Palsgrove&amp;volume=188&amp;publication_year=2018&amp;pages=1478-1485&amp;pmid=29577933&amp;doi=10.1016/j.ajpath.2018.02.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B69-biomedicines-10-00236">
<span class="label">69.</span><cite>Nagaputra J., Thike A.A., Koh V. Loss of Androgen Receptor Accompained by Paucity of PD-L1 in Prostate Cancer is Associated with Clinical Relapse. USCAP 2018 Abstracts: Genitourinary Pathology (894–1126). Meeting Abstract: 1033. Mod. Pathol. 2018;31:323–403.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Mod.%20Pathol.&amp;title=Loss%20of%20Androgen%20Receptor%20Accompained%20by%20Paucity%20of%20PD-L1%20in%20Prostate%20Cancer%20is%20Associated%20with%20Clinical%20Relapse.%20USCAP%202018%20Abstracts:%20Genitourinary%20Pathology%20(894%E2%80%931126).%20Meeting%20Abstract:%201033&amp;author=J.%20Nagaputra&amp;author=A.A.%20Thike&amp;author=V.%20Koh&amp;volume=31&amp;publication_year=2018&amp;pages=323-403&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B70-biomedicines-10-00236">
<span class="label">70.</span><cite>Tu Y.N., Tong W.L., Yavorski J.M., Blanck G. Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-γ/δ Recombinations. Cancer Microenviron. Off. J. Int. Cancer Microenviron. Soc. 2018;11:41–49. doi: 10.1007/s12307-018-0204-6.</cite> [<a href="https://doi.org/10.1007/s12307-018-0204-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6008264/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29357011/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Microenviron.%20Off.%20J.%20Int.%20Cancer%20Microenviron.%20Soc.&amp;title=Immunogenomics:%20A%20Negative%20Prostate%20Cancer%20Outcome%20Associated%20with%20TcR-%CE%B3/%CE%B4%20Recombinations&amp;author=Y.N.%20Tu&amp;author=W.L.%20Tong&amp;author=J.M.%20Yavorski&amp;author=G.%20Blanck&amp;volume=11&amp;publication_year=2018&amp;pages=41-49&amp;pmid=29357011&amp;doi=10.1007/s12307-018-0204-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B71-biomedicines-10-00236">
<span class="label">71.</span><cite>Tao Z., Xu S., Ruan H., Wang T., Song W., Qian L., Chen K. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2018;48:801–814. doi: 10.1159/000491909.</cite> [<a href="https://doi.org/10.1159/000491909" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30032144/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell.%20Physiol.%20Biochem.%20Int.%20J.%20Exp.%20Cell.%20Physiol.%20Biochem.%20Pharmacol.&amp;title=MiR-195/-16%20Family%20Enhances%20Radiotherapy%20via%20T%20Cell%20Activation%20in%20the%20Tumor%20Microenvironment%20by%20Blocking%20the%20PD-L1%20Immune%20Checkpoint&amp;author=Z.%20Tao&amp;author=S.%20Xu&amp;author=H.%20Ruan&amp;author=T.%20Wang&amp;author=W.%20Song&amp;volume=48&amp;publication_year=2018&amp;pages=801-814&amp;pmid=30032144&amp;doi=10.1159/000491909&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B72-biomedicines-10-00236">
<span class="label">72.</span><cite>Budczies J., Denkert C., Győrffy B., Schirmacher P., Stenzinger A. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. BMC Med. Genom. 2017;10:74.  doi: 10.1186/s12920-017-0308-8.</cite> [<a href="https://doi.org/10.1186/s12920-017-0308-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5719741/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29212506/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Med.%20Genom.&amp;title=Chromosome%209p%20copy%20number%20gains%20involving%20PD-L1%20are%20associated%20with%20a%20specific%20proliferation%20and%20immune-modulating%20gene%20expression%20program%20active%20across%20major%20cancer%20types&amp;author=J.%20Budczies&amp;author=C.%20Denkert&amp;author=B.%20Gy%C5%91rffy&amp;author=P.%20Schirmacher&amp;author=A.%20Stenzinger&amp;volume=10&amp;publication_year=2017&amp;pages=74&amp;pmid=29212506&amp;doi=10.1186/s12920-017-0308-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B73-biomedicines-10-00236">
<span class="label">73.</span><cite>Fankhauser C.D., Schüffler P.J., Gillessen S., Omlin A., Rupp N.J., Rueschoff J.H., Hermanns T., Poyet C., Sulser T., Moch H., et al.  Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget. 2018;9:10284–10293. doi: 10.18632/oncotarget.22888.</cite> [<a href="https://doi.org/10.18632/oncotarget.22888" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5828186/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29535806/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Comprehensive%20immunohistochemical%20analysis%20of%20PD-L1%20shows%20scarce%20expression%20in%20castration-resistant%20prostate%20cancer&amp;author=C.D.%20Fankhauser&amp;author=P.J.%20Sch%C3%BCffler&amp;author=S.%20Gillessen&amp;author=A.%20Omlin&amp;author=N.J.%20Rupp&amp;volume=9&amp;publication_year=2018&amp;pages=10284-10293&amp;pmid=29535806&amp;doi=10.18632/oncotarget.22888&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B74-biomedicines-10-00236">
<span class="label">74.</span><cite>Truillet C., Oh H.L.J., Yeo S.P., Lee C.Y., Huynh L.T., Wei J., Parker M.F.L., Blakely C., Sevillano N., Wang Y.H., et al.  Imaging PD-L1 Expression with ImmunoPET. Bioconjugate Chem. 2018;29:96–103. doi: 10.1021/acs.bioconjchem.7b00631.</cite> [<a href="https://doi.org/10.1021/acs.bioconjchem.7b00631" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5773933/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29125731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioconjugate%20Chem.&amp;title=Imaging%20PD-L1%20Expression%20with%20ImmunoPET&amp;author=C.%20Truillet&amp;author=H.L.J.%20Oh&amp;author=S.P.%20Yeo&amp;author=C.Y.%20Lee&amp;author=L.T.%20Huynh&amp;volume=29&amp;publication_year=2018&amp;pages=96-103&amp;pmid=29125731&amp;doi=10.1021/acs.bioconjchem.7b00631&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B75-biomedicines-10-00236">
<span class="label">75.</span><cite>Zhang J., Bu X., Wang H., Zhu Y., Geng Y., Nihira N.T., Tan Y., Ci Y., Wu F., Dai X., et al.  Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–95. doi: 10.1038/nature25015.</cite> [<a href="https://doi.org/10.1038/nature25015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5754234/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29160310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Cyclin%20D-CDK4%20kinase%20destabilizes%20PD-L1%20via%20cullin%203-SPOP%20to%20control%20cancer%20immune%20surveillance&amp;author=J.%20Zhang&amp;author=X.%20Bu&amp;author=H.%20Wang&amp;author=Y.%20Zhu&amp;author=Y.%20Geng&amp;volume=553&amp;publication_year=2018&amp;pages=91-95&amp;pmid=29160310&amp;doi=10.1038/nature25015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B76-biomedicines-10-00236">
<span class="label">76.</span><cite>Chen Y.P., Zhang Y., Lv J.W., Li Y.Q., Wang Y.Q., He Q.M., Yang X.J., Sun Y., Mao Y.P., Yun J.P., et al.  Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics. 2017;7:3585–3594. doi: 10.7150/thno.21471.</cite> [<a href="https://doi.org/10.7150/thno.21471" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5596445/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28912897/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=Genomic%20Analysis%20of%20Tumor%20Microenvironment%20Immune%20Types%20across%2014%20Solid%20Cancer%20Types:%20Immunotherapeutic%20Implications&amp;author=Y.P.%20Chen&amp;author=Y.%20Zhang&amp;author=J.W.%20Lv&amp;author=Y.Q.%20Li&amp;author=Y.Q.%20Wang&amp;volume=7&amp;publication_year=2017&amp;pages=3585-3594&amp;pmid=28912897&amp;doi=10.7150/thno.21471&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B77-biomedicines-10-00236">
<span class="label">77.</span><cite>Calagua C., Russo J., Sun Y., Schaefer R., Lis R., Zhang Z., Mahoney K., Bubley G.J., Loda M., Taplin M.E., et al.  Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2017;23:6812–6822. doi: 10.1158/1078-0432.CCR-17-0807.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-0807" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28893901/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=Expression%20of%20PD-L1%20in%20Hormone-na%C3%AFve%20and%20Treated%20Prostate%20Cancer%20Patients%20Receiving%20Neoadjuvant%20Abiraterone%20Acetate%20plus%20Prednisone%20and%20Leuprolide&amp;author=C.%20Calagua&amp;author=J.%20Russo&amp;author=Y.%20Sun&amp;author=R.%20Schaefer&amp;author=R.%20Lis&amp;volume=23&amp;publication_year=2017&amp;pages=6812-6822&amp;pmid=28893901&amp;doi=10.1158/1078-0432.CCR-17-0807&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B78-biomedicines-10-00236">
<span class="label">78.</span><cite>Schott D.S., Pizon M., Pachmann U., Pachmann K. Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors. Oncotarget. 2017;8:72755–72772. doi: 10.18632/oncotarget.20346.</cite> [<a href="https://doi.org/10.18632/oncotarget.20346" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5641167/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29069824/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Sensitive%20detection%20of%20PD-L1%20expression%20on%20circulating%20epithelial%20tumor%20cells%20(CETCs)%20could%20be%20a%20potential%20biomarker%20to%20select%20patients%20for%20treatment%20with%20PD-1/PD-L1%20inhibitors%20in%20early%20and%20metastatic%20solid%20tumors&amp;author=D.S.%20Schott&amp;author=M.%20Pizon&amp;author=U.%20Pachmann&amp;author=K.%20Pachmann&amp;volume=8&amp;publication_year=2017&amp;pages=72755-72772&amp;pmid=29069824&amp;doi=10.18632/oncotarget.20346&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B79-biomedicines-10-00236">
<span class="label">79.</span><cite>Petitprez F., Fossati N., Vano Y., Freschi M., Becht E., Lucianò R., Calderaro J., Guédet T., Lacroix L., Rancoita P.M.V., et al.  PD-L1 Expression and CD8(+) T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. Eur. Urol. Focus. 2019;5:192–196. doi: 10.1016/j.euf.2017.05.013.</cite> [<a href="https://doi.org/10.1016/j.euf.2017.05.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28753812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.%20Focus&amp;title=PD-L1%20Expression%20and%20CD8(+)%20T-cell%20Infiltrate%20are%20Associated%20with%20Clinical%20Progression%20in%20Patients%20with%20Node-positive%20Prostate%20Cancer&amp;author=F.%20Petitprez&amp;author=N.%20Fossati&amp;author=Y.%20Vano&amp;author=M.%20Freschi&amp;author=E.%20Becht&amp;volume=5&amp;publication_year=2019&amp;pages=192-196&amp;pmid=28753812&amp;doi=10.1016/j.euf.2017.05.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B80-biomedicines-10-00236">
<span class="label">80.</span><cite>Li G., Ross J., Yang X. Mismatch Repair (MMR) Deficiency and PD-L1 Expression in the Prostatic Ductal Adenocarcinoma. Abstracts from USCAP 2019: Genitourinary Pathology (including renal tumors) (776–992) Mod. Pathol. 2019;32:91.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Mod.%20Pathol.&amp;title=Mismatch%20Repair%20(MMR)%20Deficiency%20and%20PD-L1%20Expression%20in%20the%20Prostatic%20Ductal%20Adenocarcinoma.%20Abstracts%20from%20USCAP%202019:%20Genitourinary%20Pathology%20(including%20renal%20tumors)%20(776%E2%80%93992)&amp;author=G.%20Li&amp;author=J.%20Ross&amp;author=X.%20Yang&amp;volume=32&amp;publication_year=2019&amp;pages=91&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B81-biomedicines-10-00236">
<span class="label">81.</span><cite>Ness N., Andersen S., Khanehkenari M.R., Nordbakken C.V., Valkov A., Paulsen E.E., Nordby Y., Bremnes R.M., Donnem T., Busund L.T., et al.  The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget. 2017;8:26789–26801. doi: 10.18632/oncotarget.15817.</cite> [<a href="https://doi.org/10.18632/oncotarget.15817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5432297/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28460462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=The%20prognostic%20role%20of%20immune%20checkpoint%20markers%20programmed%20cell%20death%20protein%201%20(PD-1)%20and%20programmed%20death%20ligand%201%20(PD-L1)%20in%20a%20large,%20multicenter%20prostate%20cancer%20cohort&amp;author=N.%20Ness&amp;author=S.%20Andersen&amp;author=M.R.%20Khanehkenari&amp;author=C.V.%20Nordbakken&amp;author=A.%20Valkov&amp;volume=8&amp;publication_year=2017&amp;pages=26789-26801&amp;pmid=28460462&amp;doi=10.18632/oncotarget.15817&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B82-biomedicines-10-00236">
<span class="label">82.</span><cite>Baas W., Gershburg S., Dynda D., Delfino K., Robinson K., Nie D., Yearley J.H., Alanee S. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer. Clin. Genitourin. Cancer. 2017;15:577–581. doi: 10.1016/j.clgc.2017.04.002.</cite> [<a href="https://doi.org/10.1016/j.clgc.2017.04.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28461179/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Genitourin.%20Cancer&amp;title=Immune%20Characterization%20of%20the%20Programmed%20Death%20Receptor%20Pathway%20in%20High%20Risk%20Prostate%20Cancer&amp;author=W.%20Baas&amp;author=S.%20Gershburg&amp;author=D.%20Dynda&amp;author=K.%20Delfino&amp;author=K.%20Robinson&amp;volume=15&amp;publication_year=2017&amp;pages=577-581&amp;pmid=28461179&amp;doi=10.1016/j.clgc.2017.04.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B83-biomedicines-10-00236">
<span class="label">83.</span><cite>Gao J., Ward J.F., Pettaway C.A., Shi L.Z., Subudhi S.K., Vence L.M., Zhao H., Chen J., Chen H., Efstathiou E., et al.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 2017;23:551–555. doi: 10.1038/nm.4308.</cite> [<a href="https://doi.org/10.1038/nm.4308" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5466900/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28346412/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Med.&amp;title=VISTA%20is%20an%20inhibitory%20immune%20checkpoint%20that%20is%20increased%20after%20ipilimumab%20therapy%20in%20patients%20with%20prostate%20cancer&amp;author=J.%20Gao&amp;author=J.F.%20Ward&amp;author=C.A.%20Pettaway&amp;author=L.Z.%20Shi&amp;author=S.K.%20Subudhi&amp;volume=23&amp;publication_year=2017&amp;pages=551-555&amp;pmid=28346412&amp;doi=10.1038/nm.4308&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B84-biomedicines-10-00236">
<span class="label">84.</span><cite>Lu X., Horner J.W., Paul E., Shang X., Troncoso P., Deng P., Jiang S., Chang Q., Spring D.J., Sharma P., et al.  Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728–732. doi: 10.1038/nature21676.</cite> [<a href="https://doi.org/10.1038/nature21676" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5374023/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28321130/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Effective%20combinatorial%20immunotherapy%20for%20castration-resistant%20prostate%20cancer&amp;author=X.%20Lu&amp;author=J.W.%20Horner&amp;author=E.%20Paul&amp;author=X.%20Shang&amp;author=P.%20Troncoso&amp;volume=543&amp;publication_year=2017&amp;pages=728-732&amp;pmid=28321130&amp;doi=10.1038/nature21676&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B85-biomedicines-10-00236">
<span class="label">85.</span><cite>Tretiakova M., Fulton R., Kocherginsky M. Comparison of 4 PD-L1 Antibodies in 560 Kidney, Bladder and Prostate Cancers. Abstracts from USCAP 2019: Genitourinary Pathology (including Renal tumors) Mod. Pathol. 2017;30:210–271.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Mod.%20Pathol.&amp;title=Comparison%20of%204%20PD-L1%20Antibodies%20in%20560%20Kidney,%20Bladder%20and%20Prostate%20Cancers.%20Abstracts%20from%20USCAP%202019:%20Genitourinary%20Pathology%20(including%20Renal%20tumors)&amp;author=M.%20Tretiakova&amp;author=R.%20Fulton&amp;author=M.%20Kocherginsky&amp;volume=30&amp;publication_year=2017&amp;pages=210-271&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B86-biomedicines-10-00236">
<span class="label">86.</span><cite>Najjar S.N., Kallakury B.V.S., Sheehan C.E. Infrequent PD-L1 Protetin Expression and Gene Amplification in Prostatic Adenocarcinomas (PACs). Abstracts from USCAP 2019: Genitourinary Pathology (including Renal tumors) Mod. Pathol. 2017;30:246A.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Mod.%20Pathol.&amp;title=Infrequent%20PD-L1%20Protetin%20Expression%20and%20Gene%20Amplification%20in%20Prostatic%20Adenocarcinomas%20(PACs).%20Abstracts%20from%20USCAP%202019:%20Genitourinary%20Pathology%20(including%20Renal%20tumors)&amp;author=S.N.%20Najjar&amp;author=B.V.S.%20Kallakury&amp;author=C.E.%20Sheehan&amp;volume=30&amp;publication_year=2017&amp;pages=246A&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B87-biomedicines-10-00236">
<span class="label">87.</span><cite>Hashimoto Y., Imai A., Hatakeyama S., Yoneyama T., Koie T., Ohyama C. PD-L1 over expression may predict disease aggressiveness in prostate cancer. Meeting Abstract: 291P. Ann. Oncol. 2016;27:ix91–ix92. doi: 10.1016/S0923-7534(21)00449-X.</cite> [<a href="https://doi.org/10.1016/S0923-7534(21)00449-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=PD-L1%20over%20expression%20may%20predict%20disease%20aggressiveness%20in%20prostate%20cancer.%20Meeting%20Abstract:%20291P&amp;author=Y.%20Hashimoto&amp;author=A.%20Imai&amp;author=S.%20Hatakeyama&amp;author=T.%20Yoneyama&amp;author=T.%20Koie&amp;volume=27&amp;publication_year=2016&amp;pages=ix91-ix92&amp;doi=10.1016/S0923-7534(21)00449-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B88-biomedicines-10-00236">
<span class="label">88.</span><cite>Gevensleben H., Holmes E.E., Goltz D., Dietrich J., Sailer V., Ellinger J., Dietrich D., Kristiansen G. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget. 2016;7:79943–79955. doi: 10.18632/oncotarget.13161.</cite> [<a href="https://doi.org/10.18632/oncotarget.13161" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5346762/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27835597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=PD-L1%20promoter%20methylation%20is%20a%20prognostic%20biomarker%20for%20biochemical%20recurrence-free%20survival%20in%20prostate%20cancer%20patients%20following%20radical%20prostatectomy&amp;author=H.%20Gevensleben&amp;author=E.E.%20Holmes&amp;author=D.%20Goltz&amp;author=J.%20Dietrich&amp;author=V.%20Sailer&amp;volume=7&amp;publication_year=2016&amp;pages=79943-79955&amp;pmid=27835597&amp;doi=10.18632/oncotarget.13161&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B89-biomedicines-10-00236">
<span class="label">89.</span><cite>Zhou Q.Z., Liu C.D., Yang J.K., Guo W.B., Zhou J.H., Bian J. Changed percentage of myeloid-derived suppressor cells in the peripheral blood of prostate cancer patients and its clinical implication. Zhonghua Nan Ke Xue Natl. J. Androl. 2016;22:963–967.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/29281201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Zhonghua%20Nan%20Ke%20Xue%20Natl.%20J.%20Androl.&amp;title=Changed%20percentage%20of%20myeloid-derived%20suppressor%20cells%20in%20the%20peripheral%20blood%20of%20prostate%20cancer%20patients%20and%20its%20clinical%20implication&amp;author=Q.Z.%20Zhou&amp;author=C.D.%20Liu&amp;author=J.K.%20Yang&amp;author=W.B.%20Guo&amp;author=J.H.%20Zhou&amp;volume=22&amp;publication_year=2016&amp;pages=963-967&amp;pmid=29281201&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B90-biomedicines-10-00236">
<span class="label">90.</span><cite>Sharma V., Dong H., Kwon E., Karnes R.J. Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. Eur. Urol. Focus. 2018;4:75–79. doi: 10.1016/j.euf.2016.09.003.</cite> [<a href="https://doi.org/10.1016/j.euf.2016.09.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28753790/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.%20Focus&amp;title=Positive%20Pelvic%20Lymph%20Nodes%20in%20Prostate%20Cancer%20Harbor%20Immune%20Suppressor%20Cells%20To%20Impair%20Tumor-reactive%20T%20Cells&amp;author=V.%20Sharma&amp;author=H.%20Dong&amp;author=E.%20Kwon&amp;author=R.J.%20Karnes&amp;volume=4&amp;publication_year=2018&amp;pages=75-79&amp;pmid=28753790&amp;doi=10.1016/j.euf.2016.09.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B91-biomedicines-10-00236">
<span class="label">91.</span><cite>Goltz D., Holmes E.E., Gevensleben H., Sailer V., Dietrich J., Jung M., Röhler M., Meller S., Ellinger J., Kristiansen G., et al.  CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. Oncotarget. 2016;7:53309–53320. doi: 10.18632/oncotarget.10786.</cite> [<a href="https://doi.org/10.18632/oncotarget.10786" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5288188/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27462860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=CXCL12%20promoter%20methylation%20and%20PD-L1%20expression%20as%20prognostic%20biomarkers%20in%20prostate%20cancer%20patients&amp;author=D.%20Goltz&amp;author=E.E.%20Holmes&amp;author=H.%20Gevensleben&amp;author=V.%20Sailer&amp;author=J.%20Dietrich&amp;volume=7&amp;publication_year=2016&amp;pages=53309-53320&amp;pmid=27462860&amp;doi=10.18632/oncotarget.10786&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B92-biomedicines-10-00236">
<span class="label">92.</span><cite>Graff J.N., Alumkal J.J., Drake C.G., Thomas G.V., Redmond W.L., Farhad M., Cetnar J.P., Ey F.S., Bergan R.C., Slottke R., et al.  Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7:52810–52817. doi: 10.18632/oncotarget.10547.</cite> [<a href="https://doi.org/10.18632/oncotarget.10547" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5288150/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27429197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Early%20evidence%20of%20anti-PD-1%20activity%20in%20enzalutamide-resistant%20prostate%20cancer&amp;author=J.N.%20Graff&amp;author=J.J.%20Alumkal&amp;author=C.G.%20Drake&amp;author=G.V.%20Thomas&amp;author=W.L.%20Redmond&amp;volume=7&amp;publication_year=2016&amp;pages=52810-52817&amp;pmid=27429197&amp;doi=10.18632/oncotarget.10547&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B93-biomedicines-10-00236">
<span class="label">93.</span><cite>Satelli A., Batth I.S., Brownlee Z., Rojas C., Meng Q.H., Kopetz S., Li S. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci. Rep. 2016;6:28910. doi: 10.1038/srep28910.</cite> [<a href="https://doi.org/10.1038/srep28910" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4929464/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27363678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci.%20Rep.&amp;title=Potential%20role%20of%20nuclear%20PD-L1%20expression%20in%20cell-surface%20vimentin%20positive%20circulating%20tumor%20cells%20as%20a%20prognostic%20marker%20in%20cancer%20patients&amp;author=A.%20Satelli&amp;author=I.S.%20Batth&amp;author=Z.%20Brownlee&amp;author=C.%20Rojas&amp;author=Q.H.%20Meng&amp;volume=6&amp;publication_year=2016&amp;pages=28910&amp;pmid=27363678&amp;doi=10.1038/srep28910&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B94-biomedicines-10-00236">
<span class="label">94.</span><cite>Massari F., Ciccarese C., Caliò A., Munari E., Cima L., Porcaro A.B., Novella G., Artibani W., Sava T., Eccher A., et al.  Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Target. Oncol. 2016;11:345–351. doi: 10.1007/s11523-015-0396-3.</cite> [<a href="https://doi.org/10.1007/s11523-015-0396-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26566945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Target.%20Oncol.&amp;title=Magnitude%20of%20PD-1,%20PD-L1%20and%20T%20Lymphocyte%20Expression%20on%20Tissue%20from%20Castration-Resistant%20Prostate%20Adenocarcinoma:%20An%20Exploratory%20Analysis&amp;author=F.%20Massari&amp;author=C.%20Ciccarese&amp;author=A.%20Cali%C3%B2&amp;author=E.%20Munari&amp;author=L.%20Cima&amp;volume=11&amp;publication_year=2016&amp;pages=345-351&amp;pmid=26566945&amp;doi=10.1007/s11523-015-0396-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B95-biomedicines-10-00236">
<span class="label">95.</span><cite>Gevensleben H., Dietrich D., Golletz C., Steiner S., Jung M., Thiesler T., Majores M., Stein J., Uhl B., Müller S., et al.  The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016;22:1969–1977. doi: 10.1158/1078-0432.CCR-15-2042.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-2042" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26573597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=The%20Immune%20Checkpoint%20Regulator%20PD-L1%20Is%20Highly%20Expressed%20in%20Aggressive%20Primary%20Prostate%20Cancer&amp;author=H.%20Gevensleben&amp;author=D.%20Dietrich&amp;author=C.%20Golletz&amp;author=S.%20Steiner&amp;author=M.%20Jung&amp;volume=22&amp;publication_year=2016&amp;pages=1969-1977&amp;pmid=26573597&amp;doi=10.1158/1078-0432.CCR-15-2042&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B96-biomedicines-10-00236">
<span class="label">96.</span><cite>Martin A.M., Nirschl T.R., Nirschl C.J., Francica B.J., Kochel C.M., van Bokhoven A., Meeker A.K., Lucia M.S., Anders R.A., DeMarzo A.M., et al.  Paucity of PD-L1 expression in prostate cancer: Innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18:325–332. doi: 10.1038/pcan.2015.39.</cite> [<a href="https://doi.org/10.1038/pcan.2015.39" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4641011/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26260996/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate%20Cancer%20Prostatic%20Dis.&amp;title=Paucity%20of%20PD-L1%20expression%20in%20prostate%20cancer:%20Innate%20and%20adaptive%20immune%20resistance&amp;author=A.M.%20Martin&amp;author=T.R.%20Nirschl&amp;author=C.J.%20Nirschl&amp;author=B.J.%20Francica&amp;author=C.M.%20Kochel&amp;volume=18&amp;publication_year=2015&amp;pages=325-332&amp;pmid=26260996&amp;doi=10.1038/pcan.2015.39&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B97-biomedicines-10-00236">
<span class="label">97.</span><cite>Shalapour S., Font-Burgada J., Di Caro G., Zhong Z., Sanchez-Lopez E., Dhar D., Willimsky G., Ammirante M., Strasner A., Hansel D.E., et al.  Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521:94–98. doi: 10.1038/nature14395.</cite> [<a href="https://doi.org/10.1038/nature14395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4501632/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25924065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Immunosuppressive%20plasma%20cells%20impede%20T-cell-dependent%20immunogenic%20chemotherapy&amp;author=S.%20Shalapour&amp;author=J.%20Font-Burgada&amp;author=G.%20Di%20Caro&amp;author=Z.%20Zhong&amp;author=E.%20Sanchez-Lopez&amp;volume=521&amp;publication_year=2015&amp;pages=94-98&amp;pmid=25924065&amp;doi=10.1038/nature14395&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B98-biomedicines-10-00236">
<span class="label">98.</span><cite>Bishop J.L., Sio A., Angeles A., Roberts M.E., Azad A.A., Chi K.N., Zoubeidi A. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2015;6:234–242. doi: 10.18632/oncotarget.2703.</cite> [<a href="https://doi.org/10.18632/oncotarget.2703" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4381591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25428917/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=PD-L1%20is%20highly%20expressed%20in%20Enzalutamide%20resistant%20prostate%20cancer&amp;author=J.L.%20Bishop&amp;author=A.%20Sio&amp;author=A.%20Angeles&amp;author=M.E.%20Roberts&amp;author=A.A.%20Azad&amp;volume=6&amp;publication_year=2015&amp;pages=234-242&amp;pmid=25428917&amp;doi=10.18632/oncotarget.2703&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B99-biomedicines-10-00236">
<span class="label">99.</span><cite>Spary L.K., Salimu J., Webber J.P., Clayton A., Mason M.D., Tabi Z. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14(+) PD-L1(+) phenotype in prostate cancer. Oncoimmunology. 2014;3:e955331. doi: 10.4161/21624011.2014.955331.</cite> [<a href="https://doi.org/10.4161/21624011.2014.955331" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4292218/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25941611/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=Tumor%20stroma-derived%20factors%20skew%20monocyte%20to%20dendritic%20cell%20differentiation%20toward%20a%20suppressive%20CD14(+)%20PD-L1(+)%20phenotype%20in%20prostate%20cancer&amp;author=L.K.%20Spary&amp;author=J.%20Salimu&amp;author=J.P.%20Webber&amp;author=A.%20Clayton&amp;author=M.D.%20Mason&amp;volume=3&amp;publication_year=2014&amp;pages=e955331&amp;pmid=25941611&amp;doi=10.4161/21624011.2014.955331&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B100-biomedicines-10-00236">
<span class="label">100.</span><cite>Taube J.M. Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology. 2014;3:e963413. doi: 10.4161/21624011.2014.963413.</cite> [<a href="https://doi.org/10.4161/21624011.2014.963413" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4292419/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25914862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=Unleashing%20the%20immune%20system:%20PD-1%20and%20PD-Ls%20in%20the%20pre-treatment%20tumor%20microenvironment%20and%20correlation%20with%20response%20to%20PD-1/PD-L1%20blockade&amp;author=J.M.%20Taube&amp;volume=3&amp;publication_year=2014&amp;pages=e963413&amp;pmid=25914862&amp;doi=10.4161/21624011.2014.963413&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B101-biomedicines-10-00236">
<span class="label">101.</span><cite>Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., Chen L., Pardoll D.M., Topalian S.L., Anders R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2014;20:5064–5074. doi: 10.1158/1078-0432.CCR-13-3271.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-13-3271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4185001/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24714771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=Association%20of%20PD-1,%20PD-1%20ligands,%20and%20other%20features%20of%20the%20tumor%20immune%20microenvironment%20with%20response%20to%20anti-PD-1%20therapy&amp;author=J.M.%20Taube&amp;author=A.%20Klein&amp;author=J.R.%20Brahmer&amp;author=H.%20Xu&amp;author=X.%20Pan&amp;volume=20&amp;publication_year=2014&amp;pages=5064-5074&amp;pmid=24714771&amp;doi=10.1158/1078-0432.CCR-13-3271&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B102-biomedicines-10-00236">
<span class="label">102.</span><cite>Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366:2443–2454. doi: 10.1056/NEJMoa1200690.</cite> [<a href="https://doi.org/10.1056/NEJMoa1200690" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3544539/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22658127/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Safety,%20activity,%20and%20immune%20correlates%20of%20anti-PD-1%20antibody%20in%20cancer&amp;author=S.L.%20Topalian&amp;author=F.S.%20Hodi&amp;author=J.R.%20Brahmer&amp;author=S.N.%20Gettinger&amp;author=D.C.%20Smith&amp;volume=366&amp;publication_year=2012&amp;pages=2443-2454&amp;pmid=22658127&amp;doi=10.1056/NEJMoa1200690&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B103-biomedicines-10-00236">
<span class="label">103.</span><cite>Dulos J., Carven G.J., van Boxtel S.J., Evers S., Driessen-Engels L.J., Hobo W., Gorecka M.A., de Haan A.F., Mulders P., Punt C.J., et al.  PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J. Immunother. 2012;35:169–178. doi: 10.1097/CJI.0b013e318247a4e7.</cite> [<a href="https://doi.org/10.1097/CJI.0b013e318247a4e7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22306905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.&amp;title=PD-1%20blockade%20augments%20Th1%20and%20Th17%20and%20suppresses%20Th2%20responses%20in%20peripheral%20blood%20from%20patients%20with%20prostate%20and%20advanced%20melanoma%20cancer&amp;author=J.%20Dulos&amp;author=G.J.%20Carven&amp;author=S.J.%20van%20Boxtel&amp;author=S.%20Evers&amp;author=L.J.%20Driessen-Engels&amp;volume=35&amp;publication_year=2012&amp;pages=169-178&amp;pmid=22306905&amp;doi=10.1097/CJI.0b013e318247a4e7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B104-biomedicines-10-00236">
<span class="label">104.</span><cite>Zhou J.E., Yu J., Wang Y., Wang H., Wang J., Wang Y., Yu L., Yan Z. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed. Pharmacother. 2021;137:111339. doi: 10.1016/j.biopha.2021.111339.</cite> [<a href="https://doi.org/10.1016/j.biopha.2021.111339" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33550044/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomed.%20Pharmacother.&amp;title=ShRNA-mediated%20silencing%20of%20PD-1%20augments%20the%20efficacy%20of%20chimeric%20antigen%20receptor%20T%20cells%20on%20subcutaneous%20prostate%20and%20leukemia%20xenograft&amp;author=J.E.%20Zhou&amp;author=J.%20Yu&amp;author=Y.%20Wang&amp;author=H.%20Wang&amp;author=J.%20Wang&amp;volume=137&amp;publication_year=2021&amp;pages=111339&amp;pmid=33550044&amp;doi=10.1016/j.biopha.2021.111339&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B105-biomedicines-10-00236">
<span class="label">105.</span><cite>Wu Y., Xie J., Jin X., Lenchine R.V., Wang X., Fang D.M., Nassar Z.D., Butler L.M., Li J., Proud C.G. eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA. Biochem. J. 2020;477:4367–4381. doi: 10.1042/BCJ20200697.</cite> [<a href="https://doi.org/10.1042/BCJ20200697" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33094805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.%20J.&amp;title=eEF2K%20enhances%20expression%20of%20PD-L1%20by%20promoting%20the%20translation%20of%20its%20mRNA&amp;author=Y.%20Wu&amp;author=J.%20Xie&amp;author=X.%20Jin&amp;author=R.V.%20Lenchine&amp;author=X.%20Wang&amp;volume=477&amp;publication_year=2020&amp;pages=4367-4381&amp;pmid=33094805&amp;doi=10.1042/BCJ20200697&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B106-biomedicines-10-00236">
<span class="label">106.</span><cite>Zhang W., Shi X., Chen R., Zhu Y., Peng S., Chang Y., Nian X., Xiao G., Fang Z., Li Y., et al.  Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression. Mol. Ther. J. Am. Soc. Gene Ther. 2020;28:2473–2487. doi: 10.1016/j.ymthe.2020.06.013.</cite> [<a href="https://doi.org/10.1016/j.ymthe.2020.06.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7646212/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32592689/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Ther.%20J.%20Am.%20Soc.%20Gene%20Ther.&amp;title=Novel%20Long%20Non-coding%20RNA%20lncAMPC%20Promotes%20Metastasis%20and%20Immunosuppression%20in%20Prostate%20Cancer%20by%20Stimulating%20LIF/LIFR%20Expression&amp;author=W.%20Zhang&amp;author=X.%20Shi&amp;author=R.%20Chen&amp;author=Y.%20Zhu&amp;author=S.%20Peng&amp;volume=28&amp;publication_year=2020&amp;pages=2473-2487&amp;pmid=32592689&amp;doi=10.1016/j.ymthe.2020.06.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B107-biomedicines-10-00236">
<span class="label">107.</span><cite>Rennier K., Shin W.J., Krug E., Virdi G., Pachynski R.K. Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2020;26:5019–5035. doi: 10.1158/1078-0432.CCR-19-4245.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-4245" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32605911/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=Chemerin%20Reactivates%20PTEN%20and%20Suppresses%20PD-L1%20in%20Tumor%20Cells%20via%20Modulation%20of%20a%20Novel%20CMKLR1-mediated%20Signaling%20Cascade&amp;author=K.%20Rennier&amp;author=W.J.%20Shin&amp;author=E.%20Krug&amp;author=G.%20Virdi&amp;author=R.K.%20Pachynski&amp;volume=26&amp;publication_year=2020&amp;pages=5019-5035&amp;pmid=32605911&amp;doi=10.1158/1078-0432.CCR-19-4245&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B108-biomedicines-10-00236">
<span class="label">108.</span><cite>Philippou Y., Sjoberg H.T., Murphy E., Alyacoubi S., Jones K.I., Gordon-Weeks A.N., Phyu S., Parkes E.E., Gillies McKenna W., Lamb A.D., et al.  Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. Br. J. Cancer. 2020;123:1089–1100. doi: 10.1038/s41416-020-0956-x.</cite> [<a href="https://doi.org/10.1038/s41416-020-0956-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7525450/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32641865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br.%20J.%20Cancer&amp;title=Impacts%20of%20combining%20anti-PD-L1%20immunotherapy%20and%20radiotherapy%20on%20the%20tumour%20immune%20microenvironment%20in%20a%20murine%20prostate%20cancer%20model&amp;author=Y.%20Philippou&amp;author=H.T.%20Sjoberg&amp;author=E.%20Murphy&amp;author=S.%20Alyacoubi&amp;author=K.I.%20Jones&amp;volume=123&amp;publication_year=2020&amp;pages=1089-1100&amp;pmid=32641865&amp;doi=10.1038/s41416-020-0956-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B109-biomedicines-10-00236">
<span class="label">109.</span><cite>Wang B., Sun L., Yuan Z., Tao Z. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation. Med. Oncol. 2020;37:66. doi: 10.1007/s12032-020-01390-w.</cite> [<a href="https://doi.org/10.1007/s12032-020-01390-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32696094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Med.%20Oncol.&amp;title=Wee1%20kinase%20inhibitor%20AZD1775%20potentiates%20CD8+%E2%80%89T%20cell-dependent%20antitumour%20activity%20via%20dendritic%20cell%20activation%20following%20a%20single%20high%20dose%20of%20irradiation&amp;author=B.%20Wang&amp;author=L.%20Sun&amp;author=Z.%20Yuan&amp;author=Z.%20Tao&amp;volume=37&amp;publication_year=2020&amp;pages=66&amp;pmid=32696094&amp;doi=10.1007/s12032-020-01390-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B110-biomedicines-10-00236">
<span class="label">110.</span><cite>Papaevangelou E., Smolarek D., Smith R.A., Dasgupta P., Galustian C. Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model. ImmunoTargets Ther. 2020;9:115–130. doi: 10.2147/ITT.S257443.</cite> [<a href="https://doi.org/10.2147/ITT.S257443" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7394845/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32802803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ImmunoTargets%20Ther.&amp;title=Targeting%20Prostate%20Cancer%20Using%20Intratumoral%20Cytotopically%20Modified%20Interleukin-15%20Immunotherapy%20in%20a%20Syngeneic%20Murine%20Model&amp;author=E.%20Papaevangelou&amp;author=D.%20Smolarek&amp;author=R.A.%20Smith&amp;author=P.%20Dasgupta&amp;author=C.%20Galustian&amp;volume=9&amp;publication_year=2020&amp;pages=115-130&amp;pmid=32802803&amp;doi=10.2147/ITT.S257443&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B111-biomedicines-10-00236">
<span class="label">111.</span><cite>Wei J., Wang Y.H., Lee C.Y., Truillet C., Oh D.Y., Xu Y., Ruggero D., Flavell R.R., VanBrocklin H.F., Seo Y., et al.  An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol. Imaging Biol. 2020;22:1553–1561. doi: 10.1007/s11307-020-01527-3.</cite> [<a href="https://doi.org/10.1007/s11307-020-01527-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7669684/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32813112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Imaging%20Biol.&amp;title=An%20Analysis%20of%20Isoclonal%20Antibody%20Formats%20Suggests%20a%20Role%20for%20Measuring%20PD-L1%20with%20Low%20Molecular%20Weight%20PET%20Radiotracers&amp;author=J.%20Wei&amp;author=Y.H.%20Wang&amp;author=C.Y.%20Lee&amp;author=C.%20Truillet&amp;author=D.Y.%20Oh&amp;volume=22&amp;publication_year=2020&amp;pages=1553-1561&amp;pmid=32813112&amp;doi=10.1007/s11307-020-01527-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B112-biomedicines-10-00236">
<span class="label">112.</span><cite>Ding H., Wang Z., Pascal Laura E., Chen W., Wang Z., Wang Z. ELL2 deficiency upregulates PD-L1 expression via JAK2 signaling in prostate cancer cells. J. Urol. 2020;203((Suppl. 4)):e768. doi: 10.1097/JU.0000000000000913.012.</cite> [<a href="https://doi.org/10.1097/JU.0000000000000913.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Urol.&amp;title=ELL2%20deficiency%20upregulates%20PD-L1%20expression%20via%20JAK2%20signaling%20in%20prostate%20cancer%20cells&amp;author=H.%20Ding&amp;author=Z.%20Wang&amp;author=E.%20Pascal%20Laura&amp;author=W.%20Chen&amp;author=Z.%20Wang&amp;volume=203&amp;issue=(Suppl.%204)&amp;publication_year=2020&amp;pages=e768&amp;doi=10.1097/JU.0000000000000913.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B113-biomedicines-10-00236">
<span class="label">113.</span><cite>Sun Y., Wei Q., Huang J., Yang L. Methylation can regulate the expression of PD-L1 in small cell prostate cancer. J. Urol. 2020;203((Suppl. 4)):e219–e220. doi: 10.1016/S2666-1683(20)33643-0.</cite> [<a href="https://doi.org/10.1016/S2666-1683(20)33643-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Urol.&amp;title=Methylation%20can%20regulate%20the%20expression%20of%20PD-L1%20in%20small%20cell%20prostate%20cancer&amp;author=Y.%20Sun&amp;author=Q.%20Wei&amp;author=J.%20Huang&amp;author=L.%20Yang&amp;volume=203&amp;issue=(Suppl.%204)&amp;publication_year=2020&amp;pages=e219-e220&amp;doi=10.1016/S2666-1683(20)33643-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B114-biomedicines-10-00236">
<span class="label">114.</span><cite>Liu J., He D., Cheng L., Huang C., Zhang Y., Rao X., Kong Y., Li C., Zhang Z., Liu J., et al.  p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. Oncogene. 2020;39:3939–3951. doi: 10.1038/s41388-020-1270-z.</cite> [<a href="https://doi.org/10.1038/s41388-020-1270-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7210073/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32203167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=p300/CBP%20inhibition%20enhances%20the%20efficacy%20of%20programmed%20death-ligand%201%20blockade%20treatment%20in%20prostate%20cancer&amp;author=J.%20Liu&amp;author=D.%20He&amp;author=L.%20Cheng&amp;author=C.%20Huang&amp;author=Y.%20Zhang&amp;volume=39&amp;publication_year=2020&amp;pages=3939-3951&amp;pmid=32203167&amp;doi=10.1038/s41388-020-1270-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B115-biomedicines-10-00236">
<span class="label">115.</span><cite>Yamazaki T., Buqué A., Ames T.D., Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9:1721810. doi: 10.1080/2162402X.2020.1721810.</cite> [<a href="https://doi.org/10.1080/2162402X.2020.1721810" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7028345/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32117585/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=PT-112%20induces%20immunogenic%20cell%20death%20and%20synergizes%20with%20immune%20checkpoint%20blockers%20in%20mouse%20tumor%20models&amp;author=T.%20Yamazaki&amp;author=A.%20Buqu%C3%A9&amp;author=T.D.%20Ames&amp;author=L.%20Galluzzi&amp;volume=9&amp;publication_year=2020&amp;pages=1721810&amp;pmid=32117585&amp;doi=10.1080/2162402X.2020.1721810&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B116-biomedicines-10-00236">
<span class="label">116.</span><cite>Zhang X., Chen H., Li G., Zhou X., Shi Y., Zou F., Chen Y., Gao J., Yang S., Wu S., et al.  Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer. J. Cancer. 2020;11:648–656. doi: 10.7150/jca.29705.</cite> [<a href="https://doi.org/10.7150/jca.29705" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6959042/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31942188/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Cancer&amp;title=Increased%20Tim-3%20expression%20on%20TILs%20during%20treatment%20with%20the%20Anchored%20GM-CSF%20vaccine%20and%20anti-PD-1%20antibodies%20is%20inversely%20correlated%20with%20response%20in%20prostate%20cancer&amp;author=X.%20Zhang&amp;author=H.%20Chen&amp;author=G.%20Li&amp;author=X.%20Zhou&amp;author=Y.%20Shi&amp;volume=11&amp;publication_year=2020&amp;pages=648-656&amp;pmid=31942188&amp;doi=10.7150/jca.29705&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B117-biomedicines-10-00236">
<span class="label">117.</span><cite>Wang B., Zhou Y., Zhang J., Jin X., Wu H., Huang H. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics. 2020;10:1033–1045. doi: 10.7150/thno.38137.</cite> [<a href="https://doi.org/10.7150/thno.38137" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6956820/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31938049/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Theranostics&amp;title=Fructose-1,6-bisphosphatase%20loss%20modulates%20STAT3-dependent%20expression%20of%20PD-L1%20and%20cancer%20immunity&amp;author=B.%20Wang&amp;author=Y.%20Zhou&amp;author=J.%20Zhang&amp;author=X.%20Jin&amp;author=H.%20Wu&amp;volume=10&amp;publication_year=2020&amp;pages=1033-1045&amp;pmid=31938049&amp;doi=10.7150/thno.38137&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B118-biomedicines-10-00236">
<span class="label">118.</span><cite>Orme J.J., Jazieh K.A., Xie T., Harrington S., Liu X., Ball M., Madden B., Charlesworth M.C., Azam T.U., Lucien F., et al.  ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 2020;9:1744980. doi: 10.1080/2162402X.2020.1744980.</cite> [<a href="https://doi.org/10.1080/2162402X.2020.1744980" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7185206/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32363112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=ADAM10%20and%20ADAM17%20cleave%20PD-L1%20to%20mediate%20PD-(L)1%20inhibitor%20resistance&amp;author=J.J.%20Orme&amp;author=K.A.%20Jazieh&amp;author=T.%20Xie&amp;author=S.%20Harrington&amp;author=X.%20Liu&amp;volume=9&amp;publication_year=2020&amp;pages=1744980&amp;pmid=32363112&amp;doi=10.1080/2162402X.2020.1744980&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B119-biomedicines-10-00236">
<span class="label">119.</span><cite>Gan S., Ye J., Li J., Hu C., Wang J., Xu D., Pan X., Chu C., Chu J., Zhang J., et al.  LRP11 activates β-catenin to induce PD-L1 expression in prostate cancer. J. Drug Target. 2020;28:508–515. doi: 10.1080/1061186X.2019.1687710.</cite> [<a href="https://doi.org/10.1080/1061186X.2019.1687710" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31865764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Drug%20Target.&amp;title=LRP11%20activates%20%CE%B2-catenin%20to%20induce%20PD-L1%20expression%20in%20prostate%20cancer&amp;author=S.%20Gan&amp;author=J.%20Ye&amp;author=J.%20Li&amp;author=C.%20Hu&amp;author=J.%20Wang&amp;volume=28&amp;publication_year=2020&amp;pages=508-515&amp;pmid=31865764&amp;doi=10.1080/1061186X.2019.1687710&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B120-biomedicines-10-00236">
<span class="label">120.</span><cite>Choi B., Jung H., Yu B., Choi H., Lee J., Kim D.H. Sequential MR Image-Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxytol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy. Small. 2019;15:e1904378. doi: 10.1002/smll.201904378.</cite> [<a href="https://doi.org/10.1002/smll.201904378" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7027959/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31697036/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Small&amp;title=Sequential%20MR%20Image-Guided%20Local%20Immune%20Checkpoint%20Blockade%20Cancer%20Immunotherapy%20Using%20Ferumoxytol%20Capped%20Ultralarge%20Pore%20Mesoporous%20Silica%20Carriers%20after%20Standard%20Chemotherapy&amp;author=B.%20Choi&amp;author=H.%20Jung&amp;author=B.%20Yu&amp;author=H.%20Choi&amp;author=J.%20Lee&amp;volume=15&amp;publication_year=2019&amp;pages=e1904378&amp;pmid=31697036&amp;doi=10.1002/smll.201904378&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B121-biomedicines-10-00236">
<span class="label">121.</span><cite>Mao W., Ghasemzadeh A., Freeman Z.T., Obradovic A., Chaimowitz M.G., Nirschl T.R., McKiernan E., Yegnasubramanian S., Drake C.G. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition. J. Immunother. Cancer. 2019;7:277. doi: 10.1186/s40425-019-0758-y.</cite> [<a href="https://doi.org/10.1186/s40425-019-0758-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6814994/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31653272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=Immunogenicity%20of%20prostate%20cancer%20is%20augmented%20by%20BET%20bromodomain%20inhibition&amp;author=W.%20Mao&amp;author=A.%20Ghasemzadeh&amp;author=Z.T.%20Freeman&amp;author=A.%20Obradovic&amp;author=M.G.%20Chaimowitz&amp;volume=7&amp;publication_year=2019&amp;pages=277&amp;pmid=31653272&amp;doi=10.1186/s40425-019-0758-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B122-biomedicines-10-00236">
<span class="label">122.</span><cite>Zhou Q., Xiong W., Zhou X., Gao R.S., Lin Q.F., Liu H.Y., Li J.N., Tian X.F. CTHRC1 and PD-1/PD-L1 expression predicts tumor recurrence in prostate cancer. Mol. Med. Rep. 2019;20:4244–4252. doi: 10.3892/mmr.2019.10690.</cite> [<a href="https://doi.org/10.3892/mmr.2019.10690" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6797961/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31545446/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Med.%20Rep.&amp;title=CTHRC1%20and%20PD-1/PD-L1%20expression%20predicts%20tumor%20recurrence%20in%20prostate%20cancer&amp;author=Q.%20Zhou&amp;author=W.%20Xiong&amp;author=X.%20Zhou&amp;author=R.S.%20Gao&amp;author=Q.F.%20Lin&amp;volume=20&amp;publication_year=2019&amp;pages=4244-4252&amp;pmid=31545446&amp;doi=10.3892/mmr.2019.10690&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B123-biomedicines-10-00236">
<span class="label">123.</span><cite>Xu Q., Long Q., Zhu D., Fu D., Zhang B., Han L., Qian M., Guo J., Xu J., Cao L., et al.  Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. Aging Cell. 2019;18:e13027. doi: 10.1111/acel.13027.</cite> [<a href="https://doi.org/10.1111/acel.13027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6826133/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31493351/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Aging%20Cell&amp;title=Targeting%20amphiregulin%20(AREG)%20derived%20from%20senescent%20stromal%20cells%20diminishes%20cancer%20resistance%20and%20averts%20programmed%20cell%20death%201%20ligand%20(PD-L1)-mediated%20immunosuppression&amp;author=Q.%20Xu&amp;author=Q.%20Long&amp;author=D.%20Zhu&amp;author=D.%20Fu&amp;author=B.%20Zhang&amp;volume=18&amp;publication_year=2019&amp;pages=e13027&amp;pmid=31493351&amp;doi=10.1111/acel.13027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B124-biomedicines-10-00236">
<span class="label">124.</span><cite>Dudzinski S.O., Cameron B.D., Wang J., Rathmell J.C., Giorgio T.D., Kirschner A.N. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. J. Immunother. Cancer. 2019;7:218. doi: 10.1186/s40425-019-0704-z.</cite> [<a href="https://doi.org/10.1186/s40425-019-0704-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6694548/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31412954/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=Combination%20immunotherapy%20and%20radiotherapy%20causes%20an%20abscopal%20treatment%20response%20in%20a%20mouse%20model%20of%20castration%20resistant%20prostate%20cancer&amp;author=S.O.%20Dudzinski&amp;author=B.D.%20Cameron&amp;author=J.%20Wang&amp;author=J.C.%20Rathmell&amp;author=T.D.%20Giorgio&amp;volume=7&amp;publication_year=2019&amp;pages=218&amp;pmid=31412954&amp;doi=10.1186/s40425-019-0704-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B125-biomedicines-10-00236">
<span class="label">125.</span><cite>Li X., Wang Z., Huang J., Luo H., Zhu S., Yi H., Zheng L., Hu B., Yu L., Li L., et al.  Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression. FEBS Open Bio. 2019;9:1063–1070. doi: 10.1002/2211-5463.12568.</cite> [<a href="https://doi.org/10.1002/2211-5463.12568" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6551500/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31090214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Open%20Bio&amp;title=Specific%20zinc%20finger-induced%20methylation%20of%20PD-L1%20promoter%20inhibits%20its%20expression&amp;author=X.%20Li&amp;author=Z.%20Wang&amp;author=J.%20Huang&amp;author=H.%20Luo&amp;author=S.%20Zhu&amp;volume=9&amp;publication_year=2019&amp;pages=1063-1070&amp;pmid=31090214&amp;doi=10.1002/2211-5463.12568&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B126-biomedicines-10-00236">
<span class="label">126.</span><cite>Liu K., Zhou Z., Gao H., Yang F., Qian Y., Jin H., Guo Y., Liu Y., Li H., Zhang C., et al.  JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression. Cell Biol. Int. 2019;43:642–650. doi: 10.1002/cbin.11139.</cite> [<a href="https://doi.org/10.1002/cbin.11139" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30958600/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Biol.%20Int.&amp;title=JQ1,%20a%20BET-bromodomain%20inhibitor,%20inhibits%20human%20cancer%20growth%20and%20suppresses%20PD-L1%20expression&amp;author=K.%20Liu&amp;author=Z.%20Zhou&amp;author=H.%20Gao&amp;author=F.%20Yang&amp;author=Y.%20Qian&amp;volume=43&amp;publication_year=2019&amp;pages=642-650&amp;pmid=30958600&amp;doi=10.1002/cbin.11139&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B127-biomedicines-10-00236">
<span class="label">127.</span><cite>Xu N., Huang L., Li X., Watanabe M., Li C., Xu A., Liu C., Li Q., Araki M., Wada K., et al.  The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. Int. J. Biol. Sci. 2019;15:919–928. doi: 10.7150/ijbs.32259.</cite> [<a href="https://doi.org/10.7150/ijbs.32259" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6535792/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31182913/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Biol.%20Sci.&amp;title=The%20Novel%20Combination%20of%20Nitroxoline%20and%20PD-1%20Blockade,%20Exerts%20a%20Potent%20Antitumor%20Effect%20in%20a%20Mouse%20Model%20of%20Prostate%20Cancer&amp;author=N.%20Xu&amp;author=L.%20Huang&amp;author=X.%20Li&amp;author=M.%20Watanabe&amp;author=C.%20Li&amp;volume=15&amp;publication_year=2019&amp;pages=919-928&amp;pmid=31182913&amp;doi=10.7150/ijbs.32259&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B128-biomedicines-10-00236">
<span class="label">128.</span><cite>Yoneda T., Kunimura N., Kitagawa K., Fukui Y., Saito H., Narikiyo K., Ishiko M., Otsuki N., Nibu K.I., Fujisawa M., et al.  Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo. Cancer Gene Ther. 2019;26:388–399. doi: 10.1038/s41417-018-0075-5.</cite> [<a href="https://doi.org/10.1038/s41417-018-0075-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30607005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Gene%20Ther.&amp;title=Overexpression%20of%20SOCS3%20mediated%20by%20adenovirus%20vector%20in%20mouse%20and%20human%20castration-resistant%20prostate%20cancer%20cells%20increases%20the%20sensitivity%20to%20NK%20cells%20in%20vitro%20and%20in%20vivo&amp;author=T.%20Yoneda&amp;author=N.%20Kunimura&amp;author=K.%20Kitagawa&amp;author=Y.%20Fukui&amp;author=H.%20Saito&amp;volume=26&amp;publication_year=2019&amp;pages=388-399&amp;pmid=30607005&amp;doi=10.1038/s41417-018-0075-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B129-biomedicines-10-00236">
<span class="label">129.</span><cite>Fenerty K.E., Padget M., Wolfson B., Gameiro S.R., Su Z., Lee J.H., Rabizadeh S., Soon-Shiong P., Hodge J.W. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. J. Immunother. Cancer. 2018;6:133. doi: 10.1186/s40425-018-0445-4.</cite> [<a href="https://doi.org/10.1186/s40425-018-0445-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6264611/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30486888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunother.%20Cancer&amp;title=Immunotherapy%20utilizing%20the%20combination%20of%20natural%20killer-%20and%20antibody%20dependent%20cellular%20cytotoxicity%20(ADCC)-mediating%20agents%20with%20poly%20(ADP-ribose)%20polymerase%20(PARP)%20inhibition&amp;author=K.E.%20Fenerty&amp;author=M.%20Padget&amp;author=B.%20Wolfson&amp;author=S.R.%20Gameiro&amp;author=Z.%20Su&amp;volume=6&amp;publication_year=2018&amp;pages=133&amp;pmid=30486888&amp;doi=10.1186/s40425-018-0445-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B130-biomedicines-10-00236">
<span class="label">130.</span><cite>Krueger T.E., Thorek D.L.J., Meeker A.K., Isaacs J.T., Brennen W.N. Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer? Prostate. 2019;79:320–330. doi: 10.1002/pros.23738.</cite> [<a href="https://doi.org/10.1002/pros.23738" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6549513/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30488530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=Tumor-infiltrating%20mesenchymal%20stem%20cells:%20Drivers%20of%20the%20immunosuppressive%20tumor%20microenvironment%20in%20prostate%20cancer?&amp;author=T.E.%20Krueger&amp;author=D.L.J.%20Thorek&amp;author=A.K.%20Meeker&amp;author=J.T.%20Isaacs&amp;author=W.N.%20Brennen&amp;volume=79&amp;publication_year=2019&amp;pages=320-330&amp;pmid=30488530&amp;doi=10.1002/pros.23738&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B131-biomedicines-10-00236">
<span class="label">131.</span><cite>Medina Enríquez M.M., Félix A.J., Ciudad C.J., Noé V. Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells. PLoS ONE. 2018;13:e0206818.  doi: 10.1371/journal.pone.0206818.</cite> [<a href="https://doi.org/10.1371/journal.pone.0206818" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6219785/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30399174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Cancer%20immunotherapy%20using%20PolyPurine%20Reverse%20Hoogsteen%20hairpins%20targeting%20the%20PD-1/PD-L1%20pathway%20in%20human%20tumor%20cells&amp;author=M.M.%20Medina%20Enr%C3%ADquez&amp;author=A.J.%20F%C3%A9lix&amp;author=C.J.%20Ciudad&amp;author=V.%20No%C3%A9&amp;volume=13&amp;publication_year=2018&amp;pages=e0206818&amp;pmid=30399174&amp;doi=10.1371/journal.pone.0206818&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B132-biomedicines-10-00236">
<span class="label">132.</span><cite>Moreira D., Adamus T., Zhao X., Su Y.L., Zhang Z., White S.V., Swiderski P., Lu X., DePinho R.A., Pal S.K., et al.  STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2018;24:5948–5962. doi: 10.1158/1078-0432.CCR-18-1277.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-1277" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6279477/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30337279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.%20Off.%20J.%20Am.%20Assoc.%20Cancer%20Res.&amp;title=STAT3%20Inhibition%20Combined%20with%20CpG%20Immunostimulation%20Activates%20Antitumor%20Immunity%20to%20Eradicate%20Genetically%20Distinct%20Castration-Resistant%20Prostate%20Cancers&amp;author=D.%20Moreira&amp;author=T.%20Adamus&amp;author=X.%20Zhao&amp;author=Y.L.%20Su&amp;author=Z.%20Zhang&amp;volume=24&amp;publication_year=2018&amp;pages=5948-5962&amp;pmid=30337279&amp;doi=10.1158/1078-0432.CCR-18-1277&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B133-biomedicines-10-00236">
<span class="label">133.</span><cite>Zhang L., Xu L.J., Zhu J., Li J., Xue B.X., Gao J., Sun C.Y., Zang Y.C., Zhou Y.B., Yang D.R., et al.  ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgen-independent prostate cancer. Mol. Med. Rep. 2018;17:7045–7054. doi: 10.3892/mmr.2018.8781.</cite> [<a href="https://doi.org/10.3892/mmr.2018.8781" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5928660/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29568923/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Med.%20Rep.&amp;title=ATM-JAK-PD-L1%20signaling%20pathway%20inhibition%20decreases%20EMT%20and%20metastasis%20of%20androgen-independent%20prostate%20cancer&amp;author=L.%20Zhang&amp;author=L.J.%20Xu&amp;author=J.%20Zhu&amp;author=J.%20Li&amp;author=B.X.%20Xue&amp;volume=17&amp;publication_year=2018&amp;pages=7045-7054&amp;pmid=29568923&amp;doi=10.3892/mmr.2018.8781&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B134-biomedicines-10-00236">
<span class="label">134.</span><cite>Yin C., Wang Y., Ji J., Cai B., Chen H., Yang Z., Wang K., Luo C., Zhang W., Yuan C., et al.  Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device. Anal. Chem. 2018;90:3744–3751. doi: 10.1021/acs.analchem.7b03536.</cite> [<a href="https://doi.org/10.1021/acs.analchem.7b03536" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29464943/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anal.%20Chem.&amp;title=Molecular%20Profiling%20of%20Pooled%20Circulating%20Tumor%20Cells%20from%20Prostate%20Cancer%20Patients%20Using%20a%20Dual-Antibody-Functionalized%20Microfluidic%20Device&amp;author=C.%20Yin&amp;author=Y.%20Wang&amp;author=J.%20Ji&amp;author=B.%20Cai&amp;author=H.%20Chen&amp;volume=90&amp;publication_year=2018&amp;pages=3744-3751&amp;pmid=29464943&amp;doi=10.1021/acs.analchem.7b03536&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B135-biomedicines-10-00236">
<span class="label">135.</span><cite>Ahern E., Harjunpää H., O’Donnell J.S., Allen S., Dougall W.C., Teng M.W.L., Smyth M.J. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. Oncoimmunology. 2018;7:e1431088. doi: 10.1080/2162402X.2018.1431088.</cite> [<a href="https://doi.org/10.1080/2162402X.2018.1431088" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5980384/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29872559/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=RANKL%20blockade%20improves%20efficacy%20of%20PD1-PD-L1%20blockade%20or%20dual%20PD1-PD-L1%20and%20CTLA4%20blockade%20in%20mouse%20models%20of%20cancer&amp;author=E.%20Ahern&amp;author=H.%20Harjunp%C3%A4%C3%A4&amp;author=J.S.%20O%E2%80%99Donnell&amp;author=S.%20Allen&amp;author=W.C.%20Dougall&amp;volume=7&amp;publication_year=2018&amp;pages=e1431088&amp;pmid=29872559&amp;doi=10.1080/2162402X.2018.1431088&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B136-biomedicines-10-00236">
<span class="label">136.</span><cite>Xu L., Shen M., Chen X., Yang D.R., Tsai Y., Keng P.C., Lee S.O., Chen Y. In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells. Exp. Cell Res. 2018;364:113–123. doi: 10.1016/j.yexcr.2018.01.041.</cite> [<a href="https://doi.org/10.1016/j.yexcr.2018.01.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29408565/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp.%20Cell%20Res.&amp;title=In%20vitro-induced%20M2%20type%20macrophages%20induces%20the%20resistance%20of%20prostate%20cancer%20cells%20to%20cytotoxic%20action%20of%20NK%20cells&amp;author=L.%20Xu&amp;author=M.%20Shen&amp;author=X.%20Chen&amp;author=D.R.%20Yang&amp;author=Y.%20Tsai&amp;volume=364&amp;publication_year=2018&amp;pages=113-123&amp;pmid=29408565&amp;doi=10.1016/j.yexcr.2018.01.041&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B137-biomedicines-10-00236">
<span class="label">137.</span><cite>Xu L., Chen X., Shen M., Yang D.R., Fang L., Weng G., Tsai Y., Keng P.C., Chen Y., Lee S.O. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. Mol. Oncol. 2018;12:269–286. doi: 10.1002/1878-0261.12135.</cite> [<a href="https://doi.org/10.1002/1878-0261.12135" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5830627/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28865178/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Oncol.&amp;title=Inhibition%20of%20IL-6-JAK/Stat3%20signaling%20in%20castration-resistant%20prostate%20cancer%20cells%20enhances%20the%20NK%20cell-mediated%20cytotoxicity%20via%20alteration%20of%20PD-L1/NKG2D%20ligand%20levels&amp;author=L.%20Xu&amp;author=X.%20Chen&amp;author=M.%20Shen&amp;author=D.R.%20Yang&amp;author=L.%20Fang&amp;volume=12&amp;publication_year=2018&amp;pages=269-286&amp;pmid=28865178&amp;doi=10.1002/1878-0261.12135&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B138-biomedicines-10-00236">
<span class="label">138.</span><cite>Xu L., Shen M., Chen X., Zhu R., Yang D.R., Tsai Y., Keng P.C., Chen Y., Lee S.O. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells. Prostate. 2018;78:353–364. doi: 10.1002/pros.23479.</cite> [<a href="https://doi.org/10.1002/pros.23479" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29330929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prostate&amp;title=Adipocytes%20affect%20castration-resistant%20prostate%20cancer%20cells%20to%20develop%20the%20resistance%20to%20cytotoxic%20action%20of%20NK%20cells%20with%20alterations%20of%20PD-L1/NKG2D%20ligand%20levels%20in%20tumor%20cells&amp;author=L.%20Xu&amp;author=M.%20Shen&amp;author=X.%20Chen&amp;author=R.%20Zhu&amp;author=D.R.%20Yang&amp;volume=78&amp;publication_year=2018&amp;pages=353-364&amp;pmid=29330929&amp;doi=10.1002/pros.23479&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B139-biomedicines-10-00236">
<span class="label">139.</span><cite>Zhang Y., Zhu S., Qian P., Wang X., Xu Z., Sun W., Xu Y. RelB upregulates PD-L1 in advanced prostate cancer: An insight into tumor immunoescape. Cancer Res. 2019;79((Suppl. 13)):2791.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=RelB%20upregulates%20PD-L1%20in%20advanced%20prostate%20cancer:%20An%20insight%20into%20tumor%20immunoescape&amp;author=Y.%20Zhang&amp;author=S.%20Zhu&amp;author=P.%20Qian&amp;author=X.%20Wang&amp;author=Z.%20Xu&amp;volume=79&amp;issue=(Suppl.%2013)&amp;publication_year=2019&amp;pages=2791&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B140-biomedicines-10-00236">
<span class="label">140.</span><cite>Shimizu N., De Velasco M.A., Kura Y. PD-L1 immune checkpoint blockade in genetically engineered mouse models of prostate cancer; Proceedings of the 76th Annual Meeting of the Japanese Cancer Association; Yokohama, Japan. 28–30 September 2017; p. 292.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings%20of%20the%2076th%20Annual%20Meeting%20of%20the%20Japanese%20Cancer%20Association&amp;title=PD-L1%20immune%20checkpoint%20blockade%20in%20genetically%20engineered%20mouse%20models%20of%20prostate%20cancer&amp;author=N.%20Shimizu&amp;author=M.A.%20De%20Velasco&amp;author=Y.%20Kura&amp;pages=292&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B141-biomedicines-10-00236">
<span class="label">141.</span><cite>Maher C.M., Thomas J.D., Haas D.A., Longen C.G., Oyer H.M., Tong J.Y., Kim F.J. Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1. Mol. Cancer Res. MCR. 2018;16:243–255. doi: 10.1158/1541-7786.MCR-17-0166.</cite> [<a href="https://doi.org/10.1158/1541-7786.MCR-17-0166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29117944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cancer%20Res.%20MCR&amp;title=Small-Molecule%20Sigma1%20Modulator%20Induces%20Autophagic%20Degradation%20of%20PD-L1&amp;author=C.M.%20Maher&amp;author=J.D.%20Thomas&amp;author=D.A.%20Haas&amp;author=C.G.%20Longen&amp;author=H.M.%20Oyer&amp;volume=16&amp;publication_year=2018&amp;pages=243-255&amp;pmid=29117944&amp;doi=10.1158/1541-7786.MCR-17-0166&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B142-biomedicines-10-00236">
<span class="label">142.</span><cite>Shi X., Zhang X., Li J., Zhao H., Mo L., Shi X., Hu Z., Gao J., Tan W. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer. Cancer Lett. 2017;406:27–35. doi: 10.1016/j.canlet.2017.07.029.</cite> [<a href="https://doi.org/10.1016/j.canlet.2017.07.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28797844/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Lett.&amp;title=PD-1/PD-L1%20blockade%20enhances%20the%20efficacy%20of%20SA-GM-CSF%20surface-modified%20tumor%20vaccine%20in%20prostate%20cancer&amp;author=X.%20Shi&amp;author=X.%20Zhang&amp;author=J.%20Li&amp;author=H.%20Zhao&amp;author=L.%20Mo&amp;volume=406&amp;publication_year=2017&amp;pages=27-35&amp;pmid=28797844&amp;doi=10.1016/j.canlet.2017.07.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B143-biomedicines-10-00236">
<span class="label">143.</span><cite>Cappuccini F., Pollock E., Stribbling S., Hill A.V.S., Redchenko I. 5T4 oncofoetal glycoprotein: An old target for a novel prostate cancer immunotherapy. Oncotarget. 2017;8:47474–47489. doi: 10.18632/oncotarget.17666.</cite> [<a href="https://doi.org/10.18632/oncotarget.17666" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5564579/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28537896/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=5T4%20oncofoetal%20glycoprotein:%20An%20old%20target%20for%20a%20novel%20prostate%20cancer%20immunotherapy&amp;author=F.%20Cappuccini&amp;author=E.%20Pollock&amp;author=S.%20Stribbling&amp;author=A.V.S.%20Hill&amp;author=I.%20Redchenko&amp;volume=8&amp;publication_year=2017&amp;pages=47474-47489&amp;pmid=28537896&amp;doi=10.18632/oncotarget.17666&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B144-biomedicines-10-00236">
<span class="label">144.</span><cite>De Velasco M.A., Kura Y., Ando N., Sato N., Sakai K., Davies B.R., Sugimoto K., Nozawa M., Yoshimura K., Yoshikawa K., et al.  PD-L1 blockade in preclinical models of PTEN-deficient prostate cancer. Cancer Res. 2017;77((Suppl. 13)):4702.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=PD-L1%20blockade%20in%20preclinical%20models%20of%20PTEN-deficient%20prostate%20cancer&amp;author=M.A.%20De%20Velasco&amp;author=Y.%20Kura&amp;author=N.%20Ando&amp;author=N.%20Sato&amp;author=K.%20Sakai&amp;volume=77&amp;issue=(Suppl.%2013)&amp;publication_year=2017&amp;pages=4702&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B145-biomedicines-10-00236">
<span class="label">145.</span><cite>Liu Z., Zhao Y., Fang J., Cui R., Xiao Y., Xu Q. SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget. 2017;8:53518–53530. doi: 10.18632/oncotarget.18591.</cite> [<a href="https://doi.org/10.18632/oncotarget.18591" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5581127/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28881828/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=SHP2%20negatively%20regulates%20HLA-ABC%20and%20PD-L1%20expression%20via%20STAT1%20phosphorylation%20in%20prostate%20cancer%20cells&amp;author=Z.%20Liu&amp;author=Y.%20Zhao&amp;author=J.%20Fang&amp;author=R.%20Cui&amp;author=Y.%20Xiao&amp;volume=8&amp;publication_year=2017&amp;pages=53518-53530&amp;pmid=28881828&amp;doi=10.18632/oncotarget.18591&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B146-biomedicines-10-00236">
<span class="label">146.</span><cite>Tanoue K., Rosewell Shaw A., Watanabe N., Porter C., Rana B., Gottschalk S., Brenner M., Suzuki M. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017;77:2040–2051. doi: 10.1158/0008-5472.CAN-16-1577.</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-16-1577" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5392365/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28235763/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=Armed%20Oncolytic%20Adenovirus-Expressing%20PD-L1%20Mini-Body%20Enhances%20Antitumor%20Effects%20of%20Chimeric%20Antigen%20Receptor%20T%20Cells%20in%20Solid%20Tumors&amp;author=K.%20Tanoue&amp;author=A.%20Rosewell%20Shaw&amp;author=N.%20Watanabe&amp;author=C.%20Porter&amp;author=B.%20Rana&amp;volume=77&amp;publication_year=2017&amp;pages=2040-2051&amp;pmid=28235763&amp;doi=10.1158/0008-5472.CAN-16-1577&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B147-biomedicines-10-00236">
<span class="label">147.</span><cite>Wang X., Yang L., Huang F., Zhang Q., Liu S., Ma L., You Z. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol. Lett. 2017;184:7–14. doi: 10.1016/j.imlet.2017.02.006.</cite> [<a href="https://doi.org/10.1016/j.imlet.2017.02.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5362328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28223102/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunol.%20Lett.&amp;title=Inflammatory%20cytokines%20IL-17%20and%20TNF-%CE%B1%20up-regulate%20PD-L1%20expression%20in%20human%20prostate%20and%20colon%20cancer%20cells&amp;author=X.%20Wang&amp;author=L.%20Yang&amp;author=F.%20Huang&amp;author=Q.%20Zhang&amp;author=S.%20Liu&amp;volume=184&amp;publication_year=2017&amp;pages=7-14&amp;pmid=28223102&amp;doi=10.1016/j.imlet.2017.02.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B148-biomedicines-10-00236">
<span class="label">148.</span><cite>Serganova I., Moroz E., Cohen I., Moroz M., Mane M., Zurita J., Shenker L., Ponomarev V., Blasberg R. Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade. Mol. Ther. Oncolytics. 2017;4:41–54. doi: 10.1016/j.omto.2016.11.005.</cite> [<a href="https://doi.org/10.1016/j.omto.2016.11.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5363727/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28345023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Ther.%20Oncolytics&amp;title=Enhancement%20of%20PSMA-Directed%20CAR%20Adoptive%20Immunotherapy%20by%20PD-1/PD-L1%20Blockade&amp;author=I.%20Serganova&amp;author=E.%20Moroz&amp;author=I.%20Cohen&amp;author=M.%20Moroz&amp;author=M.%20Mane&amp;volume=4&amp;publication_year=2017&amp;pages=41-54&amp;pmid=28345023&amp;doi=10.1016/j.omto.2016.11.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B149-biomedicines-10-00236">
<span class="label">149.</span><cite>Rekoske B.T., Olson B.M., McNeel D.G. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016;5:e1165377. doi: 10.1080/2162402X.2016.1165377.</cite> [<a href="https://doi.org/10.1080/2162402X.2016.1165377" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4938302/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27471641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=Antitumor%20vaccination%20of%20prostate%20cancer%20patients%20elicits%20PD-1/PD-L1%20regulated%20antigen-specific%20immune%20responses&amp;author=B.T.%20Rekoske&amp;author=B.M.%20Olson&amp;author=D.G.%20McNeel&amp;volume=5&amp;publication_year=2016&amp;pages=e1165377&amp;pmid=27471641&amp;doi=10.1080/2162402X.2016.1165377&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B150-biomedicines-10-00236">
<span class="label">150.</span><cite>Rekoske B.T., Smith H.A., Olson B.M., Maricque B.B., McNeel D.G. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol. Res. 2015;3:946–955. doi: 10.1158/2326-6066.CIR-14-0206.</cite> [<a href="https://doi.org/10.1158/2326-6066.CIR-14-0206" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4527948/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26041735/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Immunol.%20Res.&amp;title=PD-1%20or%20PD-L1%20Blockade%20Restores%20Antitumor%20Efficacy%20Following%20SSX2%20Epitope-Modified%20DNA%20Vaccine%20Immunization&amp;author=B.T.%20Rekoske&amp;author=H.A.%20Smith&amp;author=B.M.%20Olson&amp;author=B.B.%20Maricque&amp;author=D.G.%20McNeel&amp;volume=3&amp;publication_year=2015&amp;pages=946-955&amp;pmid=26041735&amp;doi=10.1158/2326-6066.CIR-14-0206&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B151-biomedicines-10-00236">
<span class="label">151.</span><cite>Black M., Barsoum I.B., Truesdell P., Cotechini T., Macdonald-Goodfellow S.K., Petroff M., Siemens D.R., Koti M., Craig A.W., Graham C.H. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget. 2016;7:10557–10567. doi: 10.18632/oncotarget.7235.</cite> [<a href="https://doi.org/10.18632/oncotarget.7235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4891140/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26859684/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Activation%20of%20the%20PD-1/PD-L1%20immune%20checkpoint%20confers%20tumor%20cell%20chemoresistance%20associated%20with%20increased%20metastasis&amp;author=M.%20Black&amp;author=I.B.%20Barsoum&amp;author=P.%20Truesdell&amp;author=T.%20Cotechini&amp;author=S.K.%20Macdonald-Goodfellow&amp;volume=7&amp;publication_year=2016&amp;pages=10557-10567&amp;pmid=26859684&amp;doi=10.18632/oncotarget.7235&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B152-biomedicines-10-00236">
<span class="label">152.</span><cite>Yang S., Zhang Q., Liu S., Wang A.R., You Z. PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. Am. J. Clin. Exp. Urol. 2016;4:1–8.</cite> [<a href="/articles/PMC4749401/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27069956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Clin.%20Exp.%20Urol.&amp;title=PD-1,%20PD-L1%20and%20PD-L2%20expression%20in%20mouse%20prostate%20cancer&amp;author=S.%20Yang&amp;author=Q.%20Zhang&amp;author=S.%20Liu&amp;author=A.R.%20Wang&amp;author=Z.%20You&amp;volume=4&amp;publication_year=2016&amp;pages=1-8&amp;pmid=27069956&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B153-biomedicines-10-00236">
<span class="label">153.</span><cite>Carbotti G., Barisione G., Airoldi I., Mezzanzanica D., Bagnoli M., Ferrero S., Petretto A., Fabbi M., Ferrini S. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. 2015;6:43267–43280. doi: 10.18632/oncotarget.6530.</cite> [<a href="https://doi.org/10.18632/oncotarget.6530" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4791231/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26657115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=IL-27%20induces%20the%20expression%20of%20IDO%20and%20PD-L1%20in%20human%20cancer%20cells&amp;author=G.%20Carbotti&amp;author=G.%20Barisione&amp;author=I.%20Airoldi&amp;author=D.%20Mezzanzanica&amp;author=M.%20Bagnoli&amp;volume=6&amp;publication_year=2015&amp;pages=43267-43280&amp;pmid=26657115&amp;doi=10.18632/oncotarget.6530&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B154-biomedicines-10-00236">
<span class="label">154.</span><cite>Bernstein M.B., Garnett C.T., Zhang H., Velcich A., Wattenberg M.M., Gameiro S.R., Kalnicki S., Hodge J.W., Guha C. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother. Radiopharm. 2014;29:153–161. doi: 10.1089/cbr.2013.1578.</cite> [<a href="https://doi.org/10.1089/cbr.2013.1578" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4024843/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24693958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Biother.%20Radiopharm.&amp;title=Radiation-induced%20modulation%20of%20costimulatory%20and%20coinhibitory%20T-cell%20signaling%20molecules%20on%20human%20prostate%20carcinoma%20cells%20promotes%20productive%20antitumor%20immune%20interactions&amp;author=M.B.%20Bernstein&amp;author=C.T.%20Garnett&amp;author=H.%20Zhang&amp;author=A.%20Velcich&amp;author=M.M.%20Wattenberg&amp;volume=29&amp;publication_year=2014&amp;pages=153-161&amp;pmid=24693958&amp;doi=10.1089/cbr.2013.1578&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B155-biomedicines-10-00236">
<span class="label">155.</span><cite>Yu P., Steel J.C., Zhang M., Morris J.C., Waitz R., Fasso M., Allison J.P., Waldmann T.A. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc. Natl. Acad. Sci. USA. 2012;109:6187–6192. doi: 10.1073/pnas.1203479109.</cite> [<a href="https://doi.org/10.1073/pnas.1203479109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3341063/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22474386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc.%20Natl.%20Acad.%20Sci.%20USA&amp;title=Simultaneous%20inhibition%20of%20two%20regulatory%20T-cell%20subsets%20enhanced%20Interleukin-15%20efficacy%20in%20a%20prostate%20tumor%20model&amp;author=P.%20Yu&amp;author=J.C.%20Steel&amp;author=M.%20Zhang&amp;author=J.C.%20Morris&amp;author=R.%20Waitz&amp;volume=109&amp;publication_year=2012&amp;pages=6187-6192&amp;pmid=22474386&amp;doi=10.1073/pnas.1203479109&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B156-biomedicines-10-00236">
<span class="label">156.</span><cite>Lin H., Liu Q., Zeng X., Yu W., Xu G. Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: A retrospective study. BMC Cancer. 2021;21:399.  doi: 10.1186/s12885-021-08156-1.</cite> [<a href="https://doi.org/10.1186/s12885-021-08156-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8045189/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33849473/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Pembrolizumab%20with%20or%20without%20enzalutamide%20in%20selected%20populations%20of%20men%20with%20previously%20untreated%20metastatic%20castration-resistant%20prostate%20cancer%20harbouring%20programmed%20cell%20death%20ligand-1%20staining:%20A%20retrospective%20study&amp;author=H.%20Lin&amp;author=Q.%20Liu&amp;author=X.%20Zeng&amp;author=W.%20Yu&amp;author=G.%20Xu&amp;volume=21&amp;publication_year=2021&amp;pages=399&amp;pmid=33849473&amp;doi=10.1186/s12885-021-08156-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B157-biomedicines-10-00236">
<span class="label">157.</span><cite>Morel K.L., Sheahan A.V., Burkhart D.L., Baca S.C., Boufaied N., Liu Y., Qiu X., Cañadas I., Roehle K., Heckler M., et al.  EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat. Cancer. 2021;2:444–456. doi: 10.1038/s43018-021-00185-w.</cite> [<a href="https://doi.org/10.1038/s43018-021-00185-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8061902/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33899001/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Cancer&amp;title=EZH2%20inhibition%20activates%20a%20dsRNA-STING-interferon%20stress%20axis%20that%20potentiates%20response%20to%20PD-1%20checkpoint%20blockade%20in%20prostate%20cancer&amp;author=K.L.%20Morel&amp;author=A.V.%20Sheahan&amp;author=D.L.%20Burkhart&amp;author=S.C.%20Baca&amp;author=N.%20Boufaied&amp;volume=2&amp;publication_year=2021&amp;pages=444-456&amp;pmid=33899001&amp;doi=10.1038/s43018-021-00185-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B158-biomedicines-10-00236">
<span class="label">158.</span><cite>Ribbat-Idel J., Dressler F.F., Krupar R., Watermann C., Paulsen F.O., Kuppler P., Klapper L., Offermann A., Wollenberg B., Rades D., et al.  Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma. Front. Med. 2021;8:640515. doi: 10.3389/fmed.2021.640515.</cite> [<a href="https://doi.org/10.3389/fmed.2021.640515" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8110724/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33987192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Med.&amp;title=Performance%20of%20Different%20Diagnostic%20PD-L1%20Clones%20in%20Head%20and%20Neck%20Squamous%20Cell%20Carcinoma&amp;author=J.%20Ribbat-Idel&amp;author=F.F.%20Dressler&amp;author=R.%20Krupar&amp;author=C.%20Watermann&amp;author=F.O.%20Paulsen&amp;volume=8&amp;publication_year=2021&amp;pages=640515&amp;pmid=33987192&amp;doi=10.3389/fmed.2021.640515&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B159-biomedicines-10-00236">
<span class="label">159.</span><cite>Lopez-Beltran A., López-Rios F., Montironi R., Wildsmith S., Eckstein M. Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. Cancers. 2021;13:1424.  doi: 10.3390/cancers13061424.</cite> [<a href="https://doi.org/10.3390/cancers13061424" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8003923/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33804698/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Immune%20Checkpoint%20Inhibitors%20in%20Urothelial%20Carcinoma:%20Recommendations%20for%20Practical%20Approaches%20to%20PD-L1%20and%20Other%20Potential%20Predictive%20Biomarker%20Testing&amp;author=A.%20Lopez-Beltran&amp;author=F.%20L%C3%B3pez-Rios&amp;author=R.%20Montironi&amp;author=S.%20Wildsmith&amp;author=M.%20Eckstein&amp;volume=13&amp;publication_year=2021&amp;pages=1424&amp;pmid=33804698&amp;doi=10.3390/cancers13061424&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B160-biomedicines-10-00236">
<span class="label">160.</span><cite>Powles T., Sridhar S.S., Loriot Y., Bellmunt J., Mu X.J., Ching K.A., Pu J., Sternberg C.N., Petrylak D.P., Tambaro R., et al.  Avelumab maintenance in advanced urothelial carcinoma: Biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat. Med. 2021;27:2200–2211. doi: 10.1038/s41591-021-01579-0.</cite> [<a href="https://doi.org/10.1038/s41591-021-01579-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34893775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Med.&amp;title=Avelumab%20maintenance%20in%20advanced%20urothelial%20carcinoma:%20Biomarker%20analysis%20of%20the%20phase%203%20JAVELIN%20Bladder%20100%20trial&amp;author=T.%20Powles&amp;author=S.S.%20Sridhar&amp;author=Y.%20Loriot&amp;author=J.%20Bellmunt&amp;author=X.J.%20Mu&amp;volume=27&amp;publication_year=2021&amp;pages=2200-2211&amp;pmid=34893775&amp;doi=10.1038/s41591-021-01579-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B161-biomedicines-10-00236">
<span class="label">161.</span><cite>Sicklick J.K., Kato S., Okamura R., Patel H., Nikanjam M., Fanta P.T., Hahn M.E., De P., Williams C., Guido J., et al.  Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome. Med. 2021;13:155. doi: 10.1186/s13073-021-00969-w.</cite> [<a href="https://doi.org/10.1186/s13073-021-00969-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8491393/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34607609/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome.%20Med.&amp;title=Molecular%20profiling%20of%20advanced%20malignancies%20guides%20first-line%20N-of-1%20treatments%20in%20the%20I-PREDICT%20treatment-na%C3%AFve%20study&amp;author=J.K.%20Sicklick&amp;author=S.%20Kato&amp;author=R.%20Okamura&amp;author=H.%20Patel&amp;author=M.%20Nikanjam&amp;volume=13&amp;publication_year=2021&amp;pages=155&amp;pmid=34607609&amp;doi=10.1186/s13073-021-00969-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B162-biomedicines-10-00236">
<span class="label">162.</span><cite>Huang R.S.P., Severson E., Haberberger J., Duncan D.L., Hemmerich A., Edgerly C., Ferguson N.L., Frampton G., Owens C., Williams E., et al.  Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Pathol. Oncol. Res. 2021;27:592997. doi: 10.3389/pore.2021.592997.</cite> [<a href="https://doi.org/10.3389/pore.2021.592997" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8262230/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34257540/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pathol.%20Oncol.%20Res.&amp;title=Landscape%20of%20Biomarkers%20in%20Non-small%20Cell%20Lung%20Cancer%20Using%20Comprehensive%20Genomic%20Profiling%20and%20PD-L1%20Immunohistochemistry&amp;author=R.S.P.%20Huang&amp;author=E.%20Severson&amp;author=J.%20Haberberger&amp;author=D.L.%20Duncan&amp;author=A.%20Hemmerich&amp;volume=27&amp;publication_year=2021&amp;pages=592997&amp;pmid=34257540&amp;doi=10.3389/pore.2021.592997&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B163-biomedicines-10-00236">
<span class="label">163.</span><cite>Roy R., Chun J., Powell S.N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer. 2012;12:68–78. doi: 10.1038/nrc3181.</cite> [<a href="https://doi.org/10.1038/nrc3181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4972490/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22193408/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Cancer&amp;title=BRCA1%20and%20BRCA2:%20Different%20roles%20in%20a%20common%20pathway%20of%20genome%20protection&amp;author=R.%20Roy&amp;author=J.%20Chun&amp;author=S.N.%20Powell&amp;volume=12&amp;publication_year=2012&amp;pages=68-78&amp;pmid=22193408&amp;doi=10.1038/nrc3181&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B164-biomedicines-10-00236">
<span class="label">164.</span><cite>Moro L., Arbini A.A., Yao J.L., Di Sant’Agnese P.A., Marra E., Greco M. Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci. 2008;99:553–563. doi: 10.1111/j.1349-7006.2007.00719.x.</cite> [<a href="https://doi.org/10.1111/j.1349-7006.2007.00719.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11158040/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18167127/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Sci.&amp;title=Loss%20of%20BRCA2%20promotes%20prostate%20cancer%20cell%20invasion%20through%20up-regulation%20of%20matrix%20metalloproteinase-9&amp;author=L.%20Moro&amp;author=A.A.%20Arbini&amp;author=J.L.%20Yao&amp;author=P.A.%20Di%20Sant%E2%80%99Agnese&amp;author=E.%20Marra&amp;volume=99&amp;publication_year=2008&amp;pages=553-563&amp;pmid=18167127&amp;doi=10.1111/j.1349-7006.2007.00719.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B165-biomedicines-10-00236">
<span class="label">165.</span><cite>De Bono J., Goh J., Ojamaa K., Rodriguez J., Drake C.G., Hoimes C., Haiyan W., Heinrich Poehlen C., Antonarakis E.S. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC) J. Clin. Oncol. 2018;36:5007. doi: 10.1200/JCO.2018.36.15_suppl.5007.</cite> [<a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.5007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=KEYNOTE-199:%20Pembrolizumab%20(pembro)%20for%20docetaxel-refractory%20metastatic%20castration-resistant%20prostate%20cancer%20(mCRPC)&amp;author=J.%20De%20Bono&amp;author=J.%20Goh&amp;author=K.%20Ojamaa&amp;author=J.%20Rodriguez&amp;author=C.G.%20Drake&amp;volume=36&amp;publication_year=2018&amp;pages=5007&amp;doi=10.1200/JCO.2018.36.15_suppl.5007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B166-biomedicines-10-00236">
<span class="label">166.</span><cite>Nilbert M., Planck M., Fernebro E., Borg A., Johnson A. Microsatellite instability is rare in rectal carcinomas and signifies hereditary cancer. Eur. J. Cancer. 1999;35:942–945. doi: 10.1016/S0959-8049(99)00045-3.</cite> [<a href="https://doi.org/10.1016/S0959-8049(99)00045-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10533476/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Cancer&amp;title=Microsatellite%20instability%20is%20rare%20in%20rectal%20carcinomas%20and%20signifies%20hereditary%20cancer&amp;author=M.%20Nilbert&amp;author=M.%20Planck&amp;author=E.%20Fernebro&amp;author=A.%20Borg&amp;author=A.%20Johnson&amp;volume=35&amp;publication_year=1999&amp;pages=942-945&amp;pmid=10533476&amp;doi=10.1016/S0959-8049(99)00045-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B167-biomedicines-10-00236">
<span class="label">167.</span><cite>Graham L.S., Montgomery B., Cheng H.H., Yu E.Y., Nelson P.S., Pritchard C., Erickson S., Alva A., Schweizer M.T. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. PLoS ONE. 2020;15:e0233260.  doi: 10.1371/journal.pone.0233260.</cite> [<a href="https://doi.org/10.1371/journal.pone.0233260" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7250457/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32453797/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Mismatch%20repair%20deficiency%20in%20metastatic%20prostate%20cancer:%20Response%20to%20PD-1%20blockade%20and%20standard%20therapies&amp;author=L.S.%20Graham&amp;author=B.%20Montgomery&amp;author=H.H.%20Cheng&amp;author=E.Y.%20Yu&amp;author=P.S.%20Nelson&amp;volume=15&amp;publication_year=2020&amp;pages=e0233260&amp;pmid=32453797&amp;doi=10.1371/journal.pone.0233260&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B168-biomedicines-10-00236">
<span class="label">168.</span><cite>Win A.K., Lindor N.M., Young J.P., Macrae F.A., Young G.P., Williamson E., Parry S., Goldblatt J., Lipton L., Winship I., et al.  Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J. Natl. Cancer Inst. 2012;104:1363–1372. doi: 10.1093/jnci/djs351.</cite> [<a href="https://doi.org/10.1093/jnci/djs351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3529597/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22933731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Natl.%20Cancer%20Inst.&amp;title=Risks%20of%20primary%20extracolonic%20cancers%20following%20colorectal%20cancer%20in%20lynch%20syndrome&amp;author=A.K.%20Win&amp;author=N.M.%20Lindor&amp;author=J.P.%20Young&amp;author=F.A.%20Macrae&amp;author=G.P.%20Young&amp;volume=104&amp;publication_year=2012&amp;pages=1363-1372&amp;pmid=22933731&amp;doi=10.1093/jnci/djs351&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B169-biomedicines-10-00236">
<span class="label">169.</span><cite>Crocetto F., Barone B., Caputo V.F., Fontana M., de Cobelli O., Ferro M. BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored. Diagnostics. 2021;11:908.  doi: 10.3390/diagnostics11050908.</cite> [<a href="https://doi.org/10.3390/diagnostics11050908" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8161324/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34069669/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics&amp;title=BRCA%20Germline%20Mutations%20in%20Prostate%20Cancer:%20The%20Future%20Is%20Tailored&amp;author=F.%20Crocetto&amp;author=B.%20Barone&amp;author=V.F.%20Caputo&amp;author=M.%20Fontana&amp;author=O.%20de%20Cobelli&amp;volume=11&amp;publication_year=2021&amp;pages=908&amp;pmid=34069669&amp;doi=10.3390/diagnostics11050908&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B170-biomedicines-10-00236">
<span class="label">170.</span><cite>Raymond V.M., Mukherjee B., Wang F., Huang S.C., Stoffel E.M., Kastrinos F., Syngal S., Cooney K.A., Gruber S.B. Elevated risk of prostate cancer among men with Lynch syndrome. J. Clin. Oncol. 2013;31:1713–1718. doi: 10.1200/JCO.2012.44.1238.</cite> [<a href="https://doi.org/10.1200/JCO.2012.44.1238" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3641694/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23530095/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Elevated%20risk%20of%20prostate%20cancer%20among%20men%20with%20Lynch%20syndrome&amp;author=V.M.%20Raymond&amp;author=B.%20Mukherjee&amp;author=F.%20Wang&amp;author=S.C.%20Huang&amp;author=E.M.%20Stoffel&amp;volume=31&amp;publication_year=2013&amp;pages=1713-1718&amp;pmid=23530095&amp;doi=10.1200/JCO.2012.44.1238&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B171-biomedicines-10-00236">
<span class="label">171.</span><cite>Pritchard C.C., Morrissey C., Kumar A., Zhang X., Smith C., Coleman I., Salipante S.J., Milbank J., Yu M., Grady W.M., et al.  Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun. 2014;5:4988. doi: 10.1038/ncomms5988.</cite> [<a href="https://doi.org/10.1038/ncomms5988" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4176888/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25255306/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Complex%20MSH2%20and%20MSH6%20mutations%20in%20hypermutated%20microsatellite%20unstable%20advanced%20prostate%20cancer&amp;author=C.C.%20Pritchard&amp;author=C.%20Morrissey&amp;author=A.%20Kumar&amp;author=X.%20Zhang&amp;author=C.%20Smith&amp;volume=5&amp;publication_year=2014&amp;pages=4988&amp;pmid=25255306&amp;doi=10.1038/ncomms5988&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B172-biomedicines-10-00236">
<span class="label">172.</span><cite>Schweizer M.T., Cheng H.H., Tretiakova M.S., Vakar-Lopez F., Klemfuss N., Konnick E.Q., Mostaghel E.A., Nelson P.S., Yu E.Y., Montgomery B., et al.  Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget. 2016;7:82504–82510. doi: 10.18632/oncotarget.12697.</cite> [<a href="https://doi.org/10.18632/oncotarget.12697" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5347709/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27756888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Mismatch%20repair%20deficiency%20may%20be%20common%20in%20ductal%20adenocarcinoma%20of%20the%20prostate&amp;author=M.T.%20Schweizer&amp;author=H.H.%20Cheng&amp;author=M.S.%20Tretiakova&amp;author=F.%20Vakar-Lopez&amp;author=N.%20Klemfuss&amp;volume=7&amp;publication_year=2016&amp;pages=82504-82510&amp;pmid=27756888&amp;doi=10.18632/oncotarget.12697&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B173-biomedicines-10-00236">
<span class="label">173.</span><cite>Fraune C., Simon R., Höflmayer D., Möller K., Dum D., Büscheck F., Hube-Magg C., Makrypidi-Fraune G., Kluth M., Hinsch A., et al.  High homogeneity of mismatch repair deficiency in advanced prostate cancer. Virchows Archiv. 2020;476:745–752. doi: 10.1007/s00428-019-02701-x.</cite> [<a href="https://doi.org/10.1007/s00428-019-02701-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31811435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Virchows%20Archiv.&amp;title=High%20homogeneity%20of%20mismatch%20repair%20deficiency%20in%20advanced%20prostate%20cancer&amp;author=C.%20Fraune&amp;author=R.%20Simon&amp;author=D.%20H%C3%B6flmayer&amp;author=K.%20M%C3%B6ller&amp;author=D.%20Dum&amp;volume=476&amp;publication_year=2020&amp;pages=745-752&amp;pmid=31811435&amp;doi=10.1007/s00428-019-02701-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B174-biomedicines-10-00236">
<span class="label">174.</span><cite>Antonarakis E.S., Shaukat F., Isaacsson Velho P., Kaur H., Shenderov E., Pardoll D.M., Lotan T.L. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. Eur. Urol. 2019;75:378–382. doi: 10.1016/j.eururo.2018.10.009.</cite> [<a href="https://doi.org/10.1016/j.eururo.2018.10.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6377812/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30337059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.&amp;title=Clinical%20Features%20and%20Therapeutic%20Outcomes%20in%20Men%20with%20Advanced%20Prostate%20Cancer%20and%20DNA%20Mismatch%20Repair%20Gene%20Mutations&amp;author=E.S.%20Antonarakis&amp;author=F.%20Shaukat&amp;author=P.%20Isaacsson%20Velho&amp;author=H.%20Kaur&amp;author=E.%20Shenderov&amp;volume=75&amp;publication_year=2019&amp;pages=378-382&amp;pmid=30337059&amp;doi=10.1016/j.eururo.2018.10.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B175-biomedicines-10-00236">
<span class="label">175.</span><cite>Tucker M.D., Zhu J., Marin D., Gupta R.T., Gupta S., Berry W.R., Ramalingam S., Zhang T., Harrison M., Wu Y., et al.  Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Med. 2019;8:4644–4655. doi: 10.1002/cam4.2375.</cite> [<a href="https://doi.org/10.1002/cam4.2375" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6712455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31270961/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Med.&amp;title=Pembrolizumab%20in%20men%20with%20heavily%20treated%20metastatic%20castrate-resistant%20prostate%20cancer&amp;author=M.D.%20Tucker&amp;author=J.%20Zhu&amp;author=D.%20Marin&amp;author=R.T.%20Gupta&amp;author=S.%20Gupta&amp;volume=8&amp;publication_year=2019&amp;pages=4644-4655&amp;pmid=31270961&amp;doi=10.1002/cam4.2375&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B176-biomedicines-10-00236">
<span class="label">176.</span><cite>Abida W., Armenia J., Gopalan A., Brennan R., Walsh M., Barron D., Danila D., Rathkopf D., Morris M., Slovin S., et al.  Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis. Oncol. 2017;2017:PO.17.00029. doi: 10.1200/PO.17.00029.</cite> [<a href="https://doi.org/10.1200/PO.17.00029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5558263/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28825054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Precis.%20Oncol.&amp;title=Prospective%20Genomic%20Profiling%20of%20Prostate%20Cancer%20Across%20Disease%20States%20Reveals%20Germline%20and%20Somatic%20Alterations%20That%20May%20Affect%20Clinical%20Decision%20Making&amp;author=W.%20Abida&amp;author=J.%20Armenia&amp;author=A.%20Gopalan&amp;author=R.%20Brennan&amp;author=M.%20Walsh&amp;volume=2017&amp;publication_year=2017&amp;pages=PO.17.00029&amp;pmid=28825054&amp;doi=10.1200/PO.17.00029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B177-biomedicines-10-00236">
<span class="label">177.</span><cite>Robinson D., Van Allen E.M., Wu Y.M., Schultz N., Lonigro R.J., Mosquera J.M., Montgomery B., Taplin M.E., Pritchard C.C., Attard G., et al.  Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228. doi: 10.1016/j.cell.2015.05.001.</cite> [<a href="https://doi.org/10.1016/j.cell.2015.05.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4484602/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26000489/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Integrative%20clinical%20genomics%20of%20advanced%20prostate%20cancer&amp;author=D.%20Robinson&amp;author=E.M.%20Van%20Allen&amp;author=Y.M.%20Wu&amp;author=N.%20Schultz&amp;author=R.J.%20Lonigro&amp;volume=161&amp;publication_year=2015&amp;pages=1215-1228&amp;pmid=26000489&amp;doi=10.1016/j.cell.2015.05.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B178-biomedicines-10-00236">
<span class="label">178.</span><cite>Bancroft E.K., Page E.C., Brook M.N., Thomas S., Taylor N., Pope J., McHugh J., Jones A.B., Karlsson Q., Merson S., et al.  A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): Initial results from an international prospective study. Lancet Oncol. 2021;22:1618–1631. doi: 10.1016/S1470-2045(21)00522-2.</cite> [<a href="https://doi.org/10.1016/S1470-2045(21)00522-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8576477/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34678156/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&amp;title=A%20prospective%20prostate%20cancer%20screening%20programme%20for%20men%20with%20pathogenic%20variants%20in%20mismatch%20repair%20genes%20(IMPACT):%20Initial%20results%20from%20an%20international%20prospective%20study&amp;author=E.K.%20Bancroft&amp;author=E.C.%20Page&amp;author=M.N.%20Brook&amp;author=S.%20Thomas&amp;author=N.%20Taylor&amp;volume=22&amp;publication_year=2021&amp;pages=1618-1631&amp;pmid=34678156&amp;doi=10.1016/S1470-2045(21)00522-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B179-biomedicines-10-00236">
<span class="label">179.</span><cite>Sessine M.S., Das S., Park B., Salami S.S., Kaffenberger S.D., Kasputis A., Solorzano M., Luke M., Vince R.A., Kaye D.R., et al.  Initial Findings from a High Genetic Risk Prostate Cancer Clinic. Urology. 2021;156:96–103. doi: 10.1016/j.urology.2021.05.078.</cite> [<a href="https://doi.org/10.1016/j.urology.2021.05.078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34280438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Urology&amp;title=Initial%20Findings%20from%20a%20High%20Genetic%20Risk%20Prostate%20Cancer%20Clinic&amp;author=M.S.%20Sessine&amp;author=S.%20Das&amp;author=B.%20Park&amp;author=S.S.%20Salami&amp;author=S.D.%20Kaffenberger&amp;volume=156&amp;publication_year=2021&amp;pages=96-103&amp;pmid=34280438&amp;doi=10.1016/j.urology.2021.05.078&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B180-biomedicines-10-00236">
<span class="label">180.</span><cite>Chalmers Z.R., Connelly C.F., Fabrizio D., Gay L., Ali S.M., Ennis R., Schrock A., Campbell B., Shlien A., Chmielecki J., et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. doi: 10.1186/s13073-017-0424-2.</cite> [<a href="https://doi.org/10.1186/s13073-017-0424-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5395719/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28420421/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome%20Med.&amp;title=Analysis%20of%20100,000%20human%20cancer%20genomes%20reveals%20the%20landscape%20of%20tumor%20mutational%20burden&amp;author=Z.R.%20Chalmers&amp;author=C.F.%20Connelly&amp;author=D.%20Fabrizio&amp;author=L.%20Gay&amp;author=S.M.%20Ali&amp;volume=9&amp;publication_year=2017&amp;pages=34&amp;pmid=28420421&amp;doi=10.1186/s13073-017-0424-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B181-biomedicines-10-00236">
<span class="label">181.</span><cite>Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer. 2008;8:497–511. doi: 10.1038/nrc2402.</cite> [<a href="https://doi.org/10.1038/nrc2402" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2711688/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18563191/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Cancer&amp;title=Recurrent%20gene%20fusions%20in%20prostate%20cancer&amp;author=C.%20Kumar-Sinha&amp;author=S.A.%20Tomlins&amp;author=A.M.%20Chinnaiyan&amp;volume=8&amp;publication_year=2008&amp;pages=497-511&amp;pmid=18563191&amp;doi=10.1038/nrc2402&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B182-biomedicines-10-00236">
<span class="label">182.</span><cite>Worley B.S., van den Broeke L.T., Goletz T.J., Pendleton C.D., Daschbach E.M., Thomas E.K., Marincola F.M., Helman L.J., Berzofsky J.A. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001;61:6868–6875.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/11559563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=Antigenicity%20of%20fusion%20proteins%20from%20sarcoma-associated%20chromosomal%20translocations&amp;author=B.S.%20Worley&amp;author=L.T.%20van%20den%20Broeke&amp;author=T.J.%20Goletz&amp;author=C.D.%20Pendleton&amp;author=E.M.%20Daschbach&amp;volume=61&amp;publication_year=2001&amp;pages=6868-6875&amp;pmid=11559563&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B183-biomedicines-10-00236">
<span class="label">183.</span><cite>Whitehair R., Peres L.C., Mills A.M. Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status. Int. J. Gynecol. Pathol. 2020;39:558–566. doi: 10.1097/PGP.0000000000000657.</cite> [<a href="https://doi.org/10.1097/PGP.0000000000000657" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31851060/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Gynecol.%20Pathol.&amp;title=Expression%20of%20the%20Immune%20Checkpoints%20LAG-3%20and%20PD-L1%20in%20High-grade%20Serous%20Ovarian%20Carcinoma:%20Relationship%20to%20Tumor-associated%20Lymphocytes%20and%20Germline%20BRCA%20Status&amp;author=R.%20Whitehair&amp;author=L.C.%20Peres&amp;author=A.M.%20Mills&amp;volume=39&amp;publication_year=2020&amp;pages=558-566&amp;pmid=31851060&amp;doi=10.1097/PGP.0000000000000657&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B184-biomedicines-10-00236">
<span class="label">184.</span><cite>Wang J., Yang Z., Zhang C., Ouyang J., Zhang G., Wu C. A four-gene signature in the tumor microenvironment that significantly associates with the prognosis of patients with breast cancer. Gene. 2020;30:145049. doi: 10.1016/j.gene.2020.145049.</cite> [<a href="https://doi.org/10.1016/j.gene.2020.145049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32791092/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gene&amp;title=A%20four-gene%20signature%20in%20the%20tumor%20microenvironment%20that%20significantly%20associates%20with%20the%20prognosis%20of%20patients%20with%20breast%20cancer&amp;author=J.%20Wang&amp;author=Z.%20Yang&amp;author=C.%20Zhang&amp;author=J.%20Ouyang&amp;author=G.%20Zhang&amp;volume=30&amp;publication_year=2020&amp;pages=145049&amp;pmid=32791092&amp;doi=10.1016/j.gene.2020.145049&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B185-biomedicines-10-00236">
<span class="label">185.</span><cite>Castro E., Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J. Androl. 2012;14:409–414. doi: 10.1038/aja.2011.150.</cite> [<a href="https://doi.org/10.1038/aja.2011.150" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3720154/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22522501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Asian%20J.%20Androl.&amp;title=The%20role%20of%20BRCA1%20and%20BRCA2%20in%20prostate%20cancer&amp;author=E.%20Castro&amp;author=R.%20Eeles&amp;volume=14&amp;publication_year=2012&amp;pages=409-414&amp;pmid=22522501&amp;doi=10.1038/aja.2011.150&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B186-biomedicines-10-00236">
<span class="label">186.</span><cite>Nyberg T., Frost D., Barrowdale D., Evans D.G., Bancroft E., Adlard J., Ahmed M., Barwell J., Brady A.F., Brewer C., et al.  Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur. Urol. 2020;77:24–35. doi: 10.1016/j.eururo.2019.08.025.</cite> [<a href="https://doi.org/10.1016/j.eururo.2019.08.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6926480/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31495749/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.&amp;title=Prostate%20Cancer%20Risks%20for%20Male%20BRCA1%20and%20BRCA2%20Mutation%20Carriers:%20A%20Prospective%20Cohort%20Study&amp;author=T.%20Nyberg&amp;author=D.%20Frost&amp;author=D.%20Barrowdale&amp;author=D.G.%20Evans&amp;author=E.%20Bancroft&amp;volume=77&amp;publication_year=2020&amp;pages=24-35&amp;pmid=31495749&amp;doi=10.1016/j.eururo.2019.08.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B187-biomedicines-10-00236">
<span class="label">187.</span><cite>Castro E., Goh C., Olmos D., Saunders E., Leongamornlert D., Tymrakiewicz M., Mahmud N., Dadaev T., Govindasami K., Guy M., et al.  Germline BRCA Mutations Are Associated with Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. J. Clin. Oncol. 2013;31:1748–1757. doi: 10.1200/JCO.2012.43.1882.</cite> [<a href="https://doi.org/10.1200/JCO.2012.43.1882" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3641696/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23569316/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Germline%20BRCA%20Mutations%20Are%20Associated%20with%20Higher%20Risk%20of%20Nodal%20Involvement,%20Distant%20Metastasis,%20and%20Poor%20Survival%20Outcomes%20in%20Prostate%20Cancer&amp;author=E.%20Castro&amp;author=C.%20Goh&amp;author=D.%20Olmos&amp;author=E.%20Saunders&amp;author=D.%20Leongamornlert&amp;volume=31&amp;publication_year=2013&amp;pages=1748-1757&amp;pmid=23569316&amp;doi=10.1200/JCO.2012.43.1882&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B188-biomedicines-10-00236">
<span class="label">188.</span><cite>Castro E., Romero-Laorden N., del Pozo A. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer. J. Clin. Oncol. 2019;37:490–503. doi: 10.1200/JCO.18.00358.</cite> [<a href="https://doi.org/10.1200/JCO.18.00358" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30625039/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=PROREPAIR-B:%20A%20Prospective%20Cohort%20Study%20of%20the%20Impact%20of%20Germline%20DNA%20Repair%20Mutations%20on%20the%20Outcomes%20of%20Patients%20with%20Metastatic%20Castration-Resistant%20Prostate%20Cancer&amp;author=E.%20Castro&amp;author=N.%20Romero-Laorden&amp;author=A.%20del%20Pozo&amp;volume=37&amp;publication_year=2019&amp;pages=490-503&amp;pmid=30625039&amp;doi=10.1200/JCO.18.00358&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B189-biomedicines-10-00236">
<span class="label">189.</span><cite>Cancer Genome Atlas Research Network  The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163:1011–1025. doi: 10.1016/j.cell.2015.10.025.</cite> [<a href="https://doi.org/10.1016/j.cell.2015.10.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4695400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26544944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The%20Molecular%20Taxonomy%20of%20Primary%20Prostate%20Cancer&amp;volume=163&amp;publication_year=2015&amp;pages=1011-1025&amp;pmid=26544944&amp;doi=10.1016/j.cell.2015.10.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B190-biomedicines-10-00236">
<span class="label">190.</span><cite>Nicolosi P., Ledet E., Yang S. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019;5:523–528. doi: 10.1001/jamaoncol.2018.6760.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2018.6760" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6459112/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30730552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&amp;title=Prevalence%20of%20Germline%20Variants%20in%20Prostate%20Cancer%20and%20Implications%20for%20Current%20Genetic%20Testing%20Guidelines&amp;author=P.%20Nicolosi&amp;author=E.%20Ledet&amp;author=S.%20Yang&amp;volume=5&amp;publication_year=2019&amp;pages=523-528&amp;pmid=30730552&amp;doi=10.1001/jamaoncol.2018.6760&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B191-biomedicines-10-00236">
<span class="label">191.</span><cite>De Bono J., Mateo J., Fizazi K., Saad F. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2020;382:2091–2102. doi: 10.1056/NEJMoa1911440.</cite> [<a href="https://doi.org/10.1056/NEJMoa1911440" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32343890/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Olaparib%20for%20Metastatic%20Castration-Resistant%20Prostate%20Cancer&amp;author=J.%20De%20Bono&amp;author=J.%20Mateo&amp;author=K.%20Fizazi&amp;author=F.%20Saad&amp;volume=382&amp;publication_year=2020&amp;pages=2091-2102&amp;pmid=32343890&amp;doi=10.1056/NEJMoa1911440&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B192-biomedicines-10-00236">
<span class="label">192.</span><cite>Attard G., Parker C., Eeles R.A., Schröder F., Tomlins S.A., Tannock I., Drake C.G., de Bono J.S. Prostate cancer. Lancet. 2016;387:70–82. doi: 10.1016/S0140-6736(14)61947-4.</cite> [<a href="https://doi.org/10.1016/S0140-6736(14)61947-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26074382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Prostate%20cancer&amp;author=G.%20Attard&amp;author=C.%20Parker&amp;author=R.A.%20Eeles&amp;author=F.%20Schr%C3%B6der&amp;author=S.A.%20Tomlins&amp;volume=387&amp;publication_year=2016&amp;pages=70-82&amp;pmid=26074382&amp;doi=10.1016/S0140-6736(14)61947-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B193-biomedicines-10-00236">
<span class="label">193.</span><cite>Pomerantz M.M., Spisák S., Jia L., Cronin A.M., Csabai I., Ledet E., Sartor A.O., Rainville I., Ba E.P.O., Herbert Z.T., et al.  The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017;123:3532–3539. doi: 10.1002/cncr.30808.</cite> [<a href="https://doi.org/10.1002/cncr.30808" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5802871/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28608931/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=The%20association%20between%20germline%20BRCA2%20variants%20and%20sensitivity%20to%20platinum-based%20chemotherapy%20among%20men%20with%20metastatic%20prostate%20cancer&amp;author=M.M.%20Pomerantz&amp;author=S.%20Spis%C3%A1k&amp;author=L.%20Jia&amp;author=A.M.%20Cronin&amp;author=I.%20Csabai&amp;volume=123&amp;publication_year=2017&amp;pages=3532-3539&amp;pmid=28608931&amp;doi=10.1002/cncr.30808&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B194-biomedicines-10-00236">
<span class="label">194.</span><cite>Schmid S., Omlin A., Higano C., Sweeney C., Chanza N.M., Mehra N., Kuppen M.C.P., Beltran H., Conteduca V., De Almeida D.V.P., et al.  Activity of Platinum-Based Chemotherapy in Patients with Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw. Open. 2020;3:e2021692. doi: 10.1001/jamanetworkopen.2020.21692.</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2020.21692" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7593810/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33112397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Netw.%20Open&amp;title=Activity%20of%20Platinum-Based%20Chemotherapy%20in%20Patients%20with%20Advanced%20Prostate%20Cancer%20With%20and%20Without%20DNA%20Repair%20Gene%20Aberrations&amp;author=S.%20Schmid&amp;author=A.%20Omlin&amp;author=C.%20Higano&amp;author=C.%20Sweeney&amp;author=N.M.%20Chanza&amp;volume=3&amp;publication_year=2020&amp;pages=e2021692&amp;pmid=33112397&amp;doi=10.1001/jamanetworkopen.2020.21692&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B195-biomedicines-10-00236">
<span class="label">195.</span><cite>Gasser S., Raulet D.H. The DNA damage response arouses the immune system. Cancer Res. 2006;66:3959–3962. doi: 10.1158/0008-5472.CAN-05-4603.</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-05-4603" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16618710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=The%20DNA%20damage%20response%20arouses%20the%20immune%20system&amp;author=S.%20Gasser&amp;author=D.H.%20Raulet&amp;volume=66&amp;publication_year=2006&amp;pages=3959-3962&amp;pmid=16618710&amp;doi=10.1158/0008-5472.CAN-05-4603&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B196-biomedicines-10-00236">
<span class="label">196.</span><cite>Abida W., Patnaik A., Campbell D., Shapiro J., Bryce A.H., McDermott R., Sautois B., Vogelzang N.J., Bambury R.M., Voog E., et al.  Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J. Clin. Oncol. 2020;38:3763–3772. doi: 10.1200/JCO.20.01035.</cite> [<a href="https://doi.org/10.1200/JCO.20.01035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7655021/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32795228/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Rucaparib%20in%20Men%20with%20Metastatic%20Castration-Resistant%20Prostate%20Cancer%20Harboring%20a%20BRCA1%20or%20BRCA2%20Gene%20Alteration&amp;author=W.%20Abida&amp;author=A.%20Patnaik&amp;author=D.%20Campbell&amp;author=J.%20Shapiro&amp;author=A.H.%20Bryce&amp;volume=38&amp;publication_year=2020&amp;pages=3763-3772&amp;pmid=32795228&amp;doi=10.1200/JCO.20.01035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B197-biomedicines-10-00236">
<span class="label">197.</span><cite>Abiraterone-Olaparib Combo Aids Men with mCRPC (news brief) Cancer Discov. 2018;8:OF4. doi: 10.1158/2159-8290.CD-NB2018-084.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-NB2018-084" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29954730/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov.&amp;title=Abiraterone-Olaparib%20Combo%20Aids%20Men%20with%20mCRPC%20(news%20brief)&amp;volume=8&amp;publication_year=2018&amp;pages=OF4&amp;pmid=29954730&amp;doi=10.1158/2159-8290.CD-NB2018-084&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B198-biomedicines-10-00236">
<span class="label">198.</span><cite>Smith M., Sandhu S., Kelly W., Scher H., Efstathiou E., Lara P., Yu E., George D., Chi K., Saad F., et al.  Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD) Ann. Oncol. 2019;30:v884–v885. doi: 10.1093/annonc/mdz394.043.</cite> [<a href="https://doi.org/10.1093/annonc/mdz394.043" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=Pre-specified%20interim%20analysis%20of%20GALAHAD:%20A%20phase%20II%20study%20of%20niraparib%20in%20patients%20(pts)%20with%20metastatic%20castration-resistant%20prostate%20cancer%20(mCRPC)%20and%20biallelic%20DNA-repair%20gene%20defects%20(DRD)&amp;author=M.%20Smith&amp;author=S.%20Sandhu&amp;author=W.%20Kelly&amp;author=H.%20Scher&amp;author=E.%20Efstathiou&amp;volume=30&amp;publication_year=2019&amp;pages=v884-v885&amp;doi=10.1093/annonc/mdz394.043&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B199-biomedicines-10-00236">
<span class="label">199.</span><cite>Gandhi, Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N. Engl. J. Med. 2003;349:366–381. doi: 10.1056/NEJMra021562.</cite> [<a href="https://doi.org/10.1056/NEJMra021562" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12878745/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Prostate%20cancer&amp;author=%20Gandhi&amp;author=W.G.%20Nelson&amp;author=A.M.%20De%20Marzo&amp;author=W.B.%20Isaacs&amp;volume=349&amp;publication_year=2003&amp;pages=366-381&amp;pmid=12878745&amp;doi=10.1056/NEJMra021562&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B200-biomedicines-10-00236">
<span class="label">200.</span><cite>de Bono J.S., De Giorgi U., Massard C., Bracarda S., Nava Rodrigues D., Kocak I., Font Pous A., Arranz Arija J., Shih K., Radavoi G.D., et al.  PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) Ann. Oncol. 2016;27:243–265. doi: 10.1093/annonc/mdw372.02.</cite> [<a href="https://doi.org/10.1093/annonc/mdw372.02" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=PTEN%20loss%20as%20a%20predictive%20biomarker%20for%20the%20Akt%20inhibitor%20ipatasertib%20combined%20with%20abiraterone%20acetate%20in%20patients%20with%20metastatic%20castration-resistant%20prostate%20cancer%20(mCRPC)&amp;author=J.S.%20de%20Bono&amp;author=U.%20De%20Giorgi&amp;author=C.%20Massard&amp;author=S.%20Bracarda&amp;author=D.%20Nava%20Rodrigues&amp;volume=27&amp;publication_year=2016&amp;pages=243-265&amp;doi=10.1093/annonc/mdw372.02&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B201-biomedicines-10-00236">
<span class="label">201.</span><cite>Parsa A.T., Waldron J.S., Panner A., Crane C.A., Parney I.F., Barry J.J., Cachola K.E., Murray J.C., Tihan T., Jensen M.C., et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 2007;13:84–88. doi: 10.1038/nm1517.</cite> [<a href="https://doi.org/10.1038/nm1517" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17159987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Med.&amp;title=Loss%20of%20tumor%20suppressor%20PTEN%20function%20increases%20B7-H1%20expression%20and%20immunoresistance%20in%20glioma&amp;author=A.T.%20Parsa&amp;author=J.S.%20Waldron&amp;author=A.%20Panner&amp;author=C.A.%20Crane&amp;author=I.F.%20Parney&amp;volume=13&amp;publication_year=2007&amp;pages=84-88&amp;pmid=17159987&amp;doi=10.1038/nm1517&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B202-biomedicines-10-00236">
<span class="label">202.</span><cite>Cha J.H., Chan L.C., Li C.W., Hsu J.L., Hung M.C. Mechanisms Controlling PD-L1 Expression in Cancer. Mol. Cell. 2019;76:359–370. doi: 10.1016/j.molcel.2019.09.030.</cite> [<a href="https://doi.org/10.1016/j.molcel.2019.09.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6981282/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31668929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cell&amp;title=Mechanisms%20Controlling%20PD-L1%20Expression%20in%20Cancer&amp;author=J.H.%20Cha&amp;author=L.C.%20Chan&amp;author=C.W.%20Li&amp;author=J.L.%20Hsu&amp;author=M.C.%20Hung&amp;volume=76&amp;publication_year=2019&amp;pages=359-370&amp;pmid=31668929&amp;doi=10.1016/j.molcel.2019.09.030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B203-biomedicines-10-00236">
<span class="label">203.</span><cite>Mulholland D.J., Kobayashi N., Ruscetti M., Zhi A., Tran L.M., Huang J., Gleave M., Wu H. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012;72:1878–1889. doi: 10.1158/0008-5472.CAN-11-3132.</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-11-3132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3319847/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22350410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=Pten%20loss%20and%20RAS/MAPK%20activation%20cooperate%20to%20promote%20EMT%20and%20metastasis%20initiated%20from%20prostate%20cancer%20stem/progenitor%20cells&amp;author=D.J.%20Mulholland&amp;author=N.%20Kobayashi&amp;author=M.%20Ruscetti&amp;author=A.%20Zhi&amp;author=L.M.%20Tran&amp;volume=72&amp;publication_year=2012&amp;pages=1878-1889&amp;pmid=22350410&amp;doi=10.1158/0008-5472.CAN-11-3132&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B204-biomedicines-10-00236">
<span class="label">204.</span><cite>Walker S.R., Abdelsalam R., Ghosh S., Livingstone J., Palanisamy N., Boutros P.C., Yip S.M., Lees-Miller S.P., Bismar T.A. Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease. Eur. Urol. Open Sci. 2021;12:93–101. doi: 10.1016/j.euros.2021.05.004.</cite> [<a href="https://doi.org/10.1016/j.euros.2021.05.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8317877/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34337539/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.%20Open%20Sci.&amp;title=Decreased%20ATM%20Protein%20Expression%20Is%20Substantiated%20with%20PTEN%20Loss%20in%20Defining%20Aggressive%20Phenotype%20of%20Prostate%20Cancer%20Associated%20with%20Lethal%20Disease&amp;author=S.R.%20Walker&amp;author=R.%20Abdelsalam&amp;author=S.%20Ghosh&amp;author=J.%20Livingstone&amp;author=N.%20Palanisamy&amp;volume=12&amp;publication_year=2021&amp;pages=93-101&amp;pmid=34337539&amp;doi=10.1016/j.euros.2021.05.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B205-biomedicines-10-00236">
<span class="label">205.</span><cite>Abou-Ouf H., Assem H., Ghosh S., Karnes R.J., Stoletov K., Palanisamy N., Lewis J.D., Bismar T.A. High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival. Eur. Urol. Open Sci. 2020;23:1–8. doi: 10.1016/j.euros.2020.11.005.</cite> [<a href="https://doi.org/10.1016/j.euros.2020.11.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8317848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34337483/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20Urol.%20Open%20Sci.&amp;title=High%20Serine-arginine%20Protein%20Kinase%201%20Expression%20with%20PTEN%20Loss%20Defines%20Aggressive%20Phenotype%20of%20Prostate%20Cancer%20Associated%20with%20Lethal%20Outcome%20and%20Decreased%20Overall%20Survival&amp;author=H.%20Abou-Ouf&amp;author=H.%20Assem&amp;author=S.%20Ghosh&amp;author=R.J.%20Karnes&amp;author=K.%20Stoletov&amp;volume=23&amp;publication_year=2020&amp;pages=1-8&amp;pmid=34337483&amp;doi=10.1016/j.euros.2020.11.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B206-biomedicines-10-00236">
<span class="label">206.</span><cite>De Velasco M.A., Kura Y., Yoshikawa K., Nishio K., Davies B.R., Uemura H. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. Oncotarget. 2016;7:15959–15976. doi: 10.18632/oncotarget.7557.</cite> [<a href="https://doi.org/10.18632/oncotarget.7557" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4941290/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26910118/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Efficacy%20of%20targeted%20AKT%20inhibition%20in%20genetically%20engineered%20mouse%20models%20of%20PTEN-deficient%20prostate%20cancer&amp;author=M.A.%20De%20Velasco&amp;author=Y.%20Kura&amp;author=K.%20Yoshikawa&amp;author=K.%20Nishio&amp;author=B.R.%20Davies&amp;volume=7&amp;publication_year=2016&amp;pages=15959-15976&amp;pmid=26910118&amp;doi=10.18632/oncotarget.7557&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B207-biomedicines-10-00236">
<span class="label">207.</span><cite>Chappell W.H., Lehmann B.D., Terrian D.M., Abrams S.L., Steelman L.S., McCubrey J.A. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle. 2012;11:4579–4588. doi: 10.4161/cc.22852.</cite> [<a href="https://doi.org/10.4161/cc.22852" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3562303/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23187804/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Cycle&amp;title=p53%20expression%20controls%20prostate%20cancer%20sensitivity%20to%20chemotherapy%20and%20the%20MDM2%20inhibitor%20Nutlin-3&amp;author=W.H.%20Chappell&amp;author=B.D.%20Lehmann&amp;author=D.M.%20Terrian&amp;author=S.L.%20Abrams&amp;author=L.S.%20Steelman&amp;volume=11&amp;publication_year=2012&amp;pages=4579-4588&amp;pmid=23187804&amp;doi=10.4161/cc.22852&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B208-biomedicines-10-00236">
<span class="label">208.</span><cite>Huang H., Tang Y., Li P., Ye X., Chen W., Xie H., Zheng Y. Significance of TP53 and immune-related genes to prostate cancer. Transl. Androl. Urol. 2021;10:1754–1768. doi: 10.21037/tau-21-179.</cite> [<a href="https://doi.org/10.21037/tau-21-179" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8100849/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33968663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transl.%20Androl.%20Urol.&amp;title=Significance%20of%20TP53%20and%20immune-related%20genes%20to%20prostate%20cancer&amp;author=H.%20Huang&amp;author=Y.%20Tang&amp;author=P.%20Li&amp;author=X.%20Ye&amp;author=W.%20Chen&amp;volume=10&amp;publication_year=2021&amp;pages=1754-1768&amp;pmid=33968663&amp;doi=10.21037/tau-21-179&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B209-biomedicines-10-00236">
<span class="label">209.</span><cite>Sun H., Wang Y., Chinnam M., Zhang X., Hayward S.W., Foster B.A., Nikitin A.Y., Wills M., Goodrich D.W. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. Proc. Natl. Acad. Sci. USA. 2011;108:704–709. doi: 10.1073/pnas.1015027108.</cite> [<a href="https://doi.org/10.1073/pnas.1015027108" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3021049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21187395/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc.%20Natl.%20Acad.%20Sci.%20USA&amp;title=E2f%20binding-deficient%20Rb1%20protein%20suppresses%20prostate%20tumor%20progression%20in%20vivo&amp;author=H.%20Sun&amp;author=Y.%20Wang&amp;author=M.%20Chinnam&amp;author=X.%20Zhang&amp;author=S.W.%20Hayward&amp;volume=108&amp;publication_year=2011&amp;pages=704-709&amp;pmid=21187395&amp;doi=10.1073/pnas.1015027108&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B210-biomedicines-10-00236">
<span class="label">210.</span><cite>Koh C.M., Bieberich C.J., Dang C.V., Nelson W.G., Yegnasubramanian S., De Marzo A.M. MYC and Prostate Cancer. Genes Cancer. 2010;1:617–628. doi: 10.1177/1947601910379132.</cite> [<a href="https://doi.org/10.1177/1947601910379132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3092219/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21779461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes%20Cancer&amp;title=MYC%20and%20Prostate%20Cancer&amp;author=C.M.%20Koh&amp;author=C.J.%20Bieberich&amp;author=C.V.%20Dang&amp;author=W.G.%20Nelson&amp;author=S.%20Yegnasubramanian&amp;volume=1&amp;publication_year=2010&amp;pages=617-628&amp;pmid=21779461&amp;doi=10.1177/1947601910379132&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B211-biomedicines-10-00236">
<span class="label">211.</span><cite>Han H., Jain A.D., Truica M.I., Izquierdo-Ferrer J., Anker J.F., Lysy B., Sagar V., Luan Y., Chalmers Z.R., Unno K., et al.  Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 2019;36:483–497.e15. doi: 10.1016/j.ccell.2019.10.001.</cite> [<a href="https://doi.org/10.1016/j.ccell.2019.10.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6939458/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31679823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Small-Molecule%20MYC%20Inhibitors%20Suppress%20Tumor%20Growth%20and%20Enhance%20Immunotherapy&amp;author=H.%20Han&amp;author=A.D.%20Jain&amp;author=M.I.%20Truica&amp;author=J.%20Izquierdo-Ferrer&amp;author=J.F.%20Anker&amp;volume=36&amp;publication_year=2019&amp;pages=483-497.e15&amp;pmid=31679823&amp;doi=10.1016/j.ccell.2019.10.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B212-biomedicines-10-00236">
<span class="label">212.</span><cite>Carver B.S., Tran J., Chen Z., Carracedo-Perez A., Alimonti A., Nardella C., Gopalan A., Scardino P.T., Cordon-Cardo C., Gerald W., et al.  ETS rearrangements and prostate cancer initiation. Nature. 2009;457:E1. doi: 10.1038/nature07738.</cite> [<a href="https://doi.org/10.1038/nature07738" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2967456/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19212347/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=ETS%20rearrangements%20and%20prostate%20cancer%20initiation&amp;author=B.S.%20Carver&amp;author=J.%20Tran&amp;author=Z.%20Chen&amp;author=A.%20Carracedo-Perez&amp;author=A.%20Alimonti&amp;volume=457&amp;publication_year=2009&amp;pages=E1&amp;pmid=19212347&amp;doi=10.1038/nature07738&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B213-biomedicines-10-00236">
<span class="label">213.</span><cite>Hagglof C., Hammarsten P., Stromvall K., Egevad L., Josefsson A., Stattin P., Granfors T., Bergh A. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS ONE. 2014;9:e86824.  doi: 10.1371/journal.pone.0086824.</cite> [<a href="https://doi.org/10.1371/journal.pone.0086824" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3914792/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24505269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=TMPRSS2-ERG%20expression%20predicts%20prostate%20cancer%20survival%20and%20associates%20with%20stromal%20biomarkers&amp;author=C.%20Hagglof&amp;author=P.%20Hammarsten&amp;author=K.%20Stromvall&amp;author=L.%20Egevad&amp;author=A.%20Josefsson&amp;volume=9&amp;publication_year=2014&amp;pages=e86824&amp;pmid=24505269&amp;doi=10.1371/journal.pone.0086824&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B214-biomedicines-10-00236">
<span class="label">214.</span><cite>Dai X., Gan W., Li X., Wang S., Zhang W., Huang L., Liu S., Zhong Q., Guo J., Zhang J., et al.  Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat. Med. 2017;23:1063–1071. doi: 10.1038/nm.4378.</cite> [<a href="https://doi.org/10.1038/nm.4378" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5625299/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28805820/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Med.&amp;title=Prostate%20cancer-associated%20SPOP%20mutations%20confer%20resistance%20to%20BET%20inhibitors%20through%20stabilization%20of%20BRD4&amp;author=X.%20Dai&amp;author=W.%20Gan&amp;author=X.%20Li&amp;author=S.%20Wang&amp;author=W.%20Zhang&amp;volume=23&amp;publication_year=2017&amp;pages=1063-1071&amp;pmid=28805820&amp;doi=10.1038/nm.4378&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B215-biomedicines-10-00236">
<span class="label">215.</span><cite>Young C., Horton R. Putting clinical trials into context. Lancet. 2005;366:107–108. doi: 10.1016/S0140-6736(05)66846-8.</cite> [<a href="https://doi.org/10.1016/S0140-6736(05)66846-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16005318/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Putting%20clinical%20trials%20into%20context&amp;author=C.%20Young&amp;author=R.%20Horton&amp;volume=366&amp;publication_year=2005&amp;pages=107-108&amp;pmid=16005318&amp;doi=10.1016/S0140-6736(05)66846-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B216-biomedicines-10-00236">
<span class="label">216.</span><cite>Palicelli A., Giaccherini L., Zanelli M., Bonasoni M.P., Gelli M.C., Bisagni A., Zanetti E., De Marco L., Torricelli F., Manzotti G., et al.  How Can We Treat Vulvar Carcinoma in Pregnancy? A Systematic Review of the Literature. Cancers. 2021;13:836.  doi: 10.3390/cancers13040836.</cite> [<a href="https://doi.org/10.3390/cancers13040836" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7921964/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33671249/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=How%20Can%20We%20Treat%20Vulvar%20Carcinoma%20in%20Pregnancy?%20A%20Systematic%20Review%20of%20the%20Literature&amp;author=A.%20Palicelli&amp;author=L.%20Giaccherini&amp;author=M.%20Zanelli&amp;author=M.P.%20Bonasoni&amp;author=M.C.%20Gelli&amp;volume=13&amp;publication_year=2021&amp;pages=836&amp;pmid=33671249&amp;doi=10.3390/cancers13040836&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B217-biomedicines-10-00236">
<span class="label">217.</span><cite>Oxman A.D., Cook D.J., Guyatt G.H. Users’ guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. JAMA. 1994;272:1367–1371. doi: 10.1001/jama.1994.03520170077040.</cite> [<a href="https://doi.org/10.1001/jama.1994.03520170077040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7933399/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Users%E2%80%99%20guides%20to%20the%20medical%20literature.%20VI.%20How%20to%20use%20an%20overview.%20Evidence-Based%20Medicine%20Working%20Group&amp;author=A.D.%20Oxman&amp;author=D.J.%20Cook&amp;author=G.H.%20Guyatt&amp;volume=272&amp;publication_year=1994&amp;pages=1367-1371&amp;pmid=7933399&amp;doi=10.1001/jama.1994.03520170077040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B218-biomedicines-10-00236">
<span class="label">218.</span><cite>Swingler G.H., Volmink J., Ioannidis J.P. Number of published systematic reviews and global burden of disease: Database analysis. BMJ. 2003;327:1083–1084. doi: 10.1136/bmj.327.7423.1083.</cite> [<a href="https://doi.org/10.1136/bmj.327.7423.1083" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC261743/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14604930/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Number%20of%20published%20systematic%20reviews%20and%20global%20burden%20of%20disease:%20Database%20analysis&amp;author=G.H.%20Swingler&amp;author=J.%20Volmink&amp;author=J.P.%20Ioannidis&amp;volume=327&amp;publication_year=2003&amp;pages=1083-1084&amp;pmid=14604930&amp;doi=10.1136/bmj.327.7423.1083&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B219-biomedicines-10-00236">
<span class="label">219.</span><cite>Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 2009;151:264–269. doi: 10.7326/0003-4819-151-4-200908180-00135.</cite> [<a href="https://doi.org/10.7326/0003-4819-151-4-200908180-00135" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19622511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Intern.%20Med.&amp;title=PRISMA%20Group.%20Preferred%20reporting%20items%20for%20systematic%20reviews%20and%20meta-analyses:%20The%20PRISMA%20statement&amp;author=D.%20Moher&amp;author=A.%20Liberati&amp;author=J.%20Tetzlaff&amp;author=D.G.%20Altman&amp;volume=151&amp;publication_year=2009&amp;pages=264-269&amp;pmid=19622511&amp;doi=10.7326/0003-4819-151-4-200908180-00135&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B220-biomedicines-10-00236">
<span class="label">220.</span><cite>Sanguedolce F., Calò B., Mancini V., Zanelli M., Palicelli A., Zizzo M., Ascani S., Carrieri G., Cormio L. Non-Muscle Invasive Bladder Cancer with Variant Histology: Biological Features and Clinical Implications. Oncology. 2021;99:345–358. doi: 10.1159/000514759.</cite> [<a href="https://doi.org/10.1159/000514759" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33735905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncology&amp;title=Non-Muscle%20Invasive%20Bladder%20Cancer%20with%20Variant%20Histology:%20Biological%20Features%20and%20Clinical%20Implications&amp;author=F.%20Sanguedolce&amp;author=B.%20Cal%C3%B2&amp;author=V.%20Mancini&amp;author=M.%20Zanelli&amp;author=A.%20Palicelli&amp;volume=99&amp;publication_year=2021&amp;pages=345-358&amp;pmid=33735905&amp;doi=10.1159/000514759&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B221-biomedicines-10-00236">
<span class="label">221.</span><cite>Zhong J., Slevin F., Scarsbrook A.F., Serra M., Choudhury A., Hoskin P.J., Brown S., Henry A.M. Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review. Front. Oncol. 2021;11:681448. doi: 10.3389/fonc.2021.681448.</cite> [<a href="https://doi.org/10.3389/fonc.2021.681448" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8459721/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34568012/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=Salvage%20Reirradiation%20Options%20for%20Locally%20Recurrent%20Prostate%20Cancer:%20A%20Systematic%20Review&amp;author=J.%20Zhong&amp;author=F.%20Slevin&amp;author=A.F.%20Scarsbrook&amp;author=M.%20Serra&amp;author=A.%20Choudhury&amp;volume=11&amp;publication_year=2021&amp;pages=681448&amp;pmid=34568012&amp;doi=10.3389/fonc.2021.681448&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B222-biomedicines-10-00236">
<span class="label">222.</span><cite>Yao H.H., Hoe V., Shamout S., Sengupta S., O’Connell H.E., Carlson K.V., Baverstock R.J. Impact of radiotherapy for localized prostate cancer on bladder function as demonstrated on urodynamics study: A systematic review. Can. Urol. Assoc. J. 2021;15 doi: 10.5489/cuaj.7265.</cite> [<a href="https://doi.org/10.5489/cuaj.7265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8631837/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34171214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can.%20Urol.%20Assoc.%20J.&amp;title=Impact%20of%20radiotherapy%20for%20localized%20prostate%20cancer%20on%20bladder%20function%20as%20demonstrated%20on%20urodynamics%20study:%20A%20systematic%20review&amp;author=H.H.%20Yao&amp;author=V.%20Hoe&amp;author=S.%20Shamout&amp;author=S.%20Sengupta&amp;author=H.E.%20O%E2%80%99Connell&amp;volume=15&amp;publication_year=2021&amp;pmid=34171214&amp;doi=10.5489/cuaj.7265&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B223-biomedicines-10-00236">
<span class="label">223.</span><cite>Zanelli M., Sanguedolce F., Zizzo M., Palicelli A., Bassi M.C., Santandrea G., Martino G., Soriano A., Caprera C., Corsi M., et al.  Primary effusion lymphoma occurring in the setting of transplanted patients: A systematic review of a rare, life-threatening post-transplantation occurrence. BMC Cancer. 2021;21:468.  doi: 10.1186/s12885-021-08215-7.</cite> [<a href="https://doi.org/10.1186/s12885-021-08215-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8077837/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33906629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Primary%20effusion%20lymphoma%20occurring%20in%20the%20setting%20of%20transplanted%20patients:%20A%20systematic%20review%20of%20a%20rare,%20life-threatening%20post-transplantation%20occurrence&amp;author=M.%20Zanelli&amp;author=F.%20Sanguedolce&amp;author=M.%20Zizzo&amp;author=A.%20Palicelli&amp;author=M.C.%20Bassi&amp;volume=21&amp;publication_year=2021&amp;pages=468&amp;pmid=33906629&amp;doi=10.1186/s12885-021-08215-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B224-biomedicines-10-00236">
<span class="label">224.</span><cite>Palicelli A., Neri P., Marchioro G., De Angelis P., Bondonno G., Ramponi A. Paratesticular seminoma: Echographic features and histological diagnosis with review of the literature. APMIS. 2018;126:267–272. doi: 10.1111/apm.12806.</cite> [<a href="https://doi.org/10.1111/apm.12806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29411910/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=APMIS&amp;title=Paratesticular%20seminoma:%20Echographic%20features%20and%20histological%20diagnosis%20with%20review%20of%20the%20literature&amp;author=A.%20Palicelli&amp;author=P.%20Neri&amp;author=G.%20Marchioro&amp;author=P.%20De%20Angelis&amp;author=G.%20Bondonno&amp;volume=126&amp;publication_year=2018&amp;pages=267-272&amp;pmid=29411910&amp;doi=10.1111/apm.12806&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B225-biomedicines-10-00236">
<span class="label">225.</span><cite>Sanguedolce F., Zanelli M., Zizzo M., Bisagni A., Soriano A., Cocco G., Palicelli A., Santandrea G., Caprera C., Corsi M., et al.  Primary Pulmonary B-Cell Lymphoma: A Review and Update. Cancers. 2021;13:415.  doi: 10.3390/cancers13030415.</cite> [<a href="https://doi.org/10.3390/cancers13030415" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7865219/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33499258/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Primary%20Pulmonary%20B-Cell%20Lymphoma:%20A%20Review%20and%20Update&amp;author=F.%20Sanguedolce&amp;author=M.%20Zanelli&amp;author=M.%20Zizzo&amp;author=A.%20Bisagni&amp;author=A.%20Soriano&amp;volume=13&amp;publication_year=2021&amp;pages=415&amp;pmid=33499258&amp;doi=10.3390/cancers13030415&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B226-biomedicines-10-00236">
<span class="label">226.</span><cite>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al.  The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</cite> [<a href="https://doi.org/10.1136/bmj.n71" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8005924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33782057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=The%20PRISMA%202020%20statement:%20An%20updated%20guideline%20for%20reporting%20systematic%20reviews&amp;author=M.J.%20Page&amp;author=J.E.%20McKenzie&amp;author=P.M.%20Bossuyt&amp;author=I.%20Boutron&amp;author=T.C.%20Hoffmann&amp;volume=372&amp;publication_year=2021&amp;pages=n71&amp;pmid=33782057&amp;doi=10.1136/bmj.n71&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B227-biomedicines-10-00236">
<span class="label">227.</span><cite>Zanelli M., Ricci S., Sanguedolce F., Palicelli A., Farnetti E., Tafuni A., Zizzo M., Valli R., Celis M.I.A., Cavazza A., et al.  Cutaneous Localization of Classic Hodgkin Lymphoma Associated with Mycosis Fungoides: Report of a Rare Event and Review of the Literature. Life. 2021;11:1069.  doi: 10.3390/life11101069.</cite> [<a href="https://doi.org/10.3390/life11101069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8537882/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34685440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Life&amp;title=Cutaneous%20Localization%20of%20Classic%20Hodgkin%20Lymphoma%20Associated%20with%20Mycosis%20Fungoides:%20Report%20of%20a%20Rare%20Event%20and%20Review%20of%20the%20Literature&amp;author=M.%20Zanelli&amp;author=S.%20Ricci&amp;author=F.%20Sanguedolce&amp;author=A.%20Palicelli&amp;author=E.%20Farnetti&amp;volume=11&amp;publication_year=2021&amp;pages=1069&amp;pmid=34685440&amp;doi=10.3390/life11101069&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B228-biomedicines-10-00236">
<span class="label">228.</span><cite>Bonasoni M.P., Comitini G., Barbieri V., Palicelli A., Salfi N., Pilu G. Fetal Presentation of Mediastinal Immature Teratoma: Ultrasound, Autopsy and Cytogenetic Findings. Diagnostics. 2021;11:1543.  doi: 10.3390/diagnostics11091543.</cite> [<a href="https://doi.org/10.3390/diagnostics11091543" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8468681/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34573885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics&amp;title=Fetal%20Presentation%20of%20Mediastinal%20Immature%20Teratoma:%20Ultrasound,%20Autopsy%20and%20Cytogenetic%20Findings&amp;author=M.P.%20Bonasoni&amp;author=G.%20Comitini&amp;author=V.%20Barbieri&amp;author=A.%20Palicelli&amp;author=N.%20Salfi&amp;volume=11&amp;publication_year=2021&amp;pages=1543&amp;pmid=34573885&amp;doi=10.3390/diagnostics11091543&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B229-biomedicines-10-00236">
<span class="label">229.</span><cite>Liu L., Dong H., Jin X., Brooke-Wavell K. Tackling Dementia: A Systematic Review of Interventions Based on Physical Activity. J. Geriatr. Phys. Ther. 2021 doi: 10.1519/JPT.0000000000000332.</cite> [<a href="https://doi.org/10.1519/JPT.0000000000000332" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34570041/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Geriatr.%20Phys.%20Ther.&amp;title=Tackling%20Dementia:%20A%20Systematic%20Review%20of%20Interventions%20Based%20on%20Physical%20Activity&amp;author=L.%20Liu&amp;author=H.%20Dong&amp;author=X.%20Jin&amp;author=K.%20Brooke-Wavell&amp;publication_year=2021&amp;pmid=34570041&amp;doi=10.1519/JPT.0000000000000332&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B230-biomedicines-10-00236">
<span class="label">230.</span><cite>Storoni S., Treurniet S., Micha D., Celli M., Bugiani M., van den Aardweg J.G., Eekhoff E.M.W. Pathophysiology of respiratory failure in patients with osteogenesis imperfecta: A systematic review. Ann. Med. 2021;53:1676–1687. doi: 10.1080/07853890.2021.1980819.</cite> [<a href="https://doi.org/10.1080/07853890.2021.1980819" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8477932/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34569391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Med.&amp;title=Pathophysiology%20of%20respiratory%20failure%20in%20patients%20with%20osteogenesis%20imperfecta:%20A%20systematic%20review&amp;author=S.%20Storoni&amp;author=S.%20Treurniet&amp;author=D.%20Micha&amp;author=M.%20Celli&amp;author=M.%20Bugiani&amp;volume=53&amp;publication_year=2021&amp;pages=1676-1687&amp;pmid=34569391&amp;doi=10.1080/07853890.2021.1980819&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B231-biomedicines-10-00236">
<span class="label">231.</span><cite>Bonasoni M.P., Palicelli A., Dalla Dea G., Comitini G., Pazzola G., Russello G., Bertoldi G., Bardaro M., Zuelli C., Carretto E. Kingella kingae Intrauterine Infection: An Unusual Cause of Chorioamnionitis and Miscarriage in a Patient with Undifferentiated Connective Tissue Disease. Diagnostics. 2021;11:243.  doi: 10.3390/diagnostics11020243.</cite> [<a href="https://doi.org/10.3390/diagnostics11020243" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7914692/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33557386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics&amp;title=Kingella%20kingae%20Intrauterine%20Infection:%20An%20Unusual%20Cause%20of%20Chorioamnionitis%20and%20Miscarriage%20in%20a%20Patient%20with%20Undifferentiated%20Connective%20Tissue%20Disease&amp;author=M.P.%20Bonasoni&amp;author=A.%20Palicelli&amp;author=G.%20Dalla%20Dea&amp;author=G.%20Comitini&amp;author=G.%20Pazzola&amp;volume=11&amp;publication_year=2021&amp;pages=243&amp;pmid=33557386&amp;doi=10.3390/diagnostics11020243&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B232-biomedicines-10-00236">
<span class="label">232.</span><cite>Wing-Cheuk Wong R., Palicelli A., Hoang L., Singh N. Interpretation of p16, p53 and mismatch repair protein immunohistochemistry in gynaecological neoplasia. Diagn. Histopathol. 2020;26:257–277. doi: 10.1016/j.mpdhp.2020.03.002.</cite> [<a href="https://doi.org/10.1016/j.mpdhp.2020.03.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagn.%20Histopathol.&amp;title=Interpretation%20of%20p16,%20p53%20and%20mismatch%20repair%20protein%20immunohistochemistry%20in%20gynaecological%20neoplasia&amp;author=R.%20Wing-Cheuk%20Wong&amp;author=A.%20Palicelli&amp;author=L.%20Hoang&amp;author=N.%20Singh&amp;volume=26&amp;publication_year=2020&amp;pages=257-277&amp;doi=10.1016/j.mpdhp.2020.03.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B233-biomedicines-10-00236">
<span class="label">233.</span><cite>Olivadese R., Ramponi A., Boldorini R., Dalla Dea G., Palicelli A. Mitotically Active Cellular Fibroma of the Ovary Recurring After the Longest Interval of Time (16 yr): A Challenging Case With Systematic Literature Review. Int. J. Gynecol. Pathol. 2021;40:441–447. doi: 10.1097/PGP.0000000000000731.</cite> [<a href="https://doi.org/10.1097/PGP.0000000000000731" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33252401/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Gynecol.%20Pathol.&amp;title=Mitotically%20Active%20Cellular%20Fibroma%20of%20the%20Ovary%20Recurring%20After%20the%20Longest%20Interval%20of%20Time%20(16%E2%80%89yr):%20A%20Challenging%20Case%20With%20Systematic%20Literature%20Review&amp;author=R.%20Olivadese&amp;author=A.%20Ramponi&amp;author=R.%20Boldorini&amp;author=G.%20Dalla%20Dea&amp;author=A.%20Palicelli&amp;volume=40&amp;publication_year=2021&amp;pages=441-447&amp;pmid=33252401&amp;doi=10.1097/PGP.0000000000000731&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B234-biomedicines-10-00236">
<span class="label">234.</span><cite>Zanelli M., Ricci S., Zizzo M., Sanguedolce F., De Giorgi F., Palicelli A., Martino G., Ascani S. Systemic Mastocytosis Associated with "Smoldering" Multiple Myeloma. Diagnostics. 2021;11:88.  doi: 10.3390/diagnostics11010088.</cite> [<a href="https://doi.org/10.3390/diagnostics11010088" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7825792/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33430341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics&amp;title=Systemic%20Mastocytosis%20Associated%20with%20%22Smoldering%22%20Multiple%20Myeloma&amp;author=M.%20Zanelli&amp;author=S.%20Ricci&amp;author=M.%20Zizzo&amp;author=F.%20Sanguedolce&amp;author=F.%20De%20Giorgi&amp;volume=11&amp;publication_year=2021&amp;pages=88&amp;pmid=33430341&amp;doi=10.3390/diagnostics11010088&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B235-biomedicines-10-00236">
<span class="label">235.</span><cite>Bonasoni M.P., Palicelli A., Dalla Dea G., Comitini G., Nardini P., Vizzini L., Russello G., Bardaro M., Carretto E. Klebsiella pneumoniae Chorioamnionitis: An Underrecognized Cause of Preterm Premature Rupture of Membranes in the Second Trimester. Microorganisms. 2021;9:96.  doi: 10.3390/microorganisms9010096.</cite> [<a href="https://doi.org/10.3390/microorganisms9010096" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7824054/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33401648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Microorganisms&amp;title=Klebsiella%20pneumoniae%20Chorioamnionitis:%20An%20Underrecognized%20Cause%20of%20Preterm%20Premature%20Rupture%20of%20Membranes%20in%20the%20Second%20Trimester&amp;author=M.P.%20Bonasoni&amp;author=A.%20Palicelli&amp;author=G.%20Dalla%20Dea&amp;author=G.%20Comitini&amp;author=P.%20Nardini&amp;volume=9&amp;publication_year=2021&amp;pages=96&amp;pmid=33401648&amp;doi=10.3390/microorganisms9010096&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B236-biomedicines-10-00236">
<span class="label">236.</span><cite>Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P.A., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136/bmj.b2700.</cite> [<a href="https://doi.org/10.1136/bmj.b2700" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2714672/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19622552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=The%20PRISMA%20statement%20for%20reporting%20systematic%20reviews%20and%20meta-analyses%20of%20studies%20that%20evaluate%20healthcare%20interventions:%20Explanation%20and%20elaboration&amp;author=A.%20Liberati&amp;author=D.G.%20Altman&amp;author=J.%20Tetzlaff&amp;author=C.%20Mulrow&amp;author=P.C.%20G%C3%B8tzsche&amp;volume=339&amp;publication_year=2009&amp;pages=b2700&amp;pmid=19622552&amp;doi=10.1136/bmj.b2700&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B237-biomedicines-10-00236">
<span class="label">237.</span><cite>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L.M., Tetzlaff J.M., Moher D. Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. J. Clin. Epidemiol. 2021;134:103–112. doi: 10.1016/j.jclinepi.2021.02.003.</cite> [<a href="https://doi.org/10.1016/j.jclinepi.2021.02.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33577987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Epidemiol.&amp;title=Updating%20guidance%20for%20reporting%20systematic%20reviews:%20Development%20of%20the%20PRISMA%202020%20statement&amp;author=M.J.%20Page&amp;author=J.E.%20McKenzie&amp;author=P.M.%20Bossuyt&amp;author=I.%20Boutron&amp;author=T.C.%20Hoffmann&amp;volume=134&amp;publication_year=2021&amp;pages=103-112&amp;pmid=33577987&amp;doi=10.1016/j.jclinepi.2021.02.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B238-biomedicines-10-00236">
<span class="label">238.</span><cite>Palicelli A. What do we know about the cytological features of pure intraductal carcinomas of the salivary glands? Cytopathology. 2020;31:185–192. doi: 10.1111/cyt.12790.</cite> [<a href="https://doi.org/10.1111/cyt.12790" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31749241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cytopathology&amp;title=What%20do%20we%20know%20about%20the%20cytological%20features%20of%20pure%20intraductal%20carcinomas%20of%20the%20salivary%20glands?&amp;author=A.%20Palicelli&amp;volume=31&amp;publication_year=2020&amp;pages=185-192&amp;pmid=31749241&amp;doi=10.1111/cyt.12790&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B239-biomedicines-10-00236">
<span class="label">239.</span><cite>D’Agostino C., Surico D., Monga G., Palicelli A. Pregnancy-related decidualization of subcutaneous endometriosis occurring in a post-caesarean section scar: Case study and review of the literature. Pathol. Res. Pract. 2019;215:828–831. doi: 10.1016/j.prp.2019.01.024.</cite> [<a href="https://doi.org/10.1016/j.prp.2019.01.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30683477/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pathol.%20Res.%20Pract.&amp;title=Pregnancy-related%20decidualization%20of%20subcutaneous%20endometriosis%20occurring%20in%20a%20post-caesarean%20section%20scar:%20Case%20study%20and%20review%20of%20the%20literature&amp;author=C.%20D%E2%80%99Agostino&amp;author=D.%20Surico&amp;author=G.%20Monga&amp;author=A.%20Palicelli&amp;volume=215&amp;publication_year=2019&amp;pages=828-831&amp;pmid=30683477&amp;doi=10.1016/j.prp.2019.01.024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B240-biomedicines-10-00236">
<span class="label">240.</span><cite>Disanto M.G., Mercalli F., Palicelli A., Arnulfo A., Boldorini R. A unique case of bilateral ovarian splenosis and review of the literature. APMIS. 2017;125:844–848. doi: 10.1111/apm.12714.</cite> [<a href="https://doi.org/10.1111/apm.12714" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28543860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=APMIS&amp;title=A%20unique%20case%20of%20bilateral%20ovarian%20splenosis%20and%20review%20of%20the%20literature&amp;author=M.G.%20Disanto&amp;author=F.%20Mercalli&amp;author=A.%20Palicelli&amp;author=A.%20Arnulfo&amp;author=R.%20Boldorini&amp;volume=125&amp;publication_year=2017&amp;pages=844-848&amp;pmid=28543860&amp;doi=10.1111/apm.12714&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B241-biomedicines-10-00236">
<span class="label">241.</span><cite>Palicelli A. Intraductal carcinomas of the salivary glands: Systematic review and classification of 93 published cases. APMIS. 2020;128:191–200. doi: 10.1111/apm.13009.</cite> [<a href="https://doi.org/10.1111/apm.13009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31697865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=APMIS&amp;title=Intraductal%20carcinomas%20of%20the%20salivary%20glands:%20Systematic%20review%20and%20classification%20of%2093%20published%20cases&amp;author=A.%20Palicelli&amp;volume=128&amp;publication_year=2020&amp;pages=191-200&amp;pmid=31697865&amp;doi=10.1111/apm.13009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B242-biomedicines-10-00236">
<span class="label">242.</span><cite>Ardighieri L., Palicelli A., Ferrari F., Bugatti M., Drera E., Sartori E., Odicino F. Endometrial Carcinomas with Intestinal-Type Metaplasia/Differentiation: Does Mismatch Repair System Defects Matter? Case Report and Systematic Review of the Literature. J. Clin. Med. 2020;9:2552.  doi: 10.3390/jcm9082552.</cite> [<a href="https://doi.org/10.3390/jcm9082552" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7465332/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32781666/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Med.&amp;title=Endometrial%20Carcinomas%20with%20Intestinal-Type%20Metaplasia/Differentiation:%20Does%20Mismatch%20Repair%20System%20Defects%20Matter?%20Case%20Report%20and%20Systematic%20Review%20of%20the%20Literature&amp;author=L.%20Ardighieri&amp;author=A.%20Palicelli&amp;author=F.%20Ferrari&amp;author=M.%20Bugatti&amp;author=E.%20Drera&amp;volume=9&amp;publication_year=2020&amp;pages=2552&amp;pmid=32781666&amp;doi=10.3390/jcm9082552&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B243-biomedicines-10-00236">
<span class="label">243.</span><cite>Porreca A., Colicchia M., Tafuri A., D’Agostino D., Busetto G.M., Crestani A., Odorizzi K., Amigoni N., Rizzetto R., Gozzo A., et al.  Perioperative Outcomes of Holmium Laser Enucleation of the Prostate: A Systematic Review. Urol. Int. 2021;21:1–13. doi: 10.1159/000518560.</cite> [<a href="https://doi.org/10.1159/000518560" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34569529/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Urol.%20Int.&amp;title=Perioperative%20Outcomes%20of%20Holmium%20Laser%20Enucleation%20of%20the%20Prostate:%20A%20Systematic%20Review&amp;author=A.%20Porreca&amp;author=M.%20Colicchia&amp;author=A.%20Tafuri&amp;author=D.%20D%E2%80%99Agostino&amp;author=G.M.%20Busetto&amp;volume=21&amp;publication_year=2021&amp;pages=1-13&amp;pmid=34569529&amp;doi=10.1159/000518560&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B244-biomedicines-10-00236">
<span class="label">244.</span><cite>Palicelli A., Barbieri P., Mariani N., Re P., Galla S., Sorrentino R., Locatelli F., Salfi N., Valente G. Unicystic high-grade intraductal carcinoma of the parotid gland: Cytological and histological description with clinic-pathologic review of the literature. APMIS. 2018;126:771–776. doi: 10.1111/apm.12882.</cite> [<a href="https://doi.org/10.1111/apm.12882" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30160016/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=APMIS&amp;title=Unicystic%20high-grade%20intraductal%20carcinoma%20of%20the%20parotid%20gland:%20Cytological%20and%20histological%20description%20with%20clinic-pathologic%20review%20of%20the%20literature&amp;author=A.%20Palicelli&amp;author=P.%20Barbieri&amp;author=N.%20Mariani&amp;author=P.%20Re&amp;author=S.%20Galla&amp;volume=126&amp;publication_year=2018&amp;pages=771-776&amp;pmid=30160016&amp;doi=10.1111/apm.12882&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B245-biomedicines-10-00236">
<span class="label">245.</span><cite>Anderson E.M., Kim S., Sandler H.M., Kamrava M. High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: A systematic review and meta-analysis. J. Contemp. Brachyther. 2021;13:365–372. doi: 10.5114/jcb.2021.108590.</cite> [<a href="https://doi.org/10.5114/jcb.2021.108590" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8407258/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34484350/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Contemp.%20Brachyther.&amp;title=High-dose-rate%20fractionated%20brachytherapy%20monotherapy%20for%20localized%20prostate%20cancer:%20A%20systematic%20review%20and%20meta-analysis&amp;author=E.M.%20Anderson&amp;author=S.%20Kim&amp;author=H.M.%20Sandler&amp;author=M.%20Kamrava&amp;volume=13&amp;publication_year=2021&amp;pages=365-372&amp;pmid=34484350&amp;doi=10.5114/jcb.2021.108590&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B246-biomedicines-10-00236">
<span class="label">246.</span><cite>Zanelli M., Smith M., Zizzo M., Carloni A., Valli R., De Marco L., Foroni M., Palicelli A., Martino G., Ascani S. A tricky and rare cause of pulmonary eosinophilia: Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA. BMC Pulm. Med. 2019;19:216.  doi: 10.1186/s12890-019-0967-7.</cite> [<a href="https://doi.org/10.1186/s12890-019-0967-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6862820/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31744552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Pulm.%20Med.&amp;title=A%20tricky%20and%20rare%20cause%20of%20pulmonary%20eosinophilia:%20Myeloid/lymphoid%20neoplasm%20with%20eosinophilia%20and%20rearrangement%20of%20PDGFRA&amp;author=M.%20Zanelli&amp;author=M.%20Smith&amp;author=M.%20Zizzo&amp;author=A.%20Carloni&amp;author=R.%20Valli&amp;volume=19&amp;publication_year=2019&amp;pages=216&amp;pmid=31744552&amp;doi=10.1186/s12890-019-0967-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B247-biomedicines-10-00236">
<span class="label">247.</span><cite>Kočo L., Weekenstroo H.H.A., Lambregts D.M.J., Sedelaar J.P.M., Prokop M., Fütterer J.J., Mann R.M. The Effects of Multidisciplinary Team Meetings on Clinical Practice for Colorectal, Lung, Prostate and Breast Cancer: A Systematic Review. Cancers. 2021;13:4159.  doi: 10.3390/cancers13164159.</cite> [<a href="https://doi.org/10.3390/cancers13164159" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8394238/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34439312/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=The%20Effects%20of%20Multidisciplinary%20Team%20Meetings%20on%20Clinical%20Practice%20for%20Colorectal,%20Lung,%20Prostate%20and%20Breast%20Cancer:%20A%20Systematic%20Review&amp;author=L.%20Ko%C4%8Do&amp;author=H.H.A.%20Weekenstroo&amp;author=D.M.J.%20Lambregts&amp;author=J.P.M.%20Sedelaar&amp;author=M.%20Prokop&amp;volume=13&amp;publication_year=2021&amp;pages=4159&amp;pmid=34439312&amp;doi=10.3390/cancers13164159&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B248-biomedicines-10-00236">
<span class="label">248.</span><cite>Palicelli A., Boldorini R., Campisi P., Disanto M.G., Gatti L., Portigliotti L., Tosoni A., Rivasi F. Tungiasis in Italy: An imported case of Tunga penetrans and review of the literature. Pathol. Res. Pract. 2016;212:475–483. doi: 10.1016/j.prp.2016.02.003.</cite> [<a href="https://doi.org/10.1016/j.prp.2016.02.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26876782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pathol.%20Res.%20Pract.&amp;title=Tungiasis%20in%20Italy:%20An%20imported%20case%20of%20Tunga%20penetrans%20and%20review%20of%20the%20literature&amp;author=A.%20Palicelli&amp;author=R.%20Boldorini&amp;author=P.%20Campisi&amp;author=M.G.%20Disanto&amp;author=L.%20Gatti&amp;volume=212&amp;publication_year=2016&amp;pages=475-483&amp;pmid=26876782&amp;doi=10.1016/j.prp.2016.02.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B249-biomedicines-10-00236">
<span class="label">249.</span><cite>Ambrosetti F., Palicelli A., Bulfamante G., Rivasi F. Langer mesomelic dysplasia in early fetuses: Two cases and a literature review. Fetal Pediatr. Pathol. 2014;33:71–83. doi: 10.3109/15513815.2013.807322.</cite> [<a href="https://doi.org/10.3109/15513815.2013.807322" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23883335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Fetal%20Pediatr.%20Pathol.&amp;title=Langer%20mesomelic%20dysplasia%20in%20early%20fetuses:%20Two%20cases%20and%20a%20literature%20review&amp;author=F.%20Ambrosetti&amp;author=A.%20Palicelli&amp;author=G.%20Bulfamante&amp;author=F.%20Rivasi&amp;volume=33&amp;publication_year=2014&amp;pages=71-83&amp;pmid=23883335&amp;doi=10.3109/15513815.2013.807322&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B250-biomedicines-10-00236">
<span class="label">250.</span><cite>Mandato V.D., Mastrofilippo V., Palicelli A., Silvotti M., Serra S., Giaccherini L., Aguzzoli L. Solitary vulvar metastasis from early-stage endometrial cancer: Case report and literature review. Medicine. 2021;100:e25863. doi: 10.1097/MD.0000000000025863.</cite> [<a href="https://doi.org/10.1097/MD.0000000000025863" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8183741/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34087828/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine&amp;title=Solitary%20vulvar%20metastasis%20from%20early-stage%20endometrial%20cancer:%20Case%20report%20and%20literature%20review&amp;author=V.D.%20Mandato&amp;author=V.%20Mastrofilippo&amp;author=A.%20Palicelli&amp;author=M.%20Silvotti&amp;author=S.%20Serra&amp;volume=100&amp;publication_year=2021&amp;pages=e25863&amp;pmid=34087828&amp;doi=10.1097/MD.0000000000025863&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B251-biomedicines-10-00236">
<span class="label">251.</span><cite>Palicelli A., Disanto M.G., Panzarasa G., Veggiani C., Galizia G., Dal Cin S., Gruppioni E., Boldorini R. Orbital meningeal melanocytoma: Histological, immunohistochemical and molecular characterization of a case and review of the literature. Pathol. Res. Pract. 2016;212:946–953. doi: 10.1016/j.prp.2016.07.009.</cite> [<a href="https://doi.org/10.1016/j.prp.2016.07.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27499153/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pathol.%20Res.%20Pract.&amp;title=Orbital%20meningeal%20melanocytoma:%20Histological,%20immunohistochemical%20and%20molecular%20characterization%20of%20a%20case%20and%20review%20of%20the%20literature&amp;author=A.%20Palicelli&amp;author=M.G.%20Disanto&amp;author=G.%20Panzarasa&amp;author=C.%20Veggiani&amp;author=G.%20Galizia&amp;volume=212&amp;publication_year=2016&amp;pages=946-953&amp;pmid=27499153&amp;doi=10.1016/j.prp.2016.07.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B252-biomedicines-10-00236">
<span class="label">252.</span><cite>Ardighieri L., Palicelli A., Ferrari F., Ragnoli M., Ghini I., Bugatti M., Bercich L., Sartori E., Odicino F.E. Risk Assessment in Solitary Fibrous Tumor of the Uterine Corpus: Report of a Case and Systematic Review of the Literature. Int. J. Surg. Pathol. 2021;28:10668969211025759. doi: 10.1177/10668969211025759.</cite> [<a href="https://doi.org/10.1177/10668969211025759" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34180727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Surg.%20Pathol.&amp;title=Risk%20Assessment%20in%20Solitary%20Fibrous%20Tumor%20of%20the%20Uterine%20Corpus:%20Report%20of%20a%20Case%20and%20Systematic%20Review%20of%20the%20Literature&amp;author=L.%20Ardighieri&amp;author=A.%20Palicelli&amp;author=F.%20Ferrari&amp;author=M.%20Ragnoli&amp;author=I.%20Ghini&amp;volume=28&amp;publication_year=2021&amp;pages=10668969211025759&amp;pmid=34180727&amp;doi=10.1177/10668969211025759&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B253-biomedicines-10-00236">
<span class="label">253.</span><cite>Zanelli M., Pizzi M., Sanguedolce F., Zizzo M., Palicelli A., Soriano A., Bisagni A., Martino G., Caprera C., Moretti M., et al.  Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach. Cancers. 2021;13:3316.  doi: 10.3390/cancers13133316.</cite> [<a href="https://doi.org/10.3390/cancers13133316" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8269078/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34282774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Gastrointestinal%20Manifestations%20in%20Systemic%20Mastocytosis:%20The%20Need%20of%20a%20Multidisciplinary%20Approach&amp;author=M.%20Zanelli&amp;author=M.%20Pizzi&amp;author=F.%20Sanguedolce&amp;author=M.%20Zizzo&amp;author=A.%20Palicelli&amp;volume=13&amp;publication_year=2021&amp;pages=3316&amp;pmid=34282774&amp;doi=10.3390/cancers13133316&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B254-biomedicines-10-00236">
<span class="label">254.</span><cite>Donegani E., Ambassa J.C., Mvondo C., Giamberti A., Ramponi A., Palicelli A., Chelo D. Linfoma di Burkitt cardiaco primitivo in un giovane ragazzo africano [Primary cardiac Burkitt lymphoma in an African child] G. Ital. Cardiol. 2013;14:481–484. doi: 10.1714/1280.14165.</cite> [<a href="https://doi.org/10.1714/1280.14165" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23748548/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=G.%20Ital.%20Cardiol.&amp;title=Linfoma%20di%20Burkitt%20cardiaco%20primitivo%20in%20un%20giovane%20ragazzo%20africano%20%5BPrimary%20cardiac%20Burkitt%20lymphoma%20in%20an%20African%20child%5D&amp;author=E.%20Donegani&amp;author=J.C.%20Ambassa&amp;author=C.%20Mvondo&amp;author=A.%20Giamberti&amp;author=A.%20Ramponi&amp;volume=14&amp;publication_year=2013&amp;pages=481-484&amp;pmid=23748548&amp;doi=10.1714/1280.14165&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B255-biomedicines-10-00236">
<span class="label">255.</span><cite>Aleksandra C.Z., Iris H., Maarten J.V.L., Jean-Paul P.M.V., Michel M.P.J.R., Clark J.Z. Systematic Review on the Mid-Term Outcomes of Elective Endovascular Aneurysm Sealing in Comparison to Endovascular Aneurysm Repair. J. Endovasc. Ther. 2021;27:15266028211047941. doi: 10.1177/15266028211047941.</cite> [<a href="https://doi.org/10.1177/15266028211047941" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9096591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34569337/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Endovasc.%20Ther.&amp;title=Systematic%20Review%20on%20the%20Mid-Term%20Outcomes%20of%20Elective%20Endovascular%20Aneurysm%20Sealing%20in%20Comparison%20to%20Endovascular%20Aneurysm%20Repair&amp;author=C.Z.%20Aleksandra&amp;author=H.%20Iris&amp;author=J.V.L.%20Maarten&amp;author=P.M.V.%20Jean-Paul&amp;author=M.P.J.R.%20Michel&amp;volume=27&amp;publication_year=2021&amp;pages=15266028211047941&amp;pmid=34569337&amp;doi=10.1177/15266028211047941&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B256-biomedicines-10-00236">
<span class="label">256.</span><cite>Zanelli M., Sanguedolce F., Palicelli A., Zizzo M., Martino G., Caprera C., Fragliasso V., Soriano A., Valle L., Ricci S., et al.  EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1) Cancers. 2021;13:4578.  doi: 10.3390/cancers13184578.</cite> [<a href="https://doi.org/10.3390/cancers13184578" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8465149/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34572803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=EBV-Driven%20Lymphoproliferative%20Disorders%20and%20Lymphomas%20of%20the%20Gastrointestinal%20Tract:%20A%20Spectrum%20of%20Entities%20with%20a%20Common%20Denominator%20(Part%201)&amp;author=M.%20Zanelli&amp;author=F.%20Sanguedolce&amp;author=A.%20Palicelli&amp;author=M.%20Zizzo&amp;author=G.%20Martino&amp;volume=13&amp;publication_year=2021&amp;pages=4578&amp;pmid=34572803&amp;doi=10.3390/cancers13184578&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B257-biomedicines-10-00236">
<span class="label">257.</span><cite>Zanelli M., Sanguedolce F., Palicelli A., Zizzo M., Martino G., Caprera C., Fragliasso V., Soriano A., Valle L., Ricci S., et al.  EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2) Cancers. 2021;13:4527.  doi: 10.3390/cancers13184527.</cite> [<a href="https://doi.org/10.3390/cancers13184527" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8465149/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34572803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=EBV-Driven%20Lymphoproliferative%20Disorders%20and%20Lymphomas%20of%20the%20Gastrointestinal%20Tract:%20A%20Spectrum%20of%20Entities%20with%20a%20Common%20Denominator%20(Part%202)&amp;author=M.%20Zanelli&amp;author=F.%20Sanguedolce&amp;author=A.%20Palicelli&amp;author=M.%20Zizzo&amp;author=G.%20Martino&amp;volume=13&amp;publication_year=2021&amp;pages=4527&amp;pmid=34572803&amp;doi=10.3390/cancers13184527&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B258-biomedicines-10-00236">
<span class="label">258.</span><cite>Zanelli M., Sanguedolce F., Palicelli A., Zizzo M., Martino G., Caprera C., Fragliasso V., Soriano A., Gozzi F., Cimino L., et al.  EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3) Cancers. 2021;13:6021.  doi: 10.3390/cancers13236021.</cite> [<a href="https://doi.org/10.3390/cancers13236021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8656853/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34885131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=EBV-Driven%20Lymphoproliferative%20Disorders%20and%20Lymphomas%20of%20the%20Gastrointestinal%20Tract:%20A%20Spectrum%20of%20Entities%20with%20a%20Common%20Denominator%20(Part%203)&amp;author=M.%20Zanelli&amp;author=F.%20Sanguedolce&amp;author=A.%20Palicelli&amp;author=M.%20Zizzo&amp;author=G.%20Martino&amp;volume=13&amp;publication_year=2021&amp;pages=6021&amp;pmid=34885131&amp;doi=10.3390/cancers13236021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B259-biomedicines-10-00236">
<span class="label">259.</span><cite>De Leo A., Santini D., Ceccarelli C., Santandrea G., Palicelli A., Acquaviva G., Chiarucci F., Rosini F., Ravegnini G., Pession A., et al.  What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics. 2021;11:697.  doi: 10.3390/diagnostics11040697.</cite> [<a href="https://doi.org/10.3390/diagnostics11040697" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8070731/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33919741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics&amp;title=What%20Is%20New%20on%20Ovarian%20Carcinoma:%20Integrated%20Morphologic%20and%20Molecular%20Analysis%20Following%20the%20New%202020%20World%20Health%20Organization%20Classification%20of%20Female%20Genital%20Tumors&amp;author=A.%20De%20Leo&amp;author=D.%20Santini&amp;author=C.%20Ceccarelli&amp;author=G.%20Santandrea&amp;author=A.%20Palicelli&amp;volume=11&amp;publication_year=2021&amp;pages=697&amp;pmid=33919741&amp;doi=10.3390/diagnostics11040697&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B260-biomedicines-10-00236">
<span class="label">260.</span><cite>Palicelli A., Bonacini M., Croci S., Magi-Galluzzi C., Cañete-Portillo S., Chaux A., Bisagni A., Zanetti E., De Biase D., Melli B., et al.  What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables. Cells. 2021;10:3166.  doi: 10.3390/cells10113166.</cite> [<a href="https://doi.org/10.3390/cells10113166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8625301/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34831389/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=What%20do%20we%20have%20to%20know%20about%20PD-L1%20expression%20in%20prostate%20cancer?%20A%20systematic%20literature%20review.%20Part%201:%20Focus%20on%20immunohistochemical%20results%20with%20discussion%20of%20pre-analytical%20and%20interpretation%20variables&amp;author=A.%20Palicelli&amp;author=M.%20Bonacini&amp;author=S.%20Croci&amp;author=C.%20Magi-Galluzzi&amp;author=S.%20Ca%C3%B1ete-Portillo&amp;volume=10&amp;publication_year=2021&amp;pages=3166&amp;pmid=34831389&amp;doi=10.3390/cells10113166&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B261-biomedicines-10-00236">
<span class="label">261.</span><cite>Palicelli A., Bonacini M., Croci S., Magi-Galluzzi C., Cañete-Portillo S., Chaux A., Bisagni A., Zanetti E., De Biase D., Melli B., et al.  What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 2: Clinic-pathologic correlations. Cells. 2021;10:3165.  doi: 10.3390/cells10113165.</cite> [<a href="https://doi.org/10.3390/cells10113165" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8618408/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34831388/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=What%20do%20we%20have%20to%20know%20about%20PD-L1%20expression%20in%20prostate%20cancer?%20A%20systematic%20literature%20review.%20Part%202:%20Clinic-pathologic%20correlations&amp;author=A.%20Palicelli&amp;author=M.%20Bonacini&amp;author=S.%20Croci&amp;author=C.%20Magi-Galluzzi&amp;author=S.%20Ca%C3%B1ete-Portillo&amp;volume=10&amp;publication_year=2021&amp;pages=3165&amp;pmid=34831388&amp;doi=10.3390/cells10113165&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B262-biomedicines-10-00236">
<span class="label">262.</span><cite>Palicelli A., Croci S., Bisagni A., Zanetti E., De Biase D., Melli B., Sanguedolce F., Ragazzi M., Zanelli M., Chaux A., et al.  What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 3: PD-L1, intracellular signaling pathways and tumor microenvironment. Int. J. Mol. Sci. 2021;22:12330.  doi: 10.3390/ijms222212330.</cite> [<a href="https://doi.org/10.3390/ijms222212330" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8618001/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34830209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=What%20do%20we%20have%20to%20know%20about%20PD-L1%20expression%20in%20prostate%20cancer?%20A%20systematic%20literature%20review.%20Part%203:%20PD-L1,%20intracellular%20signaling%20pathways%20and%20tumor%20microenvironment&amp;author=A.%20Palicelli&amp;author=S.%20Croci&amp;author=A.%20Bisagni&amp;author=E.%20Zanetti&amp;author=D.%20De%20Biase&amp;volume=22&amp;publication_year=2021&amp;pages=12330&amp;pmid=34830209&amp;doi=10.3390/ijms222212330&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B263-biomedicines-10-00236">
<span class="label">263.</span><cite>Palicelli A., Croci S., Bisagni A., Zanetti E., De Biase D., Melli B., Sanguedolce F., Ragazzi M., Zanelli M., Chaux A., et al.  What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 4: Experimental treatments in pre-clinical studies (cell lines and mouse models) Int. J. Mol. Sci. 2021;22:12297.  doi: 10.3390/ijms222212297.</cite> [<a href="https://doi.org/10.3390/ijms222212297" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8618402/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34830179/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=What%20do%20we%20have%20to%20know%20about%20PD-L1%20expression%20in%20prostate%20cancer?%20A%20systematic%20literature%20review.%20Part%204:%20Experimental%20treatments%20in%20pre-clinical%20studies%20(cell%20lines%20and%20mouse%20models)&amp;author=A.%20Palicelli&amp;author=S.%20Croci&amp;author=A.%20Bisagni&amp;author=E.%20Zanetti&amp;author=D.%20De%20Biase&amp;volume=22&amp;publication_year=2021&amp;pages=12297&amp;pmid=34830179&amp;doi=10.3390/ijms222212297&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B264-biomedicines-10-00236">
<span class="label">264.</span><cite>Palicelli A., Croci S., Bisagni A., Zanetti E., De Biase D., Melli B., Sanguedolce F., Ragazzi M., Zanelli M., Chaux A., et al.  What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 5: Epigenetic regulation of PD-L1. Int. J. Mol. Sci. 2021;22:12314.  doi: 10.3390/ijms222212314.</cite> [<a href="https://doi.org/10.3390/ijms222212314" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8619683/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34830196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=What%20do%20we%20have%20to%20know%20about%20PD-L1%20expression%20in%20prostate%20cancer?%20A%20systematic%20literature%20review.%20Part%205:%20Epigenetic%20regulation%20of%20PD-L1&amp;author=A.%20Palicelli&amp;author=S.%20Croci&amp;author=A.%20Bisagni&amp;author=E.%20Zanetti&amp;author=D.%20De%20Biase&amp;volume=22&amp;publication_year=2021&amp;pages=12314&amp;pmid=34830196&amp;doi=10.3390/ijms222212314&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B265-biomedicines-10-00236">
<span class="label">265.</span><cite>Palicelli A., Bonacini M., Croci S., Bisagni A., Zanetti E., De Biase D., Sanguedolce F., Ragazzi M., Zanelli M., Chaux A., et al.  What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 7: PD-L1 and liquid biopsy. J. Pers. Med. 2021;11:1312.  doi: 10.3390/jpm11121312.</cite> [<a href="https://doi.org/10.3390/jpm11121312" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8709072/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34945784/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Pers.%20Med.&amp;title=What%20do%20we%20have%20to%20know%20about%20PD-L1%20expression%20in%20prostate%20cancer?%20A%20systematic%20literature%20review.%20Part%207:%20PD-L1%20and%20liquid%20biopsy&amp;author=A.%20Palicelli&amp;author=M.%20Bonacini&amp;author=S.%20Croci&amp;author=A.%20Bisagni&amp;author=E.%20Zanetti&amp;volume=11&amp;publication_year=2021&amp;pages=1312&amp;pmid=34945784&amp;doi=10.3390/jpm11121312&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/8868626/bin/biomedicines-10-00236-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (373.1KB, zip) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Biomedicines are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3390/biomedicines10020236"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/biomedicines-10-00236.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (993.5 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/8868626/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/8868626/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8868626%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8868626/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC8868626/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC8868626/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/35203446/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC8868626/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/35203446/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC8868626/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/8868626/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="NjsOa9hDT0g9l64VauPog4ZgzhKPosiaptS1W1KbaIKtwczWqtdYNcSWG992rdNF">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
